<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="mco270560" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MedComm (2020)</journal-id><journal-id journal-id-type="iso-abbrev">MedComm (2020)</journal-id><journal-id journal-id-type="pmc-domain-id">4101</journal-id><journal-id journal-id-type="pmc-domain">mcomm</journal-id><journal-id journal-id-type="publisher-id">MCO2</journal-id><journal-title-group><journal-title>MedComm</journal-title></journal-title-group><issn pub-type="epub">2688-2663</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12778424</article-id><article-id pub-id-type="pmcid-ver">PMC12778424.1</article-id><article-id pub-id-type="pmcaid">12778424</article-id><article-id pub-id-type="pmcaiid">12778424</article-id><article-id pub-id-type="pmid">41510186</article-id><article-id pub-id-type="doi">10.1002/mco2.70560</article-id><article-id pub-id-type="publisher-id">MCO270560</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention</article-title></title-group><contrib-group><contrib id="mco270560-cr-0001" contrib-type="author"><name name-style="western"><surname>Lei</surname><given-names initials="H">Huijun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9398-5472</contrib-id><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270560-cr-0002" contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="J">Jinzhen</given-names></name><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mco270560-cr-0003" contrib-type="author"><name name-style="western"><surname>Gu</surname><given-names initials="W">Wei</given-names></name><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mco270560-cr-0004" contrib-type="author"><name name-style="western"><surname>Qiao</surname><given-names initials="H">Hongjin</given-names></name><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mco270560-cr-0005" contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="H">Huixue</given-names></name><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="mco270560-cr-0006" contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zijian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4677-0361</contrib-id><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270560-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mco270560-cr-0007" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="SM">San Ming</given-names></name><xref rid="mco270560-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270560-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="T">Tianhui</given-names></name><xref rid="mco270560-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>chenth@zjcc.org.cn</email></address></contrib></contrib-group><aff id="mco270560-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM)</named-content>
<institution>Chinese Academy of Sciences</institution>
<city>Hangzhou</city>
<named-content content-type="country-part">Zhejiang</named-content>
<country country="CN">China</country>
</aff><aff id="mco270560-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Faculty of Health Sciences</named-content>
<institution>University of Macau</institution>
<city>Taipa</city>
<named-content content-type="country-part">Macau</named-content>
<country country="CN">China</country>
</aff><aff id="mco270560-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital)</institution>
<city>Wenzhou</city>
<named-content content-type="country-part">Zhejiang</named-content>
<country country="CN">China</country>
</aff><aff id="mco270560-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Hangzhou Normal University</institution>
<city>Hangzhou</city>
<named-content content-type="country-part">Zhejiang</named-content>
<country country="CN">China</country>
</aff><pub-date pub-type="epub"><day>07</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>7</volume><issue seq="150">1</issue><issue-id pub-id-type="pmc-issue-id">502813</issue-id><issue-id pub-id-type="doi">10.1002/mco2.v7.1</issue-id><elocation-id>e70560</elocation-id><history><date date-type="rev-recd"><day>21</day><month>11</month><year>2025</year></date><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>08</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-09 09:25:14.850"><day>09</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2026 The Author(s). <italic toggle="yes">MedComm</italic> published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="MCO2-7-e70560.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:MCO2-7-e70560.pdf"/><abstract><title>ABSTRACT</title><p>Breast cancer is the most common cancer and the leading cause of cancer&#8208;related death among women worldwide. Advances in molecular biology, high&#8208;throughput sequencing, and integrative&#8208;omics have deepened the understanding of its heterogeneity by clarifying mechanisms linked to genetic susceptibility, epigenetic regulation, oncogenic signaling, and immune evasion. Although those developments have driven progress in targeted therapy and screening, concerns on drug resistance, toxicity, global inequities, and suboptimal risk stratification continue to limit outcomes. This review systematically summarizes current advances across four interconnected areas of breast cancer research and management, including molecular pathogenesis, targeted therapy, screening, and prevention. It describes key biological processes that shape tumor heterogeneity and examines targeted therapies, including endocrine agents, HER2&#8208;directed drugs, CDK4/6 and PI3K/AKT/mTOR inhibitors, antibody&#8211;drug conjugates, and immunotherapies, together with mechanisms of resistance and emerging treatment targets. It also evaluates evolving approaches in risk stratification and screening, highlighting progress in digital breast tomosynthesis, magnetic resonance imaging, contrast&#8208;enhanced mammography, and artificial intelligence&#8208;assisted interpretation. By integrating cutting&#8208;edge molecular insights with clinical advances, this review further highlights the expanding opportunities for personalized therapy and precision prevention. It outlines future directions linking multiomics and artificial intelligence to more equitable and effective breast cancer management.</p></abstract><abstract id="mco270560-abs-0001" abstract-type="graphical"><p>The review manuscript examines the molecular pathogenesis, screening, prevention advances, and evolving targeted therapies in breast cancer. It highlights the integration of AI and multiomics for precision prevention and personalized treatment, pointing toward future directions in equitable cancer care.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="MCO2-7-e70560-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mco270560-kwd-0001">breast cancer</kwd><kwd id="mco270560-kwd-0002">pathogenesis</kwd><kwd id="mco270560-kwd-0003">targeted therapy</kwd><kwd id="mco270560-kwd-0004">screening</kwd><kwd id="mco270560-kwd-0005">prevention</kwd><kwd id="mco270560-kwd-0006">risk assessment</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Key Research&#8208;Development Program of China</institution></institution-wrap></funding-source><award-id>2019YFE0198800</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Key Research&#8208;Development Program of Zhejiang Province</institution></institution-wrap></funding-source><award-id>2017C03013</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Ten&#8208;Thousand Talents Plan of Zhejiang Province</institution></institution-wrap></funding-source><award-id>2021R52020</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="4"/><page-count count="41"/><word-count count="29797"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:07.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="mco270560-cit-0001"><string-name name-style="western"><given-names>H.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Gu</surname></string-name>, et al. &#8220;<article-title>Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention</article-title>.&#8221; <source>MedComm</source><volume>7</volume>, no. <issue>1</issue> (<year>2026</year>): <elocation-id>e70560</elocation-id>. <pub-id pub-id-type="doi">10.1002/mco2.70560</pub-id></mixed-citation>
</p></notes></front><body><sec id="mco270560-sec-0010"><label>1</label><title>Introduction</title><p>Breast cancer is the most common cancer and the leading cause of cancer&#8208;related mortality among women worldwide, imposing a significant economic and social burden on healthcare systems [<xref rid="mco270560-bib-0001" ref-type="bibr">1</xref>]. Recent data show a continuing increase in breast cancer incidence [<xref rid="mco270560-bib-0002" ref-type="bibr">2</xref>], driven in part by improved screening capabilities [<xref rid="mco270560-bib-0003" ref-type="bibr">3</xref>]. In 2022, approximately 2.3 million new cases and 670,000 deaths were reported globally, accounting for 25% of new cancer diagnoses and 15.5% of cancer deaths among women. Globally, breast cancer accounts for one in four female cancers and one in six female cancer&#8208;related mortality [<xref rid="mco270560-bib-0001" ref-type="bibr">1</xref>]. By 2050, projected incidence shall increase by 38% while mortality shall increase by 68%, with the heaviest burden expected in countries with low scores of human development index scores [<xref rid="mco270560-bib-0004" ref-type="bibr">4</xref>].</p><p>Breast cancer is a heterogeneous disease encompassing multiple subtypes with distinct molecular and clinical features. Current clinical classification of breast cancer relies largely on the use of immunohistochemistry (IHC) markers of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki&#8208;67 to classify breast cancer into four subtypes, that is, Luminal A (ER+ and/or PR+, HER2&#8722;, low Ki&#8208;67), Luminal B (ER+, HER2&#177;, high Ki&#8208;67), HER2&#8208;enriched (ER&#8722;, PR&#8722;, HER2+), and triple&#8208;negative breast cancer (TNBC). These subgroups differ in prognosis, biology, and therapeutic response [<xref rid="mco270560-bib-0005" ref-type="bibr">5</xref>]. However, the field is moving rapidly beyond IHC&#8208;based classification toward high&#8208;resolution, omics&#8208;driven system that captures tumor complexity at genomic, transcriptomic, and proteomic levels [<xref rid="mco270560-bib-0006" ref-type="bibr">6</xref>, <xref rid="mco270560-bib-0007" ref-type="bibr">7</xref>]. Single&#8208;cell RNA sequencing (scRNA&#8208;seq) further delineates intratumoral heterogeneity, identifying rare cellular subpopulations implicated in resistance and metastasis [<xref rid="mco270560-bib-0008" ref-type="bibr">8</xref>]. Together, these advances underpin a more nuanced molecular taxonomy that informs therapeutic development.</p><p>Breast cancer has also been a typical example for precision medicine. Tailored treatment according to tumor biology has yielded major therapeutic advances and established new clinically meaningful subtypes. For example, trastuzumab deruxtecan (T&#8208;DXd), an antibody&#8211;drug conjugate, has extended the HER2&#8208;directed therapy into the HER2&#8208;low setting, conferring significant survival benefit and reshaping the therapeutic paradigm [<xref rid="mco270560-bib-0009" ref-type="bibr">9</xref>, <xref rid="mco270560-bib-0010" ref-type="bibr">10</xref>]. Similarly, the CAPItello&#8208;291 trial demonstrated that the AKT inhibitor capivasertib combined with fulvestrant improves progression&#8208;free survival (PFS) in patients with hormone receptor (+) HER2(&#8722;) tumors harboring PIK3CA, AKT1, or PTEN alterations [<xref rid="mco270560-bib-0011" ref-type="bibr">11</xref>, <xref rid="mco270560-bib-0012" ref-type="bibr">12</xref>]. TNBC was considered uniformly aggressive, however, the KEYNOTE&#8208;355 trial showed that pembrolizumab plus chemotherapy extended survival in patients with programmed death&#8208;ligand 1 (PD&#8208;L1)&#8208;high tumors [<xref rid="mco270560-bib-0013" ref-type="bibr">13</xref>]. These successes highlight the causal link between molecular drivers and therapeutic benefit, affirming that precision medicine is now a clinical reality rather than a theoretical consideration. Comprehensive molecular profiling is likely to become routine in the near future as the current ER, PR, and HER2 testing.</p><p>A number of risk factors for breast cancer have been identified, for example, genetics, family history, personal history of breast disease, radiation, and dense breast [<xref rid="mco270560-bib-0014" ref-type="bibr">14</xref>, <xref rid="mco270560-bib-0015" ref-type="bibr">15</xref>, <xref rid="mco270560-bib-0016" ref-type="bibr">16</xref>, <xref rid="mco270560-bib-0017" ref-type="bibr">17</xref>, <xref rid="mco270560-bib-0018" ref-type="bibr">18</xref>]. As these risk factors are rarely amenable to modification through intervention, the primary objective of breast cancer prevention and control is the early detection and treatment of the disease. The use of screening mammograms prior to the onset of symptoms allows for the early detection of breast cancer [<xref rid="mco270560-bib-0019" ref-type="bibr">19</xref>, <xref rid="mco270560-bib-0020" ref-type="bibr">20</xref>], thereby reducing mortality and the incidence of advanced cancer. Breast cancer screening serves as a fundamental component of preventive healthcare. In recent decades, numerous developed countries are practicing population&#8208;based breast cancer screening programs [<xref rid="mco270560-bib-0021" ref-type="bibr">21</xref>, <xref rid="mco270560-bib-0022" ref-type="bibr">22</xref>, <xref rid="mco270560-bib-0023" ref-type="bibr">23</xref>], whereas in many low&#8208; and middle&#8208;income countries, lack of resources hampers the implementation of mass screening programs. The mortality rate of breast cancer is higher and the disease is often diagnosed at later stage for women in those countries, compared with women in high&#8208;income countries [<xref rid="mco270560-bib-0024" ref-type="bibr">24</xref>].</p><p>The principles of precision medicine are now extending into prevention and screening. Risk assessment models are being refined to support tailored interventions. While the traditional tools such as the Gail model demonstrate variable accuracy across populations, the approach of polygenic risk score (PRS) enable more granular lifetime risk estimation, guiding decisions on enhanced screening or preventive therapy [<xref rid="mco270560-bib-0025" ref-type="bibr">25</xref>]. Screening technologies are also evolving. While digital breast tomosynthesis (DBT) and magnetic resonance imaging (MRI) offer superior diagnostic accuracy [<xref rid="mco270560-bib-0026" ref-type="bibr">26</xref>], and artificial intelligence (AI)&#8208;assisted image interpretation has shown to increase cancer detection rates by 13&#8211;18% [<xref rid="mco270560-bib-0027" ref-type="bibr">27</xref>, <xref rid="mco270560-bib-0028" ref-type="bibr">28</xref>, <xref rid="mco270560-bib-0029" ref-type="bibr">29</xref>]. Nonetheless, concerns on efficacy, risks, cost effectiveness and inconsistency among different guidelines (e.g., starting age at screening for women with average risk) may hinder widespread implementation.</p><p>This review critically appraises four domains central to contemporary breast cancer management: molecular pathogenesis, targeted therapy, screening technologies, and prevention strategies. Advances in these areas are promoting deeper understanding cancer heterogeneity, propelling integration of precision medicine into routine care, transforming therapeutic potentials, reshaping the risk assessment, screening, and prevention of breast cancer.</p></sec><sec id="mco270560-sec-0020"><label>2</label><title>Molecular Pathogenesis of Breast Cancer</title><p>The initiation and progression of breast cancer are driven by a complex interplay of genetic susceptibility, hormonal dysregulation, epigenetic and transcriptomic alterations, immune dysregulation, and interactions with the tumor microenvironment (TME) (Figure&#160;<xref rid="mco270560-fig-0001" ref-type="fig">1</xref>). These processes drive genomic instability and clonal evolution, leading to marked cellular subtype differentiation and variability in therapeutic responses among breast cancers [<xref rid="mco270560-bib-0030" ref-type="bibr">30</xref>]. With the rapid advancement of multiomics technologies, including single&#8208;cell transcriptomics, spatial transcriptomics, and circulating cell&#8208;free DNA sequencing, our understanding of breast cancer pathogenesis is shifting from static, single&#8208;factor models to dynamic, systems&#8208;level network frameworks [<xref rid="mco270560-bib-0007" ref-type="bibr">7</xref>, <xref rid="mco270560-bib-0031" ref-type="bibr">31</xref>]. This paradigm provides a theoretical foundation to refine molecular classification and develop individualized treatment and early intervention strategies.</p><fig position="float" fig-type="FIGURE" id="mco270560-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Key molecular mechanisms in the development and progression of breast cancer. The figure summarizes four major mechanisms that drive breast cancer initiation and progression: (A) genetic and genomic alterations; (B) epigenetic and transcriptomic regulation; (C) key oncogenic signaling pathways; (D) tumor microenvironment and immune evasion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="MCO2-7-e70560-g003.jpg"/></fig><sec id="mco270560-sec-0030"><label>2.1</label><title>Genetic Mechanism</title><p>Germline mutation constitutes a significant genetic basis of breast cancer susceptibility, particularly in patients with early&#8208;onset, family history, or bilateral breast cancer. Among them, pathogenic variants in the <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> genes are the most prevalent and the major risk factor for hereditary breast and ovarian cancer syndrome (HBOC) [<xref rid="mco270560-bib-0032" ref-type="bibr">32</xref>]. These two genes play critical roles in repairing double&#8208;strand DNA breaks through the DNA homologous recombination repair pathway, and their functional defects lead to increased genomic instability and elevated risk of breast and ovarian cancers by approximately 60% [<xref rid="mco270560-bib-0033" ref-type="bibr">33</xref>]. In addition to <italic toggle="yes">BRCA1/2</italic>, other genes such as <italic toggle="yes">PALB2</italic>, <italic toggle="yes">BARD1</italic>, <italic toggle="yes">PTEN</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">ATM</italic>, and <italic toggle="yes">CHEK2</italic> are also associated with elevated breast cancer risk [<xref rid="mco270560-bib-0034" ref-type="bibr">34</xref>]. Recent studies have shown that germline mutations in these genes are not only associated with breast cancer risk but also implicated in distant metastasis, as exemplified by <italic toggle="yes">PCSK9</italic> [<xref rid="mco270560-bib-0035" ref-type="bibr">35</xref>].</p><p>Somatic mutation is a direct driver of malignant transformation and progression of breast cancer cells. Somatic mutation in <italic toggle="yes">TP53</italic> is the most common genetic alterations in tumors, occurring in over 30% of breast cancers, typically arising in the early stages of tumorigenesis. These mutations are linked to a more aggressive disease course and poorer overall survival (OS), particularly prevalent in TNBC [<xref rid="mco270560-bib-0036" ref-type="bibr">36</xref>]. Somatic mutation in <italic toggle="yes">PIK3CA</italic> is another frequent somatic alteration in breast cancer, with a prevalence of up to 40% in ER(+) disease [<xref rid="mco270560-bib-0037" ref-type="bibr">37</xref>]. <italic toggle="yes">PIK3CA</italic> mutation leads to the abnormal activation of the PI3K/AKT/mTOR signaling pathway, which plays a central role in cell proliferation, survival, invasion, migration, apoptosis, glucose metabolism, and DNA repair [<xref rid="mco270560-bib-0037" ref-type="bibr">37</xref>]. The <italic toggle="yes">ESR1</italic> gene encodes ER&#8208;&#945;, which is a key driver in ER(+) breast cancer. Somatic mutation in <italic toggle="yes">ESR1</italic> mainly occurs in patients who relapse or develop metastases after endocrine therapy. The mutation enables ligand&#8208;independent activation of the ER signaling pathway, thereby resulting in endocrine resistance [<xref rid="mco270560-bib-0038" ref-type="bibr">38</xref>].</p><p>Certain gene mutations not only serve as molecular hallmarks of tumorigenesis but also are actionable therapeutic targets. For instance, defined targeted treatment strategies have been developed for the patients with mutations in <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">BRCA1/2</italic>, and <italic toggle="yes">ESR1</italic>. <italic toggle="yes">PIK3CA</italic>&#8208;mutated breast cancer can be treated with the PI3K&#945;&#8208;specific inhibitor alpelisib, which has been approved by the United States Food and Drug Administration (US FDA) for ER(+)/HER2(&#8722;) advanced disease [<xref rid="mco270560-bib-0039" ref-type="bibr">39</xref>]; patients with germline <italic toggle="yes">BRCA1/2</italic> mutations benefit from poly(ADP&#8208;ribose) polymerase (PARP) inhibitors such as olaparib or talazoparib [<xref rid="mco270560-bib-0040" ref-type="bibr">40</xref>]. Moreover, <italic toggle="yes">ESR1</italic> mutation suggests endocrine therapy failure, thus necessitating the use of selective ER degraders, such as fulvestrant or the combination of CDK4/6 inhibitors (CDK4/6i) to overcome drug resistance [<xref rid="mco270560-bib-0041" ref-type="bibr">41</xref>, <xref rid="mco270560-bib-0042" ref-type="bibr">42</xref>].</p><p>Nevertheless, the pronounced molecular heterogeneity of breast cancer remains a major obstacle in elucidating its pathogenesis and guiding treatment strategies, functional annotation of mutations in noncoding regions remains insufficient, and integrative analyses of multiomics data face challenges of standardization, reproducibility, and interpretation. Therefore, future research will require the combination between the use of systems biology approaches and functional validation to identify truly pathogenic and druggable variants, thereby providing a more precise molecular foundation for dynamic monitoring of breast cancer development and individualized treatment.</p></sec><sec id="mco270560-sec-0040"><label>2.2</label><title>Epigenetic Regulatory Mechanisms</title><p>Unlike genetic mutations, epigenetic regulation is reversible [<xref rid="mco270560-bib-0043" ref-type="bibr">43</xref>]. Epigenetic regulation modifies cellular functions by influencing gene expression without altering the DNA sequence, and it plays a pivotal role in the initiation and progression of breast cancer [<xref rid="mco270560-bib-0044" ref-type="bibr">44</xref>]. DNA methylation (DNAme), histone modifications, and chromatin remodeling can reprogram gene expression, while noncoding RNAs (ncRNAs) regulate tumor cell proliferation, metastasis, and drug resistance through complex networks [<xref rid="mco270560-bib-0045" ref-type="bibr">45</xref>].</p><p>DNAme refers to the covalent methylation of cytosine residues in DNA molecules, occurring mainly at CpG dinucleotide sites [<xref rid="mco270560-bib-0046" ref-type="bibr">46</xref>]. In breast cancer, abnormal DNAme manifests as promoter hypermethylation of tumor suppressor genes and hypomethylation of oncogenes or repetitive sequences, where hypermethylation leads to gene silencing and hypomethylation results in gene activation or genomic instability [<xref rid="mco270560-bib-0046" ref-type="bibr">46</xref>, <xref rid="mco270560-bib-0047" ref-type="bibr">47</xref>]. The unbalanced methylation is a common alteration across multiple molecular subtypes of breast cancer and is particularly pronounced in TNBC [<xref rid="mco270560-bib-0048" ref-type="bibr">48</xref>]. The WID&#8208;BC index, developed based on DNAme patterns in cervical samples, has been shown to effectively identify women at high risk of breast cancer, highlighting the potential of DNAme as a key molecular biomarker for early diagnosis and prognosis [<xref rid="mco270560-bib-0049" ref-type="bibr">49</xref>]. Moreover, analysis of DNAme profiles has enabled the classification of TNBC into two distinct epigenetic subtypes, the basal&#8208;like and nonbasal&#8208;like, providing novel insights into the epigenetic underpinnings of TNBC and potential targets for developing novel therapies [<xref rid="mco270560-bib-0050" ref-type="bibr">50</xref>].</p><p>Histone modification includes acetylation and methylation, which influence transcriptional activity through regulating chromatin structure [<xref rid="mco270560-bib-0051" ref-type="bibr">51</xref>]. Histone acetylation is dynamically regulated by the balanced histone acetyltransferases and histone deacetylases (HDACs). In breast cancer, aberrant overexpression of HDACs leads to histone deacetylation, resulting in condensed chromatin and gene silencing, thereby suppressing tumor suppressor gene expression [<xref rid="mco270560-bib-0052" ref-type="bibr">52</xref>]. HDAC inhibitors have shown therapeutic potential in preclinical and clinical trials, especially when combined with immunotherapy, as they can remodel the TME, overcome immune evasion, and have emerged as potential targets for breast cancer therapy [<xref rid="mco270560-bib-0053" ref-type="bibr">53</xref>]. Dysregulation of histone methyltransferases (HMTs) and demethylases is widespread in breast cancer. EZH2, a histone H3K27 methyltransferase, promotes the initiation and progression of breast tumors by epigenetically regulating the Wnt and mTORC1 signaling pathways [<xref rid="mco270560-bib-0054" ref-type="bibr">54</xref>]. NSD2/WHSC1, an H3K36me2 methyltransferase, has been shown to promote TNBC metastasis by activating ULK1&#8208;dependent autophagy. This finding revealed a novel mechanism of NSD2 in TNBC metastasis and provided NSD2 as a potential therapeutic target [<xref rid="mco270560-bib-0055" ref-type="bibr">55</xref>].</p><p>ncRNAs are a class of RNA molecules that do not encode proteins but play important roles in the regulation of gene expression. Among them, microRNAs (miRNAs) and long ncRNAs (lncRNAs) are the two most widely studied types [<xref rid="mco270560-bib-0056" ref-type="bibr">56</xref>]. miRNAs are short RNA molecules of approximately 20&#8211;25 nucleotides in length, which bind to the 3&#8242; untranslated regions of target mRNAs to inhibit their translation or promote their degradation, thereby negatively regulating gene expression [<xref rid="mco270560-bib-0057" ref-type="bibr">57</xref>]. In breast cancer, many miRNAs are aberrantly expressed, including both oncogenic miRNAs and tumor&#8208;suppressive miRNAs [57,<xref rid="mco270560-bib-0058" ref-type="bibr">58</xref>]. lncRNAs are ncRNAs longer than 200 nucleotides, which regulate gene expression through multiple mechanisms, including chromatin remodeling, transcriptional regulation, posttranscriptional regulation, and acting as miRNA sponges [<xref rid="mco270560-bib-0059" ref-type="bibr">59</xref>]. In breast cancer, numerous lncRNAs have been found to be aberrantly expressed and involved in tumor initiation and progression. For example, lncRNA NAMPT&#8211;AS is upregulated in TNBC and promotes tumor progression and metastasis by epigenetically activating NAMPT expression [<xref rid="mco270560-bib-0060" ref-type="bibr">60</xref>]. Complex interaction networks exist between miRNAs and lncRNAs. Many lncRNAs can act as competing endogenous RNAs, competitively binding to miRNAs and thereby relieving their suppression of target mRNAs, indirectly upregulating the expression of target genes [<xref rid="mco270560-bib-0061" ref-type="bibr">61</xref>].</p><p>Traditional transcriptomic studies are usually based on the average expression profiles of large numbers of cells, which obscure intra&#8208;tumoral cellular heterogeneity. Single&#8208;cell and spatial transcriptomics technologies provide new opportunities to uncover the epigenetic and transcriptomic heterogeneity of breast cancer. Recent studies integrating DNAme data with spatial transcriptomics have demonstrated that epigenetic regulation underlies cellular state transitions in highly heterogeneous subtypes such as metaplastic breast carcinoma [<xref rid="mco270560-bib-0062" ref-type="bibr">62</xref>]. In addition, multiomics investigations combined with functional analyses have identified a novel chromatin remodeling complex, ARID1B&#8211;SMARCC2/SMARCB1, which suppresses epigenetic modification and drives malignant progression of TNBC [<xref rid="mco270560-bib-0063" ref-type="bibr">63</xref>]. These findings emphasize that multiomics approaches can uncover convergent epigenetic mechanisms governing tumor plasticity and progression, therefore, providing potential entry points for the development of epigenetic&#8208;targeted therapies.</p><p>However, the diversity nature of epigenetic regulation makes it difficult to identify universal therapeutic targets. Because epigenetic modifications are highly dynamic, plastic, and variable among different breast cancer subtypes and even within an individual tumor, it remains a challenge to develop epigenetic&#8208;targeted therapies that are universally effective for all patients. Although single&#8208;omics technologies have achieved significant progress, it remains a formidable task to integrate epigenetic information of DNAme, histone modifications, and ncRNAs together with gene expression data, to construct comprehensive regulatory networks and uncover their synergistic roles in breast cancer pathogenesis. This task requires more advanced bioinformatics tools and computational modeling.</p></sec><sec id="mco270560-sec-0050"><label>2.3</label><title>Key Oncogenic Signaling Pathways</title><p>Development and progression of breast cancer involve multiple signaling pathways. Aberrant activation or inactivation of these pathways can lead to uncontrolled cell proliferation, impaired apoptosis, and enhanced invasion and metastasis. The PI3K/AKT/mTOR signaling pathway is one of the most critical intracellular pathways. It plays key roles in cell proliferation, survival, metabolism, migration, and angiogenesis [<xref rid="mco270560-bib-0037" ref-type="bibr">37</xref>]. In breast cancer, this pathway is frequently hyperactivated due to PIK3CA mutations, loss or inactivation of the tumor suppressor PTEN, and hyperactivation of upstream receptor tyrosine kinases (RTKs) such as HER2 and epidermal growth factor receptor (EGFR) [<xref rid="mco270560-bib-0037" ref-type="bibr">37</xref>, <xref rid="mco270560-bib-0064" ref-type="bibr">64</xref>]. Aberrant activation of the PI3K/AKT/mTOR pathway promotes tumor cell growth and survival, and is also strongly associated with the resistance to chemotherapy and endocrine therapy [<xref rid="mco270560-bib-0038" ref-type="bibr">38</xref>]. Combining with endocrine therapy, PI3K inhibitors alpelisib, AKT inhibitors capivasertib, and mTOR inhibitors everolimus have been applied clinically in breast cancer treatment, especially in hormone receptor (+)/HER2(&#8722;) subtypes, to overcome resistance [<xref rid="mco270560-bib-0038" ref-type="bibr">38</xref>, <xref rid="mco270560-bib-0064" ref-type="bibr">64</xref>].</p><p>The ER signaling pathway is the central driver of hormone receptor (+) breast cancer, accounting for approximately 65&#8211;70% of all cases [<xref rid="mco270560-bib-0065" ref-type="bibr">65</xref>]. Estrogen binds to ER, induces ER dimerization and nuclear translocation, where it binds to estrogen response elements on DNA to regulate the transcription of its target genes, promoting proliferation and survival of breast cancer cells [<xref rid="mco270560-bib-0038" ref-type="bibr">38</xref>]. Endocrine therapy, including selective ER modulators (SERMs), aromatase inhibitors (AIs), and selective ER degraders (SERDs), suppress ER signaling by blocking estrogen&#8208;ER binding or inhibiting estrogen synthesis. Endocrine therapy is the standard treatment for hormone receptor (+) breast cancer [<xref rid="mco270560-bib-0038" ref-type="bibr">38</xref>, <xref rid="mco270560-bib-0065" ref-type="bibr">65</xref>].</p><p>The MAPK pathway, also known as the RAS&#8211;RAF&#8211;MEK&#8211;ERK pathway, plays essential roles in cell proliferation, differentiation, migration, and apoptosis. In breast cancer, aberrant MAPK pathway activation is often caused by overexpression of upstream RTKs (e.g., EGFR, HER2) or mutations in oncogenes such as RAS and BRAF [<xref rid="mco270560-bib-0066" ref-type="bibr">66</xref>]. Sustained activation of the MAPK pathway promotes malignant proliferation and invasion of tumor cells and is associated with resistance to endocrine therapy and chemotherapy. lncRNAs have been identified as critical regulators of the PI3K/AKT, MAPK, and TGF&#8208;&#946; pathways, with many lncRNAs exerting oncogenic functions by enhancing activation of these signaling cascades [<xref rid="mco270560-bib-0059" ref-type="bibr">59</xref>].</p><p>The CDK4/6&#8211;Rb axis is a central regulator of the G1 to S phase cell cycle transition [<xref rid="mco270560-bib-0067" ref-type="bibr">67</xref>]. In breast cancer, ER&#593; overactivation is a common oncogenic feature, leading to phosphorylation and inactivation of RB protein, thereby releasing E2F transcription factors to promote cell cycle progression and proliferation [<xref rid="mco270560-bib-0068" ref-type="bibr">68</xref>]. Combination of CDK4/6i with endocrine therapy has significantly improved PFS in patients with hormone receptor (+)/HER2(&#8722;) advanced breast cancer by effectively targeting dysregulated cell cycle progression [<xref rid="mco270560-bib-0069" ref-type="bibr">69</xref>, <xref rid="mco270560-bib-0070" ref-type="bibr">70</xref>, <xref rid="mco270560-bib-0071" ref-type="bibr">71</xref>, <xref rid="mco270560-bib-0072" ref-type="bibr">72</xref>]. Evidence indicates that the CDK4/6i abemaciclib promotes lysosomal degradation of B7&#8208;H4, which in turn mitigates B7&#8208;H4&#8208;mediated immunosuppression, suggesting that CDK4/6i may exert immunomodulatory effects and open perspectives for combination with immunotherapy [<xref rid="mco270560-bib-0073" ref-type="bibr">73</xref>].</p><p>In addition, several other signaling pathways have recently attracted attention. For example, RANK signaling can upregulate stemness&#8208;associated genes through the NF&#8208;&#954;B pathway and drive the expansion of breast cancer stem cell populations. RANK plays a dual role in the breast cancer signaling network, acting as a suppressor of early tumor initiation while accelerating malignant progression after tumor formation [<xref rid="mco270560-bib-0074" ref-type="bibr">74</xref>]. In solid tumors, cancer stem cell was first identified and isolated in breast cancer, and it plays critical roles in tumor initiation and progression. Kita&#8208;Kyushu lung cancer antigen&#8208;1 (KK&#8208;LC&#8208;1) has recently been identified as a novel marker of TNBC stem cells, and the &#8220;KK&#8208;LC&#8208;1&#8211;FAT1&#8211;Hippo&#8211;YAP&#8211;ALDH1A1&#8221; axis plays a central role in regulating TNBC stem cells. These offer breast cancer stem cells as potential new targets [<xref rid="mco270560-bib-0075" ref-type="bibr">75</xref>].</p><p>Intracellular signaling pathways in breast cancer do not function in isolation but constitute a highly complex network with extensive crosstalk and feedback regulation. When targeting a single signaling pathway, tumor cells may activate alternative bypass or downstream pathways to evade therapy, leading to drug resistance or substantially reducing treatment responses. Although many critical oncogenic pathways have been identified, predicting individual patient responses to specific pathway inhibitors remains challenging. Future research will require the development of more sensitive and specific biomarkers, combined with noninvasive approaches such as liquid biopsy, to enable dynamic monitoring of pathway activity and parallel evaluation of multiple signaling cascades. The development of tools capable of simultaneously assessing multiple pathway activities and guiding treatment decisions remains a critical challenge.</p></sec><sec id="mco270560-sec-0060"><label>2.4</label><title>TME and Immune Evasion</title><p>TME is a complex ecological system on which tumor cells depend for survival, consisting of tumor cells, immune cells, stromal cells, blood vessels, lymphatic vessels, and extracellular matrix, among others [<xref rid="mco270560-bib-0076" ref-type="bibr">76</xref>]. The composition and function of the TME have a decisive impact on the progression, metastasis, and therapeutic response of breast cancer. Tumor immune evasion is a key mechanism by which tumor cells escape immune surveillance and represents a major obstacle to immunotherapy.</p><p>The TME contains diverse immune cell populations, including tumor&#8208;associated macrophages (TAMs), T cells, B cells, natural killer (NK) cells, myeloid&#8208;derived suppressor cells (MDSCs), and dendritic cells, among others [<xref rid="mco270560-bib-0077" ref-type="bibr">77</xref>]. These immune cells play dual roles in tumor progression, exerting both suppressive and promotive effects, as described by the concept of &#8220;cancer immunoediting&#8221; [<xref rid="mco270560-bib-0078" ref-type="bibr">78</xref>]. TAMs are among the most abundant immune cells in the TME, and their infiltration levels are closely correlated with breast cancer prognosis. Increased M2&#8208;type TAMs often indicate higher grade and poorer survival outcomes [<xref rid="mco270560-bib-0079" ref-type="bibr">79</xref>]. In addition, tumor&#8208;infiltrating lymphocytes, particularly CD8+ T cells, are generally associated with a favorable prognosis. However, TME in breast cancer are often functionally impaired due to suppression by immune checkpoint pathways such as programmed cell death protein 1 (PD&#8208;1)/PD&#8208;L1 [<xref rid="mco270560-bib-0080" ref-type="bibr">80</xref>]. At the same time, immunosuppressive cytokines play crucial roles in breast cancer. For example, IL&#8208;10, TGF&#8208;&#946;, and IL&#8208;35 are widely present in the TME, where they inhibit antitumor immune responses and recruit additional immunosuppressive cells into the TME [<xref rid="mco270560-bib-0081" ref-type="bibr">81</xref>]. Notably, IL&#8208;35 produced by regulatory T cells (Tregs) and breast cancer cells can convert conventional T cells into immunosuppressive Tregs and suppress the secretion of proinflammatory cytokines, thereby facilitating immune evasion [<xref rid="mco270560-bib-0082" ref-type="bibr">82</xref>]. Immune cells and cytokines in breast cancer act synergistically within the TME. Cancer&#8208;associated fibroblasts (CAFs) are the most abundant stromal cell type in the TME and constitute a key component promoting tumor growth, invasion, metastasis, and angiogenesis. On the one hand, CAFs remodel the extracellular matrix, secreting collagen, fibronectin, and other matrix proteins to construct a scaffold that facilitates tumor cell adhesion and migration, thereby establishing a &#8220;tumor&#8208;friendly&#8221; stromal environment [<xref rid="mco270560-bib-0083" ref-type="bibr">83</xref>]. On the other hand, CAFs secrete cytokines, growth factors, and various proangiogenic mediators, inducing proliferation of neighboring endothelial cells and promoting neovascularization, which provides a continuous supply of oxygen and nutrients to breast cancer [<xref rid="mco270560-bib-0084" ref-type="bibr">84</xref>]. Vascular endothelial growth factor (VEGF) is the major angiogenic factor and is frequently overexpressed in breast cancer. Under hypoxic conditions, CAFs upregulate VEGF expression through HIF&#8208;1&#945; signaling, further promoting angiogenesis [<xref rid="mco270560-bib-0085" ref-type="bibr">85</xref>, <xref rid="mco270560-bib-0086" ref-type="bibr">86</xref>]. Aberrant tumor vasculature supplies oxygen and nutrients for metastatic dissemination. CXCL12 secreted by breast cancer CAFs markedly enhances vascular permeability and neovascular formation, facilitating cancer cell intravasation and thus promoting metastasis [<xref rid="mco270560-bib-0087" ref-type="bibr">87</xref>]. Based on these mechanisms, the proangiogenic function of CAFs not only supports the acquisition of sufficient oxygen and nutrients by tumor cells but also provides both structural and signaling support for vascular infiltration and metastatic spread.</p><p>Immune evasion in breast cancer results from the combined effects of cellular components, molecular signaling, and the metabolic milieu through diverse mechanisms. First, tumor cells and immunosuppressive cells in the TME (such as Tregs and MDSCs) can highly express immune checkpoint molecules such as PD&#8208;L1 and CTLA&#8208;4. These molecules bind to corresponding receptors on T cells, suppressing their activation and function, thereby leading to T&#8208;cell exhaustion and immune suppression [<xref rid="mco270560-bib-0088" ref-type="bibr">88</xref>, <xref rid="mco270560-bib-0089" ref-type="bibr">89</xref>]. For example, HDAC2 can upregulate PD&#8208;L1 expression and enhance immune evasion by suppressing T&#8208;cell activity [<xref rid="mco270560-bib-0090" ref-type="bibr">90</xref>]. Breast cancer cells also secrete various chemokines to recruit immunosuppressive cells such as Tregs, MDSCs, and M2&#8208;type TAMs into the TME, thereby establishing an immunosuppressive microenvironment [<xref rid="mco270560-bib-0081" ref-type="bibr">81</xref>]. Moreover, breast cancer stem cells mediate tumor metabolic reprogramming by secreting macrophage migration inhibitory factor, thereby driving immune evasion [<xref rid="mco270560-bib-0091" ref-type="bibr">91</xref>]. Migration inhibitory factor activates the WNT/&#946;&#8208;catenin signaling pathway and upregulates c&#8208;MYC&#8208;mediated transcription of the glycolytic enzyme aldolase C, thereby promoting glycolysis, enhancing tumor growth and metastasis, and driving immune evasion [<xref rid="mco270560-bib-0091" ref-type="bibr">91</xref>].</p><p>Single&#8208;cell and spatial omics technologies have made remarkable progress in revealing TME heterogeneity. These approaches can characterize the molecular features, spatial distribution, and interactions of different cell types within the TME, providing a more comprehensive understanding of how the TME promotes tumor progression and immune evasion [<xref rid="mco270560-bib-0092" ref-type="bibr">92</xref>, <xref rid="mco270560-bib-0093" ref-type="bibr">93</xref>]. Using single&#8208;cell and spatial transcriptomics, recent work has shown that breast cancer cells secrete arginine to drive polyamine biosynthesis and TDG&#8208;mediated epigenetic reprogramming in TAMs, which polarizes them toward a protumor immunosuppressive phenotype and suppresses CD8+ T&#8208;cell activity, thereby playing a critical role in immune evasion [<xref rid="mco270560-bib-0094" ref-type="bibr">94</xref>].</p><p>Despite growing insights into the TME and immune evasion, significant challenges remain. The microenvironment of metastatic lesions differs markedly from that of primary tumors, which explains why immunotherapies effective against primary sites often show limited efficacy in metastases. Understanding site&#8208;specific characteristics of the TME and developing tailored immunotherapeutic strategies will be a key to overcome the clinical barriers in treating metastatic breast cancer.</p></sec></sec><sec id="mco270560-sec-0070"><label>3</label><title>Targeted Therapies for Breast Cancer</title><p>Since the approval of tamoxifen in the 1970s, targeted therapies for breast cancer have advanced over five decades (Figure&#160;<xref rid="mco270560-fig-0002" ref-type="fig">2</xref>). Currently, at least 35 reagents have been approved worldwide, involving endocrine therapies, anti&#8208;HER2 drugs, CDK4/6i, PI3K/AKT/mTOR inhibitors, antibody&#8211;drug conjugates (ADCs), and immunotherapies. By interfering with specific molecular drivers or the TME, these therapies suppress tumor growth and improve survival. In this section, we summarize and discuss the major classes of targeted drugs, outlining their development, clinical impact, and future directions.</p><fig position="float" fig-type="FIGURE" id="mco270560-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Timeline of approval for targeted therapeutic agents in breast cancer. Approved agents are positioned along a horizontal timeline according to their initial regulatory approval year(s). (*Drugs received US FDA's &#8220;accelerated approval&#8221;; T&#8208;DM1, trastuzumab emtansine; T&#8208;DXd, trastuzumab deruxtecan; SG, sacituzumab govitecan; Dato&#8208;DXd, datopotamab deruxtecan; sac&#8208;TMT, sacituzumab tirumotecan).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="MCO2-7-e70560-g005.jpg"/></fig><sec id="mco270560-sec-0080"><label>3.1</label><title>Endocrine Therapy</title><p>Endocrine therapy for breast cancer inhibits tumor growth by blocking the stimulating effect of estrogen on cancer cells. It is the cornerstone of the treatment of hormone receptor&#8208;positive breast cancer, which accounts for the majority of cases. Agents are broadly classified as SERMs, SERDs, and AIs, each with distinct mechanisms and clinical implications.</p><p>Tamoxifen, the prototypical SERM, has long been established as effective in both treatment and prevention of ER&#8208;positive disease, including in pre&#8208; and postmenopausal women [<xref rid="mco270560-bib-0095" ref-type="bibr">95</xref>, <xref rid="mco270560-bib-0096" ref-type="bibr">96</xref>]. Long&#8208;term follow&#8208;up has consistently demonstrated reduced recurrence, yet its use is offset by increased risks of endometrial cancer and venous thromboembolism [<xref rid="mco270560-bib-0097" ref-type="bibr">97</xref>, <xref rid="mco270560-bib-0098" ref-type="bibr">98</xref>]. Recent evidence from the TAM&#8208;01 trial suggests that low&#8208;dose tamoxifen (5&#160;mg daily for 3 years) significantly reduces recurrence of noninvasive disease with a more favorable safety profile, highlighting the need to balance efficacy against toxicity [<xref rid="mco270560-bib-0099" ref-type="bibr">99</xref>]. Two other SERMs, toremifene and raloxifene, also approved for the treatment of breast cancer have shown acceptable efficacy and tolerability in subsequent clinical trials [<xref rid="mco270560-bib-0100" ref-type="bibr">100</xref>, <xref rid="mco270560-bib-0101" ref-type="bibr">101</xref>].</p><p>Fulvestrant is a SERD for endocrine therapy of advanced hormone receptor&#8208;positive breast cancer that demonstrated superior PFS over anastrozole in the Phase III FALCON trial (median PFS 16.6&#160;vs. 13.8 months) [<xref rid="mco270560-bib-0102" ref-type="bibr">102</xref>]. The final OS [median, 44.8 vs. 42.7 months; hazard ratio (HR)&#160;=&#160;0.97; 95% confidence interval (CI) 0.77&#8211;1.21; <italic toggle="yes">p</italic>&#160;=&#160;0.7579] analysis of the FALCON trial showed no significant difference between fulvestrant and anastrozole [<xref rid="mco270560-bib-0103" ref-type="bibr">103</xref>]. However, it is often accompanied by adverse reactions such as hot flushes and arthralgia [<xref rid="mco270560-bib-0102" ref-type="bibr">102</xref>]. These limitations have driven the development of next&#8208;generation oral SERDs with improved bioavailability and convenience.</p><p>AIs act by inhibiting androgen to estrogen conversion. The third&#8208;generation AIs commonly used in breast cancer treatment include anastrozole, exemestane, and letrozole. Due to the role of compensatory physiological regulation, these drugs are contra&#8208;indicated for premenopausal women [<xref rid="mco270560-bib-0104" ref-type="bibr">104</xref>]. The ATAC trial compared the efficacy of anastrozole and tamoxifen in the adjuvant treatment of early breast cancer. The 10&#8208;year follow&#8208;up results showed that anastrozole was more effective and safer than tamoxifen in the long&#8208;term adjuvant treatment of postmenopausal women with ER(+) and/or PR(+) early breast cancer [<xref rid="mco270560-bib-0105" ref-type="bibr">105</xref>]. Exemestane is often used as an alternative treatment for postmenopausal patients with advanced breast cancer after tamoxifen treatment [<xref rid="mco270560-bib-0106" ref-type="bibr">106</xref>]. In premenopausal women, AIs require concomitant ovarian function suppression (OFS) to be effective. Long&#8208;term follow&#8208;up of the SOFT and the TEXT trials demonstrated that OFS combined with either tamoxifen or exemestane significantly improved disease&#8208;free survival (DFS) compared with tamoxifen alone, underscoring the clinical value of ovarian suppression in younger patients at higher risk [<xref rid="mco270560-bib-0107" ref-type="bibr">107</xref>]. Letrozole also has similar biological effects to anastrozole and exemestane. OFS can be achieved by gonadotropin&#8208;releasing hormone (GnRH) agonists, ovariectomy, or ovarian radiotherapy. Common GnRH agonists include goserelin and leuprolide, which are commonly used in ER(+) and/or PR(+) premenopausal women with breast cancer. In the SOFT trial, premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen combined with OFS, or exemestane combined with OFS [<xref rid="mco270560-bib-0108" ref-type="bibr">108</xref>]. After 12 years of long&#8208;term follow&#8208;up, the results showed that compared with tamoxifen monotherapy, OFS combined with tamoxifen had significant improvements in DFS (76.1&#160;vs. 71.9%, HR&#160;=&#160;0.82; 95% CI 0.69&#8211;0.98) and OS (89.0&#160;vs. 86.8%, HR&#160;=&#160;0.78; 95% CI 0.60&#8211;1.01) [<xref rid="mco270560-bib-0108" ref-type="bibr">108</xref>]. The result suggests the long&#8208;term effectiveness of OFS in adjuvant endocrine therapy for premenopausal breast cancer.</p><p>The introduction of oral SERDs represents a major therapeutic advance. Elacestrant is currently the only oral SERD approved for use in ER(+) metastatic breast cancer combined with <italic toggle="yes">ESR1</italic> mutated patients [<xref rid="mco270560-bib-0109" ref-type="bibr">109</xref>]. Improved PFS was observed with Elacestrant compared with standard endocrine monotherapy in patients who progressed after CDK4/6i in the Phase III EMERALD trial, particularly those with <italic toggle="yes">ESR1</italic> mutations [<xref rid="mco270560-bib-0110" ref-type="bibr">110</xref>]. Camizestrant is a next&#8208;generation oral SERD. The latest SERENA&#8208;6 trial data showed that first&#8208;line camizestrant plus a CDK4/6i significantly prolongs median PFS (16.0 vs. 9.2 months, HR&#160;=&#160;0.44; 95% CI 0.31&#8211;0.60; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) compared with continued AIs&#8208;based combination therapy in patients with newly detected <italic toggle="yes">ESR1</italic>&#8208;mutant, ER(+)/HER2(&#8722;) advanced breast cancer [<xref rid="mco270560-bib-0042" ref-type="bibr">42</xref>]. Other agents, such as giredestrant and imlunestrant, are under active Phase III investigation (Table&#160;<xref rid="mco270560-tbl-0001" ref-type="table">1</xref>). Giredestrant and imlunestrant are two additional oral SERDs currently under investigation. They both act by binding to the ER and triggering its degradation. Although the Phase II acelERA BC trial of giredestrant missed statistical significance for its primary endpoint of investigator&#8208;assessed PFS, a favorable benefit trend was observed in patients with <italic toggle="yes">ESR1</italic>&#8208;mutant tumors, the finding that provides a strong rationale for the ongoing Phase III programme [<xref rid="mco270560-bib-0111" ref-type="bibr">111</xref>]. The Phase III EMBER&#8208;3 trial demonstrated that imlunestrant monotherapy significantly prolonged PFS versus standard&#8208;of&#8208;care in patients harboring <italic toggle="yes">ESR1</italic> mutations, and that the imlunestrant&#8211;abemaciclib combination improved PFS irrespective of <italic toggle="yes">ESR1</italic> mutation status [<xref rid="mco270560-bib-0112" ref-type="bibr">112</xref>]. Novel oral SERDs, which are currently a major focus of breast&#8208;cancer drug development, illustrate a paradigm shift. But their ultimate place in therapy will depend on whether PFS gains translate into durable survival improvements and whether tolerability profiles support long&#8208;term use.</p><table-wrap position="float" id="mco270560-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Emerging target drugs for breast cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr><th rowspan="2" align="left" colspan="1">Target molecule</th><th rowspan="2" align="center" colspan="1">Agents</th><th rowspan="2" align="center" colspan="1">Mechanism</th><th colspan="2" style="border-bottom:solid 1px #000000" align="center" rowspan="1">Current clinical trial stage</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" rowspan="1" colspan="1">Ongoing trials, Phase</th><th align="center" rowspan="1" colspan="1">Ongoing/all</th></tr></thead><tbody><tr><td rowspan="8" align="left" colspan="1">ER</td><td align="center" rowspan="1" colspan="1">Lasofoxifene</td><td align="center" rowspan="1" colspan="1">
<p>In bone tissue: activating ER, suppressing osteoclasts, and stimulating osteoblasts</p>
<p>In breast tissue: binding to the ER and blocks the estrogen signaling pathway (especially in ESR1 mutant ER+ breast cancer)</p>
</td><td align="center" rowspan="1" colspan="1">
<p>ELAINE I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03781063">NCT03781063</ext-link>), II</p>
<p>ELAINE III (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05696626">NCT05696626</ext-link>), III</p>
</td><td align="center" rowspan="1" colspan="1">SERMs: 2/3</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Camizestrant</p>
<p>(AZD9833)</p>
</td><td align="center" rowspan="1" colspan="1">Binding to the ER and induces a conformational change that results in the degradation of the receptor</td><td align="center" rowspan="1" colspan="1">
<p>CAMBRIA&#8208;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05952557">NCT05952557</ext-link>), III</p>
<p>CAMBRIA&#8208;1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05774951">NCT05774951</ext-link>), III</p>
<p>EvoPAR&#8208;BR01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06380751">NCT06380751</ext-link>), III</p>
<p>SERENA&#8208;1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03616587">NCT03616587</ext-link>), I</p>
<p>SERENA&#8208;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04214288">NCT04214288</ext-link>), II</p>
<p>SERENA&#8208;4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04711252">NCT04711252</ext-link>), III</p>
<p>SERENA&#8208;6 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04964934">NCT04964934</ext-link>), III</p>
</td><td rowspan="3" align="center" colspan="1">Oral SERDs: 21/27</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Giredestrant</p>
<p>(GDC&#8208;9545)</p>
</td><td align="center" rowspan="1" colspan="1">Binding to the ER, induces a conformational change that facilitates ubiquitin&#8211;ligase recognition and tagging of the receptor, leading to ER protein degradation via the proteasomal pathway</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03332797">NCT03332797</ext-link>, Ia/Ib</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07100106">NCT07100106</ext-link>, Ib/II</p>
<p>Neo&#8208;AGILE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06259929">NCT06259929</ext-link>), II</p>
<p>PREcoopERA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05896566">NCT05896566</ext-link>), II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04576455">NCT04576455</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04961996">NCT04961996</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04546009">NCT04546009</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05296798">NCT05296798</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06065748">NCT06065748</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05306340">NCT05306340</ext-link>, III</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Imlunestrant</p>
<p>(LY3484356)</p>
</td><td align="center" rowspan="1" colspan="1">Competitively binding the ER, thereby inducing conformational changes and subsequent degradation of ER.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05509790">NCT05509790</ext-link>, I</p>
<p>EMBER (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04188548">NCT04188548</ext-link>), I</p>
<p>EMBER&#8208;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04975308">NCT04975308</ext-link>), III</p>
<p>EMBER&#8208;4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05514054">NCT05514054</ext-link>), III</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Vepdegestrant</p>
<p>(ARV&#8208;471)</p>
</td><td align="center" rowspan="1" colspan="1">Harnessing the ubiquitin&#8211;proteasome system to induce direct ubiquitination and subsequent degradation of ER</td><td align="center" rowspan="1" colspan="1">
<p>TACTIVE&#8208;E (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501769">NCT05501769</ext-link>), I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04072952">NCT04072952</ext-link>, I/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06206837">NCT06206837</ext-link>, Ib/II</p>
<p>TACTIVE&#8208;U:Sub&#8208;Study A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05548127">NCT05548127</ext-link>), Ib/II</p>
<p>TACTIVE&#8208;U:Sub&#8208;Study B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05573555">NCT05573555</ext-link>), Ib/II</p>
<p>TACTIVE&#8208;U:Sub&#8208;Study C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06125522">NCT06125522</ext-link>), Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05549505">NCT05549505</ext-link>, II</p>
<p>VERITAC&#8208;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05654623">NCT05654623</ext-link>), III</p>
<p>VERITAC&#8208;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05909397">NCT05909397</ext-link>), III</p>
</td><td align="center" rowspan="1" colspan="1">PROTAC: 9/11</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Palazestrant</p>
<p>(OP&#8208;1250)</p>
</td><td align="center" rowspan="1" colspan="1">Blocking both transcriptional activation function domains, AF1 and AF2, required for the estradiol&#8208;generated transcriptional activity of ER</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05266105">NCT05266105</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05508906">NCT05508906</ext-link>, Ib</p>
<p>OPERA&#8208;01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06016738">NCT06016738</ext-link>), III</p>
<p>OPERA&#8208;02 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07085767">NCT07085767</ext-link>), III</p>
</td><td align="center" rowspan="1" colspan="1">CERAN: 4/5</td></tr><tr><td align="center" rowspan="1" colspan="1">HRS8807</td><td align="center" rowspan="1" colspan="1">Binding to the ER, inhibiting both ligand&#8208;dependent and potentially ligand&#8208;independent signaling pathways</td><td align="center" rowspan="1" colspan="1"/><td rowspan="2" align="center" colspan="1">SERCA: 2/4</td></tr><tr><td align="center" rowspan="1" colspan="1">H3B&#8208;6545</td><td align="center" rowspan="1" colspan="1">Inactivating both wild&#8208;type and mutant ER&#945; by targeting C530 and enforcing antagonist conformation</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04568902">NCT04568902</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04288089">NCT04288089</ext-link>, I</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">GnRH receptor</td><td align="center" rowspan="1" colspan="1">Triptorelin</td><td align="center" rowspan="1" colspan="1">First stimulating and then suppressing the pituitary&#8211;gonadal axis, achieving pharmacological castration</td><td align="center" rowspan="1" colspan="1">
<p>SOLTI&#8208;2104 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05982093">NCT05982093</ext-link>), II</p>
<p>ESCALATE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06225284">NCT06225284</ext-link>), II</p>
<p>OFSET (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05879926">NCT05879926</ext-link>), III</p>
<p>ProFertil (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05328258">NCT05328258</ext-link>), III</p>
</td><td align="center" rowspan="1" colspan="1">OFS: 4/24</td></tr><tr><td rowspan="7" align="left" colspan="1">HER&#8208;2</td><td align="center" rowspan="1" colspan="1">BNT&#8208;323</td><td align="center" rowspan="1" colspan="1">Involving an antibody that binds to HER2 receptors on cancer cells, delivering a topoisomerase&#8208;1 inhibitor payload into the cell to destroy it</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06827236">NCT06827236</ext-link>, I/II</td><td align="center" rowspan="1" colspan="1">HER2 mAb: 1/1</td></tr><tr><td align="center" rowspan="1" colspan="1">BNT&#8208;323/DB&#8208;1303</td><td align="center" rowspan="1" colspan="1">An ADC that targets HER2&#8208;expressing cancer cells by using a humanized monoclonal antibody to deliver a topoisomerase I inhibitor drug directly into the cancer cells, leading to their destruction</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05150691">NCT05150691</ext-link>, I/IIa</p>
<p>Dynasty&#8208;Breast01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06265428">NCT06265428</ext-link>), III</p>
<p>Dynasty&#8208;Breast02 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06018337">NCT06018337</ext-link>), III</p>
</td><td rowspan="5" align="center" colspan="1">ADCs(HER2&#8208;targeted): 50/60</td></tr><tr><td align="center" rowspan="1" colspan="1">FS&#8208;1502</td><td align="center" rowspan="1" colspan="1">A HER2&#8208;targeting ADC comprising a cancer&#8208;selective cleavable &#946;&#8208;glucuronide linker, an anti&#8208;HER2 antibody derived from trastuzumab, and an antimitotic agent, monomethyl auristatin F (MMAF), which inhibits tubulin polymerization</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05755048">NCT05755048</ext-link>, III</td></tr><tr><td align="center" rowspan="1" colspan="1">ARX&#8208;788</td><td align="center" rowspan="1" colspan="1">An ADC consisting of a HER2&#8208;targeting antibody site&#8208;specifically conjugated with a potent antitubulin cytotoxic drug&#8208;linker, AS269; The site&#8208;specific conjugation is achieved by first incorporating the nonnatural amino acid, para&#8208;acetyl phenylalanine (pAF), into the antibody, followed by covalent conjugation of AS269 to the pAF to form a highly stable oxime bond resulting in a DAR 2 ADC.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06578286">NCT06578286</ext-link>, II</p>
<p>ACE&#8208;Breast&#8208;03 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04829604">NCT04829604</ext-link>), II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04983121">NCT04983121</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06224673">NCT06224673</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06663748">NCT06663748</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05426486">NCT05426486</ext-link>, II/III</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Zanidatamab</p>
<p>(ZW25)</p>
</td><td align="center" rowspan="1" colspan="1">Binding to HER2 across a range of expression levels, formation of receptor clusters, and receptor internalization resulting in HER2 downregulation, inhibits growth factor&#8208;dependent and growth factor&#8208;independent tumour&#8208;cell proliferation and activates immune&#8208;mediated responses.</td><td align="center" rowspan="1" colspan="1">
<p>EmpowHER 208 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07102381">NCT07102381</ext-link>), II</p>
<p>DiscovHER PAN&#8208;206 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06695845">NCT06695845</ext-link>), II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05035836">NCT05035836</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06435429">NCT06435429</ext-link>, III</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">SHR&#8208;A1811</td><td align="center" rowspan="1" colspan="1">Comprising a humanized HER2&#8208;directed mAb (trastuzumab) conjugated to DNA topoisomerase I inhibitors (SHR169265) via cleavable tetrapeptide&#8208;based linkers</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07177950">NCT07177950</ext-link>, I/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05911958">NCT05911958</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07129187">NCT07129187</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06788197">NCT06788197</ext-link>, Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05353361">NCT05353361</ext-link>, Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05845138">NCT05845138</ext-link>, Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07111832">NCT07111832</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06126640">NCT06126640</ext-link>, III</p>
<p>&#8230;</p>
<p>A total of 36 trials</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">ZN&#8208;A&#8208;1041</td><td align="center" rowspan="1" colspan="1">Binding to and inhibit the HER2 protein. By blocking HER2's activity, it inhibits tumor cell growth.</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05593094">NCT05593094</ext-link>, I</td><td align="center" rowspan="1" colspan="1">TKIs: 1/2</td></tr><tr><td align="left" rowspan="1" colspan="1">CDK2/4/6</td><td align="center" rowspan="1" colspan="1">RGT&#8208;419B</td><td align="center" rowspan="1" colspan="1">Targeting and inhibiting CDK2, CDK4, and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase and prevents CDK&#8208;mediated G1&#8208;S&#8208;phase transition.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06299124">NCT06299124</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05304962">NCT05304962</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07100106">NCT07100106</ext-link>, Ib/II</p>
</td><td rowspan="4" align="center" colspan="1">CDKI: 15/19</td></tr><tr><td align="left" rowspan="1" colspan="1">CDK4/6</td><td align="center" rowspan="1" colspan="1">Trilaciclib</td><td align="center" rowspan="1" colspan="1">A short acting inhibitor of CDK4/6; trilaciclib causes transient G1 cell cycle arrest in hematopoietic cells protecting them against the myelosuppression caused by cytotoxic antineoplastic medications.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05862610">NCT05862610</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06955156">NCT06955156</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06297811">NCT06297811</ext-link>, II</p>
<p>SMA&#8208;BC&#8208;002 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05978648">NCT05978648</ext-link>), II</p>
<p>ToPCourT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06027268">NCT06027268</ext-link>), II</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CDK4</td><td align="center" rowspan="1" colspan="1">
<p>Atirmociclib</p>
<p>(PF&#8208;07220060)</p>
</td><td align="center" rowspan="1" colspan="1">Targeting the CDK4 kinase, rendering the retinoblastoma (Rb)/E2F transcription system inactive, which ultimately leads to cell cycle arrest in the G1 phase</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04557449">NCT04557449</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05262400">NCT05262400</ext-link>, Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06206837">NCT06206837</ext-link>, Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06465368">NCT06465368</ext-link>, II</p>
<p>FOURLIGHT&#8208;1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06105632">NCT06105632</ext-link>), II</p>
<p>FourLight&#8208;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06760637">NCT06760637</ext-link>), III</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CDK2</td><td align="center" rowspan="1" colspan="1">
<p>Tegtociclib</p>
<p>(PF&#8208;07104091)</p>
</td><td align="center" rowspan="1" colspan="1">Selectively binding to, and inhibiting the activity of CDK2, which may lead to cell cycle arrest through reduced phosphorylation of Rb, and other phosphotargets</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04553133">NCT04553133</ext-link>, I/IIa</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05262400">NCT05262400</ext-link>, Ib/II</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PARP1/2/3</td><td align="center" rowspan="1" colspan="1">
<p>Rucaparib</p>
<p>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG014699">AG014699</ext-link>)</p>
</td><td align="center" rowspan="1" colspan="1">Inhibiting PARP1, PARP2, and PARP3; inhibiting PARP traps the enzyme on damaged DNA, halting the repair process and forming toxic PARP&#8211;DNA complexes</td><td align="center" rowspan="1" colspan="1"/><td rowspan="6" align="center" colspan="1">PARPi: 14/58</td></tr><tr><td align="left" rowspan="1" colspan="1">PARP1/2</td><td align="center" rowspan="1" colspan="1">
<p>Veliparib</p>
<p>(ABT&#8208;888)</p>
</td><td align="center" rowspan="1" colspan="1">Working by inhibiting PARP enzymes, particularly PARP1 and PARP2; this inhibition causes an accumulation of DNA damage in cancer cells, leading to cell cycle arrest and apoptosis (cell death).</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01351909">NCT01351909</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01251874">NCT01251874</ext-link>, I</p>
</td></tr><tr><td rowspan="3" align="left" colspan="1">PARP1</td><td align="center" rowspan="1" colspan="1">
<p>Saruparib</p>
<p>(AZD5305)</p>
</td><td align="center" rowspan="1" colspan="1">Selectively targeting and binding to PARP and prevents PARP&#8208;mediated DNA repair of single&#8208;strand DNA breaks via the base&#8211;excision repair pathway; this enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis.</td><td align="center" rowspan="1" colspan="1">
<p>PETRA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04644068">NCT04644068</ext-link>), I/IIa</p>
<p>EvoPAR&#8208;BR01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06380751">NCT06380751</ext-link>), III</p>
<p>EvoPAR&#8208;PR02 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06952803">NCT06952803</ext-link>), III</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AZD9574</td><td align="center" rowspan="1" colspan="1">By selectively binding to and &#8220;trapping&#8221; PARP1 on damaged DNA, AZD9574 prevents base excision repair (BER), leading to the accumulation of DNA strand breaks and genomic instability, ultimately triggering cancer cell death (apoptosis).</td><td align="center" rowspan="1" colspan="1">CERTIS1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05417594">NCT05417594</ext-link>), I/IIa</td></tr><tr><td align="center" rowspan="1" colspan="1">Fluzoparib</td><td align="center" rowspan="1" colspan="1">Inhibiting PARP enzymes and induces DNA&#8208;double strands breaks, G2/M arrest and apoptosis in homologous recombination repair&#8208;deficient cells</td><td align="center" rowspan="1" colspan="1">
<p>BCTOP&#8208;L&#8208;A01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05891093">NCT05891093</ext-link>), III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07162051">NCT07162051</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05834582">NCT05834582</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05656131">NCT05656131</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06561022">NCT06561022</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06254066">NCT06254066</ext-link>, II</p>
<p>IMPARP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05761470">NCT05761470</ext-link>), II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06255392">NCT06255392</ext-link>, III</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PARP1/2 + Tankyrase 1/2</td><td align="center" rowspan="1" colspan="1">
<p>Stenoparib</p>
<p>(E7449/2X&#8208;121)</p>
</td><td align="center" rowspan="1" colspan="1">Working through a dual&#8208;action mechanism, inhibiting both PARP to disrupt DNA repair in tumor cells and tankyrase enzymes to interfere with the Wnt/&#946;&#8208;catenin signaling pathway</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Class I PI3K + mTORC1/2</td><td align="center" rowspan="1" colspan="1">
<p>Gedatolisib</p>
<p>(PF&#8208;05212384)</p>
</td><td align="center" rowspan="1" colspan="1">A pan&#8208;class I PI3K and mTOR inhibitor that works by binding to and inhibiting the PI3K and mTOR kinases, which are involved in cell growth, proliferation, and survival pathways</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03911973">NCT03911973</ext-link>, II</p>
<p>VIKTORIA&#8208;1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501886">NCT05501886</ext-link>), III</p>
<p>VIKTORIA&#8208;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06757634">NCT06757634</ext-link>), III</p>
</td><td rowspan="5" align="center" colspan="1">PI3K/AKT/mTOR Inhibitors: 11/32</td></tr><tr><td align="left" rowspan="1" colspan="1">Class I PI3K</td><td align="center" rowspan="1" colspan="1">MEN1611</td><td align="center" rowspan="1" colspan="1">Inhibiting the p110&#945; isoform of PI3K, inducing a dose&#8208;dependent depletion of the p110&#945; protein, and modulating the tumor microenvironment by promoting a proinflammatory macrophage phenotype</td><td align="center" rowspan="1" colspan="1">SABINA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05810870">NCT05810870</ext-link>), II</td></tr><tr><td align="left" rowspan="1" colspan="1">PI3K&#945;</td><td align="center" rowspan="1" colspan="1">STX&#8208;478</td><td align="center" rowspan="1" colspan="1">Binding to a distinct allosteric site on the mutant enzyme, preventing its function and leading to tumor regression without causing the severe metabolic side effects (like hyperglycemia) associated with earlier, nonselective PI3K&#945; inhibitors</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05768139">NCT05768139</ext-link>, I/II</td></tr><tr><td align="left" rowspan="1" colspan="1">PI3K&#948;/&#947;</td><td align="center" rowspan="1" colspan="1">
<p>Tenalisib</p>
<p>(RP6530)</p>
</td><td align="center" rowspan="1" colspan="1">Inhibiting the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT&#8208;mediated signaling pathway; this may lead to a reduction in cellular proliferation in PI3K delta/gamma&#8208;expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms.</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06189209">NCT06189209</ext-link>, II</td></tr><tr><td align="left" rowspan="1" colspan="1">AKT1/2/3</td><td align="center" rowspan="1" colspan="1">
<p>Ipatasertib</p>
<p>(GDC&#8208;0068)</p>
</td><td align="center" rowspan="1" colspan="1">Binding to and inhibits the activity of Akt in a non&#8208;ATP&#8208;competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis</td><td align="center" rowspan="1" colspan="1">
<p>TAKTIC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03959891">NCT03959891</ext-link>), I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05554380">NCT05554380</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04920708">NCT04920708</ext-link>, II</p>
<p>BARBICAN (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05498896">NCT05498896</ext-link>), II</p>
<p>FINER (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04650581">NCT04650581</ext-link>), III</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TROP&#8208;2</td><td align="center" rowspan="1" colspan="1">SKB264</td><td align="center" rowspan="1" colspan="1">Delivering a cytotoxic payload, a belotecan&#8208;derived topoisomerase inhibitor, directly to cancer cells, inhibiting tumor growth and proliferation; upon cellular uptake, the linker releases the toxin, which then exerts its cytotoxic effect.</td><td align="center" rowspan="1" colspan="1">
<p>MK&#8208;2870&#8208;001 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04152499">NCT04152499</ext-link>), I/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07054242">NCT07054242</ext-link>, II</p>
<p>NeoSaciA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07109284">NCT07109284</ext-link>), II</p>
<p>SHINE&#8208;HER (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07182721">NCT07182721</ext-link>), II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07071337">NCT07071337</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05347134">NCT05347134</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06081959">NCT06081959</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06279364">NCT06279364</ext-link>, III</p>
</td><td rowspan="2" align="center" colspan="1">ADCs (non&#8208;HER2&#8208;targeted): 16/20</td></tr><tr><td align="left" rowspan="1" colspan="1">HER&#8208;3</td><td align="center" rowspan="1" colspan="1">Patritumab deruxtecan (HER3&#8208;DXd)</td><td align="center" rowspan="1" colspan="1">Binding to HER3&#8208;expressing tumor cells, delivering a topoisomerase I inhibitor payload that induces targeted cell death</td><td align="center" rowspan="1" colspan="1">
<p>MK&#8208;1022&#8208;009 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06686394">NCT06686394</ext-link>), Ib/II</p>
<p>ICARUSBREAST02 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06298084">NCT06298084</ext-link>), Ib/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04965766">NCT04965766</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06172478">NCT06172478</ext-link>, II</p>
<p>MK&#8208;1022&#8208;010 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06797635">NCT06797635</ext-link>), II</p>
<p>VALENTINE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05569811">NCT05569811</ext-link>), II</p>
<p>TUXEDO&#8208;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05865990">NCT05865990</ext-link>), II</p>
<p>MK&#8208;1022&#8208;016 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07060807">NCT07060807</ext-link>), III</p>
</td></tr><tr><td rowspan="6" align="left" colspan="1">PD&#8208;1</td><td align="center" rowspan="1" colspan="1">
<p>Pucotenlimab</p>
<p>(HX008)</p>
</td><td align="center" rowspan="1" colspan="1">Binding to PD&#8208;1 and blocks its interaction with its ligands, PD&#8208;L1 and PD&#8208;L2, thereby restoring the ability of immune cells to target cancer cells</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06889610">NCT06889610</ext-link>, II</td><td rowspan="10" align="center" colspan="1">ICIs: 69/170</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Dostarlimab</p>
<p>(TSR&#8208;042)</p>
</td><td align="center" rowspan="1" colspan="1">An anti&#8208;PD&#8208;1 monoclonal antibody that binds with high affinity to the PD&#8208;1 receptor and effectively blocks interaction with PD&#8208;L1 and PD&#8208;L2, restoring cytotoxic T&#8208;cell activity and freeing the T&#8208;cell to kill tumour cells</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04673448">NCT04673448</ext-link>, Ib</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04584255">NCT04584255</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04837209">NCT04837209</ext-link>, II</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<p>Cemiplimab</p>
<p>(REGN2810)</p>
</td><td align="center" rowspan="1" colspan="1">Blocking the PD&#8208;1 receptor, preventing binding and activation of PD&#8208;L1 and PD&#8208;L2; the inhibition of the PD&#8208;1 pathway results in immune checkpoint enhancing T&#8208;cell&#8208;mediated immune response leading to T&#8208;cell activation and proliferation against tumor cells.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05064085">NCT05064085</ext-link>, I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06860815">NCT06860815</ext-link>, II</p>
<p>CemiHALT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04243616">NCT04243616</ext-link>), II</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Sintilimab</td><td align="center" rowspan="1" colspan="1">A fully human IgG4 monoclonal antibody that binds to programmed cell death receptor&#8208;1 (PD&#8208;1), thereby blocking the interaction of PD&#8208;1 with its ligands (PD&#8208;L1 and PL&#8208;L2) and consequently helping to restore the endogenous antitumor T&#8208;cell response.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06308939">NCT06308939</ext-link>, II</p>
<p>NeoSACT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04877821">NCT04877821</ext-link>), II</p>
<p>NeoSTEP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05843292">NCT05843292</ext-link>), IV</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Camrelizumab</td><td align="center" rowspan="1" colspan="1">Blocking the PD&#8208;1 pathway, which allows tumors to evade the immune system; as a humanized monoclonal antibody, it binds to PD&#8208;1 receptors on immune cells, preventing tumor cells from interacting with their PD&#8208;L1 ligands.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04395989">NCT04395989</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06313463">NCT06313463</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05760378">NCT05760378</ext-link>, III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06889688">NCT06889688</ext-link>, III</p>
<p>BCTOP&#8208;T&#8208;N01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05999149">NCT05999149</ext-link>), III</p>
<p>&#8230;</p>
<p>A total of 28 trials</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Nivolumab</td><td align="center" rowspan="1" colspan="1">Binding to and blocking the protein PD&#8208;1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system; this allows the immune system to attack the cancer cells.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03650894">NCT03650894</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03789110">NCT03789110</ext-link>, II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03414684">NCT03414684</ext-link>, II</p>
<p>&#8230;</p>
<p>A total of 27 trials</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CTLA&#8208;4</td><td align="center" rowspan="1" colspan="1">Tremelimumab</td><td align="center" rowspan="1" colspan="1">An anti&#8208;CTLA4 monoclonal antibody that blocks the inhibitory signal resulting from CTLA&#8208;4 binding to CD80/86, leading to prolongation and enhancement of T&#8208;cell activation and expansion.</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">TIGIT</td><td align="center" rowspan="1" colspan="1">Tiragolumab</td><td align="center" rowspan="1" colspan="1">Targeting T&#8208;cell immunoreceptor on activated T&#8208;cell and NK cell subsets and prevents interaction with CD155 (poliovirus receptor) to limit cellular proliferation, effector cytokine production, and killing of target tumor cells.</td><td align="center" rowspan="1" colspan="1">
<p>SKYLINE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06175390">NCT06175390</ext-link>), II</p>
<p>TONIC&#8208;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06342037">NCT06342037</ext-link>), II</p>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Domvanalimab</td><td align="center" rowspan="1" colspan="1">An Fc&#8208;silent humanized IgG1 anti&#8208;TIGIT monoclonal antibody that blocks interaction between TIGIT and its ligand CD155, thus reducing immunosuppression of T&#8208;cells and NK cells, promoting antitumor activity.</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07134556">NCT07134556</ext-link>, II</td></tr><tr><td align="left" rowspan="1" colspan="1">LAG&#8208;3</td><td align="center" rowspan="1" colspan="1">Relatlimab</td><td align="center" rowspan="1" colspan="1">Blocking the lymphocyte&#8208;activation gene 3 (LAG&#8208;3) pathway; by binding to and inhibiting the LAG&#8208;3 receptor on T cells, relatlimab prevents LAG&#8208;3 from interacting with its ligands.</td><td align="center" rowspan="1" colspan="1">SIMONE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06963905">NCT06963905</ext-link>), Ib</td></tr><tr><td align="left" rowspan="1" colspan="1">GRPR</td><td align="center" rowspan="1" colspan="1">Lu&#8208;NeoB ([177Lu]Lu&#8208;NeoB/177Lu&#8208;NeoBOMB1)</td><td align="center" rowspan="1" colspan="1">Targeting and binding to GRPRs present on certain tumor cells; upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR&#8208;expressing cells.</td><td align="center" rowspan="1" colspan="1">
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05870579">NCT05870579</ext-link>, I</p>
<p>NeoB&#8208;Cap1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06247995">NCT06247995</ext-link>), I/II</p>
</td><td align="center" rowspan="1" colspan="1">innovative technology: 2/2</td></tr></tbody></table><table-wrap-foot><fn id="mco270560-tbl1-note-0001"><p>All trials in the table were retrieved from ClinicalTrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">https://clinicaltrials.gov/</ext-link>, accessed on September 20, 2025).</p></fn><fn id="mco270560-tbl1-note-0002"><p>
<italic toggle="yes">Abbreviations</italic>: estrogen receptor (ER); selective estrogen receptor modulators (SERMs); selective estrogen receptor degraders (SERDs); proteolysis&#8208;targeting chimera (PROTAC); complete estrogen receptor antagonist (CERAN); selective estrogen receptor covalent antagonist (SERCA); ovarian function suppression (OFS); human epidermal growth factor receptor 2 (HER2); antibody&#8211;drug conjugates (ADCs); tyrosine kinase inhibitor (TKI); cyclin&#8208;dependent kinase (CDK); poly (ADP&#8208;ribose) polymerase (PARP); phosphatidylinositol 3&#8208;kinase&#8211;protein kinase B&#8211;mechanistic target of rapamycin signaling pathway (PI3K&#8211;AKT&#8211;MTOR); human epidermal growth factor receptor 3 (HER3); programmed cell death protein 1 (PD&#8208;1); programmed death&#8208;ligand 1/2 (PD&#8208;L1/2); immune checkpoint inhibitors (ICIs); cytotoxic T&#8208;lymphocyte antigen 4 (CTLA&#8208;4); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation gene&#8208;3 (LAG&#8208;3); gastrin&#8208;releasing peptide receptor (GRPR).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="mco270560-sec-0090"><label>3.2</label><title>HER2&#8208;Targeted Therapies</title><p>The identification of HER2 (also known as ERBB2) marked a major advance in breast cancer therapeutics. Targeted strategies, including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and ADCs, have transformed outcomes for patients with HER2(+) disease. Trastuzumab is the first humanized monoclonal antibody targeting HER2. The research on trastuzumab has expanded from the initial metastatic breast cancer to the neoadjuvant and adjuvant treatment of early breast cancer [<xref rid="mco270560-bib-0113" ref-type="bibr">113</xref>, <xref rid="mco270560-bib-0114" ref-type="bibr">114</xref>]. Treating with trastuzumab is associated with cardiac toxicity, necessitating monitoring of left ventricular ejection fraction [<xref rid="mco270560-bib-0115" ref-type="bibr">115</xref>]. However, many patients ultimately experience resistance and relapse [<xref rid="mco270560-bib-0116" ref-type="bibr">116</xref>].</p><p>The development of pertuzumab and its combination with trastuzumab significantly improved treatment efficacy [<xref rid="mco270560-bib-0116" ref-type="bibr">116</xref>]. The Phase III clinical trial of CLEOPATRA showed that, compared with trastuzumab&#160;+&#160;docetaxel, the treatment of HER2(+) metastatic breast cancer with pertuzumab combined with trastuzumab and docetaxel significantly prolonged the median PFS and OS of patients with HER2(+) metastatic breast cancer [<xref rid="mco270560-bib-0117" ref-type="bibr">117</xref>, <xref rid="mco270560-bib-0118" ref-type="bibr">118</xref>]. Yet, in early breast cancer, the APHINITY trial showed only a modest absolute benefit in invasive DFS (iDFS; 4.9% improvement in node&#8208;positive patients; HR 0.72, 95% CI 0.60&#8211;0.87) without OS advantage, demonstrating the challenges in achieving durable benefit in the curative setting [<xref rid="mco270560-bib-0119" ref-type="bibr">119</xref>].</p><p>Beyond trastuzumab and pertuzumab, other HER2&#8208;directed antibodies are under investigation. In the Phase III SOPHIA trial, margetuximab plus chemotherapy modestly improved PFS compared with trastuzumab&#8208;based therapy [<xref rid="mco270560-bib-0120" ref-type="bibr">120</xref>]. Further exploration analyses suggest differential efficacy by CD16A genotype [<xref rid="mco270560-bib-0121" ref-type="bibr">121</xref>]. These findings highlight the potential importance of host immunogenetic factors in optimizing antibody therapy.</p><p>Small&#8208;molecule TKIs have further expanded therapeutic options. Lapatinib is an oral TKI that can dual inhibit EGFR (HER1) and HER2 to exert antitumor activity [<xref rid="mco270560-bib-0116" ref-type="bibr">116</xref>]. Lapatinib has unique advantages in the treatment of recurrent HER2(+) breast cancer because it can pass through the blood&#8208;brain barrier, where up to 50% of patients with HER2(+) BC develop brain metastases [<xref rid="mco270560-bib-0116" ref-type="bibr">116</xref>]. The Phase II study LANDSCAPE results support the combination of lapatinib and capecitabine as a first&#8208;line treatment for brain metastasis of HER2(+) breast cancer [<xref rid="mco270560-bib-0122" ref-type="bibr">122</xref>]. Neratinib, an irreversible pan&#8208;HER TKI, has shown sustained activity in HER2&#8208;mutated and amplified tumors [<xref rid="mco270560-bib-0123" ref-type="bibr">123</xref>]. The Phase III NALA trial demonstrated that, similar to lapatinib, the combination of naratinib and capecitabine improved the prognosis of HER2(+) metastatic breast cancer [<xref rid="mco270560-bib-0124" ref-type="bibr">124</xref>]. More recently, the HER2&#8208;selective TKI tucatinib has demonstrated superior activity with favorable tolerability. In the HER2CLIMB trial, the addition of tucatinib to capecitabine and trastuzumab significantly prolonged PFS (7.8&#160;vs. 5.6 months, HR 0.54) and OS (21.9&#160;vs. 17.4 months, HR 0.66), including in patients with brain metastases, establishing this regimen as a new standard [<xref rid="mco270560-bib-0125" ref-type="bibr">125</xref>]. Ongoing basket trials are assessing tucatinib activity in HER2&#8208;mutant cancers beyond breast cancer (Table&#160;<xref rid="mco270560-tbl-0001" ref-type="table">1</xref>).</p><p>ADCs have greatly promoted the treatment of HER2(+) breast cancer. Ado&#8208;trastuzumab emtansine (T&#8208;DM1) is the first developed anti&#8208;HER2 ADC. It improved both PFS (9.6&#160;vs. 6.4 months, HR 0.65) and OS (30.9&#160;vs. 25.1 months, HR 0.68) in the EMILIA trial, compared with lapatinib and capecitabine [<xref rid="mco270560-bib-0126" ref-type="bibr">126</xref>]. In the KAMILLA trial, T&#8208;DM1 also showed its effectiveness in a subgroup of brain metastasis patients. Another ADC, T&#8208;DXd, has demonstrated superior potency and broader applicability. In the DESTINY&#8211;Breast03 trial, T&#8208;DXd significantly improved outcomes in patients previously treated with trastuzumab and T&#8208;DM1, with a response rate of 60.9% [<xref rid="mco270560-bib-0127" ref-type="bibr">127</xref>]. DESTINY&#8211;Breast12 prospective study on T&#8208;DXd shows significant and persistent intracranial activity of T&#8208;DXd [<xref rid="mco270560-bib-0128" ref-type="bibr">128</xref>]. Importantly, the DESTINY&#8211;Breast06 study extended these benefits to patients with HER2&#8208;low or ultralow tumors (median PFS 13.2&#160;vs. 8.1 months, HR 0.62), leading to regulatory approval and redefining the biological and therapeutic boundaries of HER2 [<xref rid="mco270560-bib-0129" ref-type="bibr">129</xref>]. The results also greatly promoted the therapeutic advances to the HER2&#8208;low subtype. The safety and efficacy of T&#8208;DXd remain to be fully elucidated. As interstitial lung disease remains a safety concern, careful monitoring is needed. Ongoing trials such as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06551220">NCT06551220</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06429761">NCT06429761</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06210776">NCT06210776</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07030569">NCT07030569</ext-link> may provide valuable insights.</p><p>Disitamab vedotin is the first next&#8208;generation agent that is expanding therapeutic options. This agent combines direct cytotoxicity with immune&#8208;mediated activity and has shown promising efficacy in both HER2(+) and HER2(&#8722;) advanced breast cancer, with objective response rates (ORR) of 42.9 and 33.3%, respectively [<xref rid="mco270560-bib-0130" ref-type="bibr">130</xref>]. Phase III studies such as ROSY (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05904964">NCT05904964</ext-link>) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06278870">NCT06278870</ext-link> are underway to clarify its role.</p><p>Taken together, HER2&#8208;directed therapies now span monoclonal antibodies, TKIs, and ADCs, achieving substantial improvements in survival for many patients. However, resistance and relapse are common, durable benefit in early&#8208;stage disease is uncertain, and safety profiles require vigilance. Future advantages may rely on integrating these agents, refining patient selection through molecular and immunogenetic markers, and extending benefits to HER2&#8208;low and HER2&#8208;mutant subsets.</p></sec><sec id="mco270560-sec-0100"><label>3.3</label><title>Targeting Cell Cycle and DNA Repair</title><p>Cell cycle dysregulation is a central mechanism of tumorigenesis. CDK4/6i inhibit the proliferation of malignant cells by binding to the ATP domain of CDK4/6, which plays a key role in the G1&#8208;S checkpoint [<xref rid="mco270560-bib-0067" ref-type="bibr">67</xref>], and then inducing G1 arrest [<xref rid="mco270560-bib-0131" ref-type="bibr">131</xref>]. When combined with endocrine therapy, CDK4/6i are widely used as first&#8208; or second&#8208;line treatment for patients with hormone receptor&#8208;positive, HER2(&#8722;) advanced breast cancer.</p><p>The PALOMA&#8208;2 trial confirmed that compared with placebo plus letrozole in ER(+)/HER2(&#8722;) advanced breast cancer, the PFS of palbociclib plus letrozole was statistically and clinically significantly improved [<xref rid="mco270560-bib-0132" ref-type="bibr">132</xref>]. However, extended follow&#8208;up showed no statistically significant OS benefit (53.8&#160;vs. 49.8 months; HR&#160;=&#160;0.92) [<xref rid="mco270560-bib-0133" ref-type="bibr">133</xref>]. This contrasts with the MONALEESA&#8208;2 trial, where ribociclib plus letrozole conferred a clear OS advantage of more than 12 months [<xref rid="mco270560-bib-0134" ref-type="bibr">134</xref>]. Similarly, abemaciclib in MONARCH&#8208;3 improved median OS when combined with nonsteroidal AIs [<xref rid="mco270560-bib-0135" ref-type="bibr">135</xref>]. Dalpiciclib also demonstrated substantial PFS benefit in the DAWNA&#8208;2 trial (30.6&#160;vs. 18.2 months; HR&#160;=&#160;0.51), suggesting its potential as a new first&#8208;line standard in hormone receptor(+)/HER2(&#8722;) advanced breast cancer [<xref rid="mco270560-bib-0136" ref-type="bibr">136</xref>]. By contrast, the SONIA study raised important questions about optimal treatment sequencing, showing no significant benefit of CDK4/6i in the first&#8208;line setting compared with later introduction, but with increased toxicity due to longer exposure [<xref rid="mco270560-bib-0137" ref-type="bibr">137</xref>]. These results emphasize that while CDK4/6i are effective, however, the optimal timing of CDK4/6i introduction warrants careful deliberation. Moreover, resistance invariably develops, and predictive biomarkers remain limited. Aside from ER positivity, which guides clinical use, candidate markers such as cyclin D, CDKN2A, and RB1 status have yet to be translated into practice [<xref rid="mco270560-bib-0137" ref-type="bibr">137</xref>].</p><p>PARP inhibitors are the first targeted therapy that can improve the prognosis of patients with hereditary tumors [<xref rid="mco270560-bib-0138" ref-type="bibr">138</xref>]. PARP inhibitors (PARPi) have two main mechanisms of action: (1) Catalytic inhibition through competition with NAD+ binding. (2) Generation of PARP&#8211;DNA complexes that block replication forks [<xref rid="mco270560-bib-0139" ref-type="bibr">139</xref>]. Cancer patients with <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> germline mutations are sensitive to PARPi [<xref rid="mco270560-bib-0140" ref-type="bibr">140</xref>]. Olaparib is the first developed PARPi, which have been proved by the OlympiA trial to improve OS in germline BRCA1/2&#8208;mutated early breast cancer (HR&#160;=&#160;0.68) [<xref rid="mco270560-bib-0141" ref-type="bibr">141</xref>]. The latest trial of neoadjuvant olaparib with chemotherapy in TNBC showed that in patients with germline <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> wild&#8208;type TNBC, neoadjuvant olaparib combined with carboplatin&#8208;paclitaxel and anthracycline chemotherapy did not improve the pathologic complete response (pCR) rate, event&#8208;free survival (EFS) or OS [<xref rid="mco270560-bib-0142" ref-type="bibr">142</xref>].</p><p>Other agents have shown efficacy in broader contexts. Talazoparib demonstrated benefit in germline PALB2&#8208;mutated advanced breast cancer [<xref rid="mco270560-bib-0143" ref-type="bibr">143</xref>, <xref rid="mco270560-bib-0144" ref-type="bibr">144</xref>]. Veliparib improved PFS in BRCA&#8208;mutated or &#8220;BRCA&#8208;like&#8221; TNBC when added to chemotherapy (BROCADE3, HR&#160;=&#160;0.71) [<xref rid="mco270560-bib-0145" ref-type="bibr">145</xref>]. New agent AZD5305, which is a selective PARP1 inhibitor, aims to minimize hematologic toxicity associated with dual PARP1/2 blockade [<xref rid="mco270560-bib-0146" ref-type="bibr">146</xref>]. However, trials of PARPi in <italic toggle="yes">BRCA</italic> wild&#8208;type disease, including neoadjuvant settings, have largely been negative, suggests the need for more precise patient selection. Resistance to PARPi occurs in nearly all patients. Although several resistance mechanisms have been identified, how to effectively target them is largely unknown. Combining PARP inhibitors with ADCs may be a potential solution [<xref rid="mco270560-bib-0141" ref-type="bibr">141</xref>, <xref rid="mco270560-bib-0147" ref-type="bibr">147</xref>].</p></sec><sec id="mco270560-sec-0110"><label>3.4</label><title>PI3K/AKT/mTOR Inhibitors</title><p>Dysregulation of the PI3K/AKT/mTOR pathway is among the most frequent molecular alterations in breast cancer and plays a central role in resistance to both endocrine therapy and CDK4/6 inhibition [<xref rid="mco270560-bib-0148" ref-type="bibr">148</xref>]. PI3K/AKT/mTOR inhibitors targeting this pathway have a positive impact on strengthening the treatment and improving the prognosis of breast cancer patients.</p><p>Alpelisib is the first oral &#945;&#8208;selective PI3K inhibitor. SOLAR&#8208;1 trial showed that fulvestrant plus alpelisib had statistically significant and PFS benefits on PIK3CA&#8208;mutation, hormone receptor&#8208;positive, HER2(&#8722;) advanced breast cancer [<xref rid="mco270560-bib-0039" ref-type="bibr">39</xref>, <xref rid="mco270560-bib-0149" ref-type="bibr">149</xref>]. Although the numerical improvement in median OS in the follow&#8208;up analysis was 7.9 months, it did not cross the predetermined statistical significance boundary [<xref rid="mco270560-bib-0150" ref-type="bibr">150</xref>] [median OS was 39.3 months (95% CI 34.1&#8211;44.9) for alpelisib&#8211;fulvestrant and 31.4 months (95% CI 26.8&#8211;41.3) for placebo&#8208;fulvestrant (HR&#160;=&#160;0.86, 95% CI 0.64&#8211;1.15; <italic toggle="yes">p</italic>&#160;=&#160;0.15)]. Subsequent trials of alpelisib monotherapy confirmed activity in ER(+) disease but not in TNBC [<xref rid="mco270560-bib-0151" ref-type="bibr">151</xref>]. Inavolisib is a novel potent PI3K&#945;&#8208;selective inhibitor. In a Phase III, double&#8208;blind, randomized trial, INAVO120, inavolisib plus palbociclib&#8211;fulvestrant significantly prolonged both PFS (15.0 vs. 7.3 months) [<xref rid="mco270560-bib-0152" ref-type="bibr">152</xref>] and OS (34.0 vs. 27.0 months) [<xref rid="mco270560-bib-0153" ref-type="bibr">153</xref>] compared with placebo. It has now been approved by the US FDA and NMPA for endocrine&#8208;resistant, <italic toggle="yes">PIK3CA</italic> mutated, hormone receptor&#8208;positive, HER2(&#8722;) locally advanced or metastatic breast cancer. Nevertheless, adverse events remain a limiting factor, with discontinuation rates notably higher than placebo. Efforts to improve safety have led to the development of more selective agents, such as STX&#8208;478 [<xref rid="mco270560-bib-0154" ref-type="bibr">154</xref>] and tenalisib, which are currently in early&#8208;phase trials and may offer a more favorable therapeutic index.</p><p>AKT inhibitors have also shown promise for downstream targets in the pathway. Capivasertib selectively inhibits all three Akt subtypes. It improved both PFS and OS in the Phase II FAKTION trial [<xref rid="mco270560-bib-0155" ref-type="bibr">155</xref>] and demonstrated consistent PFS benefit in the Phase III CAPItello&#8208;291 study [<xref rid="mco270560-bib-0156" ref-type="bibr">156</xref>], including in patients previously treated with CDK4/6i. These findings have been reinforced in the expanded Chinese cohort, suggesting broad clinical relevance [<xref rid="mco270560-bib-0157" ref-type="bibr">157</xref>]. By contrast, ipatasertib failed to improve outcomes in either the neoadjuvant FAIRLANE trial [<xref rid="mco270560-bib-0158" ref-type="bibr">158</xref>] or the Phase III IPATunity130 study [<xref rid="mco270560-bib-0159" ref-type="bibr">159</xref>], highlighting the variability of efficacy within AKT inhibitors. Resistance mechanisms and toxicity remain critical challenges. Novel agents such as the dual p70S6K/AKT inhibitor M2698 have shown manageable safety and preliminary antitumor activity in resistant disease [<xref rid="mco270560-bib-0160" ref-type="bibr">160</xref>].</p><p>Targeting mTOR has been explored with everolimus, an allosteric inhibitor of mTORC1. The BOLERO&#8208;2 trial established everolimus plus exemestane as an effective strategy for endocrine&#8208;resistant, hormone receptor&#8211;positive/HER2(&#8211;) advanced breast cancer, leading to regulatory approval [<xref rid="mco270560-bib-0161" ref-type="bibr">161</xref>]. A recent Phase III randomized, placebo&#8208;controlled trial evaluated the efficacy of everolimus&#160;+&#160;endocrine therapy as adjuvant therapy for high&#8208;risk, hormone receptor&#8208;positive/HER2(&#8722;) breast cancer after adjuvant/neoadjuvant chemotherapy [<xref rid="mco270560-bib-0162" ref-type="bibr">162</xref>]. The results showed that 1 year of everolimus&#160;+&#160;endocrine therapy adjuvant therapy did not improve the overall results [<xref rid="mco270560-bib-0162" ref-type="bibr">162</xref>]. Gedatolisib is a dual inhibitor of class I PI3K and mTOR. In an open&#8208;label Phase Ib trial, gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate (ORR) with acceptable safety in women with hormone receptor&#8208;positive, HER2(&#8722;) advanced breast cancer [<xref rid="mco270560-bib-0163" ref-type="bibr">163</xref>].</p><p>Overall, inhibitors of the PI3K/AKT/mTOR axis have expanded treatment options for patients with hormone receptor&#8208;positive breast cancer, particularly those with PIK3CA mutations. Yet, the clinical impact is tempered by issues of drug resistance, limited efficacy in TNBC, and treatment&#8208;limiting toxicities. Ongoing trials of next&#8208;generation inhibitors with improved selectivity will be crucial in defining whether these limitations can be overcome and whether broader patient populations can benefit from pathway&#8208;targeted strategies.</p></sec><sec id="mco270560-sec-0120"><label>3.5</label><title>ADCs for Novel Targets</title><p>ADCs are rapidly reshaping the therapeutic landscape of breast cancer. Sacituzumab govitecan (SG), the first&#8208;in&#8208;class Trop&#8208;2 ADC, significantly improved PFS (5.5&#160;vs. 4.0 months; HR&#160;=&#160;0.66) and OS (14.4&#160;vs. 11.2 months; HR&#160;=&#160;0.79) comparing with chemotherapy in the TROPiCS&#8208;02 trial, with consistent benefits reported in Asian populations. Hematologic toxicities such as neutropenia and anemia remain the most frequent high&#8208;grade adverse events [<xref rid="mco270560-bib-0164" ref-type="bibr">164</xref>, <xref rid="mco270560-bib-0165" ref-type="bibr">165</xref>, <xref rid="mco270560-bib-0166" ref-type="bibr">166</xref>, <xref rid="mco270560-bib-0167" ref-type="bibr">167</xref>]. Datopotamab deruxtecan (Dato&#8208;DXd) is a trop2 ADC with a humanized IgG1 mAb conjugated to a Top1 inhibitor [<xref rid="mco270560-bib-0165" ref-type="bibr">165</xref>]. The results from the Phase I TROPION&#8208;PanTumor01 study showed that Dato&#8208;DXD showed promising clinical activity in patients with advanced hormone receptor&#8208;positive/HER2(&#8722;) BC and TNBC [<xref rid="mco270560-bib-0168" ref-type="bibr">168</xref>]. The ORRs of hormone receptor&#8208;positive/HER2(&#8722;) BC and TNBC patients were 26.8% (95% CI 14.2&#8211;42.9) and 31.8% (95% CI 18.6&#8211;47.6), respectively [<xref rid="mco270560-bib-0168" ref-type="bibr">168</xref>]. Phase III trials, such as the tropion&#8208;breast01 and tropion&#8208;breast02 trial, are conducting further evaluation and research on Dato&#8208;DXD.</p><p>Sacituzumab tirumotecan has been approved by the China National Drug Administration for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two systemic therapies. The Phase III OptiTROP&#8208;Breast01 trial evaluated the therapeutic efficacy of Sacituzumab tirumotecan in patients with locally recurrent or metastatic TNBC [<xref rid="mco270560-bib-0169" ref-type="bibr">169</xref>]. The results showed that Sacituzumab tirumotecan had a statistically significant and clinically significant improvement in PFS compared with chemotherapy (median 6.7 vs. 2.5 months, HR&#160;=&#160;0.32; 95% CI 0.24&#8211;0.44; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.00001) [<xref rid="mco270560-bib-0169" ref-type="bibr">169</xref>]. Although some targeted ADCs have shown clinical benefits and have been used as standard treatments, clinical needs remain unmet due to accessibility differences. The application of new ADCs in breast cancer still has great prospects. Patritumab deruxtecan (HER3 DXD) may be one of them [<xref rid="mco270560-bib-0170" ref-type="bibr">170</xref>].</p><p>Although ADCs have yielded impressive responses, not all trials have met expectations. Pertuzumab&#8208;containing regimens in the APHINITY trial improved invasive DFS but failed to show a clear OS benefit at interim analyses [<xref rid="mco270560-bib-0119" ref-type="bibr">119</xref>]. Similarly, some ADCs demonstrate high response rates without durable benefit, and toxicity such as interstitial lung disease with T&#8208;DXd remains a concern [<xref rid="mco270560-bib-0171" ref-type="bibr">171</xref>]. These findings caution against overgeneralizing early positive signals and highlight the need for long&#8208;term follow&#8208;up and real&#8208;world validation.</p></sec><sec id="mco270560-sec-0130"><label>3.6</label><title>Immunotherapy and Combination Approaches</title><p>Immunotherapy controls and eliminates tumors by mobilizing the host immune system, offering new therapeutic opportunities for breast cancer subtypes lacking clear treatment targets, such as TNBC. Among the most widely investigated approaches are immune checkpoint inhibitors (ICIs), evaluated both as monotherapy and in combination with chemotherapy or targeted therapy.</p><p>Pembrolizumab is a monoclonal antibody that binds to the PD&#8208;1 receptor and blocks its interaction with PD&#8208;L1 and PD&#8208;L2, releasing PD&#8208;1 pathway&#8208;mediated inhibition of the immune response, including the antitumor immune response. In the Phase III KEYNOTE&#8208;119 trial, its superiority over chemotherapy was evident only in metastatic TNBC patients with high PD&#8208;L1 expression [<xref rid="mco270560-bib-0172" ref-type="bibr">172</xref>]. More robust evidence came from KEYNOTE&#8208;355, where pembrolizumab plus chemotherapy significantly prolonged PFS (9.7&#160;vs. 5.6 months; HR&#160;=&#160;0.65, 95% CI 0.49&#8211;0.86) and OS (23.0&#160;vs. 16.1 months; HR&#160;=&#160;0.73, 95% CI 0.55&#8211;0.95) in PD&#8208;L1&#8211;positive (CPS&#160;&#8805;&#160;10) metastatic TNBC [<xref rid="mco270560-bib-0173" ref-type="bibr">173</xref>, <xref rid="mco270560-bib-0174" ref-type="bibr">174</xref>]. In the early disease setting, KEYNOTE&#8208;522 confirmed that adding pembrolizumab to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab, improved both EFS (84.5&#160;vs. 76.8% at 36 months) and OS (86.6&#160;vs. 81.7% at 60 months) [<xref rid="mco270560-bib-0175" ref-type="bibr">175</xref>, <xref rid="mco270560-bib-0176" ref-type="bibr">176</xref>]. Notably, exploratory analyses suggested benefit even among patients who did not achieve a pCR, underscoring a broader role beyond pCR improvement [<xref rid="mco270560-bib-0177" ref-type="bibr">177</xref>, <xref rid="mco270560-bib-0178" ref-type="bibr">178</xref>].</p><p>The efficacy of pabolizumab in non&#8208;TNBC is being explored. Encouraged by these results, ongoing trials are assessing pembrolizumab in non&#8208;TNBC subtypes. KEYNOTE&#8208;756 showed a significant increase in pCR (24.3&#160;vs. 15.6%; <italic toggle="yes">p</italic>&#160;=&#160;0.00005) when pembrolizumab was added to neoadjuvant chemotherapy in high&#8208;risk, early&#8208;stage ER(+)/HER2(&#8722;) breast cancer, although EFS data remain immature [<xref rid="mco270560-bib-0179" ref-type="bibr">179</xref>]. Preliminary findings from the Phase II WSG&#8208;KEYRICHED&#8208;1 study also point to therapeutic potential when pembrolizumab is combined with dual HER2 blockade in HER2&#8208;enriched early breast cancer [<xref rid="mco270560-bib-0180" ref-type="bibr">180</xref>].</p><p>Other ICIs have produced mixed outcomes. Atezolizumab is a monoclonal antibody that binds to PD&#8208;L1 and blocks its interactions with both PD&#8208;1 and B7.1 receptors. In the IMpassion130 trial, atezolizumab combined with nanoparticle albumin&#8208;bound&#8208;paclitaxel (nab&#8208;paclitaxel) prolonged PFS in the treatment of mTNBC [<xref rid="mco270560-bib-0181" ref-type="bibr">181</xref>]. However, the results of IMpassion130, a Phase III randomized clinical trial, showed that compared with paclitaxel alone, the combination of atezolizumab and paclitaxel did not improve PFS and OS in patients with advanced TNBC [<xref rid="mco270560-bib-0182" ref-type="bibr">182</xref>]. Therefore, the US FDA withdrew the previously approved alitizumab for TNBC patients with PD&#8208;L1 expression. Tislelizumab, with enhanced PD&#8208;1 binding affinity, achieved a pCR rate of 68% in the Phase II TREND trial when combined with anthracycline&#8208; and taxane&#8208;based chemotherapy in TNBC [<xref rid="mco270560-bib-0183" ref-type="bibr">183</xref>]. Moreover, it has shown improved PFS in PD&#8208;L1&#8208;positive advanced TNBC in the Phase III TORCHLIGHT trial [<xref rid="mco270560-bib-0184" ref-type="bibr">184</xref>]. nivolumab significantly increased pCR rates in high&#8208;risk ER+/HER2&#8211; disease in CheckMate 7FL, particularly among PD&#8208;L1&#8211;high patients [<xref rid="mco270560-bib-0185" ref-type="bibr">185</xref>].</p><p>Although ICIs have been studied rapidly in breast cancer, their therapeutic effect is limited by tumor heterogeneity, tumor subtypes and TME. The identification of prognostic biomarkers other than PD&#8208;L1 is helpful to enhance the efficacy of ICIS. In addition, the development of adoptive T cell immunotherapy and anticancer vaccines are also further explored in the immunotherapy of breast cancer.</p></sec><sec id="mco270560-sec-0140"><label>3.7</label><title>Mechanisms of Resistance and Overcoming Therapeutic Failure</title><p>Drug resistance is a problem that cannot be ignored in drug therapy. Although most ER(+) tumors are initially sensitive to anti estrogen drugs, they will develop resistance with the extension of antiestrogen drug treatment time. It is usually characterized by clinical recurrence and involves genetic and epigenetic changes. Tumors that initially rely on estrogen for proliferation usually evolve to reactivate ER&#8208;directed signals under anti estrogen treatment. This points out the direction for the development of next&#8208;generation endoplasmic reticulum targeted therapies. LBD acquired mutations in <italic toggle="yes">ESR1</italic> are important drivers of treatment resistance [<xref rid="mco270560-bib-0186" ref-type="bibr">186</xref>, <xref rid="mco270560-bib-0187" ref-type="bibr">187</xref>, <xref rid="mco270560-bib-0188" ref-type="bibr">188</xref>, <xref rid="mco270560-bib-0189" ref-type="bibr">189</xref>, <xref rid="mco270560-bib-0190" ref-type="bibr">190</xref>]. It is the main source of AIs resistance [<xref rid="mco270560-bib-0191" ref-type="bibr">191</xref>, <xref rid="mco270560-bib-0192" ref-type="bibr">192</xref>]. In addition to <italic toggle="yes">ESR1</italic> point mutations, structural variations of <italic toggle="yes">ESR1</italic> are also involved in therapeutic resistance, such as <italic toggle="yes">ESR1</italic> fusion [<xref rid="mco270560-bib-0193" ref-type="bibr">193</xref>]. HER2&#8208;amplified tumors usually show therapeutic resistance to endocrine therapy at the time of initial drug exposure [<xref rid="mco270560-bib-0193" ref-type="bibr">193</xref>]. <italic toggle="yes">ERBB2</italic>&#8208;point mutation is an acquired drug resistance mechanism. <italic toggle="yes">ERBB2</italic>&#8208;mutated tumors have reduced sensitivity to estrogen inhibitors, SERM tamoxifen, SERD fulvestin, and CDK4/CDK6 inhibitors. The activation of PI3K&#8211;Akt pathway and RAS&#8211;RAF&#8211;MAPK pathway (RTK downstream signaling pathway) can induce breast cancer cells to resist endocrine therapy. Evidence shows that the activation of RTK and its downstream signaling effectors promotes the proliferation of ER(+) breast cancer cells independent of ER activity, and the alteration of transcription factors other than ER is considered as a potential mechanism of endocrine resistance. Amplification and hotspot mutations of MYC and CTCF are common in tumors that progress after metastatic endocrine therapy [<xref rid="mco270560-bib-0192" ref-type="bibr">192</xref>]. Mutations in FOXA1 are also strongly associated with the prognosis of ER(+) breast cancer patients treated with AIs [<xref rid="mco270560-bib-0194" ref-type="bibr">194</xref>]. Approximately 10&#8211;20% of metastatic ER(+) breast tumors exhibit loss or reduction of ER expression [<xref rid="mco270560-bib-0195" ref-type="bibr">195</xref>]. This suggests that lineage plasticity may also play a role in breast cancer treatment resistance. In breast cancer treated with endocrine therapy, a large part of endocrine therapy resistance is related to the characteristics and limitations of endocrine therapy nowadays, so one of the effective means to solve endocrine therapy resistance is to develop more optimized ER&#8208;targeted drugs. Oral SERDs, such as elacestrant, have demonstrated efficacy in <italic toggle="yes">ESR1</italic>&#8208;mutant tumors, suggesting that it can be a common mechanism of endocrine resistance. In the EMERALD Phase III trial, elacestrant significantly improved PFS compared with standard endocrine therapy in patients with <italic toggle="yes">ESR1</italic> mutations [<xref rid="mco270560-bib-0196" ref-type="bibr">196</xref>] (HR&#160;=&#160;0.55; 95% CI: 0.39&#8211;0.77; <italic toggle="yes">p</italic>&#160;=&#160;0.0005). These agents not only degrade ER but also modulate immune&#8208;related gene expression, potentially enhancing tumor immunogenicity.</p><p>Other SERDs, such as camizestrat and giredstrat, have also shown clinical benefits [<xref rid="mco270560-bib-0197" ref-type="bibr">197</xref>, <xref rid="mco270560-bib-0198" ref-type="bibr">198</xref>], but further Phase III clinical trials are still ongoing. The new endocrine therapy proteolysis&#8208;targeting chimaera (PROTAC) and selective ER covalent antagonists (SERCAs) have expanded the understanding of the path of endocrine therapy. Emerging evidence indicates that both PROTAC technology and next&#8208;generation SERCAs can restore drug sensitivity in endocrine&#8208;resistant, hormone receptor&#8208;positive tumors by rectifying the tumor&#8211;immune interface [<xref rid="mco270560-bib-0199" ref-type="bibr">199</xref>]. CDK4/6i, including palbociclib and abemaciclib, induce cell cycle arrest and promote T&#8208;cell activation by suppressing Tregs and increasing antigen presentation. In preclinical models, CDK4/6i upregulated MHC class I expression and enhanced PD&#8208;L1 sensitivity, suggesting synergy with ICIs [<xref rid="mco270560-bib-0200" ref-type="bibr">200</xref>]. Inhibition of CDK4/6 combined with ER inhibition is currently the most effective combination treatment strategy in clinic. In addition, PI3K&#8208;Akt&#8208;mTOR pathway activation, which is commonly seen in ER(+) patients, is also associated with endocrine resistance. Drugs targeting the PI3K&#8211;Akt&#8211;mTOR pathway, such as alpelisib, have been shown to have significant PFS improvements [<xref rid="mco270560-bib-0039" ref-type="bibr">39</xref>]. The emergence of ADCs has changed the traditional treatment. ADCs, such as T&#8208;DXd, offer targeted cytotoxicity with immune&#8208;stimulatory bystander effects. They may overcome immune resistance by inducing immunogenic cell death and enhancing tumor&#8208;infiltrating lymphocyte activity. These drugs can not only control the cell cycle while being well tolerated but also take into the account for the tumor heterogeneity between and within patients.</p><p>TME is crucial in immunotherapy. Stromal cells such as CAFs, TAMs, and MDSCs are all associated with immune resistance. CAFs, TAMs, and MDSCs induce the differentiation of Treg cells, antigen uptake and maturation of dendritic cells, and M2 polarization, which also inhibit the activation and recruitment of CD8+ and NK cells [<xref rid="mco270560-bib-0079" ref-type="bibr">79</xref>]. Tumor metabolism, especially glycolysis and TCA cycle, is also associated with immune tolerance in breast cancer [<xref rid="mco270560-bib-0079" ref-type="bibr">79</xref>]. Targeting these cells and their metabolic regulation, combined therapy can overcome immune resistance and improve the efficacy of breast cancer immunotherapy. In addition, new therapeutic methods such as photodynamic therapy, photoimmunotherapy, and nanoparticle mediated drug delivery are being explored [<xref rid="mco270560-bib-0201" ref-type="bibr">201</xref>, <xref rid="mco270560-bib-0202" ref-type="bibr">202</xref>, <xref rid="mco270560-bib-0203" ref-type="bibr">203</xref>].</p></sec><sec id="mco270560-sec-0150"><label>3.8</label><title>Emerging Targets and Future Directions</title><p>In addition to established therapies, several novel targeted agents are under clinical or preclinical investigation (Table&#160;<xref rid="mco270560-tbl-0001" ref-type="table">1</xref>). Vepdegestrat is an oral PROTAC ER degrader that can function using the ubiquitin proteasome system [<xref rid="mco270560-bib-0204" ref-type="bibr">204</xref>]. In the Phase III VERITAC&#8208;2 trial for advanced breast cancer, vepdegestrat significantly prolonged PFS in patients harboring ESR1 mutations compared with fulvestrant (5.0&#160;vs. 2.1 months; HR&#160;=&#160;0.58; 95% CI 0.43&#8211;0.78; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) [<xref rid="mco270560-bib-0205" ref-type="bibr">205</xref>]. Palazestrant is a novel oral complete ER antagonist and SERD. Palazestrant can completely block estrogen&#8208;induced transcriptional activity. Palazestrat showed potent antitumor activity in preclinical xenograft models of both <italic toggle="yes">ESR1</italic> wild&#8208;type and mutant human breast cancer [<xref rid="mco270560-bib-0206" ref-type="bibr">206</xref>]. A Phase I/&#8545; study in heavily pretreated ER(+)/HER2(&#8722;) advanced or metastatic breast cancer patients confirmed its clinical efficacy in both wild&#8208;type and ESR1&#8208;mutant tumors [<xref rid="mco270560-bib-0207" ref-type="bibr">207</xref>]. Two Phase III studies of palazestrant OPERA&#8208;01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06016738">NCT06016738</ext-link>) and OPERA&#8208;02 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07085767">NCT07085767</ext-link>) are ongoing.</p><p>Personalized therapy based on molecular profiling has emerged as a key research direction in targeted therapy. Oncotype DX was the first genomic biomarker test for breast cancer treatment. Oncotype DX was the first genomic assay developed to assess recurrence risk in ER&#8208;positive, HER2&#8208;negative, lymph node&#8211;negative invasive breast cancer and to guide tamoxifen therapy duration [<xref rid="mco270560-bib-0208" ref-type="bibr">208</xref>]. MammaPrint contains a 70&#8208;gene signature, provides prognostic insight and can identify low&#8208;risk, nonmetastatic tumors [<xref rid="mco270560-bib-0208" ref-type="bibr">208</xref>]. PAM50 detection provides additional data on tumor biology and quantitative information on proliferation, intracavitary gene expression, <italic toggle="yes">ESR1</italic>, <italic toggle="yes">PGR</italic>, and <italic toggle="yes">ERBB2</italic> [<xref rid="mco270560-bib-0208" ref-type="bibr">208</xref>]. In addition, molecular profiling tests such as EndoPredict and Breast Cancer Index have been applied in clinical practice [<xref rid="mco270560-bib-0208" ref-type="bibr">208</xref>]. Dynamic circulating tumor DNA (ctDNA) monitoring has great benefits for personalized diagnosis and treatment. Some trials [<xref rid="mco270560-bib-0209" ref-type="bibr">209</xref>, <xref rid="mco270560-bib-0210" ref-type="bibr">210</xref>, <xref rid="mco270560-bib-0211" ref-type="bibr">211</xref>] establish ctDNA as a versatile and clinically actionable biomarker across the breast cancer care pathway: first, in early&#8208;stage disease, ctDNA enables response&#8208;guided therapy and early relapse detection. Next, in advanced disease, it facilitates real&#8208;time genomic profiling and precision therapy selection.</p><p>Dynamic ctDNA monitoring offers significant advantages for personalized management. A ctDNA sequencing platform based on whole&#8208;genome sequencing demonstrates higher ctDNA detection rates in early&#8208;stage breast cancer than tumor&#8208;informed assays based on exomes, representing innovation and advancement in sequencing&#8208;platform technology [<xref rid="mco270560-bib-0212" ref-type="bibr">212</xref>]. With continued validation, ctDNA is poised to become a cornerstone of precision oncology in breast cancer, supporting personalized, dynamic, and evidence&#8208;based treatment strategies.</p><p>scRNA&#8208;seq provides high&#8208;resolution transcriptomic analysis, elucidating tumor heterogeneity and informing targeted and individualized therapies [<xref rid="mco270560-bib-0092" ref-type="bibr">92</xref>]. Molecular subtypes and stages, genetic markers, and genetic changes of breast cancer all have an impact on the treatment scheme. Individualized and precise breast cancer treatment needs to be continuously promoted.</p></sec></sec><sec id="mco270560-sec-0160"><label>4</label><title>Risk Assessment and Stratification</title><p>Accurate risk assessment and stratification form the cornerstone of breast cancer prevention, early detection, and personalized management. Traditional models based on family history, reproductive factors, and lifestyle exposures provide useful but limited estimates of individual risk (Table&#160;<xref rid="mco270560-tbl-0002" ref-type="table">2</xref>). The advances in genomics, imaging, and computational analytics open a way to refine prediction, guide tailored surveillance or preventive interventions through integrating germline mutations, PRS, breast density, and emerging biomarkers. In this section, we summarize the evolution of risk assessment strategies, highlight their strengths and limitations, and discuss how integrating novel tools with established models may optimize clinical decision&#8208;making and resource allocation in diverse populations.</p><table-wrap position="float" id="mco270560-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of breast cancer screening recommendations in high&#8208;risk women.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Organization</th><th align="center" rowspan="1" colspan="1">Published year</th><th align="center" rowspan="1" colspan="1">Country/region</th><th align="center" rowspan="1" colspan="1">References</th><th align="center" rowspan="1" colspan="1">Definitions of high&#8208;risk population</th><th align="center" rowspan="1" colspan="1">Age range for screening</th><th align="center" rowspan="1" colspan="1">Screening methods for different age group</th><th align="center" rowspan="1" colspan="1">Screening intervals</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">NCCN</td><td rowspan="2" align="center" colspan="1">2025</td><td rowspan="2" align="center" colspan="1">United States</td><td rowspan="2" align="center" colspan="1">[<xref rid="mco270560-bib-0213" ref-type="bibr">213</xref>]</td><td rowspan="2" align="center" colspan="1">Individuals with confirmed or suspected BRCA1/2 pathogenic/likely pathogenic germline variants based on testing and/or family history</td><td align="center" rowspan="1" colspan="1">25&#8211;29</td><td align="center" rowspan="1" colspan="1">MRI; MAM (only if MRI unavailable or individualized if family BC&#160;&lt;30 years)</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">30&#8211;75</td><td align="center" rowspan="1" colspan="1">MAM&#160;+&#160;MRI</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td rowspan="8" align="left" colspan="1">CACA</td><td rowspan="8" align="center" colspan="1">2024</td><td rowspan="8" align="center" colspan="1">China</td><td rowspan="8" align="center" colspan="1">[<xref rid="mco270560-bib-0214" ref-type="bibr">214</xref>]</td><td align="center" rowspan="1" colspan="1">(1) Individuals with a significant hereditary predisposition to breast cancer can be identified based on the following criteria:</td><td rowspan="8" align="center" colspan="1">Starting &lt;40</td><td rowspan="6" align="center" colspan="1">MAM&#160;&#177;&#160;MRI</td><td rowspan="6" align="center" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">&#9312; A first&#8208;degree relative has a history of breast cancer or ovarian cancer</td></tr><tr><td align="center" rowspan="1" colspan="1">&#9313; Two or more second&#8208;degree relatives diagnosed with breast cancer before the age of 50 years</td></tr><tr><td align="center" rowspan="1" colspan="1">&#9314; Two or more second&#8208;degree relatives diagnosed with ovarian cancer before the age of 50 years</td></tr><tr><td align="center" rowspan="1" colspan="1">&#9315; At least one first&#8208;degree relative carries a known pathogenic mutation in the BRCA1/2 genes, or the individual themselves carries a pathogenic mutation in the BRCA1/2 genes</td></tr><tr><td align="center" rowspan="1" colspan="1">(2) Individuals with a prior diagnosis of atypical ductal or lobular hyperplasia, or lobular carcinoma in situ (LCIS)</td></tr><tr><td align="center" rowspan="1" colspan="1">(3) Individuals who received chest radiation therapy before the age of 30 years</td><td align="center" rowspan="1" colspan="1">US, CBE</td><td align="center" rowspan="1" colspan="1">Every 6&#8211;12 months</td></tr><tr><td align="center" rowspan="1" colspan="1">(4) Using the Gail model to assess breast cancer risk based on multiple risk factors, including the individual's age, ethnicity, age at menarche, age at first childbirth, personal history of breast disease, family history of breast cancer, and number of breast biopsies. If the estimated risk of developing breast cancer within the next 5 years is &#8805;1.67%, the individual is considered to be at high risk.</td><td align="center" rowspan="1" colspan="1">MRI, when necessary</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">EMSO (Pan&#8208;Asian)</td><td align="center" rowspan="1" colspan="1">2024</td><td align="center" rowspan="1" colspan="1">China, Indonesia, India, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0215" ref-type="bibr">215</xref>, <xref rid="mco270560-bib-0216" ref-type="bibr">216</xref>]</td><td align="center" rowspan="1" colspan="1">Women with a strong family history or known germline BRCA1/2 mutations (gBRCA1/2m) and other high&#8208;risk pathogenic variants (PVs)</td><td align="center" rowspan="1" colspan="1">Start at the age of 30 years, or 5 years younger than the youngest family member with breast cancer</td><td align="center" rowspan="1" colspan="1">MRI+(may be considered in between annual MRI studies) &#9312;30&#8211;39: US&#160;&#177;&#160;MAM; &#9313;&#8805;40: MAM&#160;&#177;&#160;US</td><td align="center" rowspan="1" colspan="1">MAM: annual(but every 6 month for BRCA1); &#9312;and&#9313;:may be considered in between annual MRI studies</td></tr><tr><td align="left" rowspan="1" colspan="1">EMSO</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Europe</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0215" ref-type="bibr">215</xref>]</td><td align="center" rowspan="1" colspan="1">Women with a strong family history or known germline BRCA1/2 mutations (gBRCA1/2m) and other high&#8208;risk pathogenic variants (PVs)</td><td align="center" rowspan="1" colspan="1">Start at the age of 30 years, or 5 years younger than the youngest family member with breast cancer</td><td align="center" rowspan="1" colspan="1">MRI+(may be considered in between annual MRI studies) &#9312;30&#8211;39: US&#160;&#177;&#160;MAM; &#9313;&#8805;40: MAM&#160;&#177;&#160;US</td><td align="center" rowspan="1" colspan="1">MAM: annual(but every 6 month for BRCA1); &#9312;and&#9313;:may be considered in between annual MRI studies</td></tr><tr><td rowspan="3" align="left" colspan="1">ACR</td><td rowspan="3" align="center" colspan="1">2023</td><td rowspan="3" align="center" colspan="1">United States</td><td rowspan="3" align="center" colspan="1">[<xref rid="mco270560-bib-0217" ref-type="bibr">217</xref>]</td><td align="center" rowspan="1" colspan="1">Women with genetics&#8208;based increased risk (and their first&#8208;degree untested relatives) or with a calculated lifetime risk of 20% or more</td><td align="center" rowspan="1" colspan="1">Starting at 30</td><td align="center" rowspan="1" colspan="1">DM, &#177;DBT; MAM</td><td align="center" rowspan="1" colspan="1">DM, &#177; DBT: NA; MAM: annual</td></tr><tr><td rowspan="2" align="center" colspan="1">BRCA carriers</td><td align="center" rowspan="1" colspan="1">Starting at 30</td><td align="center" rowspan="1" colspan="1">MRI, MAM</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">Starting at 25</td><td align="center" rowspan="1" colspan="1">MRI; and MAM starting at 40</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="left" rowspan="1" colspan="1">BH</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Bosnia and Herzegovina (BiH)</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0218" ref-type="bibr">218</xref>]</td><td align="center" rowspan="1" colspan="1">High risk is defined as a &gt;20% lifelong risk by risk modeling (Tyrer&#8208;Cuzick model)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MRI and MAM, alternately</td><td align="center" rowspan="1" colspan="1">Alternately every 6 months</td></tr><tr><td align="left" rowspan="1" colspan="1">CBR, SBM, and FEBRASGO</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Brazilian</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0219" ref-type="bibr">219</xref>]</td><td align="center" rowspan="1" colspan="1">Women with a pathogenic mutation of the BRCA1 gene or not tested, but with first&#8208;degree relatives who are carriers, or a strong family history of breast cancer (lifetime risk&#160;&#8805;&#160;20%)</td><td align="center" rowspan="1" colspan="1">BRCA1: &#8805;35; other: 30</td><td align="center" rowspan="1" colspan="1">MRI: BRCA1: &#8805;25 and TP53: &#8805;20 and BRCA2: &#8805;30; MAM: BRCA1: &#8805;35 and other: &#8805;30; &#177;US</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td rowspan="5" align="left" colspan="1">NCC</td><td rowspan="5" align="center" colspan="1">2020</td><td rowspan="5" align="center" colspan="1">China</td><td rowspan="5" align="center" colspan="1">[<xref rid="mco270560-bib-0220" ref-type="bibr">220</xref>]</td><td align="center" rowspan="1" colspan="1">Personal history of precancerous lesions and/or breast cancer</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MAM and US</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">Family history of breast cancer</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MAM and US</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">Known genetic predisposition of breast cancer</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MRI</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">History of mantle or chest radiation therapy</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MRI</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">Dense breasts</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">MAM and US</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="left" rowspan="1" colspan="1">ASCO</td><td align="center" rowspan="1" colspan="1">2020</td><td align="center" rowspan="1" colspan="1">United States</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0221" ref-type="bibr">221</xref>]</td><td align="center" rowspan="1" colspan="1">Men with a history of breast cancer and a genetic predisposing mutation</td><td align="center" rowspan="1" colspan="1">NA (male)</td><td align="center" rowspan="1" colspan="1">MAM</td><td align="center" rowspan="1" colspan="1">Annual</td></tr></tbody></table><table-wrap-foot><fn id="mco270560-tbl2-note-0001"><p>
<italic toggle="yes">Abbreviations</italic>: National Comprehensive Cancer Network (NCCN); Chinese Anti&#8208;Cancer Association (CACA); European Society of Medical Oncology (EMSO); American College of Radiology (ACR); Bosnia and Herzegovina (BH); the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Society of Mastology and Brazilian Federation of Gynecology and Obstetrics Association (CBR&#8208;SBM&#8208;FEBRASGO); American Cancer Society (ACS); National Cancer Center (NCC); American Society of Clinical Oncology (ASCO).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="mco270560-sec-0170"><label>4.1</label><title>Risk Factors</title><p>Women with a genetic predisposition face a markedly elevated breast cancer risk. <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutations are the most common mutations in breast cancer, conferring lifetime risks of approximately 72 and 69% by the age of 80 years, respectively. <italic toggle="yes">BRCA1</italic> mutation carriers typically develop cancer in their 30s&#8211;40s, while <italic toggle="yes">BRCA2</italic> carriers peak later, in their 40s&#8211;50s [14]. <italic toggle="yes">TP53</italic> mutations, though rare, are associated with Li&#8211;Fraumeni syndrome and very early onset breast cancer, often before the age of 30 years [<xref rid="mco270560-bib-0222" ref-type="bibr">222</xref>]. <italic toggle="yes">PALB2</italic> mutations also confer substantial risk, with carriers having a 35% probability of developing breast cancer by the age of 70 years [<xref rid="mco270560-bib-0223" ref-type="bibr">223</xref>]. These mutations are further linked to other malignancies, including ovarian and pancreatic cancer, necessitating tailored surveillance such as early MRI and mammography, and in some cases, risk&#8208;reducing interventions [<xref rid="mco270560-bib-0224" ref-type="bibr">224</xref>, <xref rid="mco270560-bib-0225" ref-type="bibr">225</xref>, <xref rid="mco270560-bib-0226" ref-type="bibr">226</xref>, <xref rid="mco270560-bib-0227" ref-type="bibr">227</xref>]. Understanding gene&#8208;specific risks enables more precise counseling and management for high&#8208;risk women.</p><p>Family history of cancer remains an important risk factor, reflecting both inherited susceptibility and shared environmental exposures. The risk rises with the number of first&#8208;degree relatives affected [<xref rid="mco270560-bib-0015" ref-type="bibr">15</xref>].</p><p>Women with a personal history of breast cancer or premalignant lesions such as atypical ductal hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ (DCIS) are at significantly higher risk of invasive disease [<xref rid="mco270560-bib-0228" ref-type="bibr">228</xref>]. Atypical ductal hyperplasia confers a four&#8208; to fivefold increased risk, lobular carcinoma in situ an eight&#8208; to tenfold risk, and DCIS carries a long&#8208;term risk of progression lasting decades [<xref rid="mco270560-bib-0016" ref-type="bibr">16</xref>].</p><p>Prior mantle or chest radiation, especially during childhood or adolescence, increases lifetime breast cancer risk up to eight&#8208;fold, with cumulative incidence reaching 13&#8211;20% by age the of 40&#8211;45 years, comparable to <italic toggle="yes">BRCA</italic> mutation carriers [<xref rid="mco270560-bib-0017" ref-type="bibr">17</xref>, <xref rid="mco270560-bib-0229" ref-type="bibr">229</xref>, <xref rid="mco270560-bib-0230" ref-type="bibr">230</xref>]. MRI offers superior sensitivity for radiation&#8208;induced cancers, and combined screening significantly reduces breast cancer mortality in this population. Cost&#8208;effectiveness analyses also support intensive surveillance protocols [<xref rid="mco270560-bib-0231" ref-type="bibr">231</xref>, <xref rid="mco270560-bib-0232" ref-type="bibr">232</xref>].</p><p>Breast density represents another major independent risk factor. Women with dense breasts face a four&#8208; to six&#8208;fold increased risk compared with those with fatty breasts [<xref rid="mco270560-bib-0018" ref-type="bibr">18</xref>, <xref rid="mco270560-bib-0233" ref-type="bibr">233</xref>]. This is attributed both to the greater amount of glandular and stromal tissue and to reduced mammographic sensitivity, as dense tissue and tumors both appear radiopaque [<xref rid="mco270560-bib-0234" ref-type="bibr">234</xref>, <xref rid="mco270560-bib-0235" ref-type="bibr">235</xref>]. Sensitivity drops from 85.7% in fatty breasts to 61% in extremely dense ones [<xref rid="mco270560-bib-0236" ref-type="bibr">236</xref>]. Supplemental imaging modalities, including DBT, ultrasound, and particularly MRI, improve detection rates [<xref rid="mco270560-bib-0237" ref-type="bibr">237</xref>]. However, dense breast alone is an imperfect predictor of benefit. Therefore, breast density should be incorporated with age and other risk factors into multivariable models to develop risk&#8208;based screening strategies for high&#8208;risk women [<xref rid="mco270560-bib-0238" ref-type="bibr">238</xref>].</p><p>Moderate risk factors also contribute meaningfully to overall risk. Racial and ethnic background plays a role: Ashkenazi Jewish women carry a higher prevalence of <italic toggle="yes">BRCA</italic> mutations, while breast cancer incidence is higher among Black women before the age of 45 years but higher in White women thereafter; Black women also have poorer survival outcomes [<xref rid="mco270560-bib-0239" ref-type="bibr">239</xref>, <xref rid="mco270560-bib-0240" ref-type="bibr">240</xref>, <xref rid="mco270560-bib-0241" ref-type="bibr">241</xref>]. Reproductive and hormonal factors such as early menarche, late menopause, nulliparity, oral contraceptive use, and postmenopausal hormone replacement therapy influence risk, though effects vary by formulation and individual susceptibility [<xref rid="mco270560-bib-0242" ref-type="bibr">242</xref>, <xref rid="mco270560-bib-0243" ref-type="bibr">243</xref>, <xref rid="mco270560-bib-0244" ref-type="bibr">244</xref>, <xref rid="mco270560-bib-0245" ref-type="bibr">245</xref>]. Lifestyle&#8208;related exposures, including elevated BMI, physical inactivity, alcohol consumption, and night&#8208;shift work, further modify risk [<xref rid="mco270560-bib-0246" ref-type="bibr">246</xref>, <xref rid="mco270560-bib-0247" ref-type="bibr">247</xref>, <xref rid="mco270560-bib-0248" ref-type="bibr">248</xref>]. While moderate&#8208;risk factors individually confer smaller effects than high&#8208;risk factors, their cumulative interaction necessitates comprehensive risk assessment in clinical practice.</p><p>Research on traditional breast cancer risk factors has been progressively refined and expanded. Genetic studies have extended beyond <italic toggle="yes">BRCA1/2</italic> to include moderate&#8208; and low&#8208;penetrance genes [<xref rid="mco270560-bib-0249" ref-type="bibr">249</xref>], with increasing emphasis on variant&#8208;specific and locus&#8208;specific functional effects rather than entire genes [<xref rid="mco270560-bib-0250" ref-type="bibr">250</xref>]. Hormonal influences have also been delineated with greater precision, particularly regarding hormone replacement therapy, where both dosage and duration critically shape risk [<xref rid="mco270560-bib-0251" ref-type="bibr">251</xref>]. Breast density, once assessed as a static measure, is now modeled through longitudinal trajectories to better reflect dynamic risk profiles [<xref rid="mco270560-bib-0252" ref-type="bibr">252</xref>]. Advances in imaging biomarkers further highlight this shift toward precision. Beyond density, quantitative radiologic features can provide additional risk&#8208;relevant information. Parenchymal textural complexity has been demonstrated to improve prediction and model discrimination. Elevated background parenchymal enhancement on MRI corresponds to a 74% higher risk of breast cancer [<xref rid="mco270560-bib-0253" ref-type="bibr">253</xref>], while ultrasound&#8208;based quantification of glandular tissue independently predicts risk and correlates with histological lobular involution [<xref rid="mco270560-bib-0254" ref-type="bibr">254</xref>]. Together, these findings expand both the breadth and depth of understanding, underscoring the value of moving from broad indicators toward more nuanced, functionally informed risk determinants.</p></sec><sec id="mco270560-sec-0180"><label>4.2</label><title>Classical Risk Assessment Models</title><p>Several models have been developed to estimate breast cancer risk by integrating clinical, genetic, and lifestyle factors. The GAIL model, first reported in 1989 and later revised with Surveillance Epidemiology and End Results (SEER) and Breast cancer prevention trial (BCPT)&#160;data, remains widely used because it incorporates easily measured risk factors. However, it excludes genetic susceptibility such as <italic toggle="yes">BRCA</italic> mutations and is thus unsuitable for mutation carriers [<xref rid="mco270560-bib-0213" ref-type="bibr">213</xref>, <xref rid="mco270560-bib-0255" ref-type="bibr">255</xref>, <xref rid="mco270560-bib-0256" ref-type="bibr">256</xref>]. To address this, BRCAPRO and BOADICEA incorporated <italic toggle="yes">BRCA</italic> status, improving prediction for women with pathogenic variants [<xref rid="mco270560-bib-0257" ref-type="bibr">257</xref>, <xref rid="mco270560-bib-0258" ref-type="bibr">258</xref>]. The IBIS (Tyrer&#8208;Cuzick) model further advanced this approach by combining genetic and nongenetic factors, making it applicable to both carriers and noncarriers [<xref rid="mco270560-bib-0259" ref-type="bibr">259</xref>]. With breast density recognized as an independent risk factor, the breast cancer stem&#8208;cell model integrated this feature demonstrated improved calibration across racial and ethnic groups. Independent validation using the ProF&#8208;SC cohort found that BOADICEA and IBIS, which capture multigenerational family history, achieved superior predictive performance (area under the curve [AUC] 0.71 and 0.70). The findings also suggest that hybrid models incorporating polygenic risk alongside nonfamilial factors may further enhance risk stratification [<xref rid="mco270560-bib-0260" ref-type="bibr">260</xref>].</p></sec><sec id="mco270560-sec-0190"><label>4.3</label><title>Exploration of New Risk Assessment Tools</title><p>PRS assesses an individual's susceptibility to certain diseases by describing the combined risk of many risk&#8208;inducing single&#8208;nucleotide polymorphisms (SNPs). It is an estimate of an individual's genetic susceptibility to developing complex diseases such as breast cancer. A current hot topic of exploration is the integration of PRS scores into existing models. For example, the IBIS model integrates PRS based on 18 SNPs associated with breast cancer and mammography density [<xref rid="mco270560-bib-0261" ref-type="bibr">261</xref>]. The BOADICEA model integrates a PRS based on 313 SNPs [<xref rid="mco270560-bib-0262" ref-type="bibr">262</xref>]. A study performed a comparative prospective validation of these two models and found that the extended BOADICEA model improved discrimination modestly in younger women (AUC 69.7 vs. 69.1%) and substantially in older women (AUC 64.6&#160;vs. 56.8%), which is more accurate than the extended IBIS model in the European&#8208;ancestry population [<xref rid="mco270560-bib-0263" ref-type="bibr">263</xref>]. A well&#8208;documented concern is the limited applicability of current PRS models across populations of different genetic ancestries, largely due to the under&#8208;representation of non&#8208;European cohorts in breast cancer genome&#8208;wide association studies [<xref rid="mco270560-bib-0264" ref-type="bibr">264</xref>, <xref rid="mco270560-bib-0265" ref-type="bibr">265</xref>]. Population&#8208;specific PRS developed in African American women have demonstrated markedly improved predictive performance compared with models derived from European datasets, underscoring the need for ancestry&#8208;specific calibration [<xref rid="mco270560-bib-0266" ref-type="bibr">266</xref>]. Ongoing efforts aim to leverage multiethnic data to construct breast cancer risk prediction models with race&#8208;specific adjustments to enhance their utility in non&#8208;European populations; however, these approaches still require validation in prospective studies [<xref rid="mco270560-bib-0267" ref-type="bibr">267</xref>].</p><p>Deep learning&#8208; and AI&#8208;based population screening models represent promising complementary strategies [<xref rid="mco270560-bib-0268" ref-type="bibr">268</xref>]. One advantage of AI models lies in their capacity to integrate diverse data types and automatically capture nonlinear relationships and latent interactions among variables, thereby enhancing discriminatory accuracy. For example, a deep learning model based on senescent nuclear morphology predicted future breast cancer risk from benign breast biopsy samples with greater accuracy than the Gail model [<xref rid="mco270560-bib-0269" ref-type="bibr">269</xref>]. Certain AI models also demonstrate independent predictive power. Mirai, an imaging&#8208;based AI model, can predict 5&#8208;year breast cancer risk from as little as a single screening mammogram, performing comparably even in the absence of additional clinical risk factors [<xref rid="mco270560-bib-0268" ref-type="bibr">268</xref>, <xref rid="mco270560-bib-0270" ref-type="bibr">270</xref>]. In retrospective analyses, Mirai&#8208;guided criteria for recommending supplemental MRI outperformed existing guidelines based on Tyrer&#8208;Cuzick lifetime risk [<xref rid="mco270560-bib-0268" ref-type="bibr">268</xref>]. These findings highlight the ability of AI to extract biologically relevant information from raw data that conventional models cannot capture, offering the potential for widespread and equitable improvements in delivering breast cancer care.</p></sec></sec><sec id="mco270560-sec-0200"><label>5</label><title>Breast Cancer Screening</title><p>Breast cancer screening is undergoing a major transition from population&#8208;based, uniform protocols toward more individualized, risk&#8208;adapted strategies. This section reviews the full landscape of contemporary and emerging screening approaches and discuss the challenges of modern breast cancer screening, highlighting pathways toward more precise and equitable early detection.</p><sec id="mco270560-sec-0210"><label>5.1</label><title>Screening Methods for Breast Cancer</title><p>The primary objective of breast cancer screening is to maximize early detection while minimizing the risks of false&#8208;positive recalls, overdiagnosis, and unnecessary interventions. This section provides a detailed comparison of different imaging modalities, including mammography, DBT, ultrasound, MRI, and contrast&#8208;enhanced mammography (CEM), with respect to diagnostic performance, clinical applicability, cost effectiveness, and potential harms. It further explores how these technologies are driving the transition of breast cancer screening from a &#8220;one&#8208;size&#8208;fits&#8208;all&#8221; approach toward risk&#8208;stratified, personalized strategies (Figure&#160;<xref rid="mco270560-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="mco270560-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Illustration of risk&#8208;based breast cancer screening. This paradigm outlines the stratification of individuals into regular or supplemental screening pathways based on the assessment of inherent and clinical risk factors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="MCO2-7-e70560-g001.jpg"/></fig><sec id="mco270560-sec-0220"><label>5.1.1</label><title>Mammography: The Gold Standard With Limitations</title><p>Mammography has long been regarded as the gold standard in breast cancer screening. Large randomized controlled trials (RCTs) demonstrated that regular screening in women aged 50&#8211;70 years reduces breast cancer mortality by approximately 20% [<xref rid="mco270560-bib-0271" ref-type="bibr">271</xref>]. Its advantages include relatively low cost, broad accessibility, and well&#8208;established standardized protocols.</p><p>Nevertheless, mammography has notable limitations, which have spurred the development of alternative modalities. In women with dense breasts, its sensitivity is reduced by 10&#8211;20%, resulting in a higher likelihood of missed cancers, particularly among younger women [<xref rid="mco270560-bib-0272" ref-type="bibr">272</xref>, <xref rid="mco270560-bib-0273" ref-type="bibr">273</xref>]. The US FDA mandate to disclose breast density reflects growing recognition of these limitations and provides a rationale for supplemental screening [<xref rid="mco270560-bib-0274" ref-type="bibr">274</xref>]. High recall rates (6&#8211;27%) represent intrinsic harms that fuel debate over the balance of benefits and risks [<xref rid="mco270560-bib-0275" ref-type="bibr">275</xref>, <xref rid="mco270560-bib-0276" ref-type="bibr">276</xref>, <xref rid="mco270560-bib-0277" ref-type="bibr">277</xref>, <xref rid="mco270560-bib-0278" ref-type="bibr">278</xref>]. The available data are not universally applicable. European countries generally report lower recall rates, ranging from 2 to 5% per screening round [<xref rid="mco270560-bib-0279" ref-type="bibr">279</xref>, <xref rid="mco270560-bib-0280" ref-type="bibr">280</xref>, <xref rid="mco270560-bib-0281" ref-type="bibr">281</xref>]. Differences in screening strategies, image&#8208;reading approaches, and statistical methods may contribute to this variation. However, evidence suggests that these technical factors alone do not fully account for the observed disparities [<xref rid="mco270560-bib-0282" ref-type="bibr">282</xref>]. These regional differences underscore the need for context&#8208;specific evidence when formulating international screening policies and harmonizing clinical guidelines. Estimates of breast cancer overdiagnosis associated with screening vary widely across studies, with reported rates ranging from approximately 1 to 50% [<xref rid="mco270560-bib-0283" ref-type="bibr">283</xref>, <xref rid="mco270560-bib-0284" ref-type="bibr">284</xref>]. This variability reflects heterogeneity in estimation methodologies and population characteristics, emphasizing the need for caution when interpreting such data to avoid overestimating or misrepresenting the benefits of screening. However, regardless of the specific figures, the unnecessary treatments and psychological burden resulting from overdiagnosis remain a critical concern.</p></sec><sec id="mco270560-sec-0230"><label>5.1.2</label><title>DBT: A 3D Revolution</title><p>DBT addresses the tissue&#8208;overlap limitations of conventional two&#8208;dimensional mammography by reconstructing three&#8208;dimensional images [<xref rid="mco270560-bib-0026" ref-type="bibr">26</xref>, <xref rid="mco270560-bib-0276" ref-type="bibr">276</xref>]. Evidence shows clear incremental benefits in cancer detection and recall rates. In a large cohort analysis involving more than one million women, Conant et&#160;al. reported that DBT increased the detection rate from 4.5 to 5.3 cancers per 1000 women screened, while simultaneously reducing recalls [<xref rid="mco270560-bib-0285" ref-type="bibr">285</xref>]. This highlights that DBT's can provide dual advantage of improved sensitivity and reduced false positives.</p><p>Despite its superior diagnostic performance, DBT's role as a primary screening tool remains debatable. Some meta&#8208;analyses suggest that DBT alone provides no additional benefit over standard mammography [<xref rid="mco270560-bib-0286" ref-type="bibr">286</xref>]. RCTs such as TOSYMA confirmed improved detection of invasive cancers with DBT, yet its long&#8208;term clinical impact (e.g., on mortality reduction) and cost effectiveness remain to be established [<xref rid="mco270560-bib-0287" ref-type="bibr">287</xref>, <xref rid="mco270560-bib-0288" ref-type="bibr">288</xref>]. Practical barriers also limit widespread adoption: DBT increases radiologists&#8217; interpretation time and workload, and its equipment and training costs are significantly higher than those for conventional mammography, the challenges that are particularly evident in resource&#8208;limited setting [<xref rid="mco270560-bib-0289" ref-type="bibr">289</xref>, <xref rid="mco270560-bib-0290" ref-type="bibr">290</xref>].</p></sec><sec id="mco270560-sec-0240"><label>5.1.3</label><title>Ultrasound: A Complementary Tool for Dense Breasts</title><p>Ultrasound, free from ionizing radiation, is an appealing option for women with dense breasts and is particularly valuable in detecting small invasive cancers that mammography may miss [<xref rid="mco270560-bib-0291" ref-type="bibr">291</xref>, <xref rid="mco270560-bib-0292" ref-type="bibr">292</xref>]. The J&#8208;START trial demonstrated that combining ultrasound with mammography significantly improved sensitivity (91.1&#160;vs. 77.0%), especially in women with dense breasts [<xref rid="mco270560-bib-0293" ref-type="bibr">293</xref>, <xref rid="mco270560-bib-0294" ref-type="bibr">294</xref>]. However, this gain in sensitivity comes at the expense of lower specificity (87.7&#160;vs. 91.4%), resulting in substantially higher false&#8208;positive rates, unnecessary biopsies, patient anxiety, and increased healthcare costs [<xref rid="mco270560-bib-0291" ref-type="bibr">291</xref>, <xref rid="mco270560-bib-0295" ref-type="bibr">295</xref>]. Moreover, ultrasound is highly operator dependent, leading to reduced reproducibility. Automated breast ultrasound partially addresses this limitation, but its broader adoption is constrained by cost [<xref rid="mco270560-bib-0296" ref-type="bibr">296</xref>].</p></sec><sec id="mco270560-sec-0250"><label>5.1.4</label><title>MRI: High Sensitivity for High&#8208;Risk Women</title><p>MRI offers the highest sensitivity of all imaging modalities, particularly in women at elevated risk, such as <italic toggle="yes">BRCA</italic> mutation carriers. It detects cancers that mammography may miss [<xref rid="mco270560-bib-0297" ref-type="bibr">297</xref>]. However, its widespread use is hindered by high costs, lengthy examination times, and high false&#8208;positive rates, making it unsuitable for population&#8208;wide screening [<xref rid="mco270560-bib-0026" ref-type="bibr">26</xref>]. Abbreviated MRI was developed to overcome these barriers, substantially reducing scanning time while maintaining diagnostic performance comparable to full&#8208;protocol MRI, thereby offering potential advantages in cost effectiveness and accessibility [<xref rid="mco270560-bib-0298" ref-type="bibr">298</xref>, <xref rid="mco270560-bib-0299" ref-type="bibr">299</xref>, <xref rid="mco270560-bib-0300" ref-type="bibr">300</xref>]&#183;.</p></sec><sec id="mco270560-sec-0260"><label>5.1.5</label><title>CEM: A Hybrid Approach</title><p>CEM combines the accessibility of mammography with the contrast&#8208;enhancement properties of MRI, offering a pragmatic middle ground. Studies suggest that CEM lowers false&#8208;positive recalls and biopsy rates compared with standard MRI, with shorter acquisition and interpretation times [<xref rid="mco270560-bib-0301" ref-type="bibr">301</xref>]. This makes CEM a promising alternative for selected groups, such as high&#8208;risk women with dense breasts. Nonetheless, its cancer detection rate and sensitivity remain lower than MRI [<xref rid="mco270560-bib-0301" ref-type="bibr">301</xref>], and further data are needed to clarify long&#8208;term outcomes and evaluate risks associated with contrast agent exposure [<xref rid="mco270560-bib-0302" ref-type="bibr">302</xref>, <xref rid="mco270560-bib-0303" ref-type="bibr">303</xref>].</p></sec><sec id="mco270560-sec-0270"><label>5.1.6</label><title>The Future of Noninvasive Testing</title><p>One of the most innovative developments in breast cancer screening is the analysis of volatile organic compounds (VOCs) in exhaled breath. VOCs, which are generated through cancer&#8208;specific metabolic processes, can be detected using specialized analytical platforms, offering a fully noninvasive screening tool. Early clinical studies have reported sensitivity and specificity of 89.2% (222/249) and 87.7% (1355/1545), respectively, outperforming conventional mammography and ultrasound diagnostics [<xref rid="mco270560-bib-0304" ref-type="bibr">304</xref>]. Liquid biopsy approaches based on DNAme profiles from accessible mucosal samples are also emerging as promising tools. A recent large&#8208;scale study systematically compared multiple noninvasive sample types and demonstrated that DNAme classifiers from cervical (AUC 0.75) and buccal (AUC 0.66) swabs markedly outperformed blood&#8208;based assays (AUC 0.51) for breast cancer detection. Notably, DNAme alterations in these surrogate tissues closely mirrored those in breast tissue (AUC&#160;&gt;&#160;0.88), underscoring their potential application in multicancer early detection platforms that could be integrated into routine gynecological or dental practice [<xref rid="mco270560-bib-0305" ref-type="bibr">305</xref>, <xref rid="mco270560-bib-0306" ref-type="bibr">306</xref>]. Despite these encouraging findings, such noninvasive technologies remain largely experimental, with limited application in clinical practice and a scarcity of robust validation data. Well&#8208;designed, large&#8208;scale prospective trials across diverse populations are essential to confirm their accuracy, reproducibility, and clinical utility before widespread implementation.</p><p>Breast cancer screening is thus evolving from reliance on a single &#8220;gold standard&#8221; toward more diversified and personalized approaches. Mammography remains the cornerstone but should be tailored according to age and breast density; for women with dense breasts, DBT or ultrasound may serve as valuable adjuncts; and for individuals at very high risk, such as carriers of pathogenic germline mutations, MRI remains the modality of choice. Emerging technologies such as MRI and CEM may provide new opportunities to balance diagnostic accuracy with cost effectiveness.</p><p>Future research should move from isolated comparisons of screening modalities to integrated, risk&#8208;adapted models that account for family history, genetic susceptibility, and breast density. Such models, grounded in comprehensive evaluations of each modality's strengths and limitations, hold promise for maximizing the benefits of early detection while minimizing unnecessary harms and healthcare resource utilization, thereby advancing precision and efficiency in breast cancer screening.</p></sec></sec><sec id="mco270560-sec-0280"><label>5.2</label><title>Current Challenges in Breast Cancer Screening</title><sec id="mco270560-sec-0290"><label>5.2.1</label><title>The Starting Age of Breast Cancer Screening</title><p>Most current guidelines recommend age&#8208;based initiation of breast cancer screening for women at average risk, though the specific threshold varies widely (Table&#160;<xref rid="mco270560-tbl-0003" ref-type="table">3</xref>). A central controversy concerns whether mammography should begin at the age of 40 or 50 years [<xref rid="mco270560-bib-0307" ref-type="bibr">307</xref>, <xref rid="mco270560-bib-0308" ref-type="bibr">308</xref>, <xref rid="mco270560-bib-0309" ref-type="bibr">309</xref>, <xref rid="mco270560-bib-0310" ref-type="bibr">310</xref>, <xref rid="mco270560-bib-0311" ref-type="bibr">311</xref>, <xref rid="mco270560-bib-0312" ref-type="bibr">312</xref>, <xref rid="mco270560-bib-0313" ref-type="bibr">313</xref>].</p><table-wrap position="float" id="mco270560-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Summary of breast cancer screening recommendations in average&#8208;risk women.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Organization</th><th align="center" rowspan="1" colspan="1">Published year</th><th align="center" rowspan="1" colspan="1">Country/region</th><th align="center" rowspan="1" colspan="1">References</th><th align="center" rowspan="1" colspan="1">Age range for screening</th><th align="center" rowspan="1" colspan="1">Screening methods for different age group</th><th align="center" rowspan="1" colspan="1">Screening intervals</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AGO</td><td align="center" rowspan="1" colspan="1">2025</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0341" ref-type="bibr">341</xref>]</td><td align="center" rowspan="1" colspan="1">(1) Carriers of pathogenic/likely pathogenic variants (PVs) in breast&#8208;cancer risk genes; (2) women without PVs but with &#8805;5% 10&#8208;year risk by certified model; (3) breast&#8208;cancer patients meeting GC&#8208;HBOC germline testing criteria and diagnosed before the age of 46 years.</td><td align="center" rowspan="1" colspan="1">50&#8211;75: MAM</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="3" align="left" colspan="1">EMSO (Pan&#8208;Asian)</td><td rowspan="3" align="center" colspan="1">2024</td><td rowspan="3" align="center" colspan="1">China, Indonesia, India, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand</td><td rowspan="3" align="center" colspan="1">[<xref rid="mco270560-bib-0215" ref-type="bibr">215</xref>, <xref rid="mco270560-bib-0216" ref-type="bibr">216</xref>]</td><td rowspan="3" align="center" colspan="1">40&#8211;74</td><td align="center" rowspan="1" colspan="1">40&#8211;44: MAM</td><td align="center" rowspan="1" colspan="1">Regular may</td></tr><tr><td align="center" rowspan="1" colspan="1">45&#8211;69: MAM</td><td align="center" rowspan="1" colspan="1">Biennial</td></tr><tr><td align="center" rowspan="1" colspan="1">70&#8211;74: MAM</td><td align="center" rowspan="1" colspan="1">Regular may</td></tr><tr><td rowspan="2" align="left" colspan="1">CACA</td><td rowspan="2" align="center" colspan="1">2024</td><td rowspan="2" align="center" colspan="1">China</td><td rowspan="2" align="center" colspan="1">[<xref rid="mco270560-bib-0214" ref-type="bibr">214</xref>]</td><td align="center" rowspan="1" colspan="1">40&#8211;69</td><td align="center" rowspan="1" colspan="1">MAM&#160;&#177;&#160;US</td><td align="center" rowspan="1" colspan="1">Annual or biennial</td></tr><tr><td align="center" rowspan="1" colspan="1">&gt;70</td><td align="center" rowspan="1" colspan="1">MAM</td><td align="center" rowspan="1" colspan="1">Annual or biennial</td></tr><tr><td align="left" rowspan="1" colspan="1">USPSTF</td><td align="center" rowspan="1" colspan="1">2024</td><td align="center" rowspan="1" colspan="1">United States</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0342" ref-type="bibr">342</xref>]</td><td align="center" rowspan="1" colspan="1">40&#8211;74</td><td align="center" rowspan="1" colspan="1">MAM</td><td align="center" rowspan="1" colspan="1">Every other year</td></tr><tr><td rowspan="3" align="left" colspan="1">EMSO</td><td rowspan="3" align="center" colspan="1">2023</td><td rowspan="3" align="center" colspan="1">Europe</td><td rowspan="3" align="center" colspan="1">[<xref rid="mco270560-bib-0215" ref-type="bibr">215</xref>]</td><td rowspan="3" align="center" colspan="1">45&#8211;74</td><td align="center" rowspan="1" colspan="1">45&#8211;49: MAM</td><td align="center" rowspan="1" colspan="1">Regular may</td></tr><tr><td align="center" rowspan="1" colspan="1">50&#8211;69: MAM</td><td align="center" rowspan="1" colspan="1">Biennial</td></tr><tr><td align="center" rowspan="1" colspan="1">70&#8211;74: MAM</td><td align="center" rowspan="1" colspan="1">Regular may</td></tr><tr><td rowspan="3" align="left" colspan="1">ACR</td><td rowspan="3" align="center" colspan="1">2023</td><td rowspan="3" align="center" colspan="1">United States</td><td rowspan="3" align="center" colspan="1">[<xref rid="mco270560-bib-0343" ref-type="bibr">343</xref>]</td><td rowspan="3" align="center" colspan="1">&#8805;40</td><td align="center" rowspan="1" colspan="1">40&#8211;44: MAM</td><td align="center" rowspan="1" colspan="1">Switch to a MAM every other year</td></tr><tr><td align="center" rowspan="1" colspan="1">45&#8211;54: MAM</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8805;55: MAM</td><td align="center" rowspan="1" colspan="1">Switch to MAM every year, or Annual</td></tr><tr><td align="left" rowspan="1" colspan="1">BH</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Bosnia and Herzegovina (BiH)</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0218" ref-type="bibr">218</xref>]</td><td align="center" rowspan="1" colspan="1">&#8805;40</td><td align="center" rowspan="1" colspan="1">MAM</td><td align="center" rowspan="1" colspan="1">&lt;55: annual; &#8805;55: biennial at least, or annually</td></tr><tr><td align="left" rowspan="1" colspan="1">CBR, SBM, and FEBRASGO</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Brazilian</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0219" ref-type="bibr">219</xref>]</td><td align="center" rowspan="1" colspan="1">&#8805;40</td><td align="center" rowspan="1" colspan="1">MAM&#160;&#177;&#160;DBT</td><td align="center" rowspan="1" colspan="1">Annual</td></tr><tr><td rowspan="3" align="left" colspan="1">ECIB</td><td rowspan="3" align="center" colspan="1">2020</td><td rowspan="3" align="center" colspan="1">Europe</td><td rowspan="3" align="center" colspan="1">[<xref rid="mco270560-bib-0344" ref-type="bibr">344</xref>]</td><td rowspan="3" align="center" colspan="1">45&#8211;74</td><td align="center" rowspan="1" colspan="1">45&#8211;49: MAM</td><td align="center" rowspan="1" colspan="1">Either biennial or triennial mammography over annual screening</td></tr><tr><td align="center" rowspan="1" colspan="1">60&#8211;69: MAM</td><td align="center" rowspan="1" colspan="1">Against annual mammography screening (strong); biennial mammography screening over triennial mammography screening (conditional)</td></tr><tr><td align="center" rowspan="1" colspan="1">70&#8211;74: MAM</td><td align="center" rowspan="1" colspan="1">Against annual mammography screening (strong); triennial mammography screening over biennial mammography screening (conditional)</td></tr><tr><td align="left" rowspan="1" colspan="1">NCC</td><td align="center" rowspan="1" colspan="1">2020</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0220" ref-type="bibr">220</xref>]</td><td align="center" rowspan="1" colspan="1">&#8805;45</td><td align="center" rowspan="1" colspan="1">MMA, US</td><td align="center" rowspan="1" colspan="1">Annual or biennial</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The USPSTF 2023 revised its draft recommendations by lowering the starting age of breast cancer screening from 50 to 40 years. This decision was made by accumulated evidence showing meaningful benefits, although debate persists. Long&#8208;term findings from the UK Age Trial, involving 160,000 women, showed that annual screening beginning at the age of 40 years reduced mortality by 25% compared with initiation at 50 years of age, with benefits persisting over two decades despite some attenuation [<xref rid="mco270560-bib-0314" ref-type="bibr">314</xref>]. Retrospective analyses from Canada further demonstrated higher 10&#8208;year survival in women aged 40&#8211;49 years living in regions with organized screening compared with those without [<xref rid="mco270560-bib-0003" ref-type="bibr">3</xref>].</p><p>Younger women often present with aggressive, hormone&#8208;driven tumors that progress more rapidly, making early detection particularly valuable [<xref rid="mco270560-bib-0003" ref-type="bibr">3</xref>, <xref rid="mco270560-bib-0315" ref-type="bibr">315</xref>, <xref rid="mco270560-bib-0316" ref-type="bibr">316</xref>]. Modeling studies also highlight disparities, showing that Black women experience higher mortality than White women under the same biennial protocols, and that expanding screening to ages 40&#8211;74 years yields a comparable benefit&#8208;to&#8208;harm ratio for Black women as starting at 50 years of age in White women [<xref rid="mco270560-bib-0317" ref-type="bibr">317</xref>]. Our group performed population&#8208;based model analysis and similarly found that Black women reach risk thresholds earlier than White women, supporting race&#8208;adapted screening initiation [<xref rid="mco270560-bib-0318" ref-type="bibr">318</xref>].</p><p>Nonetheless, earlier screening remains controversial. Women aged 40&#8211;49 years experience a high rate of false positive (estimated at 12%), leading to anxiety, biopsies, and overtreatment [<xref rid="mco270560-bib-0319" ref-type="bibr">319</xref>]. Dense breast tissue further reduces mammographic accuracy in this group. Although DBT increases detection of small lesions, it may also heighten overdiagnosis, especially in younger women [<xref rid="mco270560-bib-0320" ref-type="bibr">320</xref>]. Critics further note that observed survival gains may stem more from advances in systemic therapies than from screening itself, as European mortality declines were greatest in women under 50 regardless of screening policies [<xref rid="mco270560-bib-0313" ref-type="bibr">313</xref>, <xref rid="mco270560-bib-0321" ref-type="bibr">321</xref>, <xref rid="mco270560-bib-0322" ref-type="bibr">322</xref>].</p><p>Considering the resource burden of expanding eligibility, universal early screening risks diverting funds from interventions with clearer population&#8208;level benefits [<xref rid="mco270560-bib-0323" ref-type="bibr">323</xref>]. Taken together, current evidence supports lowering initiation age, but the magnitude of benefit is modest and varies across subgroups. A risk&#8208;adapted, rather than uniform, approach may better optimize outcomes.</p></sec><sec id="mco270560-sec-0300"><label>5.2.2</label><title>The Stopping Age of Breast Cancer Screening</title><p>Screening in older women presents the opposite dilemma. While the potential benefits of mammography accrue over years, harms such as false positives and overtreatment are immediate [<xref rid="mco270560-bib-0324" ref-type="bibr">324</xref>, <xref rid="mco270560-bib-0325" ref-type="bibr">325</xref>]. Life expectancy and comorbidities are therefore critical in weighing net value [<xref rid="mco270560-bib-0326" ref-type="bibr">326</xref>]. Modeling studies suggest optimal stopping ages decline with increasing comorbidity, approximately 76, 74, 72, and 66 years for women with none, mild, moderate, and severe comorbidities, respectively, yielding benefit&#8211;harm balances similar to average&#8208;risk women ceasing at 74 years of age. Yet guideline recommendations remain inconsistent: some specify 70 or 75 years of age, while others offer no explicit cutoff (Table&#160;<xref rid="mco270560-tbl-0003" ref-type="table">3</xref>) [<xref rid="mco270560-bib-0327" ref-type="bibr">327</xref>].</p><p>The evidence base is weak, as women &gt;75 years are rarely included in randomized trials [<xref rid="mco270560-bib-0327" ref-type="bibr">327</xref>]. Observational and modeled studies report mixed findings that some suggest mortality reductions in women aged 70&#8211;74 years who continued screening, while benefits disappear beyond 75 years of age [325,<xref rid="mco270560-bib-0328" ref-type="bibr">328</xref>, <xref rid="mco270560-bib-0329" ref-type="bibr">329</xref>, <xref rid="mco270560-bib-0330" ref-type="bibr">330</xref>, <xref rid="mco270560-bib-0331" ref-type="bibr">331</xref>, <xref rid="mco270560-bib-0332" ref-type="bibr">332</xref>]. At the same time, harms escalate, with overdiagnosis estimated at 31% in women aged 70&#8211;74 years, 47% in those 75&#8211;84 years, and more than 50% in women over 85 years [325,<xref rid="mco270560-bib-0326" ref-type="bibr">326</xref>, <xref rid="mco270560-bib-0330" ref-type="bibr">330</xref>, <xref rid="mco270560-bib-0333" ref-type="bibr">333</xref>, <xref rid="mco270560-bib-0334" ref-type="bibr">334</xref>]. False positives, unnecessary biopsies, and detection of indolent DCIS add further burden. New modalities such as DBT have not shown consistent benefit in elderly populations, and the exclusion of older women from clinical trials exacerbates uncertainty [<xref rid="mco270560-bib-0335" ref-type="bibr">335</xref>]. Despite this, many patients and clinicians remain supportive of continued screening, partly because harms are seen as less consequential than late&#8208;stage breast cancer [<xref rid="mco270560-bib-0324" ref-type="bibr">324</xref>, <xref rid="mco270560-bib-0336" ref-type="bibr">336</xref>].</p><p>In this context, personalized decision&#8208;making is essential. Shared decision&#8208;making models that integrate life expectancy, comorbidity, functional status, and patient preferences can guide individualized cessation. Risk&#8208;adapted approaches that incorporate genetic susceptibility or prior cancer history may further refine decisions [<xref rid="mco270560-bib-0337" ref-type="bibr">337</xref>, <xref rid="mco270560-bib-0338" ref-type="bibr">338</xref>]. Such patient&#8208;centered frameworks are more appropriate than rigid chronological thresholds.</p></sec><sec id="mco270560-sec-0310"><label>5.2.3</label><title>Screening Frequency</title><p>The frequency of breast cancer screening remains unsettled. Most guidelines recommend annual or biennial intervals for women aged &#8805;40 years, with some stratification by age (Table&#160;<xref rid="mco270560-tbl-0003" ref-type="table">3</xref>).</p><p>Observational data from more than 8000 patients demonstrated that biennial or irregular screening was associated with later&#8208;stage presentation and 42% higher mortality compared with annual screening, with consistent benefits across age, race, and menopausal status [<xref rid="mco270560-bib-0339" ref-type="bibr">339</xref>]. A systematic review of randomized, observational, and modeling studies concluded that biennial screening achieves a favorable benefit&#8211;harm balance for women aged 50&#8211;69 years, whereas women aged 45&#8211;49 years may benefit more from annual intervals. For women aged &#8805;70 years, findings are inconsistent, with some suggesting reduced harms with longer intervals but limited survival impact [<xref rid="mco270560-bib-0340" ref-type="bibr">340</xref>]. However, the certainty of evidence is low due to a paucity of randomized data directly comparing frequencies. Cost&#8208;effectiveness analyses in different healthcare settings are needed to clarify optimal strategies.</p></sec><sec id="mco270560-sec-0320"><label>5.2.4</label><title>Global Inequities in Breast Cancer Screening</title><p>Screening coverage is highly uneven worldwide. By 2021, 63% of WHO member states/regions reported national screening strategies [data from the Cancer Screening in Five Continents (CanScreen5) database, accessed on July 24, 2025]. The coverage ranged from 83% in Denmark to just 0.25% in North Macedonia (Figure&#160;<xref rid="mco270560-fig-0004" ref-type="fig">4</xref> and Table <xref rid="mco270560-supinfo-0001" ref-type="">S1</xref>). These disparities reflect differences in infrastructure, resource allocation, socioeconomic development, awareness, and cultural attitudes.</p><fig position="float" fig-type="FIGURE" id="mco270560-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Global breast cancer screening program coverage. The world map depicts disparities in screening program coverage across different countries. [Map approval number GS (2016) 1665.]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="MCO2-7-e70560-g002.jpg"/></fig><p>High&#8208;income countries such as the United States, the United Kingdom, and much of Northern Europe countries operate mature, organized programs with regular mammography for women aged 40&#8211;75 years, contributing to early detection and mortality reductions. By contrast, many low&#8208; and middle&#8208;income countries face major barriers. For example, Singapore offers biennial mammography for women aged 50&#8211;69 years, while Indonesia, Thailand, and Vietnam lack organized programs; in Thailand, clinical breast examination often substitutes for mammography, reflecting resource limitations [<xref rid="mco270560-bib-0345" ref-type="bibr">345</xref>].</p><p>Within&#8208;country inequities also persist. In China, screening participation rose from 20% in 2014 to over 50% in 2022, yet regional variation remained stark: Beijing reported coverage above 80%, whereas central and western provinces lagged under 40%. Rural participation has consistently trailed urban uptake. Such disparities translate into later&#8208;stage diagnoses and poorer outcomes for disadvantaged populations [<xref rid="mco270560-bib-0346" ref-type="bibr">346</xref>].</p><p>To address these gaps, the WHO's Global Breast Cancer Initiative aims to reduce mortality by 2.5% annually, emphasizing early detection and standardized treatment, particularly in low&#8208; and middle&#8208;income countries. The initiative promotes context&#8208;appropriate strategies such as ultrasound or clinical breast examination, alongside investment in primary healthcare capacity and public health education. These efforts, if implemented equitably, could narrow disparities and improve global outcomes.</p></sec></sec><sec id="mco270560-sec-0330"><label>5.3</label><title>Promising Strategies for the Future</title><p>Risk&#8208;adapted screening offers a potential pathway to reconcile conflicting evidence on initiation, cessation, and frequency. A multicenter Chinese cohort study demonstrated that women screening at 43, 48, and 55 years of age (high, intermediate, and low risk, respectively) reached mortality risks equivalent to average&#8208;risk women starting at the age of 50 years. Such approaches optimize allocation of limited resources by targeting those most likely to benefit [<xref rid="mco270560-bib-0347" ref-type="bibr">347</xref>]. Interval stratification may further refine the efficiency. A predictive model developed by Kerlikowske and colleagues identified 12% of women who derived clear benefit from annual versus biennial screening, while most women did not. For average&#8208; and high&#8208;risk women whose outcomes were not influenced by frequency alone, alternative modalities may be necessary to improve efficacy [<xref rid="mco270560-bib-0348" ref-type="bibr">348</xref>].</p><p>Collectively, these findings underscore the limitations of one&#8208;size&#8208;fits&#8208;all policies. Moving toward individualized screening strategies&#8212;integrating genetic predisposition, race and ethnicity, health status, and comorbidities&#8212;offers the most promising route to maximizing benefits, minimizing harms, and addressing inequities in global breast cancer control.</p></sec></sec><sec id="mco270560-sec-0340"><label>6</label><title>Prevention</title><p>Breast cancer is associated with both modifiable and nonmodifiable risk factors. Modifiable risks factors, such as BMI, alcohol consumption, and physical activity, can be mitigated through lifestyle changes, whereas nonmodifiable risk factors of genetic susceptibility, breast density, and prior radiation exposure remain largely irreversible. Preventive strategies have been developed to lower cancer risk in high&#8208;risk populations. Table&#160;<xref rid="mco270560-tbl-0004" ref-type="table">4</xref> summarizes current guideline recommendations for preventive interventions.</p><table-wrap position="float" id="mco270560-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Summary of preventive inventions for high&#8208;risk women.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Organization</th><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Published year</th><th align="center" rowspan="1" colspan="1">Country/region</th><th align="center" rowspan="1" colspan="1">Aimed population</th><th align="center" rowspan="1" colspan="1">Interventions</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NCCN</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0213" ref-type="bibr">213</xref>]</td><td align="center" rowspan="1" colspan="1">2025</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">Individuals with BRCA1/2 pathogenic/likely pathogenic germline variants (and other hereditary high&#8208;risk gene carriers)</td><td align="center" rowspan="1" colspan="1">Risk&#8208;reducing mastectomy and enhanced breast MRI surveillance</td></tr><tr><td align="left" rowspan="1" colspan="1">ESMO</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0349" ref-type="bibr">349</xref>]</td><td align="center" rowspan="1" colspan="1">2025</td><td align="center" rowspan="1" colspan="1">Europe</td><td align="center" rowspan="1" colspan="1">Unaffected carriers of germline pathogenic variants in high&#8208;penetrance BC genes</td><td align="center" rowspan="1" colspan="1">Risk&#8208;reducing bilateral mastectomy (RRBM) and enhanced breast MRI surveillance</td></tr><tr><td align="left" rowspan="1" colspan="1">AIOM</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0350" ref-type="bibr">350</xref>]</td><td align="center" rowspan="1" colspan="1">2025</td><td align="center" rowspan="1" colspan="1">Italian</td><td align="center" rowspan="1" colspan="1">BRCA1/2 germline pathogenic&#8208;variant carriers, especially women already affected by breast cancer and at high contralateral/ovarian cancer risk</td><td align="center" rowspan="1" colspan="1">Bilateral risk&#8208;reducing mastectomy and/or salpingo&#8208;oophorectomy</td></tr><tr><td align="left" rowspan="1" colspan="1">EMSO (Pan&#8208;Asian)</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0215" ref-type="bibr">215</xref>, <xref rid="mco270560-bib-0216" ref-type="bibr">216</xref>]</td><td align="center" rowspan="1" colspan="1">2024</td><td align="center" rowspan="1" colspan="1">China, Indonesia, India, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan and Thailand</td><td align="center" rowspan="1" colspan="1">High&#8208;risk women with DCIS history</td><td align="center" rowspan="1" colspan="1">Tamoxifen or AIs</td></tr><tr><td align="left" rowspan="1" colspan="1">BH</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270560-bib-0218" ref-type="bibr">218</xref>]</td><td align="center" rowspan="1" colspan="1">2023</td><td align="center" rowspan="1" colspan="1">Bosnia and Herzegovina (BiH)</td><td align="center" rowspan="1" colspan="1">BRCA1, BRCA2, PALB2, PTEN, and TP53 mutation carriers</td><td align="center" rowspan="1" colspan="1">Consider bilateral prophylactic mastectomy</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="mco270560-sec-0350"><label>6.1</label><title>Risk&#8208;Reducing Medications</title><p>Randomized trials have demonstrated that some medications, including SERMs, such as tamoxifen and raloxifene, and AIs, such as anastrozole and exemestane, can reduce the risk of breast cancer [<xref rid="mco270560-bib-0351" ref-type="bibr">351</xref>, <xref rid="mco270560-bib-0352" ref-type="bibr">352</xref>, <xref rid="mco270560-bib-0353" ref-type="bibr">353</xref>, <xref rid="mco270560-bib-0354" ref-type="bibr">354</xref>, <xref rid="mco270560-bib-0355" ref-type="bibr">355</xref>]. A meta&#8208;analysis reported risk ratios (RR) of 0.69 [95% CI 0.59&#8211;0.84] for tamoxifen, 0.44 [95% CI 0.24&#8211;0.80] for raloxifene, and 0.45 [95% CI 0.26&#8211;0.70] for AIs (anastrozole and exemestane) compared with placebo [<xref rid="mco270560-bib-0356" ref-type="bibr">356</xref>]. The STAR trial demonstrated that tamoxifen was more effective than raloxifene in reducing long&#8208;term breast cancer risk, but raloxifene was associated with fewer adverse events (RR&#160;=&#160;0.55, 95% CI 0.36&#8211;0.83 for endometrial cancer, RR&#160;=&#160;0.19, 95% CI 0.12&#8211;0.29 for uterine hyperplasia, and RR&#160;=&#160;0.75, 95% CI 0.60&#8211;0.93 for thromboembolic events) [<xref rid="mco270560-bib-0357" ref-type="bibr">357</xref>]. To date, no prospective head&#8208;to&#8208;head trials directly comparing SERMs and AIs have been conducted, leaving uncertainty regarding relative efficacy and safety. Of note, tamoxifen is currently recommended only for premenopausal women, reflecting the lack of robust data in this population [<xref rid="mco270560-bib-0358" ref-type="bibr">358</xref>].</p><p>Despite their proven clinical benefits, risk&#8208;reducing medications remain underutilized [<xref rid="mco270560-bib-0359" ref-type="bibr">359</xref>]. A major barrier is women's concern about side effects, including thromboembolic events, endometrial cancer, cataracts, vasomotor symptoms, and musculoskeletal complaints [<xref rid="mco270560-bib-0356" ref-type="bibr">356</xref>, <xref rid="mco270560-bib-0360" ref-type="bibr">360</xref>, <xref rid="mco270560-bib-0361" ref-type="bibr">361</xref>]. Prior to the use of risk&#8208;reducing medications, it is imperative that the risk of disease in women be evaluated in order to ascertain which women are at elevated risk. However, it is challenging for primary care providers to identify women who are eligible for treatment due to a lack of familiarity with risk prediction models, limited time, insufficient information about risk reduction programs, inadequate counselling and training, and insufficient reimbursement [<xref rid="mco270560-bib-0362" ref-type="bibr">362</xref>]. The accuracy of existing risk models is also suboptimal. A meta&#8208;analysis of 25 studies involving over 5 million women found that most methods achieved AUCs of only 0.55&#8211;0.65, limiting clinical utility [<xref rid="mco270560-bib-0356" ref-type="bibr">356</xref>]. Emerging evidence suggests that biomarkers, such as estradiol&#8208;to&#8208;sex hormone&#8208;binding globulin ratios, may help refine the prediction of chemo&#8208;preventive efficacy, but such approaches require validation [<xref rid="mco270560-bib-0363" ref-type="bibr">363</xref>]. Nevertheless, the gap between clinical evidence and real&#8208;world uptake highlights the need for developing more precise risk assessment tools and strategies to overcome the barriers at both patient and provider levels.</p></sec><sec id="mco270560-sec-0360"><label>6.2</label><title>Risk&#8208;Reducing Mastectomy</title><p>Risk&#8208;reducing mastectomy (RRM), also known as prophylactic mastectomy, has three commonly used procedures, including simple (total) mastectomy, skin&#8208;sparing mastectomy, and nipple&#8208;sparing mastectomy, which is usually followed by breast reconstruction [<xref rid="mco270560-bib-0364" ref-type="bibr">364</xref>]. A meta&#8208;analysis showed a 90% reduction in breast cancer risk in women after RRM [<xref rid="mco270560-bib-0365" ref-type="bibr">365</xref>]. However, residual risk remains, and surgical morbidity, such as wound complications and infections, must be carefully weighed. Women with high&#8208;risk germline mutations or prior chest irradiation before the age of 30 years are most likely to benefit from RRM [<xref rid="mco270560-bib-0364" ref-type="bibr">364</xref>].</p><p>For <italic toggle="yes">BRCA1/2</italic> carriers, risk&#8208;reducing salpingo&#8208;oophorectomy (RRSO) is additionally recommended after childbearing to reduce ovarian and breast cancer risk. Prospective data demonstrate that RRSO substantially lowers the incidence of <italic toggle="yes">BRCA</italic>&#8208;related cancers (HR&#160;=&#160;0.25, 95% CI 0.08&#8211;0.74) [<xref rid="mco270560-bib-0366" ref-type="bibr">366</xref>]. Menopause symptoms, such as osteoporosis, cardiovascular disease, changes to vasomotor symptoms, sleep disturbances, and sexual discomfort, are major side effects of RRSO due to the reduction of estrogen and progesterone production [<xref rid="mco270560-bib-0367" ref-type="bibr">367</xref>]. Hormone replacement therapy alleviates these symptoms and does not appear to diminish the protective effect of RRSO [<xref rid="mco270560-bib-0368" ref-type="bibr">368</xref>]. Estrogen&#8208;only regimens may be associated with the lowest breast cancer risk [<xref rid="mco270560-bib-0369" ref-type="bibr">369</xref>].</p><p>Most studies indicate that RRM and RRSO reduce cancer&#8208;related anxiety without significantly impairing health&#8208;related quality of life [<xref rid="mco270560-bib-0367" ref-type="bibr">367</xref>]. Nevertheless, the invasive nature of these procedures necessitates a nuanced discussion of benefits, risks, reconstructive options, and menopausal management, ensuring that patients&#8217; informed choices are grounded in both oncologic outcomes and long&#8208;term quality&#8208;of&#8208;life considerations.</p></sec></sec><sec id="mco270560-sec-0370"><label>7</label><title>Perspectives</title><p>Building on these advances, it is equally important to consider how emerging discoveries may shape the future trajectory of breast cancer research and care. The following sections explore several key opportunities and challenges that are likely to shape ongoing efforts in the field.</p><sec id="mco270560-sec-0380"><label>7.1</label><title>Multiomic Integration for Precision Oncology</title><p>We are transitioning to an era of multidimensional multiomic integration, where emerging technologies such as spatial transcriptomics are unveiling tumor biology at unprecedented depth. Traditional breast cancer research has largely relied on histopathology and bulk sequencing, which provide only averaged molecular information at the tissue level and fail to capture the cellular heterogeneity within tumors. This heterogeneity is a key driver of therapeutic failure and resistance. The advent of scRNA&#8208;seq has provided a powerful tool to address this limitation [<xref rid="mco270560-bib-0370" ref-type="bibr">370</xref>]. By enabling transcriptomic profiling at the single&#8208;cell level, scRNA&#8208;seq has illuminated mechanisms of therapeutic resistance and clonal evolution in breast cancer [<xref rid="mco270560-bib-0371" ref-type="bibr">371</xref>, <xref rid="mco270560-bib-0372" ref-type="bibr">372</xref>]. Spatial transcriptomics, in turn, represents a transformative advance. It complements scRNA&#8208;seq by preserving the spatial context of cells within native tissue and thus overcoming the loss of information about cellular proximity and interactions [<xref rid="mco270560-bib-0373" ref-type="bibr">373</xref>, <xref rid="mco270560-bib-0374" ref-type="bibr">374</xref>]. This capability has revealed dynamic interactions and spatial patterns among tumor, immune, and stromal cells within the TME at an unprecedented resolution [<xref rid="mco270560-bib-0375" ref-type="bibr">375</xref>, <xref rid="mco270560-bib-0376" ref-type="bibr">376</xref>], offering critical insights into why some patients respond to immunotherapy while others do not.</p><p>Multiomic analyses allow systematic interrogation across biological layers, but they also pose the formidable challenge of extracting clinically meaningful insights from exponentially expanding datasets. AI has demonstrated considerable potential in integrating multimodal oncologic data streams [<xref rid="mco270560-bib-0377" ref-type="bibr">377</xref>]. AI plays a pivotal role in enabling precision medicine by predicting patient&#8208;specific therapeutic responses based on genomic, microenvironmental, or imaging features, thereby facilitating optimal treatment selection before therapy initiation. Generative AI is increasingly applied across the drug development pipeline, accelerating the design and screening of novel targeted agents and antibody therapeutics [<xref rid="mco270560-bib-0378" ref-type="bibr">378</xref>]. Deep learning further enables automated extraction of radiomic features from digital pathology and imaging data, shifting from purely morphological assessments toward functional and prognostic predictions [<xref rid="mco270560-bib-0270" ref-type="bibr">270</xref>]. Nevertheless, improving model interpretability and bridging the gap from algorithmic development to clinical application remain urgent priorities.</p></sec><sec id="mco270560-sec-0390"><label>7.2</label><title>Combining Data&#8208;Driven and Hypothesis&#8208;Driven Research</title><p>Unlike the traditional hypothesis&#8208;driven paradigm, which proceeds &#8220;from question to data,&#8221; data&#8208;driven research leverages large&#8208;scale datasets to identify patterns and generate novel hypotheses that can subsequently be validated through rigorous experimentation. This new paradigm has been powered by the accumulation of massive datasets deposited in large public repositories. A notable example is the analysis of breast cancer data from The Cancer Genome Atlas, which identified key prognostic factors and provided new directions for mechanistic studies and therapeutic target discovery [<xref rid="mco270560-bib-0379" ref-type="bibr">379</xref>, <xref rid="mco270560-bib-0380" ref-type="bibr">380</xref>]. Future research will increasingly require the integration of diverse data types that extend beyond conventional clinical phenotypes, encompassing molecular profiles, digital pathology images, socioeconomic variables, and lifestyle factors [<xref rid="mco270560-bib-0381" ref-type="bibr">381</xref>, <xref rid="mco270560-bib-0382" ref-type="bibr">382</xref>]. Achieving this vision necessitates multidisciplinary collaboration among clinicians, experimental scientists, biostatisticians, and machine learning experts, with data sharing and standardization as central challenges. Major obstacles include missing data, inconsistent formats, privacy concerns, and institutional barriers [<xref rid="mco270560-bib-0383" ref-type="bibr">383</xref>]. In addition, global data equity remains a pressing issue. Large&#8208;scale databases are currently dominated by populations of European ancestry, with limited representation of non&#8208;European populations [<xref rid="mco270560-bib-0384" ref-type="bibr">384</xref>]. Establishing ethnically and racially diverse databases and accounting for population diversity and data bias from the outset are essential to ensure that future research advances can benefit all patients equitably.</p></sec></sec><sec id="mco270560-sec-0400"><label>8</label><title>Summary</title><p>Breast cancer is the most common cancer and the leading cause of cancer&#8208;related death among women worldwide. Early detection and the implementation of precision treatment strategies are essential for improving clinical outcomes. This review highlights recent progress in molecular characterization, targeted therapy development, surveillance approaches, and precision prevention. A deeper understanding of the pathogenic mechanisms underlying breast cancer is critical for informing novel therapeutic strategies and refining monitoring and prevention efforts. Targeted treatments tailored to specific molecular features now play a significant role in precision oncology. The integration of endocrine therapy, HER2&#8208;directed agents, CDK4/6i, PI3K/AKT/mTOR pathway inhibitors, ADCs, and immunotherapies has profoundly expanded treatment options, improving outcomes across distinct molecular subtypes. Equally important, advances in screening and surveillance have strengthened the capacity for early detection, translating into better prognosis and reduced mortality. Improvements in diagnostic technologies, particularly imaging, have further enhanced accuracy and decreased both misdiagnosis and underdetection. Risk&#8208;reducing interventions, including preventive surgery and medications, exhibit significant protective benefit for high&#8208;risk carriers in clinical practice, albeit with nuanced considerations of surgical morbidity and long&#8208;term quality of life. These developments collectively underscore the shift from one&#8208;size&#8208;fits&#8208;all approaches toward highly individualized management. Yet, despite remarkable progress, challenges such as therapeutic resistance, toxicity, cost effectiveness, and global inequities in access persist, highlighting the needs of developing a balanced appraisal covering innovation and real&#8208;world applicability.</p><p>Looking ahead, the convergence of multiomic technologies, spatial biology, and AI is expected to broaden the possibilities for breast cancer research and clinical care. These emerging approaches enable detailed characterization of tumor heterogeneity at single&#8208;cell and spatial resolution. Coupled with genomic, transcriptomic, proteomic, radiomic, pathomic, and clinical datasets, they may open new avenues for understanding therapeutic resistance, identifying potential targets, and advancing predictive biomarker development. Importantly, the full realization of these advances will depend on robust data&#8208;sharing frameworks, increased representation of diverse populations, and effective translation from algorithmic models to bedside decision&#8208;making. As breast cancer research advances toward a more integrated, data&#8208;driven paradigm, it will be important to translate scientific insights into practical applications while maintaining an appropriate balance between technological innovation and patient&#8208;centered care. Through such efforts, precision medicine may continue to evolve in ways that benefit individuals at risk for or living with breast cancer, helping ensure that scientific progress ultimately supports improved care for all.</p></sec><sec id="mco270560-sec-0410"><title>Author Contributions</title><p>Conceptualization, data curation, figures drawing, writing &#8211; original draft: Huijun Lei, Jinzhen Fu, and Wei Gu. Figures drawing, writing &#8211; original draft: Hongjin Qiao. Conceptualization, figures drawing, writing &#8211; review and editing: Huixue Guo, Zijian Chen. Writing &#8211; review and editing: San Ming Wang. Project administration, supervision, conceptualization, writing &#8211; review and editing: Tianhui Chen. All authors have read and approved the final manuscript.</p></sec><sec id="mco270560-sec-0430"><title>Funding</title><p>This work was supported by grants from National Key Research&#8208;Development Program of China (2019YFE0198800), Key Research&#8208;Development Program of Zhejiang Province (2017C03013), Ten&#8208;Thousand Talents Plan of Zhejiang Province (2021R52020). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p></sec><sec id="mco270560-sec-0440"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="mco270560-sec-0450"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mco270560-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="mco270560-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Supporting Table 1</bold>: Global breast cancer screening program coverage.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MCO2-7-e70560-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="mco270560-sec-0420"><title>Acknowledgments</title><p>Figures&#160;<xref rid="mco270560-fig-0001" ref-type="fig">1</xref>, <xref rid="mco270560-fig-0002" ref-type="fig">2</xref>, <xref rid="mco270560-fig-0003" ref-type="fig">3</xref> and graphical abstract were created with BioRender.com under an appropriate subscription license. Figure&#160;<xref rid="mco270560-fig-0004" ref-type="fig">4</xref> was generated using ArcGIS software (Esri). The map in Figure&#160;<xref rid="mco270560-fig-0004" ref-type="fig">4</xref> was obtained from the Standard Map Service Ministry of Natural Resources of PCR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bzdt.ch.mnr.gov.cn/index.html" ext-link-type="uri">http://bzdt.ch.mnr.gov.cn/index.html</ext-link>). The authors used ChatGPT (OpenAI) and DeepSeek for linguistic refinement of the text. It is important to note that no AI tools were used in the generation of scientific content, data collection, or data analysis.</p></ack><sec sec-type="data-availability" id="mco270560-sec-0470"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list id="mco270560-bibl-0001"><title>References</title><ref id="mco270560-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mco270560-cite-0001"><string-name name-style="western"><given-names>F.</given-names><surname>Bray</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Laversanne</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Sung</surname></string-name>, et&#160;al., &#8220;<article-title>Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>,&#8221; <source>CA: A Cancer Journal for Clinicians</source><volume>74</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>229</fpage>&#8211;<lpage>263</lpage>.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></ref><ref id="mco270560-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mco270560-cite-0002"><string-name name-style="western"><given-names>W.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Qin</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Chen</surname></string-name>, &#8220;<article-title>Comparative Study of Cancer Profiles between 2020 and 2022 Using Global Cancer Statistics (GLOBOCAN)</article-title>,&#8221; <source>Journal of the National Cancer Center</source><volume>4</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>128</fpage>&#8211;<lpage>134</lpage>.<pub-id pub-id-type="pmid">39282581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jncc.2024.05.001</pub-id><pub-id pub-id-type="pmcid">PMC11390618</pub-id></mixed-citation></ref><ref id="mco270560-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mco270560-cite-0003"><string-name name-style="western"><given-names>A. N.</given-names><surname>Wilkinson</surname></string-name>, <string-name name-style="western"><given-names>L. F.</given-names><surname>Ellison</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Billette</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Seely</surname></string-name>, &#8220;<article-title>Impact of Breast Cancer Screening on 10&#8208;Year Net Survival in Canadian Women Age 40&#8211;49 Years</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>29</issue> (<year>2023</year>): <fpage>4669</fpage>&#8211;<lpage>4677</lpage>.<pub-id pub-id-type="pmid">37540825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.00348</pub-id><pub-id pub-id-type="pmcid">PMC10564321</pub-id></mixed-citation></ref><ref id="mco270560-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mco270560-cite-0004"><string-name name-style="western"><given-names>J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Harper</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>McCormack</surname></string-name>, et&#160;al., &#8220;<article-title>Global Patterns and Trends in Breast Cancer Incidence and Mortality across 185 Countries</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>1154</fpage>&#8211;<lpage>1162</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03502-3</pub-id><pub-id pub-id-type="pmid">39994475</pub-id></mixed-citation></ref><ref id="mco270560-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mco270560-cite-0005"><string-name name-style="western"><given-names>A. G.</given-names><surname>Waks</surname></string-name> and <string-name name-style="western"><given-names>E. P.</given-names><surname>Winer</surname></string-name>, &#8220;<article-title>Breast Cancer Treatment: a Review</article-title>,&#8221; <source>Jama</source><volume>321</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>288</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">30667505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19323</pub-id></mixed-citation></ref><ref id="mco270560-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mco270560-cite-0006"><string-name name-style="western"><given-names>X.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;F.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>Molecular Classification of Hormone Receptor&#8208;positive HER2&#8208;negative Breast Cancer</article-title>,&#8221; <source>Nature Genetics</source><volume>55</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>1696</fpage>&#8211;<lpage>1708</lpage>.<pub-id pub-id-type="pmid">37770634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-023-01507-7</pub-id></mixed-citation></ref><ref id="mco270560-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mco270560-cite-0007"><string-name name-style="western"><given-names>C.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Niu</surname></string-name>, et&#160;al., &#8220;<article-title>Molecular Classification of Hormone Receptor&#8208;positive /HER2&#8208;positive Breast Cancer Reveals Potential Neoadjuvant Therapeutic Strategies</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>10</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>97</fpage>.<pub-id pub-id-type="pmid">40133264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-025-02181-3</pub-id><pub-id pub-id-type="pmcid">PMC11937365</pub-id></mixed-citation></ref><ref id="mco270560-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mco270560-cite-0008"><string-name name-style="western"><given-names>S. Z.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Al&#8208;Eryani</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Roden</surname></string-name>, et&#160;al., &#8220;<article-title>A Single&#8208;cell and Spatially Resolved Atlas of human Breast Cancers</article-title>,&#8221; <source>Nature Genetics</source><volume>53</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>1334</fpage>&#8211;<lpage>1347</lpage>.<pub-id pub-id-type="pmid">34493872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00911-1</pub-id><pub-id pub-id-type="pmcid">PMC9044823</pub-id></mixed-citation></ref><ref id="mco270560-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mco270560-cite-0009"><string-name name-style="western"><given-names>T.</given-names><surname>Fehm</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Cottone</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Dunton</surname></string-name>, et&#160;al., &#8220;<article-title>Trastuzumab deruxtecan versus Treatment of Physician's Choice in Patients with HER2&#8208;positive Metastatic Breast Cancer (DESTINY&#8208;Breast02): Patient&#8208;reported Outcomes from a Randomised, Open&#8208;label, Multicentre, Phase 3 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>25</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>614</fpage>&#8211;<lpage>625</lpage>.<pub-id pub-id-type="pmid">38697155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(24)00128-1</pub-id></mixed-citation></ref><ref id="mco270560-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mco270560-cite-0010"><string-name name-style="western"><given-names>Y.</given-names><surname>Eguchi</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Ishikawa</surname></string-name>, &#8220;<article-title>Synthesis Studies on Anti&#8208;atherosclerotic Agents</article-title>,&#8221; <source>Tokyo Ika Shika Daigaku Iyo Kizai Kenkyusho Hokoku Reports of the Institute for Medical and Dental Engineering, Tokyo Medical and Dental University</source><volume>19</volume> (<year>1985</year>): <fpage>39</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">3869715</pub-id></mixed-citation></ref><ref id="mco270560-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mco270560-cite-0011"><string-name name-style="western"><given-names>A.</given-names><surname>Dilawari</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Buturla</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Osgood</surname></string-name>, et&#160;al., &#8220;<article-title>US Food and Drug Administration Approval Summary: Capivasertib with Fulvestrant for Hormone Receptor&#8208;Positive, Human Epidermal Growth Factor Receptor 2&#8208;Negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alterations</article-title>,&#8221; <source>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</source><volume>42</volume>, no. <issue>34</issue> (<year>2024</year>): <fpage>4103</fpage>&#8211;<lpage>4113</lpage>.<pub-id pub-id-type="pmid">39159418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.24.00427</pub-id><pub-id pub-id-type="pmcid">PMC11588547</pub-id></mixed-citation></ref><ref id="mco270560-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mco270560-cite-0012"><string-name name-style="western"><given-names>M.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Howell</surname></string-name>, et&#160;al., &#8220;<article-title>Capivasertib and fulvestrant for Patients with Hormone Receptor&#8208;positive, HER2&#8208;negative Advanced Breast Cancer (CAPItello&#8208;291): Patient&#8208;reported Outcomes from a Phase 3, Randomised, Double&#8208;blind, Placebo&#8208;controlled Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>25</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1231</fpage>&#8211;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">39214106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(24)00373-5</pub-id></mixed-citation></ref><ref id="mco270560-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mco270560-cite-0013"><string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Cescon</surname></string-name>, et&#160;al., &#8220;<article-title>Results from the Randomized KEYNOTE&#8208;355 Study of Pembrolizumab plus Chemotherapy for Asian Patients with Advanced TNBC</article-title>,&#8221; <source>Nature partner journals breast cancer</source><volume>10</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>79</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-024-00679-7</pub-id><pub-id pub-id-type="pmcid">PMC11393332</pub-id><pub-id pub-id-type="pmid">39266535</pub-id></mixed-citation></ref><ref id="mco270560-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mco270560-cite-0014"><string-name name-style="western"><given-names>K. B.</given-names><surname>Kuchenbaecker</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Hopper</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Barnes</surname></string-name>, et&#160;al., &#8220;<article-title>Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers</article-title>,&#8221; <source>Jama</source><volume>317</volume>, no. <issue>23</issue> (<year>2017</year>): <fpage>2402</fpage>&#8211;<lpage>2416</lpage>.<pub-id pub-id-type="pmid">28632866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.7112</pub-id></mixed-citation></ref><ref id="mco270560-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mco270560-cite-0015"><collab collab-type="authors">Collaborative Group on Hormonal Factors in Breast C</collab>
. &#8220;<article-title>Familial Breast Cancer: Collaborative Reanalysis of Individual Data from 52 Epidemiological Studies Including 58,209 Women with Breast Cancer and 101,986 Women without the Disease</article-title>,&#8221; <source>Lancet</source><year>2001</year>;<volume>358</volume>(<issue>9291</issue>):<fpage>1389</fpage>&#8211;<lpage>1399</lpage>.<pub-id pub-id-type="pmid">11705483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(01)06524-2</pub-id></mixed-citation></ref><ref id="mco270560-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mco270560-cite-0016"><string-name name-style="western"><given-names>G. S.</given-names><surname>Mannu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dodwell</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Broggio</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Charman</surname></string-name>, and <string-name name-style="western"><given-names>S. C.</given-names><surname>Darby</surname></string-name>, &#8220;<article-title>Invasive Breast Cancer and Breast Cancer Death after Non&#8208;screen Detected Ductal Carcinoma in Situ from 1990 to 2018 in England: Population Based Cohort Study</article-title>,&#8221; <source>BMJ (Clinical research ed)</source><volume>384</volume> (<year>2024</year>): <elocation-id>e075498</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2023-075498</pub-id><pub-id pub-id-type="pmcid">PMC10806881</pub-id><pub-id pub-id-type="pmid">38267073</pub-id></mixed-citation></ref><ref id="mco270560-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mco270560-cite-0017"><string-name name-style="western"><given-names>M. L.</given-names><surname>De Bruin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sparidans</surname></string-name>, <string-name name-style="western"><given-names>M. B.</given-names><surname>van't Veer</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk after Smaller Radiation Volumes</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>27</volume>, no. <issue>26</issue> (<year>2009</year>): <fpage>4239</fpage>&#8211;<lpage>4246</lpage>.<pub-id pub-id-type="pmid">19667275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.19.9174</pub-id></mixed-citation></ref><ref id="mco270560-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mco270560-cite-0018"><string-name name-style="western"><given-names>V. A.</given-names><surname>McCormack</surname></string-name> and <string-name name-style="western"><given-names>I.</given-names><surname>dos Santos Silva</surname></string-name>, &#8220;<article-title>Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: a Meta&#8208;analysis</article-title>,&#8221; <source>Cancer Epidemiology, Biomarkers &amp; Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</source><volume>15</volume>, no. <issue>6</issue> (<year>2006</year>): <fpage>1159</fpage>&#8211;<lpage>1169</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-06-0034</pub-id><pub-id pub-id-type="pmid">16775176</pub-id></mixed-citation></ref><ref id="mco270560-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mco270560-cite-0019"><string-name name-style="western"><given-names>B.</given-names><surname>Lauby&#8208;Secretan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Scoccianti</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Loomis</surname></string-name>, et&#160;al., &#8220;<article-title>Breast&#8208;cancer Screening&#8211;viewpoint of the IARC Working Group</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>372</volume>, no. <issue>24</issue> (<year>2015</year>): <fpage>2353</fpage>&#8211;<lpage>2358</lpage>.<pub-id pub-id-type="pmid">26039523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMsr1504363</pub-id></mixed-citation></ref><ref id="mco270560-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mco270560-cite-0020"><collab collab-type="authors">Independent UKPoBCS</collab>
. &#8220;<article-title>The Benefits and Harms of Breast Cancer Screening: an Independent Review</article-title>,&#8221; <source>Lancet</source><year>2012</year>;<volume>380</volume>(<issue>9855</issue>):<fpage>1778</fpage>&#8211;<lpage>1786</lpage>.<pub-id pub-id-type="pmid">23117178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)61611-0</pub-id></mixed-citation></ref><ref id="mco270560-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mco270560-cite-0021"><string-name name-style="western"><given-names>A.</given-names><surname>Bleyer</surname></string-name> and <string-name name-style="western"><given-names>H. G.</given-names><surname>Welch</surname></string-name>, &#8220;<article-title>Effect of Three Decades of Screening Mammography on Breast&#8208;cancer Incidence</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>367</volume>, no. <issue>21</issue> (<year>2012</year>): <fpage>1998</fpage>&#8211;<lpage>2005</lpage>.<pub-id pub-id-type="pmid">23171096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1206809</pub-id></mixed-citation></ref><ref id="mco270560-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mco270560-cite-0022"><string-name name-style="western"><given-names>N. J.</given-names><surname>Massat</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dibden</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Parmar</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, <string-name name-style="western"><given-names>P. D.</given-names><surname>Sasieni</surname></string-name>, and <string-name name-style="western"><given-names>S. W.</given-names><surname>Duffy</surname></string-name>, &#8220;<article-title>Impact of Screening on Breast Cancer Mortality: the UK Program 20 Years On</article-title>,&#8221; <source>Cancer epidemiology, biomarkers &amp; prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</source><volume>25</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>455</fpage>&#8211;<lpage>462</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-15-0803</pub-id><pub-id pub-id-type="pmid">26646362</pub-id></mixed-citation></ref><ref id="mco270560-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mco270560-cite-0023"><string-name name-style="western"><given-names>S. K.</given-names><surname>Plevritis</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Munoz</surname></string-name>, <string-name name-style="western"><given-names>A. W.</given-names><surname>Kurian</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Screening and Treatment with Breast Cancer Mortality by Molecular Subtype in US Women, 2000&#8211;2012</article-title>,&#8221; <source>Jama</source><volume>319</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>154</fpage>&#8211;<lpage>164</lpage>.<pub-id pub-id-type="pmid">29318276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.19130</pub-id><pub-id pub-id-type="pmcid">PMC5833658</pub-id></mixed-citation></ref><ref id="mco270560-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mco270560-cite-0024"><string-name name-style="western"><given-names>I.</given-names><surname>Soerjomataram</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cabasag</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bardot</surname></string-name>, et&#160;al., &#8220;<article-title>Cancer Survival in Africa, central and South America, and Asia (SURVCAN&#8208;3): a Population&#8208;based Benchmarking Study in 32 Countries</article-title>,&#8221; <source>The Lancet Oncology</source><volume>24</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>22</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">36603919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00704-5</pub-id></mixed-citation></ref><ref id="mco270560-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="mco270560-cite-0025"><string-name name-style="western"><given-names>N.</given-names><surname>Mavaddat</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Michailidou</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Dennis</surname></string-name>, et&#160;al., &#8220;<article-title>Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes</article-title>,&#8221; <source>American Journal of Human Genetics</source><volume>104</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>21</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">30554720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2018.11.002</pub-id><pub-id pub-id-type="pmcid">PMC6323553</pub-id></mixed-citation></ref><ref id="mco270560-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mco270560-cite-0026"><string-name name-style="western"><given-names>N. K.</given-names><surname>Stout</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Miglioretti</surname></string-name>, <string-name name-style="western"><given-names>Y. R.</given-names><surname>Su</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density</article-title>,&#8221; <source>JAMA internal medicine</source><volume>184</volume>, no. <issue>10</issue> (<year>2024</year>): <fpage>1222</fpage>&#8211;<lpage>1231</lpage>.<pub-id pub-id-type="pmid">39186304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2024.4224</pub-id><pub-id pub-id-type="pmcid">PMC11348087</pub-id></mixed-citation></ref><ref id="mco270560-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="mco270560-cite-0027"><string-name name-style="western"><given-names>N.</given-names><surname>Eisemann</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bunk</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Mukama</surname></string-name>, et&#160;al., &#8220;<article-title>Nationwide Real&#8208;world Implementation of AI for Cancer Detection in Population&#8208;based Mammography Screening</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>917</fpage>&#8211;<lpage>924</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03408-6</pub-id><pub-id pub-id-type="pmcid">PMC11922743</pub-id><pub-id pub-id-type="pmid">39775040</pub-id></mixed-citation></ref><ref id="mco270560-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="mco270560-cite-0028"><string-name name-style="western"><given-names>Y.&#8208;W.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Ryu</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>An</surname></string-name>, et&#160;al., &#8220;<article-title>Artificial Intelligence for Breast Cancer Screening in Mammography (AI&#8208;STREAM): Preliminary Analysis of a Prospective Multicenter Cohort Study</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>2248</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-57469-3</pub-id><pub-id pub-id-type="pmcid">PMC11885569</pub-id><pub-id pub-id-type="pmid">40050619</pub-id></mixed-citation></ref><ref id="mco270560-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="mco270560-cite-0029"><string-name name-style="western"><given-names>M. A.</given-names><surname>Martiniussen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Larsen</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hovda</surname></string-name>, et&#160;al., &#8220;<article-title>Performance of Two Deep Learning&#8208;based AI Models for Breast Cancer Detection and Localization on Screening Mammograms from BreastScreen Norway</article-title>,&#8221; <source>Radiol Artif Intell</source><volume>7</volume>, no. <issue>3</issue> (<year>2025</year>): <elocation-id>e240039</elocation-id>.<pub-id pub-id-type="pmid">39907587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/ryai.240039</pub-id></mixed-citation></ref><ref id="mco270560-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="mco270560-cite-0030"><string-name name-style="western"><given-names>F.</given-names><surname>Derakhshan</surname></string-name> and <string-name name-style="western"><given-names>J. S.</given-names><surname>Reis&#8208;Filho</surname></string-name>, &#8220;<article-title>Pathogenesis of Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Annual review of pathology</source><volume>17</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>181</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathol-042420-093238</pub-id><pub-id pub-id-type="pmcid">PMC9231507</pub-id><pub-id pub-id-type="pmid">35073169</pub-id></mixed-citation></ref><ref id="mco270560-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="mco270560-cite-0031"><string-name name-style="western"><given-names>Y.&#8208;Z.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Jin</surname></string-name>, &#8220;<article-title>Integrated Multiomic Profiling of Breast Cancer in the Chinese Population Reveals Patient Stratification and Therapeutic Vulnerabilities</article-title>,&#8221; <source>Nature Cancer</source><volume>5</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>673</fpage>&#8211;<lpage>690</lpage>.<pub-id pub-id-type="pmid">38347143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-024-00725-0</pub-id></mixed-citation></ref><ref id="mco270560-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="mco270560-cite-0032"><string-name name-style="western"><given-names>A.</given-names><surname>Calabrese</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>von Arx</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Tafuti</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pensabene</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>De Laurentiis</surname></string-name>, &#8220;<article-title>Prevention, Diagnosis and Clinical Management of Hereditary Breast Cancer beyond BRCA1/2 Genes</article-title>,&#8221; <source>Cancer Treatment Reviews</source><volume>129</volume> (<year>2024</year>): <elocation-id>102785</elocation-id>.<pub-id pub-id-type="pmid">38870570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2024.102785</pub-id></mixed-citation></ref><ref id="mco270560-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="mco270560-cite-0033"><string-name name-style="western"><given-names>V.</given-names><surname>Barili</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Ambrosini</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Bortesi</surname></string-name>, et&#160;al., &#8220;<article-title>Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing</article-title>,&#8221; <source>Genes</source><volume>15</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>219</fpage>.<pub-id pub-id-type="pmid">38397209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes15020219</pub-id><pub-id pub-id-type="pmcid">PMC10888198</pub-id></mixed-citation></ref><ref id="mco270560-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mco270560-cite-0034"><collab collab-type="authors">Breast Cancer Association C</collab>
, <string-name name-style="western"><given-names>L.</given-names><surname>Dorling</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Carvalho</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Risk Genes &#8208; association Analysis in More than 113,000 Women</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>384</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>428</fpage>&#8211;<lpage>439</lpage>.<pub-id pub-id-type="pmid">33471991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1913948</pub-id><pub-id pub-id-type="pmcid">PMC7611105</pub-id></mixed-citation></ref><ref id="mco270560-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mco270560-cite-0035"><string-name name-style="western"><given-names>W.</given-names><surname>Mei</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Faraj Tabrizi</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Godina</surname></string-name>, &#8220;<article-title>A Commonly Inherited human PCSK9 Germline Variant Drives Breast Cancer Metastasis via LRP1 Receptor</article-title>,&#8221; <source>Cell</source><volume>188</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>371</fpage>&#8211;<lpage>389.e28</lpage>.<pub-id pub-id-type="pmid">39657676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.11.009</pub-id><pub-id pub-id-type="pmcid">PMC11770377</pub-id></mixed-citation></ref><ref id="mco270560-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mco270560-cite-0036"><string-name name-style="western"><given-names>H.</given-names><surname>Qayoom</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Ul Haq</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sofi</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Jan</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jan</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Mir</surname></string-name>, &#8220;<article-title>Targeting Mutant p53: a Key Player in Breast Cancer Pathogenesis and beyond</article-title>,&#8221; <source>Cell Commun Signaling</source><volume>22</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>484</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01863-9</pub-id><pub-id pub-id-type="pmcid">PMC11466041</pub-id><pub-id pub-id-type="pmid">39390510</pub-id></mixed-citation></ref><ref id="mco270560-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mco270560-cite-0037"><string-name name-style="western"><given-names>D.</given-names><surname>Miricescu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Totan</surname></string-name>, <string-name name-style="western"><given-names>I.&#8208;I.</given-names><surname>Stanescu&#8208;Spinu</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Badoiu</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Stefani</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Greabu</surname></string-name>, &#8220;<article-title>PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: from Molecular Landscape to Clinical Aspects</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>173</fpage>.<pub-id pub-id-type="pmid">33375317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22010173</pub-id><pub-id pub-id-type="pmcid">PMC7796017</pub-id></mixed-citation></ref><ref id="mco270560-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mco270560-cite-0038"><string-name name-style="western"><given-names>A. M.</given-names><surname>Brufsky</surname></string-name> and <string-name name-style="western"><given-names>M. N.</given-names><surname>Dickler</surname></string-name>, &#8220;<article-title>Estrogen Receptor&#8208;positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance</article-title>,&#8221; <source>The Oncologist</source><volume>23</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>528</fpage>&#8211;<lpage>539</lpage>.<pub-id pub-id-type="pmid">29352052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2017-0423</pub-id><pub-id pub-id-type="pmcid">PMC5947450</pub-id></mixed-citation></ref><ref id="mco270560-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mco270560-cite-0039"><string-name name-style="western"><given-names>F.</given-names><surname>Andr&#233;</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Ciruelos</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Rubovszky</surname></string-name>, et&#160;al., &#8220;<article-title>Alpelisib for PIK3CA&#8208;Mutated, Hormone Receptor&#8211;Positive Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>380</volume>, no. <issue>20</issue> (<year>2019</year>): <fpage>1929</fpage>&#8211;<lpage>1940</lpage>.<pub-id pub-id-type="pmid">31091374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1813904</pub-id></mixed-citation></ref><ref id="mco270560-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mco270560-cite-0040"><string-name name-style="western"><given-names>K.</given-names><surname>Kalinsky</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Bianchini</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Hamilton</surname></string-name>, et&#160;al., &#8220;<article-title>Abemaciclib Plus Fulvestrant in Advanced Breast Cancer after Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial</article-title>,&#8221; <source>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</source><volume>43</volume>, no. <issue>9</issue> (<year>2025</year>): <fpage>1101</fpage>&#8211;<lpage>1112</lpage>.<pub-id pub-id-type="pmid">39693591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO-24-02086</pub-id><pub-id pub-id-type="pmcid">PMC11936477</pub-id></mixed-citation></ref><ref id="mco270560-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mco270560-cite-0041"><string-name name-style="western"><given-names>F.&#8208;C.</given-names><surname>Bidard</surname></string-name>, <string-name name-style="western"><given-names>A.&#8208;C.</given-names><surname>Hardy&#8208;Bessard</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Dalenc</surname></string-name>, et&#160;al., &#8220;<article-title>Switch to Fulvestrant and Palbociclib versus no Switch in Advanced Breast Cancer with Rising ESR1 Mutation during Aromatase Inhibitor and Palbociclib Therapy (PADA&#8208;1): a Randomised, Open&#8208;label, Multicentre, Phase 3 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>23</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>1367</fpage>&#8211;<lpage>1377</lpage>.<pub-id pub-id-type="pmid">36183733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00555-1</pub-id></mixed-citation></ref><ref id="mco270560-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mco270560-cite-0042"><string-name name-style="western"><given-names>F.&#8208;C.</given-names><surname>Bidard</surname></string-name>, <string-name name-style="western"><given-names>E. L.</given-names><surname>Mayer</surname></string-name>, and <string-name name-style="western"><given-names>Y. H.</given-names><surname>Park</surname></string-name>, &#8220;<article-title>First&#8208;Line Camizestrant for Emerging ESR1&#8208;Mutated Advanced Breast Cancer</article-title>,&#8221; <source>The New England Journal of Medicine</source><volume>393</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>569</fpage>&#8211;<lpage>580</lpage>.<pub-id pub-id-type="pmid">40454637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2502929</pub-id></mixed-citation></ref><ref id="mco270560-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mco270560-cite-0043"><string-name name-style="western"><given-names>C.</given-names><surname>Yi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Disruption of YY1&#8208;EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development</article-title>,&#8221; <source>Cancers</source><volume>13</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>2402</fpage>.<pub-id pub-id-type="pmid">34065631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13102402</pub-id><pub-id pub-id-type="pmcid">PMC8156467</pub-id></mixed-citation></ref><ref id="mco270560-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mco270560-cite-0044"><string-name name-style="western"><given-names>R. S.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Sad</surname></string-name>, <string-name name-style="western"><given-names>D. V.</given-names><surname>Fawwal</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Spangle</surname></string-name>, &#8220;<article-title>Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response</article-title>,&#8221; <source>Cancers</source><volume>15</volume>, no. <issue>15</issue> (<year>2023</year>): <fpage>4005</fpage>.<pub-id pub-id-type="pmid">37568822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15154005</pub-id><pub-id pub-id-type="pmcid">PMC10417282</pub-id></mixed-citation></ref><ref id="mco270560-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mco270560-cite-0045"><string-name name-style="western"><given-names>N.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Yu</surname></string-name>, &#8220;<article-title>Targeting Epigenetic Regulators to Overcome Drug Resistance in Cancers</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>69</fpage>.<pub-id pub-id-type="pmid">36797239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01341-7</pub-id><pub-id pub-id-type="pmcid">PMC9935618</pub-id></mixed-citation></ref><ref id="mco270560-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mco270560-cite-0046"><string-name name-style="western"><given-names>G.</given-names><surname>Mahendran</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Shangaradas</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Romero&#8208;Moreno</surname></string-name>, et&#160;al., &#8220;<article-title>Unlocking the Epigenetic Code: New Insights into Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Frontiers in Oncology</source><volume>14</volume>, (<year>2024</year>): <elocation-id>1499950</elocation-id>.<pub-id pub-id-type="pmid">39744000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1499950</pub-id><pub-id pub-id-type="pmcid">PMC11688480</pub-id></mixed-citation></ref><ref id="mco270560-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mco270560-cite-0047"><string-name name-style="western"><given-names>R.</given-names><surname>Shukla</surname></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Upton</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mu&#241;oz&#8208;Lopez</surname></string-name>, et&#160;al., &#8220;<article-title>Endogenous Retrotransposition Activates Oncogenic Pathways in Hepatocellular Carcinoma</article-title>,&#8221; <source>Cell</source><volume>153</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>101</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="pmid">23540693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2013.02.032</pub-id><pub-id pub-id-type="pmcid">PMC3898742</pub-id></mixed-citation></ref><ref id="mco270560-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="mco270560-cite-0048"><collab collab-type="authors">The Cancer Genome Atlas Network</collab>
, &#8220;<article-title>Comprehensive Molecular Portraits of Human Breast Tumours</article-title>,&#8221; <source>Nature</source><volume>490</volume>, no. <issue>7418</issue> (<year>2012</year>): <fpage>61</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">23000897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11412</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id></mixed-citation></ref><ref id="mco270560-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="mco270560-cite-0049"><string-name name-style="western"><given-names>J. E.</given-names><surname>Barrett</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Herzog</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jones</surname></string-name>, et&#160;al., &#8220;<article-title>The WID&#8208;BC&#8208;index Identifies Women with Primary Poor Prognostic Breast Cancer Based on DNA Methylation in Cervical Samples</article-title>,&#8221; <source>Nature Communications</source><volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>449</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27918-w</pub-id><pub-id pub-id-type="pmcid">PMC8807602</pub-id><pub-id pub-id-type="pmid">35105882</pub-id></mixed-citation></ref><ref id="mco270560-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="mco270560-cite-0050"><string-name name-style="western"><given-names>M.</given-names><surname>Aine</surname></string-name>, <string-name name-style="western"><given-names>D. F.</given-names><surname>Nacer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Arbajian</surname></string-name>, et&#160;al., &#8220;<article-title>The DNA Methylation Landscape of Primary Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>3041</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-58158-x</pub-id><pub-id pub-id-type="pmcid">PMC11953470</pub-id><pub-id pub-id-type="pmid">40155623</pub-id></mixed-citation></ref><ref id="mco270560-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="mco270560-cite-0051"><string-name name-style="western"><given-names>J.</given-names><surname>Feng</surname></string-name> and <string-name name-style="western"><given-names>X.</given-names><surname>Meng</surname></string-name>, &#8220;<article-title>Histonemodificationandhistonemodification&#8208;targetedanti&#8208;cancerdrugsinbreastcancer:Fundamentalsandbeyond</article-title>,&#8221; <source>Frontiers in pharmacology</source><volume>13</volume> (<year>2022</year>): <elocation-id>946811</elocation-id>.<pub-id pub-id-type="pmid">36188615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.946811</pub-id><pub-id pub-id-type="pmcid">PMC9522521</pub-id></mixed-citation></ref><ref id="mco270560-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="mco270560-cite-0052"><string-name name-style="western"><given-names>P.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>The Histone Acetylation Modifications of Breast Cancer and Their Therapeutic Implications</article-title>,&#8221; <source>Pathology Oncology Research</source><volume>24</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>403</fpage>&#8211;<lpage>413</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12253-018-0433-5</pub-id><pub-id pub-id-type="pmid">29948617</pub-id></mixed-citation></ref><ref id="mco270560-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="mco270560-cite-0053"><string-name name-style="western"><given-names>L.</given-names><surname>Zhou</surname></string-name> and <string-name name-style="western"><given-names>C.&#8208;W.</given-names><surname>Yu</surname></string-name>, &#8220;<article-title>Epigenetic Modulations in Triple&#8208;negative Breast Cancer: Therapeutic Implications for Tumor Microenvironment</article-title>,&#8221; <source>Pharmacological Research</source><volume>204</volume> (<year>2024</year>): <elocation-id>107205</elocation-id>.<pub-id pub-id-type="pmid">38719195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2024.107205</pub-id></mixed-citation></ref><ref id="mco270560-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="mco270560-cite-0054"><string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Xiao</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hirukawa</surname></string-name>, et&#160;al., &#8220;<article-title>Ezh2 promotes Mammary Tumor Initiation through Epigenetic Regulation of the Wnt and mTORC1 Signaling Pathways</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>120</volume>, no. <issue>33</issue> (<year>2023</year>): <elocation-id>e2303010120</elocation-id>.<pub-id pub-id-type="pmid">37549258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2303010120</pub-id><pub-id pub-id-type="pmcid">PMC10438390</pub-id></mixed-citation></ref><ref id="mco270560-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="mco270560-cite-0055"><string-name name-style="western"><given-names>D.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>H3K36me2 methyltransferase NSD2/WHSC1 Promotes Triple&#8208;negative Breast Cancer Metastasis via Activation of ULK1&#8208;dependent Autophagy</article-title>,&#8221; <source>Autophagy</source><volume>21</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>1824</fpage>&#8211;<lpage>1842</lpage>.<pub-id pub-id-type="pmid">40097917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2025.2479995</pub-id><pub-id pub-id-type="pmcid">PMC12283020</pub-id></mixed-citation></ref><ref id="mco270560-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="mco270560-cite-0056"><string-name name-style="western"><given-names>R.</given-names><surname>Be&#328;a&#269;ka</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Szab&#243;ov&#225;</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Gu&#318;a&#353;ov&#225;</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Hertelyov&#225;</surname></string-name>, &#8220;<article-title>Non&#8208;coding Rnas in Breast Cancer: Diagnostic and Therapeutic Implications</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>26</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>127</fpage>.<pub-id pub-id-type="pmid">39795985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26010127</pub-id><pub-id pub-id-type="pmcid">PMC11719911</pub-id></mixed-citation></ref><ref id="mco270560-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="mco270560-cite-0057"><string-name name-style="western"><given-names>E. A.</given-names><surname>Sidorova</surname></string-name>, <string-name name-style="western"><given-names>Y. V.</given-names><surname>Zhernov</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Antsupova</surname></string-name>, et&#160;al., &#8220;<article-title>The Role of Different Types of microRNA in the Pathogenesis of Breast and Prostate Cancer</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>1980</fpage>.<pub-id pub-id-type="pmid">36768298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24031980</pub-id><pub-id pub-id-type="pmcid">PMC9916830</pub-id></mixed-citation></ref><ref id="mco270560-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="mco270560-cite-0058"><string-name name-style="western"><given-names>S.</given-names><surname>Imani</surname></string-name>, <string-name name-style="western"><given-names>R.&#8208;C.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Fu</surname></string-name>, &#8220;<article-title>MicroRNA&#8208;34 family in Breast Cancer: from Research to Therapeutic Potential</article-title>,&#8221; <source>Journal of Cancer</source><volume>9</volume>, no. <issue>20</issue> (<year>2018</year>): <fpage>3765</fpage>&#8211;<lpage>3775</lpage>.<pub-id pub-id-type="pmid">30405848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.25576</pub-id><pub-id pub-id-type="pmcid">PMC6216011</pub-id></mixed-citation></ref><ref id="mco270560-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="mco270560-cite-0059"><string-name name-style="western"><given-names>A.</given-names><surname>Maharati</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Moghbeli</surname></string-name>, &#8220;<article-title>Long Non&#8208;coding RNAs as the Critical Regulators of PI3K/AKT, TGF&#8208;&#946;, and MAPK Signaling Pathways during Breast Tumor Progression</article-title>,&#8221; <source>Journal of translational medicine</source><volume>21</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>556</fpage>.<pub-id pub-id-type="pmid">37596669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04434-7</pub-id><pub-id pub-id-type="pmcid">PMC10439650</pub-id></mixed-citation></ref><ref id="mco270560-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="mco270560-cite-0060"><string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Epigenetic Regulation of NAMPT by NAMPT&#8208;asdrives Metastatic Progression in Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Cancer Research</source><volume>79</volume>, no. <issue>13</issue> (<year>2019</year>): <fpage>3347</fpage>&#8211;<lpage>3359</lpage>.<pub-id pub-id-type="pmid">30940661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-18-3418</pub-id></mixed-citation></ref><ref id="mco270560-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="mco270560-cite-0061"><string-name name-style="western"><given-names>H.</given-names><surname>Schwarzenbach</surname></string-name> and <string-name name-style="western"><given-names>P. B.</given-names><surname>Gahan</surname></string-name>, &#8220;<article-title>Interplay between LncRNAs and microRNAs in Breast Cancer</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>8095</fpage>.<pub-id pub-id-type="pmid">37175800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24098095</pub-id><pub-id pub-id-type="pmcid">PMC10179369</pub-id></mixed-citation></ref><ref id="mco270560-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="mco270560-cite-0062"><string-name name-style="western"><given-names>Y.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Mulay</surname></string-name>, et&#160;al., &#8220;<article-title>Integrated Profiling of Metaplastic Breast Cancer Identifies Putative Master Regulators of Intratumoral Heterogeneity</article-title>,&#8221; <source>NPJ Breast Cancer</source><volume>11</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>89</fpage>.<pub-id pub-id-type="pmid">40790295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-025-00807-x</pub-id><pub-id pub-id-type="pmcid">PMC12340010</pub-id></mixed-citation></ref><ref id="mco270560-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="mco270560-cite-0063"><string-name name-style="western"><given-names>W.&#8208;Y.</given-names><surname>Sheng</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;Q.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>A Novel SWI/SNF Complex Promotes Triple&#8208;negative Breast Cancer Progression</article-title>,&#8221; <source>Cellular &amp; Molecular Biology Letters</source><volume>30</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>105</fpage>.<pub-id pub-id-type="pmid">40890601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11658-025-00788-6</pub-id><pub-id pub-id-type="pmcid">PMC12403323</pub-id></mixed-citation></ref><ref id="mco270560-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="mco270560-cite-0064"><string-name name-style="western"><given-names>C. L.</given-names><surname>Alves</surname></string-name> and <string-name name-style="western"><given-names>H. J. D.</given-names><surname>Ditzel</surname></string-name>, &#8220;<article-title>Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume>, no. <issue>5</issue> (<year>2023</year>): <fpage>4522</fpage>.<pub-id pub-id-type="pmid">36901954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054522</pub-id><pub-id pub-id-type="pmcid">PMC10003259</pub-id></mixed-citation></ref><ref id="mco270560-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="mco270560-cite-0065"><string-name name-style="western"><given-names>C.</given-names><surname>Le</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Ferreira</surname></string-name>, and <string-name name-style="western"><given-names>F. A.</given-names><surname>Pakdel</surname></string-name>, &#8220;<article-title>A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume> (<year>2023</year>): <fpage>6834</fpage>.<pub-id pub-id-type="pmid">37047814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24076834</pub-id><pub-id pub-id-type="pmcid">PMC10095386</pub-id></mixed-citation></ref><ref id="mco270560-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="mco270560-cite-0066"><string-name name-style="western"><given-names>A. E.</given-names><surname>Maennling</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Tur</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Niebert</surname></string-name>, et&#160;al., &#8220;<article-title>Molecular Targeting Therapy against EGFR family in Breast Cancer: Progress and Future Potentials</article-title>,&#8221; <source>Cancers</source><volume>11</volume>, no. <issue>12</issue> (<year>2019</year>): <fpage>1826</fpage>.<pub-id pub-id-type="pmid">31756933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11121826</pub-id><pub-id pub-id-type="pmcid">PMC6966464</pub-id></mixed-citation></ref><ref id="mco270560-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="mco270560-cite-0067"><string-name name-style="western"><given-names>S.</given-names><surname>Pernas</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Tolaney</surname></string-name>, <string-name name-style="western"><given-names>E. P.</given-names><surname>Winer</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Goel</surname></string-name>, &#8220;<article-title>CDK4/6 inhibition in Breast Cancer: Current Practice and Future Directions</article-title>,&#8221; <source>Therapeutic Advances in Medical Oncology</source><volume>10</volume> (<year>2018</year>): <elocation-id>1758835918786451</elocation-id>.<pub-id pub-id-type="pmid">30038670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1758835918786451</pub-id><pub-id pub-id-type="pmcid">PMC6050811</pub-id></mixed-citation></ref><ref id="mco270560-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="mco270560-cite-0068"><string-name name-style="western"><given-names>A.</given-names><surname>Shanabag</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Armand</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Son</surname></string-name>, and <string-name name-style="western"><given-names>H. W.</given-names><surname>Yang</surname></string-name>, &#8220;<article-title>Targeting CDK4/6 in Breast Cancer</article-title>,&#8221; <source>Experimental &amp; molecular medicine</source><volume>57</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>312</fpage>&#8211;<lpage>322</lpage>.<pub-id pub-id-type="pmid">39930131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-025-01395-3</pub-id><pub-id pub-id-type="pmcid">PMC11873051</pub-id></mixed-citation></ref><ref id="mco270560-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="mco270560-cite-0069"><string-name name-style="western"><given-names>M. P.</given-names><surname>Goetz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, et&#160;al., &#8220;<article-title>MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology</source><volume>35</volume>, no. <issue>32</issue> (<year>2017</year>): <fpage>3638</fpage>&#8211;<lpage>3646</lpage>.<pub-id pub-id-type="pmid">28968163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.75.6155</pub-id></mixed-citation></ref><ref id="mco270560-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="mco270560-cite-0070"><string-name name-style="western"><given-names>P.</given-names><surname>Neven</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Fasching</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chia</surname></string-name>, et&#160;al., &#8220;<article-title>Updated Overall Survival from the MONALEESA&#8208;3 Trial in Postmenopausal Women with HR+/HER2&#8208; advanced Breast Cancer Receiving First&#8208;line Ribociclib plus Fulvestrant</article-title>,&#8221; <source>Breast cancer research: BCR</source><volume>25</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>103</fpage>.<pub-id pub-id-type="pmid">37653397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-023-01701-9</pub-id><pub-id pub-id-type="pmcid">PMC10469877</pub-id></mixed-citation></ref><ref id="mco270560-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="mco270560-cite-0071"><string-name name-style="western"><given-names>B.</given-names><surname>O'Leary</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Cutts</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA&#8208;3 Trial</article-title>,&#8221; <source>Cancer Discovery</source><volume>8</volume>, no. <issue>11</issue> (<year>2018</year>): <fpage>1390</fpage>&#8211;<lpage>1403</lpage>.<pub-id pub-id-type="pmid">30206110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-18-0264</pub-id><pub-id pub-id-type="pmcid">PMC6368247</pub-id></mixed-citation></ref><ref id="mco270560-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="mco270560-cite-0072"><string-name name-style="western"><given-names>G. W.</given-names><surname>Sledge</surname><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toi</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Neven</surname></string-name>, et&#160;al., &#8220;<article-title>MONARCH 2: Abemaciclib in Combination with fulvestrant in Women with HR+/HER2&#8208; advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy</article-title>,&#8221; <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source><volume>35</volume>, no. <issue>25</issue> (<year>2017</year>): <fpage>2875</fpage>&#8211;<lpage>2884</lpage>.<pub-id pub-id-type="pmid">28580882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.73.7585</pub-id></mixed-citation></ref><ref id="mco270560-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="mco270560-cite-0073"><string-name name-style="western"><given-names>Y.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylation Prevents B7&#8208;H4 Lysosomal Degradation Sustaining Tumor Immune Evasion</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>4254</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-58552-5</pub-id><pub-id pub-id-type="pmcid">PMC12062253</pub-id><pub-id pub-id-type="pmid">40341398</pub-id></mixed-citation></ref><ref id="mco270560-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="mco270560-cite-0074"><string-name name-style="western"><given-names>S.</given-names><surname>Ben&#237;tez</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Cordero</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Santamar&#237;a</surname></string-name>, et&#160;al., &#8220;<article-title>RANK Links Senescence to Stemness in the Mammary Epithelia, Delaying Tumor Onset but Increasing Tumor Aggressiveness</article-title>,&#8221; <source>Developmental Cell</source><volume>56</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>1727</fpage>&#8211;<lpage>1741.e7</lpage>.<pub-id pub-id-type="pmid">34004159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2021.04.022</pub-id><pub-id pub-id-type="pmcid">PMC8221814</pub-id></mixed-citation></ref><ref id="mco270560-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="mco270560-cite-0075"><string-name name-style="western"><given-names>J.</given-names><surname>Bu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wu</surname></string-name>, et&#160;al., &#8220;<article-title>KK&#8208;LC&#8208;1 as a Therapeutic Target to Eliminate ALDH+ Stem Cells in Triple Negative Breast Cancer</article-title>,&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>2602</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-38097-1</pub-id><pub-id pub-id-type="pmcid">PMC10163259</pub-id><pub-id pub-id-type="pmid">37147285</pub-id></mixed-citation></ref><ref id="mco270560-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="mco270560-cite-0076"><string-name name-style="western"><given-names>S.</given-names><surname>Ji</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Yin</surname></string-name>, &#8220;<article-title>Macrophage Barrier in the Tumor Microenvironment and Potential Clinical Applications</article-title>,&#8221; <source>Cell Commun Signaling</source><volume>22</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>74</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-023-01424-6</pub-id><pub-id pub-id-type="pmcid">PMC10811890</pub-id><pub-id pub-id-type="pmid">38279145</pub-id></mixed-citation></ref><ref id="mco270560-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="mco270560-cite-0077"><string-name name-style="western"><given-names>N. A.</given-names><surname>Giraldo</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sanchez&#8208;Salas</surname></string-name>, <string-name name-style="western"><given-names>J. D.</given-names><surname>Peske</surname></string-name>, et&#160;al., &#8220;<article-title>The Clinical Role of the TME in Solid Cancer</article-title>,&#8221; <source>British Journal of Cancer</source><volume>120</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>45</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30413828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-018-0327-z</pub-id><pub-id pub-id-type="pmcid">PMC6325164</pub-id></mixed-citation></ref><ref id="mco270560-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="mco270560-cite-0078"><string-name name-style="western"><given-names>R. D.</given-names><surname>Schreiber</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Old</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Smyth</surname></string-name>, &#8220;<article-title>Cancer Immunoediting: Integrating Immunity's Roles in Suppression and Promotion</article-title>,&#8221; <source>Science</source><volume>331</volume>, no. <issue>6024</issue> (<year>2011</year>): <fpage>1565</fpage>&#8211;<lpage>1570</lpage>.<pub-id pub-id-type="pmid">21436444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1203486</pub-id></mixed-citation></ref><ref id="mco270560-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="mco270560-cite-0079"><string-name name-style="western"><given-names>M.</given-names><surname>Kundu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Butti</surname></string-name>, <string-name name-style="western"><given-names>V. K.</given-names><surname>Panda</surname></string-name>, et&#160;al., &#8220;<article-title>Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy&#8208;based Drug Resistance in Breast Cancer</article-title>,&#8221; <source>Molecular Cancer</source><volume>23</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>92</fpage>.<pub-id pub-id-type="pmid">38715072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-01990-4</pub-id><pub-id pub-id-type="pmcid">PMC11075356</pub-id></mixed-citation></ref><ref id="mco270560-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="mco270560-cite-0080"><string-name name-style="western"><given-names>S. S.</given-names><surname>Onkar</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Carleton</surname></string-name>, <string-name name-style="western"><given-names>P. C.</given-names><surname>Lucas</surname></string-name>, et&#160;al., &#8220;<article-title>The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes</article-title>,&#8221; <source>Cancer Discovery</source><volume>13</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>23</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">36620880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0475</pub-id><pub-id pub-id-type="pmcid">PMC9833841</pub-id></mixed-citation></ref><ref id="mco270560-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="mco270560-cite-0081"><string-name name-style="western"><given-names>R.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kang</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, &#8220;<article-title>The Role of Tumor&#8208;associated Macrophages in Tumor Immune Evasion</article-title>,&#8221; <source>Journal of Cancer Research and Clinical Oncology</source><volume>150</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>238</fpage>.<pub-id pub-id-type="pmid">38713256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-024-05777-4</pub-id><pub-id pub-id-type="pmcid">PMC11076352</pub-id></mixed-citation></ref><ref id="mco270560-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="mco270560-cite-0082"><string-name name-style="western"><given-names>S.</given-names><surname>Imani</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Farghadani</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Roozitalab</surname></string-name>, et&#160;al., &#8220;<article-title>Reprogramming the Breast Tumor Immune Microenvironment: Cold&#8208;to&#8208;hot Transition for Enhanced Immunotherapy</article-title>,&#8221; <source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>44</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>131</fpage>.<pub-id pub-id-type="pmid">40281554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-025-03394-8</pub-id><pub-id pub-id-type="pmcid">PMC12032666</pub-id></mixed-citation></ref><ref id="mco270560-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="mco270560-cite-0083"><string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Tian</surname></string-name>, &#8220;<article-title>The Role of Cancer&#8208;associated Fibroblasts in Breast Cancer Metastasis</article-title>,&#8221; <source>Frontiers in Oncology</source><volume>13</volume> (<year>2023</year>): <elocation-id>1194835</elocation-id>.<pub-id pub-id-type="pmid">37496657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1194835</pub-id><pub-id pub-id-type="pmcid">PMC10367093</pub-id></mixed-citation></ref><ref id="mco270560-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="mco270560-cite-0084"><string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yue</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>Define Cancer&#8208;associated Fibroblasts (CAFs) in the Tumor Microenvironment: New Opportunities in Cancer Immunotherapy and Advances in Clinical Trials</article-title>,&#8221; <source>Molecular Cancer</source><volume>22</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>159</fpage>.<pub-id pub-id-type="pmid">37784082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01860-5</pub-id><pub-id pub-id-type="pmcid">PMC10544417</pub-id></mixed-citation></ref><ref id="mco270560-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="mco270560-cite-0085"><string-name name-style="western"><given-names>H.</given-names><surname>Saman</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Raza</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Uddin</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Rasul</surname></string-name>, &#8220;<article-title>Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches</article-title>,&#8221; <source>Cancers</source><volume>12</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>1172</fpage>.<pub-id pub-id-type="pmid">32384792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12051172</pub-id><pub-id pub-id-type="pmcid">PMC7281705</pub-id></mixed-citation></ref><ref id="mco270560-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="mco270560-cite-0086"><string-name name-style="western"><given-names>D.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zheng</surname></string-name>, et&#160;al., &#8220;<article-title>Cancer&#8208;associated Fibroblasts in Breast Cancer: Challenges and Opportunities</article-title>,&#8221; <source>Cancer Communications</source><volume>42</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>401</fpage>&#8211;<lpage>434</lpage>.<pub-id pub-id-type="pmid">35481621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12291</pub-id><pub-id pub-id-type="pmcid">PMC9118050</pub-id></mixed-citation></ref><ref id="mco270560-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="mco270560-cite-0087"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Lei</surname></string-name>, et&#160;al., &#8220;<article-title>CXCL12&#8208;CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications</article-title>,&#8221; <source>International journal of biological sciences</source><volume>19</volume>, no. <issue>11</issue> (<year>2023</year>): <fpage>3341</fpage>&#8211;<lpage>3359</lpage>.<pub-id pub-id-type="pmid">37497001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.82317</pub-id><pub-id pub-id-type="pmcid">PMC10367567</pub-id></mixed-citation></ref><ref id="mco270560-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="mco270560-cite-0088"><string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Metabolic Reprogramming and Immune Evasion: the Interplay in the Tumor Microenvironment</article-title>,&#8221; <source>Biomarker research</source><volume>12</volume>, no. <issue>1</issue> (<year>2024</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-024-00646-1</pub-id><pub-id pub-id-type="pmcid">PMC11373140</pub-id><pub-id pub-id-type="pmid">39227970</pub-id></mixed-citation></ref><ref id="mco270560-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="mco270560-cite-0089"><string-name name-style="western"><given-names>G.&#8208;R.</given-names><surname>Khosravi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mostafavi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bastan</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ebrahimi</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Gharibvand</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Eskandari</surname></string-name>, &#8220;<article-title>Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot</article-title>,&#8221; <source>Cancer Communications</source><volume>44</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>521</fpage>&#8211;<lpage>553</lpage>.<pub-id pub-id-type="pmid">38551889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12539</pub-id><pub-id pub-id-type="pmcid">PMC11110955</pub-id></mixed-citation></ref><ref id="mco270560-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="mco270560-cite-0090"><string-name name-style="western"><given-names>P.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Pan</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Histone Deacetylase 2 Knockout Suppresses Immune Escape of Triple&#8208;negative Breast Cancer Cells via Downregulating PD&#8208;L1 Expression</article-title>,&#8221; <source>Cell death &amp; disease</source><volume>12</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>779</fpage>.<pub-id pub-id-type="pmid">34365463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-021-04047-2</pub-id><pub-id pub-id-type="pmcid">PMC8349356</pub-id></mixed-citation></ref><ref id="mco270560-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="mco270560-cite-0091"><string-name name-style="western"><given-names>L.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion</article-title>,&#8221; <source>Cancer Research</source><volume>84</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>1270</fpage>&#8211;<lpage>1285</lpage>.<pub-id pub-id-type="pmid">38335272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-2390</pub-id></mixed-citation></ref><ref id="mco270560-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="mco270560-cite-0092"><string-name name-style="western"><given-names>S.</given-names><surname>Ding</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Shen</surname></string-name>, &#8220;<article-title>Single&#8208;cell RNA Sequencing in Breast Cancer: Understanding Tumor Heterogeneity and Paving Roads to Individualized Therapy</article-title>,&#8221; <source>Cancer Commun (Lond)</source><volume>40</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>329</fpage>&#8211;<lpage>344</lpage>.<pub-id pub-id-type="pmid">32654419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12078</pub-id><pub-id pub-id-type="pmcid">PMC7427308</pub-id></mixed-citation></ref><ref id="mco270560-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="mco270560-cite-0093"><string-name name-style="western"><given-names>X.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>C.&#8208;C.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Z.&#8208;M.</given-names><surname>Shao</surname></string-name>, and <string-name name-style="western"><given-names>K.&#8208;D.</given-names><surname>Yu</surname></string-name>, &#8220;<article-title>Deciphering Breast Cancer Dynamics: Insights from Single&#8208;cell and Spatial Profiling in the Multi&#8208;omics Era</article-title>,&#8221; <source>Biomarker research</source><volume>12</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>107</fpage>.<pub-id pub-id-type="pmid">39294728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-024-00654-1</pub-id><pub-id pub-id-type="pmcid">PMC11411917</pub-id></mixed-citation></ref><ref id="mco270560-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="mco270560-cite-0094"><string-name name-style="western"><given-names>Y.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Du</surname></string-name>, et&#160;al., &#8220;<article-title>Cancer Cell&#8208;derived Arginine Fuels Polyamine Biosynthesis in Tumor&#8208;associated Macrophages to Promote Immune Evasion</article-title>,&#8221; <source>Cancer Cell</source><volume>43</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>1045</fpage>&#8211;<lpage>1060.e7</lpage>.<pub-id pub-id-type="pmid">40185095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2025.03.015</pub-id></mixed-citation></ref><ref id="mco270560-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="mco270560-cite-0095"><string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>R. B.</given-names><surname>Rumble</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Macrae</surname></string-name>, et&#160;al., &#8220;<article-title>Endocrine Therapy for Hormone Receptor&#8211;Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>34</volume>, no. <issue>25</issue> (<year>2016</year>): <fpage>3069</fpage>&#8211;<lpage>3103</lpage>.<pub-id pub-id-type="pmid">27217461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.67.1487</pub-id></mixed-citation></ref><ref id="mco270560-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="mco270560-cite-0096"><string-name name-style="western"><given-names>W. J.</given-names><surname>Gradishar</surname></string-name>, <string-name name-style="western"><given-names>B. O.</given-names><surname>Anderson</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Balassanian</surname></string-name>, et al., &#8220;<article-title>NCCN Guidelines Insights: Breast Cancer, Version 1.2017</article-title>,&#8221; <source>Journal of the National Comprehensive Cancer Network: JNCCN</source><volume>15</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>433</fpage>&#8211;<lpage>451</lpage>.<pub-id pub-id-type="pmid">28404755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2017.0044</pub-id></mixed-citation></ref><ref id="mco270560-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="mco270560-cite-0097"><string-name name-style="western"><given-names>F. E.</given-names><surname>van Leeuwen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Benraadt</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Coebergh</surname></string-name>, et&#160;al., &#8220;<article-title>Risk of endometrial cancer after tamoxifen treatment of breast cancer</article-title>,&#8221; <source>Lancet</source><volume>343</volume> no. <issue>8895</issue>, (<year>1994</year>): <fpage>448</fpage>&#8211;<lpage>452</lpage>.<pub-id pub-id-type="pmid">7905955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(94)92692-1</pub-id></mixed-citation></ref><ref id="mco270560-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="mco270560-cite-0098"><string-name name-style="western"><given-names>T.</given-names><surname>Saphner</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Tormey</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Gray</surname></string-name>, &#8220;<article-title>Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>9</volume> no. 2, (<year>1991</year>): <fpage>286</fpage>&#8211;<lpage>294</lpage>.<pub-id pub-id-type="pmid">1988575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1991.9.2.286</pub-id></mixed-citation></ref><ref id="mco270560-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="mco270560-cite-0099"><string-name name-style="western"><given-names>M.</given-names><surname>Lazzeroni</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Puntoni</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Guerrieri&#8208;Gonzaga</surname></string-name>, et&#160;al., &#8220;<article-title>Randomized Placebo Controlled Trial of Low&#8208;Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: a 10&#8208;Year Follow&#8208;Up of TAM&#8208;01 Study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>17</issue> (<year>2023</year>): <fpage>3116</fpage>&#8211;<lpage>3121</lpage>.<pub-id pub-id-type="pmid">36917758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.02900</pub-id></mixed-citation></ref><ref id="mco270560-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="mco270560-cite-0100"><string-name name-style="western"><given-names>S. R.</given-names><surname>Cummings</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Eckert</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Krueger</surname></string-name>, et al., &#8220;<article-title>The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial</article-title>,&#8221; <source>JAMA</source><volume>281</volume>, no. <issue>23</issue> (<year>1999</year>): <fpage>2189</fpage>&#8211;<lpage>2197</lpage>.<pub-id pub-id-type="pmid">10376571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.281.23.2189</pub-id></mixed-citation></ref><ref id="mco270560-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="mco270560-cite-0101"><string-name name-style="western"><given-names>D. F.</given-names><surname>Hayes</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Van Zyl</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hacking</surname></string-name>, et&#160;al., &#8220;<article-title>Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients With Metastatic Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>13</volume> no. <issue>10</issue> (<year>1995</year>): <fpage>2556</fpage>&#8211;<lpage>2566</lpage>.<pub-id pub-id-type="pmid">7595707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.10.2556</pub-id></mixed-citation></ref><ref id="mco270560-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="mco270560-cite-0102"><string-name name-style="western"><given-names>J. F. R.</given-names><surname>Robertson</surname></string-name>, <string-name name-style="western"><given-names>I. M.</given-names><surname>Bondarenko</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Trishkina</surname></string-name>, et&#160;al., &#8220;<article-title>Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor&#8208;positive Advanced Breast Cancer (FALCON): an International, Randomised, Double&#8208;blind, Phase 3 Trial</article-title>,&#8221; <source>The Lancet</source><volume>388</volume>, no. <issue>10063</issue> (<year>2016</year>): <fpage>2997</fpage>&#8211;<lpage>3005</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32389-3</pub-id><pub-id pub-id-type="pmid">27908454</pub-id></mixed-citation></ref><ref id="mco270560-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="mco270560-cite-0103"><string-name name-style="western"><given-names>J. F. R.</given-names><surname>Robertson</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Shao</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Noguchi</surname></string-name>, et&#160;al., &#8220;<article-title>Fulvestrant versus Anastrozole in Endocrine Therapy&#8211;Na&#239;ve Women with Hormone Receptor&#8211;Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>43</volume>, no. <issue>13</issue> (<year>2025</year>): <fpage>1539</fpage>&#8211;<lpage>1545</lpage>.<pub-id pub-id-type="pmid">39772884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.24.00994</pub-id><pub-id pub-id-type="pmcid">PMC12054979</pub-id></mixed-citation></ref><ref id="mco270560-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="mco270560-cite-0104"><string-name name-style="western"><given-names>H. J.</given-names><surname>Burstein</surname></string-name> and <string-name name-style="western"><given-names>D. L.</given-names><surname>Longo</surname></string-name>, &#8220;<article-title>Systemic Therapy for Estrogen Receptor&#8211;Positive, HER2&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>383</volume>, no. <issue>26</issue> (<year>2020</year>): <fpage>2557</fpage>&#8211;<lpage>2570</lpage>.<pub-id pub-id-type="pmid">33369357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1307118</pub-id></mixed-citation></ref><ref id="mco270560-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="mco270560-cite-0105"><string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Sestak</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Baum</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early&#8208;stage Breast Cancer: 10&#8208;year Analysis of the ATAC Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>11</volume>, no. <issue>12</issue> (<year>2010</year>): <fpage>1135</fpage>&#8211;<lpage>1141</lpage>.<pub-id pub-id-type="pmid">21087898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(10)70257-6</pub-id></mixed-citation></ref><ref id="mco270560-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="mco270560-cite-0106"><string-name name-style="western"><given-names>J. P.</given-names><surname>Morden</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Alvarez</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Bertelli</surname></string-name>, et&#160;al., &#8220;<article-title>Long&#8208;Term Follow&#8208;Up of the Intergroup Exemestane Study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>35</volume>, no. <issue>22</issue> (<year>2017</year>): <fpage>2507</fpage>&#8211;<lpage>2514</lpage>.<pub-id pub-id-type="pmid">28467729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.70.5640</pub-id><pub-id pub-id-type="pmcid">PMC6175047</pub-id></mixed-citation></ref><ref id="mco270560-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="mco270560-cite-0107"><string-name name-style="western"><given-names>O.</given-names><surname>Pagani</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Walley</surname></string-name>, <string-name name-style="western"><given-names>G. F.</given-names><surname>Fleming</surname></string-name>, et&#160;al., &#8220;<article-title>Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer: Long&#8208;Term Follow&#8208;Up of the Combined TEXT and SOFT Trials</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>7</issue> (<year>2023</year>): <fpage>1376</fpage>&#8211;<lpage>1382</lpage>.<pub-id pub-id-type="pmid">36521078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01064</pub-id><pub-id pub-id-type="pmcid">PMC10419413</pub-id></mixed-citation></ref><ref id="mco270560-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="mco270560-cite-0108"><string-name name-style="western"><given-names>P. A.</given-names><surname>Francis</surname></string-name>, <string-name name-style="western"><given-names>G. F.</given-names><surname>Fleming</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>L&#225;ng</surname></string-name>, et&#160;al., &#8220;<article-title>Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12&#8208;Year Results from SOFT</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>7</issue> (<year>2023</year>): <fpage>1370</fpage>&#8211;<lpage>1375</lpage>.<pub-id pub-id-type="pmid">36493334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01065</pub-id><pub-id pub-id-type="pmcid">PMC10419521</pub-id></mixed-citation></ref><ref id="mco270560-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="mco270560-cite-0109"><string-name name-style="western"><given-names>M.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lingam</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, et&#160;al., &#8220;<article-title>US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor&#8211;Positive, Human Epidermal Growth Factor Receptor 2&#8211;Negative, ESR1&#8208;Mutated Advanced or Metastatic Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>10</issue> (<year>2024</year>): <fpage>1193</fpage>&#8211;<lpage>1201</lpage>.<pub-id pub-id-type="pmid">38381994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02112</pub-id><pub-id pub-id-type="pmcid">PMC11003513</pub-id></mixed-citation></ref><ref id="mco270560-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="mco270560-cite-0110"><string-name name-style="western"><given-names>F.&#8208;C.</given-names><surname>Bidard</surname></string-name>, <string-name name-style="western"><given-names>V. G.</given-names><surname>Kaklamani</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Neven</surname></string-name>, et&#160;al., &#8220;<article-title>Elacestrant (oral selective estrogen receptor degrader) versus Standard Endocrine Therapy for Estrogen Receptor&#8211;Positive, Human Epidermal Growth Factor Receptor 2&#8211;Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume>, no. <issue>28</issue> (<year>2022</year>): <fpage>3246</fpage>&#8211;<lpage>3256</lpage>.<pub-id pub-id-type="pmid">35584336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.00338</pub-id><pub-id pub-id-type="pmcid">PMC9553388</pub-id></mixed-citation></ref><ref id="mco270560-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="mco270560-cite-0111"><string-name name-style="western"><given-names>M.</given-names><surname>Mart&#237;n</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Lim</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Chavez&#8208;MacGregor</surname></string-name>, et&#160;al., &#8220;<article-title>Giredestrant for Estrogen Receptor&#8211;Positive, HER2&#8208;Negative, Previously Treated Advanced Breast Cancer: Results from the Randomized, Phase II acelERA Breast Cancer Study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>18</issue> (<year>2024</year>): <fpage>2149</fpage>&#8211;<lpage>2160</lpage>.<pub-id pub-id-type="pmid">38537155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01500</pub-id><pub-id pub-id-type="pmcid">PMC11185917</pub-id></mixed-citation></ref><ref id="mco270560-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="mco270560-cite-0112"><string-name name-style="western"><given-names>K. L.</given-names><surname>Jhaveri</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Neven</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Casalnuovo</surname></string-name>, et&#160;al., &#8220;<article-title>Imlunestrant with or without Abemaciclib in Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>392</volume>, no. <issue>12</issue> (<year>2025</year>): <fpage>1189</fpage>&#8211;<lpage>1202</lpage>.<pub-id pub-id-type="pmid">39660834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2410858</pub-id></mixed-citation></ref><ref id="mco270560-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="mco270560-cite-0113"><string-name name-style="western"><given-names>D. J.</given-names><surname>Slamon</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Leyland&#8208;Jones</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Shak</surname></string-name>, et&#160;al., &#8220;<article-title>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>344</volume> no. <issue>11</issue>, (<year>2001</year>): <fpage>783</fpage>&#8211;<lpage>792</lpage>.<pub-id pub-id-type="pmid">11248153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200103153441101</pub-id></mixed-citation></ref><ref id="mco270560-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="mco270560-cite-0114"><string-name name-style="western"><given-names>I.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Procter</surname></string-name>, <string-name name-style="western"><given-names>R. D.</given-names><surname>Gelber</surname></string-name>, et&#160;al., &#8220;<article-title>2&#8208;year Follow&#8208;up of trastuzumab after Adjuvant Chemotherapy in HER2&#8208;positive Breast Cancer: a Randomised Controlled Trial</article-title>,&#8221; <source>The Lancet</source><volume>369</volume>, no. <issue>9555</issue> (<year>2007</year>): <fpage>29</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)60028-2</pub-id><pub-id pub-id-type="pmid">17208639</pub-id></mixed-citation></ref><ref id="mco270560-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="mco270560-cite-0115"><string-name name-style="western"><given-names>E. A.</given-names><surname>Perez</surname></string-name>, <string-name name-style="western"><given-names>V. J.</given-names><surname>Suman</surname></string-name>, <string-name name-style="western"><given-names>N. E.</given-names><surname>Davidson</surname></string-name>, et&#160;al., &#8220;<article-title>Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>26</volume>, no. <issue>8</issue> (<year>2008</year>): <fpage>1231</fpage>&#8211;<lpage>1238</lpage>.<pub-id pub-id-type="pmid">18250349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2007.13.5467</pub-id><pub-id pub-id-type="pmcid">PMC4048960</pub-id></mixed-citation></ref><ref id="mco270560-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="mco270560-cite-0116"><string-name name-style="western"><given-names>S. M.</given-names><surname>Swain</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shastry</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Hamilton</surname></string-name>, &#8220;<article-title>Targeting HER2&#8208;positive Breast Cancer: Advances and Future Directions</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>22</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>101</fpage>&#8211;<lpage>126</lpage>.<pub-id pub-id-type="pmid">36344672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-022-00579-0</pub-id><pub-id pub-id-type="pmcid">PMC9640784</pub-id></mixed-citation></ref><ref id="mco270560-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="mco270560-cite-0117"><string-name name-style="western"><given-names>J.</given-names><surname>Baselga</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cort&#233;s</surname></string-name>, and <string-name name-style="western"><given-names>S.&#8208;B.</given-names><surname>Kim</surname></string-name>, &#8220;<article-title>Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>366</volume>, no. <issue>2</issue>, (<year>2012</year>): <fpage>109</fpage>&#8211;<lpage>119</lpage>.<pub-id pub-id-type="pmid">22149875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1113216</pub-id><pub-id pub-id-type="pmcid">PMC5705202</pub-id></mixed-citation></ref><ref id="mco270560-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="mco270560-cite-0118"><string-name name-style="western"><given-names>S. M.</given-names><surname>Swain</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;B.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cort&#233;s</surname></string-name>, et&#160;al., &#8220;<article-title>Pertuzumab, Trastuzumab, and Docetaxel for HER2&#8208;positive Metastatic Breast Cancer (CLEOPATRA study): Overall Survival Results from a Randomised, Double&#8208;blind, Placebo&#8208;controlled, Phase 3 Study</article-title>,&#8221; <source>The Lancet Oncology</source><volume>14</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>461</fpage>&#8211;<lpage>471</lpage>.<pub-id pub-id-type="pmid">23602601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(13)70130-X</pub-id><pub-id pub-id-type="pmcid">PMC4076842</pub-id></mixed-citation></ref><ref id="mco270560-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="mco270560-cite-0119"><string-name name-style="western"><given-names>S.</given-names><surname>Loibl</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Jassem</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sonnenblick</surname></string-name>, et&#160;al., &#8220;<article-title>Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2&#8211;Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis with Efficacy Update</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>31</issue> (<year>2024</year>): <fpage>3643</fpage>&#8211;<lpage>3651</lpage>.<pub-id pub-id-type="pmid">39259927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02505</pub-id></mixed-citation></ref><ref id="mco270560-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="mco270560-cite-0120"><string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Cardoso</surname></string-name>, et&#160;al., &#8220;<article-title>Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2&#8208;Positive Advanced Breast Cancer</article-title>,&#8221; <source>JAMA Oncology</source><volume>7</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>573</fpage>&#8211;<lpage>584</lpage>.<pub-id pub-id-type="pmid">33480963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.7932</pub-id><pub-id pub-id-type="pmcid">PMC7823434</pub-id></mixed-citation></ref><ref id="mco270560-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="mco270560-cite-0121"><string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Cardoso</surname></string-name>, et&#160;al., &#8220;<article-title>Margetuximab versus Trastuzumab in Patients with Previously Treated HER2&#8208;Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results from a Randomized Phase 3 Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>198</fpage>&#8211;<lpage>205</lpage>.<pub-id pub-id-type="pmid">36332179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.02937</pub-id><pub-id pub-id-type="pmcid">PMC9839304</pub-id></mixed-citation></ref><ref id="mco270560-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="mco270560-cite-0122"><string-name name-style="western"><given-names>T.</given-names><surname>Bachelot</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Romieu</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, et&#160;al., &#8220;<article-title>Lapatinib plus Capecitabine in Patients with Previously Untreated Brain Metastases from HER2&#8208;positive Metastatic Breast Cancer (LANDSCAPE): a Single&#8208;group Phase 2 Study</article-title>,&#8221; <source>The Lancet Oncology</source><volume>14</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>64</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">23122784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(12)70432-1</pub-id></mixed-citation></ref><ref id="mco270560-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="mco270560-cite-0123"><string-name name-style="western"><given-names>E.</given-names><surname>Cocco</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Javier Carmona</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Razavi</surname></string-name>, &#8220;<article-title>Neratinib Is Effective in Breast Tumors Bearing both Amplification and Mutation of ERBB2 (HER2)</article-title>,&#8221; <source>Science Signaling</source><volume>11</volume>, no. <issue>551</issue> (<year>2018</year>): <elocation-id>eaat9773</elocation-id>.<pub-id pub-id-type="pmid">30301790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.aat9773</pub-id><pub-id pub-id-type="pmcid">PMC6498841</pub-id></mixed-citation></ref><ref id="mco270560-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="mco270560-cite-0124"><string-name name-style="western"><given-names>C.</given-names><surname>Saura</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;H.</given-names><surname>Feng</surname></string-name>, et&#160;al., &#8220;<article-title>Neratinib plus Capecitabine versus Lapatinib Plus Capecitabine in HER2&#8208;Positive Metastatic Breast Cancer Previously Treated with &#8805; 2 HER2&#8208;Directed Regimens: Phase III NALA Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>38</volume>, no. <issue>27</issue> (<year>2020</year>): <fpage>3138</fpage>&#8211;<lpage>3149</lpage>.<pub-id pub-id-type="pmid">32678716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.00147</pub-id><pub-id pub-id-type="pmcid">PMC7499616</pub-id></mixed-citation></ref><ref id="mco270560-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="mco270560-cite-0125"><string-name name-style="western"><given-names>R. K.</given-names><surname>Murthy</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Loi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Okines</surname></string-name>, et&#160;al., &#8220;<article-title>Tucatinib, Trastuzumab, and Capecitabine for HER2&#8208;Positive Metastatic Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>382</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>597</fpage>&#8211;<lpage>609</lpage>.<pub-id pub-id-type="pmid">31825569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1914609</pub-id></mixed-citation></ref><ref id="mco270560-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="mco270560-cite-0126"><string-name name-style="western"><given-names>S.</given-names><surname>Verma</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Miles</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Gianni</surname></string-name>, et&#160;al., &#8220;<article-title>Trastuzumab Emtansine for HER2&#8208;positive Advanced Breast Cancer</article-title>,&#8221; <source>The New England Journal of Medicine</source><volume>367</volume>, no. <issue>19</issue> (<year>2012</year>): <fpage>1783</fpage>&#8211;<lpage>1791</lpage>.<pub-id pub-id-type="pmid">23020162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1209124</pub-id><pub-id pub-id-type="pmcid">PMC5125250</pub-id></mixed-citation></ref><ref id="mco270560-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="mco270560-cite-0127"><string-name name-style="western"><given-names>S.</given-names><surname>Modi</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Saura</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Yamashita</surname></string-name>, et&#160;al., &#8220;<article-title>Trastuzumab Deruxtecan in Previously Treated HER2&#8208;Positive Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>382</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>610</fpage>&#8211;<lpage>621</lpage>.<pub-id pub-id-type="pmid">31825192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1914510</pub-id><pub-id pub-id-type="pmcid">PMC7458671</pub-id></mixed-citation></ref><ref id="mco270560-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="mco270560-cite-0128"><string-name name-style="western"><given-names>N.</given-names><surname>Harbeck</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Ciruelos</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Jerusalem</surname></string-name>, et&#160;al., &#8220;<article-title>Trastuzumab deruxtecan in HER2&#8208;positive Advanced Breast Cancer with or without Brain Metastases: a Phase 3b/4 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>30</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>3717</fpage>&#8211;<lpage>3727</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03261-7</pub-id><pub-id pub-id-type="pmcid">PMC11645283</pub-id><pub-id pub-id-type="pmid">39271844</pub-id></mixed-citation></ref><ref id="mco270560-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="mco270560-cite-0129"><string-name name-style="western"><given-names>A.</given-names><surname>Dilawari</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shah</surname></string-name>, et&#160;al., &#8220;<article-title>US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients with Hormone Receptor&#8211;Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2&#8211;Low or Human Epidermal Growth Factor Receptor 2&#8211;Ultralow Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>43</volume>, no. <issue>26</issue> (<year>2025</year>): <fpage>2942</fpage>&#8211;<lpage>2951</lpage>.<pub-id pub-id-type="pmid">40763319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO-25-00812</pub-id></mixed-citation></ref><ref id="mco270560-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="mco270560-cite-0130"><string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Disitamab vedotin, a HER2&#8208;directed Antibody&#8208;drug Conjugate, in Patients with HER2&#8208;overexpression and HER2&#8208;low Advanced Breast Cancer: a Phase I/Ib Study</article-title>,&#8221; <source>Cancer Communications</source><volume>44</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>833</fpage>&#8211;<lpage>851</lpage>.<pub-id pub-id-type="pmid">38940019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12577</pub-id><pub-id pub-id-type="pmcid">PMC11260767</pub-id></mixed-citation></ref><ref id="mco270560-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="mco270560-cite-0131"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>CDK4/6 inhibitors: a Novel Strategy for Tumor Radiosensitization</article-title>,&#8221; <source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>39</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>188</fpage>.<pub-id pub-id-type="pmid">32933570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-020-01693-w</pub-id><pub-id pub-id-type="pmcid">PMC7490904</pub-id></mixed-citation></ref><ref id="mco270560-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="mco270560-cite-0132"><string-name name-style="western"><given-names>R. S.</given-names><surname>Finn</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Martin</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, et&#160;al., &#8220;<article-title>Palbociclib and Letrozole in Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>375</volume>, no. <issue>20</issue> (<year>2016</year>): <fpage>1925</fpage>&#8211;<lpage>1936</lpage>.<pub-id pub-id-type="pmid">27959613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1607303</pub-id></mixed-citation></ref><ref id="mco270560-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="mco270560-cite-0133"><string-name name-style="western"><given-names>D. J.</given-names><surname>Slamon</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Di&#233;ras</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, et&#160;al., &#8220;<article-title>Overall Survival with Palbociclib plus Letrozole in Advanced Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>994</fpage>&#8211;<lpage>1000</lpage>.<pub-id pub-id-type="pmid">38252901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.00137</pub-id><pub-id pub-id-type="pmcid">PMC10950136</pub-id></mixed-citation></ref><ref id="mco270560-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="mco270560-cite-0134"><string-name name-style="western"><given-names>G. N.</given-names><surname>Hortobagyi</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Stemmer</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Burris</surname></string-name>, et&#160;al., &#8220;<article-title>Ribociclib as First&#8208;Line Therapy for HR&#8208;Positive, Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>375</volume>, no. <issue>18</issue> (<year>2016</year>): <fpage>1738</fpage>&#8211;<lpage>1748</lpage>.<pub-id pub-id-type="pmid">27717303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1609709</pub-id></mixed-citation></ref><ref id="mco270560-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="mco270560-cite-0135"><string-name name-style="western"><given-names>M. P.</given-names><surname>Goetz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Huober</surname></string-name>, et&#160;al., &#8220;<article-title>Abemaciclib plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy for HR+, HER2&#8722; Advanced Breast Cancer: Final Overall Survival Results of MONARCH 3</article-title>,&#8221; <source>Annals of Oncology</source><volume>35</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>718</fpage>&#8211;<lpage>727</lpage>.<pub-id pub-id-type="pmid">38729566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.04.013</pub-id></mixed-citation></ref><ref id="mco270560-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="mco270560-cite-0136"><string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Tong</surname></string-name>, et&#160;al., &#8220;<article-title>Dalpiciclib plus Letrozole or Anastrozole versus Placebo plus Letrozole or Anastrozole as First&#8208;line Treatment in Patients with Hormone Receptor&#8208;positive, HER2&#8208;negative Advanced Breast Cancer (DAWNA&#8208;2): a Multicentre, Randomised, Double&#8208;blind, Placebo&#8208;controlled, Phase 3 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>24</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>646</fpage>&#8211;<lpage>657</lpage>.<pub-id pub-id-type="pmid">37182538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00172-9</pub-id></mixed-citation></ref><ref id="mco270560-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="mco270560-cite-0137"><string-name name-style="western"><given-names>G. S.</given-names><surname>Sonke</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>van Ommen&#8208;Nijhof</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Wortelboer</surname></string-name>, et&#160;al., &#8220;<article-title>Early versus Deferred Use of CDK4/6 Inhibitors in Advanced Breast Cancer</article-title>,&#8221; <source>Nature</source><volume>636</volume>, no. <issue>8042</issue> (<year>2024</year>): <fpage>474</fpage>&#8211;<lpage>480</lpage>.<pub-id pub-id-type="pmid">39604725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08035-2</pub-id></mixed-citation></ref><ref id="mco270560-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="mco270560-cite-0138"><string-name name-style="western"><given-names>S.</given-names><surname>Morganti</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Marra</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>De Angelis</surname></string-name>, et&#160;al., &#8220;<article-title>PARP Inhibitors for Breast Cancer Treatment</article-title>,&#8221; <source>JAMA Oncology</source><volume>10</volume>, no. <issue>5</issue> (<year>2024</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2023.7322</pub-id><pub-id pub-id-type="pmid">38512229</pub-id></mixed-citation></ref><ref id="mco270560-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="mco270560-cite-0139"><string-name name-style="western"><given-names>Y.</given-names><surname>Pommier</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>O'Connor</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>de Bono</surname></string-name>, &#8220;<article-title>Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action</article-title>,&#8221; <source>Science translational medicine</source><volume>8</volume>, no. <issue>362</issue>, (<year>2016</year>): <elocation-id>362ps17</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaf9246</pub-id><pub-id pub-id-type="pmid">27797957</pub-id></mixed-citation></ref><ref id="mco270560-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="mco270560-cite-0140"><string-name name-style="western"><given-names>C. J.</given-names><surname>Lord</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Ashworth</surname></string-name>, &#8220;<article-title>PARP inhibitors: Synthetic lethality in the clinic</article-title>,&#8221; <source>Science</source><volume>355</volume>, no. <issue>6330</issue> (<year>2017</year>): <fpage>1152</fpage>&#8211;<lpage>1158</lpage>.<pub-id pub-id-type="pmid">28302823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aam7344</pub-id><pub-id pub-id-type="pmcid">PMC6175050</pub-id></mixed-citation></ref><ref id="mco270560-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="mco270560-cite-0141"><string-name name-style="western"><given-names>C. E.</given-names><surname>Geyer</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Garber</surname></string-name>, <string-name name-style="western"><given-names>R. D.</given-names><surname>Gelber</surname></string-name>, et&#160;al., &#8220;<article-title>Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1/2 and High&#8208;risk, Early Breast Cancer</article-title>,&#8221; <source>Annals of Oncology</source><volume>33</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1250</fpage>&#8211;<lpage>1268</lpage>.<pub-id pub-id-type="pmid">36228963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.09.159</pub-id><pub-id pub-id-type="pmcid">PMC10207856</pub-id></mixed-citation></ref><ref id="mco270560-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="mco270560-cite-0142"><string-name name-style="western"><given-names>J. E.</given-names><surname>Abraham</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Pinilla</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dayimu</surname></string-name>, et&#160;al., &#8220;<article-title>The PARTNER Trial of Neoadjuvant Olaparib with Chemotherapy in Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Nature</source><volume>629</volume>, no. <issue>8014</issue> (<year>2024</year>): <fpage>1142</fpage>&#8211;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">38588696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07384-2</pub-id><pub-id pub-id-type="pmcid">PMC11136660</pub-id></mixed-citation></ref><ref id="mco270560-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="mco270560-cite-0143"><string-name name-style="western"><given-names>E.</given-names><surname>Rodler</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>W. E.</given-names><surname>Barlow</surname></string-name>, et&#160;al., &#8220;<article-title>Cisplatin with Veliparib or Placebo in Metastatic Triple&#8208;negative Breast Cancer and BRCA Mutation&#8208;associated Breast Cancer (S1416): a Randomised, Double&#8208;blind, Placebo&#8208;controlled, Phase 2 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>24</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>162</fpage>&#8211;<lpage>174</lpage>.<pub-id pub-id-type="pmid">36623515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00739-2</pub-id><pub-id pub-id-type="pmcid">PMC9924094</pub-id></mixed-citation></ref><ref id="mco270560-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="mco270560-cite-0144"><string-name name-style="western"><given-names>J. J.</given-names><surname>Gruber</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Afghahi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Timms</surname></string-name>, et&#160;al., &#8220;<article-title>A Phase II Study of talazoparib Monotherapy in Patients with Wild&#8208;type BRCA1 and BRCA2 with a Mutation in Other Homologous Recombination Genes</article-title>,&#8221; <source>Nature Cancer</source><volume>3</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>1181</fpage>&#8211;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">36253484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-022-00439-1</pub-id><pub-id pub-id-type="pmcid">PMC9586861</pub-id></mixed-citation></ref><ref id="mco270560-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="mco270560-cite-0145"><string-name name-style="western"><given-names>H. S.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>B. K.</given-names><surname>Arun</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kaufman</surname></string-name>, et&#160;al., &#8220;<article-title>Veliparib Monotherapy Following Carboplatin/paclitaxel plus veliparib Combination Therapy in Patients with Germline BRCA&#8208;associated Advanced Breast Cancer: Results of Exploratory Analyses from the Phase III BROCADE3 Trial</article-title>,&#8221; <source>Annals of Oncology</source><volume>33</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>299</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="pmid">34861374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.11.018</pub-id></mixed-citation></ref><ref id="mco270560-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="mco270560-cite-0146"><collab collab-type="authors">AZD5305 More Tolerable than Earlier PARP Agents</collab>
. <source>Cancer Discovery</source><year>2022</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1602</fpage>&#8211;<lpage>1602</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-NB2022-0039</pub-id><pub-id pub-id-type="pmid">35616497</pub-id></mixed-citation></ref><ref id="mco270560-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="mco270560-cite-0147"><string-name name-style="western"><given-names>G.</given-names><surname>Bianchini</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>De Angelis</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Licata</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Gianni</surname></string-name>, &#8220;<article-title>Treatment Landscape of Triple&#8208;negative Breast Cancer &#8212; expanded Options, Evolving Needs</article-title>,&#8221; <source>Nature Reviews Clinical Oncology</source><volume>19</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>91</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00565-2</pub-id><pub-id pub-id-type="pmid">34754128</pub-id></mixed-citation></ref><ref id="mco270560-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="mco270560-cite-0148"><string-name name-style="western"><given-names>C.</given-names><surname>Hao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Meng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name>, &#8220;<article-title>PI3K/AKT/mTOR Inhibitors for Hormone Receptor&#8208;positive Advanced Breast Cancer</article-title>,&#8221; <source>Cancer Treatment Reviews</source><volume>132</volume> (<year>2025</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2024.102861</pub-id><pub-id pub-id-type="pmid">39662202</pub-id></mixed-citation></ref><ref id="mco270560-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="mco270560-cite-0149"><string-name name-style="western"><given-names>P.</given-names><surname>Narayan</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Prowell</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Gao</surname></string-name>, et&#160;al., &#8220;<article-title>FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR&#8208;positive, HER2&#8208;negative, PIK3CA&#8208;mutated, Advanced or Metastatic Breast Cancer</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>27</volume>, no. <issue>7</issue> (<year>2021</year>): <fpage>1842</fpage>&#8211;<lpage>1849</lpage>.<pub-id pub-id-type="pmid">33168657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-3652</pub-id><pub-id pub-id-type="pmcid">PMC8535764</pub-id></mixed-citation></ref><ref id="mco270560-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="mco270560-cite-0150"><string-name name-style="western"><given-names>F.</given-names><surname>Andr&#233;</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Ciruelos</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Juric</surname></string-name>, et&#160;al., &#8220;<article-title>Alpelisib plus Fulvestrant for PIK3CA&#8208;mutated, Hormone Receptor&#8208;positive, human Epidermal Growth Factor Receptor&#8208;2&#8211;negative Advanced Breast Cancer: Final Overall Survival Results from SOLAR&#8208;1</article-title>,&#8221; <source>Annals of Oncology</source><volume>32</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>208</fpage>&#8211;<lpage>217</lpage>.<pub-id pub-id-type="pmid">33246021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.11.011</pub-id></mixed-citation></ref><ref id="mco270560-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="mco270560-cite-0151"><string-name name-style="western"><given-names>P.</given-names><surname>Savas</surname></string-name>, <string-name name-style="western"><given-names>L. L.</given-names><surname>Lo</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Luen</surname></string-name>, et&#160;al., &#8220;<article-title>Alpelisib Monotherapy for PI3K&#8208;Altered, Pretreated Advanced Breast Cancer: A Phase II Study</article-title>,&#8221; <source>Cancer Discovery</source><volume>12</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>2058</fpage>&#8211;<lpage>2073</lpage>.<pub-id pub-id-type="pmid">35771551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-1696</pub-id></mixed-citation></ref><ref id="mco270560-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="mco270560-cite-0152"><string-name name-style="western"><given-names>N. C.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Saura</surname></string-name>, et&#160;al., &#8220;<article-title>Inavolisib&#8208;Based Therapy in PIK3CA&#8208;Mutated Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>391</volume>, no. <issue>17</issue> (<year>2024</year>): <fpage>1584</fpage>&#8211;<lpage>1596</lpage>.<pub-id pub-id-type="pmid">39476340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2404625</pub-id></mixed-citation></ref><ref id="mco270560-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="mco270560-cite-0153"><string-name name-style="western"><given-names>K. L.</given-names><surname>Jhaveri</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Saura</surname></string-name>, et&#160;al., &#8220;<article-title>Overall Survival with Inavolisib in PIK3CA&#8208;Mutated Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>393</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>151</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">40454641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2501796</pub-id></mixed-citation></ref><ref id="mco270560-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="mco270560-cite-0154"><string-name name-style="western"><given-names>L.</given-names><surname>Buckbinder</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>St Jean</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Tieu</surname></string-name>, &#8220;<article-title>STX&#8208;478, a Mutant&#8208;Selective, Allosteric PI3K&#945; Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3K&#945;&#8208;Mutant Xenografts</article-title>,&#8221; <source>Cancer Discovery</source><volume>13</volume>, no. <issue>11</issue> (<year>2023</year>): <fpage>2432</fpage>&#8211;<lpage>2447</lpage>.<pub-id pub-id-type="pmid">37623743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-23-0396</pub-id><pub-id pub-id-type="pmcid">PMC10618743</pub-id></mixed-citation></ref><ref id="mco270560-bib-0155"><label>155</label><mixed-citation publication-type="journal" id="mco270560-cite-0155"><string-name name-style="western"><given-names>S. J.</given-names><surname>Howell</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Casbard</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Carucci</surname></string-name>, et&#160;al., &#8220;<article-title>Fulvestrant plus capivasertib versus Placebo after Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor&#8208;positive, HER2&#8208;negative Breast Cancer (FAKTION): Overall Survival, Updated Progression&#8208;free Survival, and Expanded Biomarker Analysis from a Randomised, Phase 2 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>23</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>851</fpage>&#8211;<lpage>864</lpage>.<pub-id pub-id-type="pmid">35671774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00284-4</pub-id><pub-id pub-id-type="pmcid">PMC9630162</pub-id></mixed-citation></ref><ref id="mco270560-bib-0156"><label>156</label><mixed-citation publication-type="journal" id="mco270560-cite-0156"><string-name name-style="western"><given-names>N. C.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Howell</surname></string-name>, et&#160;al., &#8220;<article-title>Capivasertib in Hormone Receptor&#8211;Positive Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>388</volume>, no. <issue>22</issue> (<year>2023</year>): <fpage>2058</fpage>&#8211;<lpage>2070</lpage>.<pub-id pub-id-type="pmid">37256976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2214131</pub-id><pub-id pub-id-type="pmcid">PMC11335038</pub-id></mixed-citation></ref><ref id="mco270560-bib-0157"><label>157</label><mixed-citation publication-type="journal" id="mco270560-cite-0157"><string-name name-style="western"><given-names>X.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Sun</surname></string-name>, et&#160;al., &#8220;<article-title>Capivasertib plus Fulvestrant in Patients with HR&#8208;positive/HER2&#8208;negative Advanced Breast Cancer: Phase 3 CAPItello&#8208;291 Study Extended Chinese Cohort</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>4324</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-59210-6</pub-id><pub-id pub-id-type="pmcid">PMC12064754</pub-id><pub-id pub-id-type="pmid">40346047</pub-id></mixed-citation></ref><ref id="mco270560-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="mco270560-cite-0158"><string-name name-style="western"><given-names>M.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Saura</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Nuciforo</surname></string-name>, et&#160;al., &#8220;<article-title>FAIRLANE, a Double&#8208;blind Placebo&#8208;controlled Randomized Phase II Trial of Neoadjuvant ipatasertib plus paclitaxel for Early Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Annals of Oncology</source><volume>30</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>1289</fpage>&#8211;<lpage>1297</lpage>.<pub-id pub-id-type="pmid">31147675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz177</pub-id></mixed-citation></ref><ref id="mco270560-bib-0159"><label>159</label><mixed-citation publication-type="journal" id="mco270560-cite-0159"><string-name name-style="western"><given-names>N.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Dent</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>O'Shaughnessy</surname></string-name>, &#8220;<article-title>Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN&#8208;altered Hormone Receptor&#8208;positive HER2&#8208;negative Advanced Breast Cancer: Primary Results from Cohort B of the IPATunity130 Randomized Phase 3 Trial</article-title>,&#8221; <source>Breast Cancer Research and Treatment</source><volume>191</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>565</fpage>&#8211;<lpage>576</lpage>.<pub-id pub-id-type="pmid">34860318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-021-06450-x</pub-id><pub-id pub-id-type="pmcid">PMC8831286</pub-id></mixed-citation></ref><ref id="mco270560-bib-0160"><label>160</label><mixed-citation publication-type="journal" id="mco270560-cite-0160"><string-name name-style="western"><given-names>A.&#8208;M.</given-names><surname>Tsimberidou</surname></string-name>, <string-name name-style="western"><given-names>J. V.</given-names><surname>Shaw</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Juric</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1 Study of M2698, a p70S6K/AKT Dual Inhibitor, in Patients with Advanced Cancer</article-title>,&#8221; <source>Journal of Hematology &amp; Oncology</source><volume>14</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>127</fpage>.<pub-id pub-id-type="pmid">34407844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-021-01132-z</pub-id><pub-id pub-id-type="pmcid">PMC8371902</pub-id></mixed-citation></ref><ref id="mco270560-bib-0161"><label>161</label><mixed-citation publication-type="journal" id="mco270560-cite-0161"><string-name name-style="western"><given-names>M. D.</given-names><surname>Jos&#233; Baselga</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Martine Piccart</surname></string-name>, and <string-name name-style="western"><given-names>M. D.</given-names><surname>Alejandra Perez</surname></string-name>, &#8220;<article-title>Everolimus in Postmenopausal HormoneReceptor&#8211;Positive Advanced Breast Cancer</article-title>,&#8221; <source>The New England Journal of Medicine</source><volume>366</volume>, no. <issue>6</issue> (<year>2012</year>): <fpage>520</fpage>&#8211;<lpage>529</lpage>.<pub-id pub-id-type="pmid">22149876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1109653</pub-id><pub-id pub-id-type="pmcid">PMC5705195</pub-id></mixed-citation></ref><ref id="mco270560-bib-0162"><label>162</label><mixed-citation publication-type="journal" id="mco270560-cite-0162"><string-name name-style="western"><given-names>M.</given-names><surname>Chavez&#8208;MacGregor</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Miao</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pusztai</surname></string-name>, et&#160;al., &#8220;<article-title>Phase III Randomized, Placebo&#8208;Controlled Trial of Endocrine Therapy &#177; 1 Year of Everolimus in Patients with High&#8208;Risk, Hormone Receptor&#8211;Positive, Early&#8208;Stage Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>25</issue> (<year>2024</year>): <fpage>3012</fpage>&#8211;<lpage>3021</lpage>.<pub-id pub-id-type="pmid">38833643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02344</pub-id><pub-id pub-id-type="pmcid">PMC11565489</pub-id></mixed-citation></ref><ref id="mco270560-bib-0163"><label>163</label><mixed-citation publication-type="journal" id="mco270560-cite-0163"><string-name name-style="western"><given-names>R. M.</given-names><surname>Layman</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, et&#160;al., &#8220;<article-title>Gedatolisib in Combination with Palbociclib and Endocrine Therapy in Women with Hormone Receptor&#8208;positive, HER2&#8208;negative Advanced Breast Cancer: Results from the Dose Expansion Groups of an Open&#8208;label, Phase 1b Study</article-title>,&#8221; <source>The Lancet Oncology</source><volume>25</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>474</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">38547892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(24)00034-2</pub-id></mixed-citation></ref><ref id="mco270560-bib-0164"><label>164</label><mixed-citation publication-type="journal" id="mco270560-cite-0164"><string-name name-style="western"><given-names>B.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yan</surname></string-name>, et&#160;al., &#8220;<article-title>Sacituzumab Govitecan in HR+HER2&#8722; Metastatic Breast Cancer: the Randomized Phase 3 EVER&#8208;132&#8208;002 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>30</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>3709</fpage>&#8211;<lpage>3716</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03269-z</pub-id><pub-id pub-id-type="pmcid">PMC11645259</pub-id><pub-id pub-id-type="pmid">39354196</pub-id></mixed-citation></ref><ref id="mco270560-bib-0165"><label>165</label><mixed-citation publication-type="journal" id="mco270560-cite-0165"><string-name name-style="western"><given-names>B. E.</given-names><surname>Nelson</surname></string-name> and <string-name name-style="western"><given-names>F.</given-names><surname>Meric&#8208;Bernstam</surname></string-name>, &#8220;<article-title>Leveraging TROP2 Antibody&#8208;Drug Conjugates in Solid Tumors</article-title>,&#8221; <source>Annual Review of Medicine</source><volume>75</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>31</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-med-071322-065903</pub-id><pub-id pub-id-type="pmid">37758237</pub-id></mixed-citation></ref><ref id="mco270560-bib-0166"><label>166</label><mixed-citation publication-type="journal" id="mco270560-cite-0166"><string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bardia</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Marm&#233;</surname></string-name>, et&#160;al., &#8220;<article-title>Overall Survival with sacituzumab govitecan in Hormone Receptor&#8208;positive and human Epidermal Growth Factor Receptor 2&#8208;negative Metastatic Breast Cancer (TROPiCS&#8208;02): a Randomised, Open&#8208;label, Multicentre, Phase 3 Trial</article-title>,&#8221; <source>The Lancet</source><volume>402</volume>, no. <issue>10411</issue> (<year>2023</year>): <fpage>1423</fpage>&#8211;<lpage>1433</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01245-X</pub-id><pub-id pub-id-type="pmid">37633306</pub-id></mixed-citation></ref><ref id="mco270560-bib-0167"><label>167</label><mixed-citation publication-type="journal" id="mco270560-cite-0167"><string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bardia</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Marm&#233;</surname></string-name>, et&#160;al., &#8220;<article-title>Sacituzumab Govitecan in Hormone Receptor&#8211;Positive/Human Epidermal Growth Factor Receptor 2&#8211;Negative Metastatic Breast Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume>, no. <issue>29</issue> (<year>2022</year>): <fpage>3365</fpage>&#8211;<lpage>3376</lpage>.<pub-id pub-id-type="pmid">36027558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01002</pub-id></mixed-citation></ref><ref id="mco270560-bib-0168"><label>168</label><mixed-citation publication-type="journal" id="mco270560-cite-0168"><string-name name-style="western"><given-names>A.</given-names><surname>Bardia</surname></string-name>, <string-name name-style="western"><given-names>I. E.</given-names><surname>Krop</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kogawa</surname></string-name>, et&#160;al., &#8220;<article-title>Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2&#8211; and Triple&#8208;Negative Breast Cancer: Results from the Phase I TROPION&#8208;PanTumor01 Study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>19</issue> (<year>2024</year>): <fpage>2281</fpage>&#8211;<lpage>2294</lpage>.<pub-id pub-id-type="pmid">38652877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01909</pub-id><pub-id pub-id-type="pmcid">PMC11210948</pub-id></mixed-citation></ref><ref id="mco270560-bib-0169"><label>169</label><mixed-citation publication-type="journal" id="mco270560-cite-0169"><string-name name-style="western"><given-names>Y.</given-names><surname>Yin</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Ouyang</surname></string-name>, et&#160;al., &#8220;<article-title>Sacituzumab Tirumotecan in Previously Treated Metastatic Triple&#8208;negative Breast Cancer: a Randomized Phase 3 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>1969</fpage>&#8211;<lpage>1975</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03630-w</pub-id><pub-id pub-id-type="pmid">40217078</pub-id></mixed-citation></ref><ref id="mco270560-bib-0170"><label>170</label><mixed-citation publication-type="journal" id="mco270560-cite-0170"><string-name name-style="western"><given-names>I. E.</given-names><surname>Krop</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Masuda</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Mukohara</surname></string-name>, et&#160;al., &#8220;<article-title>Patritumab Deruxtecan (HER3&#8208;DXd), a Human Epidermal Growth Factor Receptor 3&#8211;Directed Antibody&#8208;Drug Conjugate, in Patients with Previously Treated Human Epidermal Growth Factor Receptor 3&#8211;Expressing Metastatic Breast Cancer: a Multicenter, Phase I/II Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>36</issue> (<year>2023</year>): <fpage>5550</fpage>&#8211;<lpage>5560</lpage>.<pub-id pub-id-type="pmid">37801674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.00882</pub-id><pub-id pub-id-type="pmcid">PMC10730028</pub-id></mixed-citation></ref><ref id="mco270560-bib-0171"><label>171</label><mixed-citation publication-type="journal" id="mco270560-cite-0171"><string-name name-style="western"><given-names>L. R.</given-names><surname>Soares</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Vilbert</surname></string-name>, <string-name name-style="western"><given-names>V. D. L.</given-names><surname>Rosa</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Deus</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Freitas&#8208;Junior</surname></string-name>, &#8220;<article-title>Incidence of Interstitial Lung Disease and Cardiotoxicity with Trastuzumab Deruxtecan in Breast Cancer Patients: a Systematic Review and Single&#8208;arm Meta&#8208;analysis</article-title>,&#8221; <source>ESMO Open</source><volume>8</volume>, no. <issue>4</issue> (<year>2023</year>): <elocation-id>101613</elocation-id>.<pub-id pub-id-type="pmid">37481956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2023.101613</pub-id><pub-id pub-id-type="pmcid">PMC10485391</pub-id></mixed-citation></ref><ref id="mco270560-bib-0172"><label>172</label><mixed-citation publication-type="journal" id="mco270560-cite-0172"><string-name name-style="western"><given-names>E. P.</given-names><surname>Winer</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Lipatov</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;A.</given-names><surname>Im</surname></string-name>, et&#160;al., &#8220;<article-title>Pembrolizumab versus Investigator&#8208;choice Chemotherapy for Metastatic Triple&#8208;negative Breast Cancer (KEYNOTE&#8208;119): a Randomised, Open&#8208;label, Phase 3 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>22</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>499</fpage>&#8211;<lpage>511</lpage>.<pub-id pub-id-type="pmid">33676601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30754-3</pub-id></mixed-citation></ref><ref id="mco270560-bib-0173"><label>173</label><mixed-citation publication-type="journal" id="mco270560-cite-0173"><string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Cescon</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, et&#160;al., &#8220;<article-title>Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple&#8208;negative Breast Cancer (KEYNOTE&#8208;355): a Randomised, Placebo&#8208;controlled, Double&#8208;blind, Phase 3 Clinical Trial</article-title>,&#8221; <source>The Lancet</source><volume>396</volume>, no. <issue>10265</issue> (<year>2020</year>): <fpage>1817</fpage>&#8211;<lpage>1828</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32531-9</pub-id><pub-id pub-id-type="pmid">33278935</pub-id></mixed-citation></ref><ref id="mco270560-bib-0174"><label>174</label><mixed-citation publication-type="journal" id="mco270560-cite-0174"><string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Cescon</surname></string-name>, et&#160;al., &#8220;<article-title>Pembrolizumab plus Chemotherapy in Advanced Triple&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>387</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>217</fpage>&#8211;<lpage>226</lpage>.<pub-id pub-id-type="pmid">35857659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2202809</pub-id></mixed-citation></ref><ref id="mco270560-bib-0175"><label>175</label><mixed-citation publication-type="journal" id="mco270560-cite-0175"><string-name name-style="western"><given-names>P.</given-names><surname>Schmid</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Dent</surname></string-name>, et&#160;al., &#8220;<article-title>Event&#8208;free Survival with Pembrolizumab in Early Triple&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>386</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>556</fpage>&#8211;<lpage>567</lpage>.<pub-id pub-id-type="pmid">35139274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2112651</pub-id></mixed-citation></ref><ref id="mco270560-bib-0176"><label>176</label><mixed-citation publication-type="journal" id="mco270560-cite-0176"><string-name name-style="western"><given-names>P.</given-names><surname>Schmid</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Dent</surname></string-name>, et&#160;al., &#8220;<article-title>Overall Survival with Pembrolizumab in Early&#8208;Stage Triple&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>391</volume>, no. <issue>21</issue> (<year>2024</year>): <fpage>1981</fpage>&#8211;<lpage>1991</lpage>.<pub-id pub-id-type="pmid">39282906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2409932</pub-id></mixed-citation></ref><ref id="mco270560-bib-0177"><label>177</label><mixed-citation publication-type="journal" id="mco270560-cite-0177"><string-name name-style="western"><given-names>P.</given-names><surname>Schmid</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cortes</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pusztai</surname></string-name>, et&#160;al., &#8220;<article-title>Pembrolizumab for Early Triple&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>382</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>810</fpage>&#8211;<lpage>821</lpage>.<pub-id pub-id-type="pmid">32101663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1910549</pub-id></mixed-citation></ref><ref id="mco270560-bib-0178"><label>178</label><mixed-citation publication-type="journal" id="mco270560-cite-0178"><string-name name-style="western"><given-names>L.</given-names><surname>Pusztai</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Denkert</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>O'Shaughnessy</surname></string-name>, &#8220;<article-title>Event&#8208;free Survival by Residual Cancer Burden with Pembrolizumab in Early&#8208;stage TNBC: Exploratory Analysis from KEYNOTE&#8208;522</article-title>,&#8221; <source>Annals of Oncology</source><volume>35</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>429</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">38369015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.02.002</pub-id></mixed-citation></ref><ref id="mco270560-bib-0179"><label>179</label><mixed-citation publication-type="journal" id="mco270560-cite-0179"><string-name name-style="western"><given-names>F.</given-names><surname>Cardoso</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>O'Shaughnessy</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Liu</surname></string-name>, &#8220;<article-title>Pembrolizumab and Chemotherapy in High&#8208;risk, Early&#8208;stage, ER+/HER2&#8722; Breast Cancer: a Randomized Phase 3 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>442</fpage>&#8211;<lpage>448</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03415-7</pub-id><pub-id pub-id-type="pmcid">PMC11835712</pub-id><pub-id pub-id-type="pmid">39838117</pub-id></mixed-citation></ref><ref id="mco270560-bib-0180"><label>180</label><mixed-citation publication-type="journal" id="mco270560-cite-0180"><string-name name-style="western"><given-names>S.</given-names><surname>Kuemmel</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Graeser</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Schmid</surname></string-name>, et&#160;al., &#8220;<article-title>Chemotherapy&#8208;free Neoadjuvant Pembrolizumab Combined with Trastuzumab and Pertuzumab in HER2&#8208;enriched Early Breast Cancer (WSG&#8208;KEYRICHED&#8208;1): a Single&#8208;arm, Phase 2 Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>26</volume>, no. <issue>5</issue> (<year>2025</year>): <fpage>629</fpage>&#8211;<lpage>640</lpage>.<pub-id pub-id-type="pmid">40318646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(25)00097-X</pub-id></mixed-citation></ref><ref id="mco270560-bib-0181"><label>181</label><mixed-citation publication-type="journal" id="mco270560-cite-0181"><string-name name-style="western"><given-names>P.</given-names><surname>Schmid</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Adams</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Rugo</surname></string-name>, et&#160;al., &#8220;<article-title>Atezolizumab and Nab&#8208;Paclitaxel in Advanced Triple&#8208;Negative Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>379</volume>, no. <issue>22</issue> (<year>2018</year>): <fpage>2108</fpage>&#8211;<lpage>2121</lpage>.<pub-id pub-id-type="pmid">30345906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1809615</pub-id></mixed-citation></ref><ref id="mco270560-bib-0182"><label>182</label><mixed-citation publication-type="journal" id="mco270560-cite-0182"><string-name name-style="western"><given-names>D.</given-names><surname>Miles</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Gligorov</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Andr&#233;</surname></string-name>, et&#160;al., &#8220;<article-title>Primary Results from IMpassion131, a Double&#8208;blind, Placebo&#8208;controlled, Randomised Phase III Trial of First&#8208;line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Annals of Oncology</source><volume>32</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>994</fpage>&#8211;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">34219000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.05.801</pub-id></mixed-citation></ref><ref id="mco270560-bib-0183"><label>183</label><mixed-citation publication-type="journal" id="mco270560-cite-0183"><string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Efficacy, Safety and Exploratory Analysis of Neoadjuvant Tislelizumab (a PD&#8208;1 inhibitor) plus Nab&#8208;paclitaxel Followed by Epirubicin/Cyclophosphamide for Triple&#8208;negative Breast Cancer: a Phase 2 TREND Trial</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>10</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>169</fpage>.<pub-id pub-id-type="pmid">40414961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-025-02254-3</pub-id><pub-id pub-id-type="pmcid">PMC12104340</pub-id></mixed-citation></ref><ref id="mco270560-bib-0184"><label>184</label><mixed-citation publication-type="journal" id="mco270560-cite-0184"><string-name name-style="western"><given-names>Z.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Ouyang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Sun</surname></string-name>, et&#160;al., &#8220;<article-title>Toripalimab plus nab&#8208;paclitaxel in Metastatic or Recurrent Triple&#8208;negative Breast Cancer: a Randomized Phase 3 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>30</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>249</fpage>&#8211;<lpage>256</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02677-x</pub-id><pub-id pub-id-type="pmid">38191615</pub-id></mixed-citation></ref><ref id="mco270560-bib-0185"><label>185</label><mixed-citation publication-type="journal" id="mco270560-cite-0185"><string-name name-style="western"><given-names>S.</given-names><surname>Loi</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Salgado</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Curigliano</surname></string-name>, et&#160;al., &#8220;<article-title>Neoadjuvant Nivolumab and Chemotherapy in Early Estrogen Receptor&#8208;positive Breast Cancer: a Randomized Phase 3 Trial</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>433</fpage>&#8211;<lpage>441</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03414-8</pub-id><pub-id pub-id-type="pmcid">PMC11835735</pub-id><pub-id pub-id-type="pmid">39838118</pub-id></mixed-citation></ref><ref id="mco270560-bib-0186"><label>186</label><mixed-citation publication-type="journal" id="mco270560-cite-0186"><string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shao</surname></string-name>, et&#160;al., &#8220;<article-title>Endocrine&#8208;Therapy&#8208;Resistant ESR1 Variants Revealed by Genomic Characterization of Breast&#8208;Cancer&#8208;Derived Xenografts</article-title>,&#8221; <source>Cell Reports</source><volume>4</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>1116</fpage>&#8211;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">24055055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2013.08.022</pub-id><pub-id pub-id-type="pmcid">PMC3881975</pub-id></mixed-citation></ref><ref id="mco270560-bib-0187"><label>187</label><mixed-citation publication-type="journal" id="mco270560-cite-0187"><string-name name-style="western"><given-names>K.</given-names><surname>Merenbakh&#8208;Lamin</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ben&#8208;Baruch</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Yeheskel</surname></string-name>, et&#160;al., &#8220;<article-title>D538G Mutation in Estrogen Receptor&#8208;&#945;: a Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer</article-title>,&#8221; <source>Cancer Research</source><volume>73</volume>, no. <issue>23</issue> (<year>2013</year>): <fpage>6856</fpage>&#8211;<lpage>6864</lpage>.<pub-id pub-id-type="pmid">24217577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-13-1197</pub-id></mixed-citation></ref><ref id="mco270560-bib-0188"><label>188</label><mixed-citation publication-type="journal" id="mco270560-cite-0188"><string-name name-style="western"><given-names>D. R.</given-names><surname>Robinson</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;M.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Vats</surname></string-name>, et&#160;al., &#8220;<article-title>Activating ESR1 Mutations in Hormone&#8208;resistant Metastatic Breast Cancer</article-title>,&#8221; <source>Nature Genetics</source><volume>45</volume>, no. <issue>12</issue> (<year>2013</year>): <fpage>1446</fpage>&#8211;<lpage>1451</lpage>.<pub-id pub-id-type="pmid">24185510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2823</pub-id><pub-id pub-id-type="pmcid">PMC4009946</pub-id></mixed-citation></ref><ref id="mco270560-bib-0189"><label>189</label><mixed-citation publication-type="journal" id="mco270560-cite-0189"><string-name name-style="western"><given-names>W.</given-names><surname>Toy</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Won</surname></string-name>, et&#160;al., &#8220;<article-title>ESR1 ligand&#8208;binding Domain Mutations in Hormone&#8208;resistant Breast Cancer</article-title>,&#8221; <source>Nature Genetics</source><volume>45</volume>, no. <issue>12</issue> (<year>2013</year>): <fpage>1439</fpage>&#8211;<lpage>1445</lpage>.<pub-id pub-id-type="pmid">24185512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2822</pub-id><pub-id pub-id-type="pmcid">PMC3903423</pub-id></mixed-citation></ref><ref id="mco270560-bib-0190"><label>190</label><mixed-citation publication-type="journal" id="mco270560-cite-0190"><string-name name-style="western"><given-names>R.</given-names><surname>Jeselsohn</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Yelensky</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Buchwalter</surname></string-name>, et&#160;al., &#8220;<article-title>Emergence of Constitutively Active Estrogen Receptor&#8208;&#945; Mutations in Pretreated Advanced Estrogen Receptor&#8211;Positive Breast Cancer</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>20</volume>, no. <issue>7</issue> (<year>2014</year>): <fpage>1757</fpage>&#8211;<lpage>1767</lpage>.<pub-id pub-id-type="pmid">24398047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-13-2332</pub-id><pub-id pub-id-type="pmcid">PMC3998833</pub-id></mixed-citation></ref><ref id="mco270560-bib-0191"><label>191</label><mixed-citation publication-type="journal" id="mco270560-cite-0191"><string-name name-style="western"><given-names>S.</given-names><surname>Chandarlapaty</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Prevalence of ESR1 Mutations in Cell&#8208;Free DNA and Outcomes in Metastatic Breast Cancer</article-title>,&#8221; <source>JAMA Oncology</source><volume>2</volume>, no. <issue>10</issue> (<year>2016</year>): <fpage>1310</fpage>&#8211;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">27532364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.1279</pub-id><pub-id pub-id-type="pmcid">PMC5063698</pub-id></mixed-citation></ref><ref id="mco270560-bib-0192"><label>192</label><mixed-citation publication-type="journal" id="mco270560-cite-0192"><string-name name-style="western"><given-names>P.</given-names><surname>Razavi</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Xu</surname></string-name>, et&#160;al., &#8220;<article-title>The Genomic Landscape of Endocrine&#8208;Resistant Advanced Breast Cancers</article-title>,&#8221; <source>Cancer Cell</source><volume>34</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>427</fpage>&#8211;<lpage>438</lpage>.<pub-id pub-id-type="pmid">30205045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2018.08.008</pub-id><pub-id pub-id-type="pmcid">PMC6327853</pub-id></mixed-citation></ref><ref id="mco270560-bib-0193"><label>193</label><mixed-citation publication-type="journal" id="mco270560-cite-0193"><string-name name-style="western"><given-names>M.</given-names><surname>Will</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Metcalfe</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Chandarlapaty</surname></string-name>, &#8220;<article-title>Therapeutic Resistance to Anti&#8208;oestrogen Therapy in Breast Cancer</article-title>,&#8221; <source>Nature Reviews Cancer</source><volume>23</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>673</fpage>&#8211;<lpage>685</lpage>.<pub-id pub-id-type="pmid">37500767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-023-00604-3</pub-id><pub-id pub-id-type="pmcid">PMC10529099</pub-id></mixed-citation></ref><ref id="mco270560-bib-0194"><label>194</label><mixed-citation publication-type="journal" id="mco270560-cite-0194"><string-name name-style="western"><given-names>A.</given-names><surname>Arruabarrena&#8208;Aristorena</surname></string-name>, <string-name name-style="western"><given-names>J. L. V.</given-names><surname>Maag</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kittane</surname></string-name>, et&#160;al., &#8220;<article-title>FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer</article-title>,&#8221; <source>Cancer Cell</source><volume>38</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>534</fpage>&#8211;<lpage>550.e9</lpage>.<pub-id pub-id-type="pmid">32888433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.08.003</pub-id><pub-id pub-id-type="pmcid">PMC8311901</pub-id></mixed-citation></ref><ref id="mco270560-bib-0195"><label>195</label><mixed-citation publication-type="journal" id="mco270560-cite-0195"><string-name name-style="western"><given-names>L. D. C.</given-names><surname>Hoefnagel</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>Moelans</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Meijer</surname></string-name>, et&#160;al., &#8220;<article-title>Prognostic Value of Estrogen Receptor &#945; and Progesterone Receptor Conversion in Distant Breast Cancer Metastases</article-title>,&#8221; <source>Cancer</source><volume>118</volume>, no. <issue>20</issue> (<year>2012</year>): <fpage>4929</fpage>&#8211;<lpage>4935</lpage>.<pub-id pub-id-type="pmid">22415862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.27518</pub-id></mixed-citation></ref><ref id="mco270560-bib-0196"><label>196</label><mixed-citation publication-type="journal" id="mco270560-cite-0196"><string-name name-style="western"><given-names>A.</given-names><surname>Bardia</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Aftimos</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Bihani</surname></string-name>, et&#160;al., &#8220;<article-title>EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer</article-title>,&#8221; <source>Future Oncology</source><volume>15</volume>, no. <issue>28</issue> (<year>2019</year>): <fpage>3209</fpage>&#8211;<lpage>3218</lpage>.<pub-id pub-id-type="pmid">31426673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2019-0370</pub-id></mixed-citation></ref><ref id="mco270560-bib-0197"><label>197</label><mixed-citation publication-type="journal" id="mco270560-cite-0197"><string-name name-style="western"><given-names>E.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Turner</surname></string-name>, et&#160;al., &#8220;<article-title>A Phase I Dose Escalation and Expansion Trial of the next&#8208;generation Oral SERD Camizestrant in Women with ER&#8208;positive, HER2&#8208;negative Advanced Breast Cancer: SERENA&#8208;1 Monotherapy Results</article-title>,&#8221; <source>Annals of Oncology</source><volume>35</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>707</fpage>&#8211;<lpage>717</lpage>.<pub-id pub-id-type="pmid">38729567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.04.012</pub-id></mixed-citation></ref><ref id="mco270560-bib-0198"><label>198</label><mixed-citation publication-type="journal" id="mco270560-cite-0198"><string-name name-style="western"><given-names>N. C.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Loi</surname></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Moore</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract PD13&#8208;07: Activity and Biomarker Analyses from a Phase Ia/b Study of Giredestrant (GDC&#8208;9545; G) with or without Palbociclib (palbo) in Patients with Estrogen Receptor&#8208;positive, HER2&#8208;negative Locally Advanced/Metastatic Breast Cancer (ER+/HER2&#8208; LA/mBC)</article-title>,&#8221; <source>Cancer Research</source><volume>82</volume>, no. <issue>4</issue>_Supplement (<year>2022</year>). PD13&#8211;07&#8211;PD13&#8211;07.</mixed-citation></ref><ref id="mco270560-bib-0199"><label>199</label><mixed-citation publication-type="journal" id="mco270560-cite-0199"><string-name name-style="western"><given-names>M. R.</given-names><surname>Lloyd</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Wander</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Razavi</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Bardia</surname></string-name>, &#8220;<article-title>Next&#8208;generation Selective Estrogen Receptor Degraders and Other Novel Endocrine Therapies for Management of Metastatic Hormone Receptor&#8208;positive Breast Cancer: Current and Emerging Role</article-title>,&#8221; <source>Therapeutic Advances in Medical Oncology</source><volume>14</volume> (<year>2022</year>): <elocation-id>17588359221113694</elocation-id>.<pub-id pub-id-type="pmid">35923930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359221113694</pub-id><pub-id pub-id-type="pmcid">PMC9340905</pub-id></mixed-citation></ref><ref id="mco270560-bib-0200"><label>200</label><mixed-citation publication-type="journal" id="mco270560-cite-0200"><string-name name-style="western"><given-names>J. L.</given-names><surname>da Silva</surname></string-name>, <string-name name-style="western"><given-names>L. J. C.</given-names><surname>Oliveira</surname></string-name>, <string-name name-style="western"><given-names>C. A. A.</given-names><surname>de Resende</surname></string-name>, et&#160;al., &#8220;<article-title>Understanding and Overcoming CDK4/6 Inhibitor Resistance in HR+/HER2&#8722; Metastatic Breast Cancer: Clinical and Molecular Perspectives</article-title>,&#8221; <source>Therapeutic Advances in Medical Oncology</source><volume>17</volume> (<year>2025</year>): <elocation-id>17588359251353623</elocation-id>.<pub-id pub-id-type="pmid">40656600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359251353623</pub-id><pub-id pub-id-type="pmcid">PMC12254669</pub-id></mixed-citation></ref><ref id="mco270560-bib-0201"><label>201</label><mixed-citation publication-type="journal" id="mco270560-cite-0201"><string-name name-style="western"><given-names>R.</given-names><surname>Pal</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Chakraborty</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nath</surname></string-name>, et&#160;al., &#8220;<article-title>Noble Metal Nanoparticle&#8208;induced Oxidative Stress Modulates Tumor Associated Macrophages (TAMs) from an M2 to M1 Phenotype: an in Vitro Approach</article-title>,&#8221; <source>International Immunopharmacology</source><volume>38</volume> (<year>2016</year>): <fpage>332</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">27344639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2016.06.006</pub-id></mixed-citation></ref><ref id="mco270560-bib-0202"><label>202</label><mixed-citation publication-type="journal" id="mco270560-cite-0202"><string-name name-style="western"><given-names>S.</given-names><surname>Soman</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kulkarni</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pandey</surname></string-name>, et&#160;al., &#8220;<article-title>2D Hetero&#8208;Nanoconstructs of Black Phosphorus for Breast Cancer Theragnosis: Technological Advancements</article-title>,&#8221; <source>Biosensors</source><volume>12</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>1009</fpage>.<pub-id pub-id-type="pmid">36421127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bios12111009</pub-id><pub-id pub-id-type="pmcid">PMC9688887</pub-id></mixed-citation></ref><ref id="mco270560-bib-0203"><label>203</label><mixed-citation publication-type="journal" id="mco270560-cite-0203"><string-name name-style="western"><given-names>S.</given-names><surname>Zanganeh</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Hutter</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Spitler</surname></string-name>, et&#160;al., &#8220;<article-title>Iron Oxide Nanoparticles Inhibit Tumour Growth by Inducing Pro&#8208;inflammatory Macrophage Polarization in Tumour Tissues</article-title>,&#8221; <source>Nature Nanotechnology</source><volume>11</volume>, no. <issue>11</issue> (<year>2016</year>): <fpage>986</fpage>&#8211;<lpage>994</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2016.168</pub-id><pub-id pub-id-type="pmcid">PMC5198777</pub-id><pub-id pub-id-type="pmid">27668795</pub-id></mixed-citation></ref><ref id="mco270560-bib-0204"><label>204</label><mixed-citation publication-type="journal" id="mco270560-cite-0204"><string-name name-style="western"><given-names>M.</given-names><surname>B&#233;k&#233;s</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Langley</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>PROTAC Targeted Protein Degraders: the Past Is Prologue</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>21</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>181</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">35042991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00371-6</pub-id><pub-id pub-id-type="pmcid">PMC8765495</pub-id></mixed-citation></ref><ref id="mco270560-bib-0205"><label>205</label><mixed-citation publication-type="journal" id="mco270560-cite-0205"><string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>De Laurentiis</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jhaveri</surname></string-name>, et&#160;al., &#8220;<article-title>Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>393</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>556</fpage>&#8211;<lpage>568</lpage>.<pub-id pub-id-type="pmid">40454645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2505725</pub-id></mixed-citation></ref><ref id="mco270560-bib-0206"><label>206</label><mixed-citation publication-type="journal" id="mco270560-cite-0206"><string-name name-style="western"><given-names>A. D.</given-names><surname>Parisian</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Barratt</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Hodges&#8208;Gallagher</surname></string-name>, &#8220;<article-title>Palazestrant (OP&#8208;1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild&#8208;type and Mutant ER&#8208;positive Breast Cancer Models as Monotherapy and in Combination</article-title>,&#8221; <source>Molecular cancer therapeutics</source><volume>23</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>285</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">38102750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0351</pub-id><pub-id pub-id-type="pmcid">PMC10911704</pub-id></mixed-citation></ref><ref id="mco270560-bib-0207"><label>207</label><mixed-citation publication-type="journal" id="mco270560-cite-0207"><string-name name-style="western"><given-names>E. P.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>V. F.</given-names><surname>Borges</surname></string-name>, et&#160;al., &#8220;<article-title>Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2&#8722; Advanced or Metastatic Breast Cancer: Phase 1/2 Study Results</article-title>,&#8221; <source>Breast Cancer Research</source><volume>27</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>119</fpage>.<pub-id pub-id-type="pmid">40598566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-025-02049-y</pub-id><pub-id pub-id-type="pmcid">PMC12210654</pub-id></mixed-citation></ref><ref id="mco270560-bib-0208"><label>208</label><mixed-citation publication-type="journal" id="mco270560-cite-0208"><string-name name-style="western"><given-names>N.</given-names><surname>Sarhangi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hajjari</surname></string-name>, <string-name name-style="western"><given-names>S. F.</given-names><surname>Heydari</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ganjizadeh</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Rouhollah</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Hasanzad</surname></string-name>, &#8220;<article-title>Breast Cancer in the Era of Precision Medicine</article-title>,&#8221; <source>Molecular Biology Reports</source><volume>49</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>10023</fpage>&#8211;<lpage>10037</lpage>.<pub-id pub-id-type="pmid">35733061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-022-07571-2</pub-id></mixed-citation></ref><ref id="mco270560-bib-0209"><label>209</label><mixed-citation publication-type="journal" id="mco270560-cite-0209"><string-name name-style="western"><given-names>M. J. M.</given-names><surname>Magbanua</surname></string-name>, <string-name name-style="western"><given-names>L. B.</given-names><surname>Swigart</surname></string-name>, <string-name name-style="western"><given-names>H. T.</given-names><surname>Wu</surname></string-name>, et&#160;al., &#8220;<article-title>Circulating Tumor DNA in Neoadjuvant&#8208;treated Breast Cancer Reflects Response and Survival</article-title>,&#8221; <source>Annals of Oncology</source><volume>32</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>229</fpage>&#8211;<lpage>239</lpage>.<pub-id pub-id-type="pmid">33232761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.11.007</pub-id><pub-id pub-id-type="pmcid">PMC9348585</pub-id></mixed-citation></ref><ref id="mco270560-bib-0210"><label>210</label><mixed-citation publication-type="journal" id="mco270560-cite-0210"><string-name name-style="western"><given-names>N. C.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kingston</surname></string-name>, <string-name name-style="western"><given-names>L. S.</given-names><surname>Kilburn</surname></string-name>, et&#160;al., &#8220;<article-title>Circulating Tumour DNA Analysis to Direct Therapy in Advanced Breast Cancer (plasmaMATCH): a Multicentre, Multicohort, Phase 2a, Platform Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>21</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>1296</fpage>&#8211;<lpage>1308</lpage>.<pub-id pub-id-type="pmid">32919527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30444-7</pub-id><pub-id pub-id-type="pmcid">PMC7599319</pub-id></mixed-citation></ref><ref id="mco270560-bib-0211"><label>211</label><mixed-citation publication-type="journal" id="mco270560-cite-0211"><string-name name-style="western"><given-names>I.</given-names><surname>Garcia&#8208;Murillas</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Chopra</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Comino&#8208;M&#233;ndez</surname></string-name>, et&#160;al., &#8220;<article-title>Assessment of Molecular Relapse Detection in Early&#8208;Stage Breast Cancer</article-title>,&#8221; <source>JAMA Oncology</source><volume>5</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>1473</fpage>&#8211;<lpage>1478</lpage>.<pub-id pub-id-type="pmid">31369045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2019.1838</pub-id><pub-id pub-id-type="pmcid">PMC6681568</pub-id></mixed-citation></ref><ref id="mco270560-bib-0212"><label>212</label><mixed-citation publication-type="journal" id="mco270560-cite-0212"><string-name name-style="western"><given-names>I.</given-names><surname>Garcia&#8208;Murillas</surname></string-name>, <string-name name-style="western"><given-names>C. W.</given-names><surname>Abbott</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Cutts</surname></string-name>, et&#160;al., &#8220;<article-title>Whole Genome Sequencing&#8208;powered ctDNA Sequencing for Breast Cancer Detection</article-title>,&#8221; <source>Annals of Oncology</source><volume>36</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>673</fpage>&#8211;<lpage>681</lpage>.<pub-id pub-id-type="pmid">39914664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2025.01.021</pub-id></mixed-citation></ref><ref id="mco270560-bib-0213"><label>213</label><mixed-citation publication-type="miscellaneous" id="mco270560-cite-0213"><collab collab-type="authors">National Comprehensive Cancer Network</collab>
. <article-title>NCCN Guidelines&#174; Insights: Genetic/Familial High&#8208;Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2026</article-title>. Accessed October, 2025, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=2%26id=1545" ext-link-type="uri">https://www.nccn.org/guidelines/guidelines&#8208;detail?category=2&amp;id=1545</ext-link>.</mixed-citation></ref><ref id="mco270560-bib-0214"><label>214</label><mixed-citation publication-type="journal" id="mco270560-cite-0214">&#8220;<article-title>Guidelines for Diagnosis and Treatment of Advanced Breast Cancer in China (2024 edition)</article-title>,&#8221; <source>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</source><year>2024</year>;<volume>46</volume>(<issue>12</issue>):<fpage>1079</fpage>&#8211;<lpage>1106</lpage>.<pub-id pub-id-type="pmid">39632259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3760/cma.j.cn112152-20241009-00435</pub-id></mixed-citation></ref><ref id="mco270560-bib-0215"><label>215</label><mixed-citation publication-type="journal" id="mco270560-cite-0215"><string-name name-style="western"><given-names>C.</given-names><surname>Sessa</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Balma&#241;a</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Bober</surname></string-name>, et&#160;al., &#8220;<article-title>Risk Reduction and Screening of Cancer in Hereditary Breast&#8208;ovarian Cancer Syndromes: ESMO Clinical Practice Guideline</article-title>,&#8221; <source>Annals of Oncology</source><volume>34</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>33</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">36307055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.10.004</pub-id></mixed-citation></ref><ref id="mco270560-bib-0216"><label>216</label><mixed-citation publication-type="journal" id="mco270560-cite-0216"><string-name name-style="western"><given-names>K. H.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Loibl</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sohn</surname></string-name>, et&#160;al., &#8220;<article-title>Pan&#8208;Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis, Treatment and Follow&#8208;up of Patients with Early Breast Cancer</article-title>,&#8221; <source>ESMO Open</source><volume>9</volume>, no. <issue>5</issue> (<year>2024</year>): <elocation-id>102974</elocation-id>.<pub-id pub-id-type="pmid">38796284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2024.102974</pub-id><pub-id pub-id-type="pmcid">PMC11145753</pub-id></mixed-citation></ref><ref id="mco270560-bib-0217"><label>217</label><mixed-citation publication-type="journal" id="mco270560-cite-0217"><string-name name-style="western"><given-names>D. L.</given-names><surname>Monticciolo</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Newell</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Moy</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Lee</surname></string-name>, and <string-name name-style="western"><given-names>S. V.</given-names><surname>Destounis</surname></string-name>, &#8220;<article-title>Breast Cancer Screening for Women at Higher&#8208;Than&#8208;Average Risk: Updated Recommendations from the ACR</article-title>,&#8221; <source>Journal of the American College of Radiology: JACR</source><volume>20</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>902</fpage>&#8211;<lpage>914</lpage>.<pub-id pub-id-type="pmid">37150275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacr.2023.04.002</pub-id></mixed-citation></ref><ref id="mco270560-bib-0218"><label>218</label><mixed-citation publication-type="journal" id="mco270560-cite-0218"><string-name name-style="western"><given-names>L.</given-names><surname>Had&#382;ikadi&#263;&#8208;Gu&#353;i&#263;</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ceri&#263;</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Marijanovi&#263;</surname></string-name>, et&#160;al., &#8220;<article-title>Guidelines for Breast Cancer Management in Bosnia and Herzegovina</article-title>,&#8221; <source>Biomol Biomed</source><volume>23</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>2</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">35880400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bjbms.2022.7504</pub-id><pub-id pub-id-type="pmcid">PMC9901905</pub-id></mixed-citation></ref><ref id="mco270560-bib-0219"><label>219</label><mixed-citation publication-type="journal" id="mco270560-cite-0219"><string-name name-style="western"><given-names>L.</given-names><surname>Urban</surname></string-name>, <string-name name-style="western"><given-names>L. F.</given-names><surname>Chala</surname></string-name>, <string-name name-style="western"><given-names>I. B.</given-names><surname>de Paula</surname></string-name>, et&#160;al., &#8220;<article-title>Recommendations for Breast Cancer Screening in Brazil, from the Brazilian College of Radiology and Diagnostic Imaging, the Brazilian Society of Mastology, and the Brazilian Federation of Gynecology and Obstetrics Associations</article-title>,&#8221; <source>Radiologia brasileira</source><volume>56</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>207</fpage>&#8211;<lpage>214</lpage>.<pub-id pub-id-type="pmid">37829583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/0100-3984.2023.0064-en</pub-id><pub-id pub-id-type="pmcid">PMC10567087</pub-id></mixed-citation></ref><ref id="mco270560-bib-0220"><label>220</label><mixed-citation publication-type="journal" id="mco270560-cite-0220"><string-name name-style="western"><given-names>J.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>W. Q.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>China Guideline for the Screening and Early Detection of Female Breast Cancer(2021, Beijing)]</article-title>,&#8221; <source>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</source><volume>43</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>357</fpage>&#8211;<lpage>382</lpage>.<pub-id pub-id-type="pmid">33902200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3760/cma.j.cn112152-20210119-00061</pub-id></mixed-citation></ref><ref id="mco270560-bib-0221"><label>221</label><mixed-citation publication-type="journal" id="mco270560-cite-0221"><string-name name-style="western"><given-names>M. J.</given-names><surname>Hassett</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Somerfield</surname></string-name>, <string-name name-style="western"><given-names>E. R.</given-names><surname>Baker</surname></string-name>, et&#160;al., &#8220;<article-title>Management of Male Breast Cancer: ASCO Guideline</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>38</volume>, no. <issue>16</issue> (<year>2020</year>): <fpage>1849</fpage>&#8211;<lpage>1863</lpage>.<pub-id pub-id-type="pmid">32058842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.03120</pub-id></mixed-citation></ref><ref id="mco270560-bib-0222"><label>222</label><mixed-citation publication-type="journal" id="mco270560-cite-0222"><string-name name-style="western"><given-names>G.</given-names><surname>Bougeard</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Renaux&#8208;Petel</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Flaman</surname></string-name>, et&#160;al., &#8220;<article-title>Revisiting Li&#8208;Fraumeni Syndrome from TP53 Mutation Carriers</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>33</volume>, no. <issue>21</issue> (<year>2015</year>): <fpage>2345</fpage>&#8211;<lpage>2352</lpage>.<pub-id pub-id-type="pmid">26014290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.59.5728</pub-id></mixed-citation></ref><ref id="mco270560-bib-0223"><label>223</label><mixed-citation publication-type="journal" id="mco270560-cite-0223"><string-name name-style="western"><given-names>A. C.</given-names><surname>Antoniou</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Casadei</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Heikkinen</surname></string-name>, et&#160;al., &#8220;<article-title>Breast&#8208;cancer Risk in Families with Mutations in PALB2</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>371</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>497</fpage>&#8211;<lpage>506</lpage>.<pub-id pub-id-type="pmid">25099575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1400382</pub-id><pub-id pub-id-type="pmcid">PMC4157599</pub-id></mixed-citation></ref><ref id="mco270560-bib-0224"><label>224</label><mixed-citation publication-type="journal" id="mco270560-cite-0224"><string-name name-style="western"><given-names>J.</given-names><surname>Mersch</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Jackson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Park</surname></string-name>, et&#160;al., &#8220;<article-title>Cancers Associated with BRCA1 and BRCA2 Mutations Other than Breast and Ovarian</article-title>,&#8221; <source>Cancer</source><volume>121</volume>, no. <issue>2</issue> (<year>2015</year>): <fpage>269</fpage>&#8211;<lpage>275</lpage>.<pub-id pub-id-type="pmid">25224030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.29041</pub-id><pub-id pub-id-type="pmcid">PMC4293332</pub-id></mixed-citation></ref><ref id="mco270560-bib-0225"><label>225</label><mixed-citation publication-type="journal" id="mco270560-cite-0225"><string-name name-style="western"><given-names>Y.</given-names><surname>Momozawa</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sasai</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Usui</surname></string-name>, et&#160;al., &#8220;<article-title>Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants</article-title>,&#8221; <source>JAMA oncology</source><volume>8</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>871</fpage>&#8211;<lpage>878</lpage>.<pub-id pub-id-type="pmid">35420638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.0476</pub-id><pub-id pub-id-type="pmcid">PMC9011177</pub-id></mixed-citation></ref><ref id="mco270560-bib-0226"><label>226</label><mixed-citation publication-type="journal" id="mco270560-cite-0226"><string-name name-style="western"><given-names>Y.</given-names><surname>Cai</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Gao</surname></string-name>, et&#160;al., &#8220;<article-title>A Systematic Review of Recommendations on Screening Strategies for Breast Cancer due to Hereditary Predisposition: Who, When, and How?</article-title>,&#8221; <source>Cancer medicine</source><volume>10</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>3437</fpage>&#8211;<lpage>3448</lpage>.<pub-id pub-id-type="pmid">33932123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3898</pub-id><pub-id pub-id-type="pmcid">PMC8124106</pub-id></mixed-citation></ref><ref id="mco270560-bib-0227"><label>227</label><mixed-citation publication-type="journal" id="mco270560-cite-0227"><string-name name-style="western"><given-names>X. A.</given-names><surname>Phi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Saadatmand</surname></string-name>, <string-name name-style="western"><given-names>G. H.</given-names><surname>De Bock</surname></string-name>, et&#160;al., &#8220;<article-title>Contribution of Mammography to MRI Screening in BRCA Mutation Carriers by BRCA Status and Age: Individual Patient Data Meta&#8208;analysis</article-title>,&#8221; <source>British Journal of Cancer</source><volume>114</volume>, no. <issue>6</issue> (<year>2016</year>): <fpage>631</fpage>&#8211;<lpage>637</lpage>.<pub-id pub-id-type="pmid">26908327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2016.32</pub-id><pub-id pub-id-type="pmcid">PMC4800299</pub-id></mixed-citation></ref><ref id="mco270560-bib-0228"><label>228</label><mixed-citation publication-type="journal" id="mco270560-cite-0228"><string-name name-style="western"><given-names>L. C.</given-names><surname>Hartmann</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Radisky</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Frost</surname></string-name>, et&#160;al., &#8220;<article-title>Understanding the Premalignant Potential of atypical Hyperplasia through Its Natural History: a Longitudinal Cohort Study</article-title>,&#8221; <source>Cancer prevention research (Philadelphia, Pa)</source><volume>7</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>211</fpage>&#8211;<lpage>217</lpage>.<pub-id pub-id-type="pmid">24480577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-13-0222</pub-id><pub-id pub-id-type="pmcid">PMC4167687</pub-id></mixed-citation></ref><ref id="mco270560-bib-0229"><label>229</label><mixed-citation publication-type="journal" id="mco270560-cite-0229"><string-name name-style="western"><given-names>T. O.</given-names><surname>Henderson</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Amsterdam</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bhatia</surname></string-name>, et&#160;al., &#8220;<article-title>Systematic Review: Surveillance for Breast Cancer in Women Treated with Chest Radiation for Childhood, Adolescent, or Young Adult Cancer</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>152</volume>, no. <issue>7</issue> (<year>2010</year>): <fpage>444</fpage>&#8211;<lpage>455</lpage>. W144&#8211;54.<pub-id pub-id-type="pmid">20368650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1059/0003-4819-152-7-201004060-00009</pub-id><pub-id pub-id-type="pmcid">PMC2857928</pub-id></mixed-citation></ref><ref id="mco270560-bib-0230"><label>230</label><mixed-citation publication-type="journal" id="mco270560-cite-0230"><string-name name-style="western"><given-names>C. S.</given-names><surname>Moskowitz</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Chou</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Wolden</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer after Chest Radiation Therapy for Childhood Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>32</volume>, no. <issue>21</issue> (<year>2014</year>): <fpage>2217</fpage>&#8211;<lpage>2223</lpage>.<pub-id pub-id-type="pmid">24752044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.54.4601</pub-id><pub-id pub-id-type="pmcid">PMC4100937</pub-id></mixed-citation></ref><ref id="mco270560-bib-0231"><label>231</label><mixed-citation publication-type="journal" id="mco270560-cite-0231"><string-name name-style="western"><given-names>V.</given-names><surname>Freitas</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Scaranelo</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Menezes</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kulkarni</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hodgson</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Crystal</surname></string-name>, &#8220;<article-title>Added Cancer Yield of Breast Magnetic Resonance Imaging Screening in Women with a Prior History of Chest Radiation Therapy</article-title>,&#8221; <source>Cancer</source><volume>119</volume>, no. <issue>3</issue> (<year>2013</year>): <fpage>495</fpage>&#8211;<lpage>503</lpage>.<pub-id pub-id-type="pmid">22952042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.27771</pub-id></mixed-citation></ref><ref id="mco270560-bib-0232"><label>232</label><mixed-citation publication-type="journal" id="mco270560-cite-0232"><string-name name-style="western"><given-names>F. L.</given-names><surname>Wong</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>W. M.</given-names><surname>Leisenring</surname></string-name>, et&#160;al., &#8220;<article-title>Health Benefits and Cost&#8208;Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest&#8208;Irradiated Hodgkin Lymphoma Survivors</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>5</issue> (<year>2023</year>): <fpage>1046</fpage>&#8211;<lpage>1058</lpage>.<pub-id pub-id-type="pmid">36265088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.00574</pub-id><pub-id pub-id-type="pmcid">PMC9928841</pub-id></mixed-citation></ref><ref id="mco270560-bib-0233"><label>233</label><mixed-citation publication-type="journal" id="mco270560-cite-0233"><string-name name-style="western"><given-names>E.</given-names><surname>Lynge</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Vejborg</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lillholm</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Nielsen</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Napolitano</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>von Euler&#8208;Chelpin</surname></string-name>, &#8220;<article-title>Breast Density and Risk of Breast Cancer</article-title>,&#8221; <source>International Journal of Cancer</source><volume>152</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>1150</fpage>&#8211;<lpage>1158</lpage>.<pub-id pub-id-type="pmid">36214783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34316</pub-id><pub-id pub-id-type="pmcid">PMC10091988</pub-id></mixed-citation></ref><ref id="mco270560-bib-0234"><label>234</label><mixed-citation publication-type="journal" id="mco270560-cite-0234"><string-name name-style="western"><given-names>A. J.</given-names><surname>Ironside</surname></string-name> and <string-name name-style="western"><given-names>J. L.</given-names><surname>Jones</surname></string-name>, &#8220;<article-title>Stromal Characteristics May Hold the Key to Mammographic Density: the Evidence to Date</article-title>,&#8221; <source>Oncotarget</source><volume>7</volume>, no. <issue>21</issue> (<year>2016</year>): <fpage>31550</fpage>&#8211;<lpage>31562</lpage>.<pub-id pub-id-type="pmid">26784251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6912</pub-id><pub-id pub-id-type="pmcid">PMC5058777</pub-id></mixed-citation></ref><ref id="mco270560-bib-0235"><label>235</label><mixed-citation publication-type="journal" id="mco270560-cite-0235"><string-name name-style="western"><given-names>N. F.</given-names><surname>Boyd</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Martin</surname></string-name>, et&#160;al., &#8220;<article-title>Mammographic Density and the Risk and Detection of Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>356</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>227</fpage>&#8211;<lpage>236</lpage>.<pub-id pub-id-type="pmid">17229950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa062790</pub-id></mixed-citation></ref><ref id="mco270560-bib-0236"><label>236</label><mixed-citation publication-type="journal" id="mco270560-cite-0236"><string-name name-style="western"><given-names>J. O.</given-names><surname>Wanders</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Holland</surname></string-name>, <string-name name-style="western"><given-names>W. B.</given-names><surname>Veldhuis</surname></string-name>, et&#160;al., &#8220;<article-title>Volumetric Breast Density Affects Performance of Digital Screening Mammography</article-title>,&#8221; <source>Breast Cancer Research and Treatment</source><volume>162</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>95</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">28012087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-016-4090-7</pub-id><pub-id pub-id-type="pmcid">PMC5288416</pub-id></mixed-citation></ref><ref id="mco270560-bib-0237"><label>237</label><mixed-citation publication-type="journal" id="mco270560-cite-0237"><string-name name-style="western"><given-names>M. F.</given-names><surname>Bakker</surname></string-name>, <string-name name-style="western"><given-names>S. V.</given-names><surname>de Lange</surname></string-name>, <string-name name-style="western"><given-names>R. M.</given-names><surname>Pijnappel</surname></string-name>, et&#160;al., &#8220;<article-title>Supplemental MRI Screening for Women with Extremely Dense Breast Tissue</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>381</volume>, no. <issue>22</issue> (<year>2019</year>): <fpage>2091</fpage>&#8211;<lpage>2102</lpage>.<pub-id pub-id-type="pmid">31774954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1903986</pub-id></mixed-citation></ref><ref id="mco270560-bib-0238"><label>238</label><mixed-citation publication-type="journal" id="mco270560-cite-0238"><string-name name-style="western"><given-names>A.</given-names><surname>Bunnell</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Valdez</surname></string-name>, <string-name name-style="western"><given-names>T. K.</given-names><surname>Wolfgruber</surname></string-name>, et&#160;al., &#8220;<article-title>Prediction of Mammographic Breast Density Based on Clinical Breast Ultrasound Images Using Deep Learning: a Retrospective Analysis</article-title>,&#8221; <source>Lancet regional health Americas</source><volume>46</volume> (<year>2025</year>): <elocation-id>101096</elocation-id>.<pub-id pub-id-type="pmid">40290129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lana.2025.101096</pub-id><pub-id pub-id-type="pmcid">PMC12032905</pub-id></mixed-citation></ref><ref id="mco270560-bib-0239"><label>239</label><mixed-citation publication-type="journal" id="mco270560-cite-0239"><string-name name-style="western"><given-names>J. P.</given-names><surname>Struewing</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Abeliovich</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Peretz</surname></string-name>, et&#160;al., &#8220;<article-title>The Carrier Frequency of the BRCA1 185delAG Mutation Is Approximately 1 Percent in Ashkenazi Jewish Individuals</article-title>,&#8221; <source>Nature Genetics</source><volume>11</volume>, no. <issue>2</issue> (<year>1995</year>): <fpage>198</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">7550349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng1095-198</pub-id></mixed-citation></ref><ref id="mco270560-bib-0240"><label>240</label><mixed-citation publication-type="journal" id="mco270560-cite-0240"><string-name name-style="western"><given-names>T. D.</given-names><surname>Ellington</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Henley</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Wilson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>L. C.</given-names><surname>Richardson</surname></string-name>, &#8220;<article-title>Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age among Women Aged &gt;/= 20 Years &#8208; United States, 1999&#8211;2018</article-title>,&#8221; <source>Mmwr Morbidity and Mortality Weekly Report</source><volume>71</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>43</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">35025856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7102a2</pub-id><pub-id pub-id-type="pmcid">PMC8757618</pub-id></mixed-citation></ref><ref id="mco270560-bib-0241"><label>241</label><mixed-citation publication-type="journal" id="mco270560-cite-0241"><string-name name-style="western"><given-names>K.</given-names><surname>Kerlikowske</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>M. C. S.</given-names><surname>Bissell</surname></string-name>, et&#160;al., &#8220;<article-title>Population Attributable Risk of Advanced&#8208;Stage Breast Cancer by Race and Ethnicity</article-title>,&#8221; <source>JAMA oncology</source><volume>10</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>167</fpage>&#8211;<lpage>175</lpage>.<pub-id pub-id-type="pmid">38060241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2023.5242</pub-id><pub-id pub-id-type="pmcid">PMC10704341</pub-id></mixed-citation></ref><ref id="mco270560-bib-0242"><label>242</label><mixed-citation publication-type="journal" id="mco270560-cite-0242"><collab collab-type="authors">Collaborative Group on Hormonal Factors in Breast C</collab>
. &#8220;<article-title>Menarche, Menopause, and Breast Cancer Risk: Individual Participant Meta&#8208;analysis, Including 118 964 Women with Breast Cancer from 117 Epidemiological Studies</article-title>,&#8221; <source>The Lancet Oncology</source><year>2012</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1141</fpage>&#8211;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">23084519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(12)70425-4</pub-id><pub-id pub-id-type="pmcid">PMC3488186</pub-id></mixed-citation></ref><ref id="mco270560-bib-0243"><label>243</label><mixed-citation publication-type="journal" id="mco270560-cite-0243"><string-name name-style="western"><given-names>G. A.</given-names><surname>Colditz</surname></string-name> and <string-name name-style="western"><given-names>B.</given-names><surname>Rosner</surname></string-name>, &#8220;<article-title>Cumulative Risk of Breast Cancer to Age 70 Years According to Risk Factor Status: Data from the Nurses' Health Study</article-title>,&#8221; <source>American Journal of Epidemiology</source><volume>152</volume>, no. <issue>10</issue> (<year>2000</year>): <fpage>950</fpage>&#8211;<lpage>964</lpage>.<pub-id pub-id-type="pmid">11092437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/152.10.950</pub-id></mixed-citation></ref><ref id="mco270560-bib-0244"><label>244</label><mixed-citation publication-type="journal" id="mco270560-cite-0244"><string-name name-style="western"><given-names>L. A.</given-names><surname>Torres&#8208;de la Roche</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Acevedo&#8208;Mesa</surname></string-name>, <string-name name-style="western"><given-names>I. L.</given-names><surname>Lizarazo</surname></string-name>, et&#160;al., &#8220;<article-title>Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: a Meta&#8208;Analysis</article-title>,&#8221; <source>Cancers (Basel)</source><volume>15</volume>, no. <issue>23</issue> (<year>2023</year>): <fpage>5624</fpage>.<pub-id pub-id-type="pmid">38067328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15235624</pub-id><pub-id pub-id-type="pmcid">PMC10705112</pub-id></mixed-citation></ref><ref id="mco270560-bib-0245"><label>245</label><mixed-citation publication-type="journal" id="mco270560-cite-0245"><collab collab-type="authors">Collaborative Group on Hormonal Factors in Breast C</collab>
. &#8220;<article-title>Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta&#8208;analysis of the Worldwide Epidemiological Evidence</article-title>,&#8221; <source>Lancet</source><year>2019</year>;<volume>394</volume>(<issue>10204</issue>):<fpage>1159</fpage>&#8211;<lpage>1168</lpage>.<pub-id pub-id-type="pmid">31474332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31709-X</pub-id><pub-id pub-id-type="pmcid">PMC6891893</pub-id></mixed-citation></ref><ref id="mco270560-bib-0246"><label>246</label><mixed-citation publication-type="journal" id="mco270560-cite-0246"><string-name name-style="western"><given-names>B.</given-names><surname>Lauby&#8208;Secretan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Scoccianti</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Loomis</surname></string-name>, et&#160;al., &#8220;<article-title>Body Fatness and Cancer&#8211;Viewpoint of the IARC Working Group</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>375</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>794</fpage>&#8211;<lpage>798</lpage>.<pub-id pub-id-type="pmid">27557308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMsr1606602</pub-id><pub-id pub-id-type="pmcid">PMC6754861</pub-id></mixed-citation></ref><ref id="mco270560-bib-0247"><label>247</label><mixed-citation publication-type="journal" id="mco270560-cite-0247"><string-name name-style="western"><given-names>D.</given-names><surname>Hauner</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Gunther</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Schederecker</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of a Comprehensive Lifestyle Intervention Program on Body Weight and Health Behavior in Women with Breast Cancer: Results from a Randomized Controlled Trial</article-title>,&#8221; <source>Clinical Nutrition</source><volume>43</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1937</fpage>&#8211;<lpage>1951</lpage>.<pub-id pub-id-type="pmid">39024773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2024.07.002</pub-id></mixed-citation></ref><ref id="mco270560-bib-0248"><label>248</label><mixed-citation publication-type="journal" id="mco270560-cite-0248"><string-name name-style="western"><given-names>E. S.</given-names><surname>Schernhammer</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Laden</surname></string-name>, <string-name name-style="western"><given-names>F. E.</given-names><surname>Speizer</surname></string-name>, et&#160;al., &#8220;<article-title>Rotating Night Shifts and Risk of Breast Cancer in Women Participating in the Nurses' health Study</article-title>,&#8221; <source>Journal of the National Cancer Institute</source><volume>93</volume>, no. <issue>20</issue> (<year>2001</year>): <fpage>1563</fpage>&#8211;<lpage>1568</lpage>.<pub-id pub-id-type="pmid">11604480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/93.20.1563</pub-id></mixed-citation></ref><ref id="mco270560-bib-0249"><label>249</label><mixed-citation publication-type="journal" id="mco270560-cite-0249"><string-name name-style="western"><given-names>C.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Hart</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Gnanaolivu</surname></string-name>, et&#160;al., &#8220;<article-title>A Population&#8208;Based Study of Genes Previously Implicated in Breast Cancer</article-title>,&#8221; <source>The New England Journal of Medicine</source><volume>384</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>440</fpage>&#8211;<lpage>451</lpage>.<pub-id pub-id-type="pmid">33471974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2005936</pub-id><pub-id pub-id-type="pmcid">PMC8127622</pub-id></mixed-citation></ref><ref id="mco270560-bib-0250"><label>250</label><mixed-citation publication-type="journal" id="mco270560-cite-0250"><string-name name-style="western"><given-names>M. P.</given-names><surname>Akamandisa</surname></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>Boddicker</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Yadav</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population</article-title>,&#8221; <source>Annals of Oncology</source><volume>36</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>954</fpage>&#8211;<lpage>963</lpage>.<pub-id pub-id-type="pmid">40288678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2025.04.010</pub-id><pub-id pub-id-type="pmcid">PMC12288856</pub-id></mixed-citation></ref><ref id="mco270560-bib-0251"><label>251</label><mixed-citation publication-type="journal" id="mco270560-cite-0251"><string-name name-style="western"><given-names>K.&#8208;A.</given-names><surname>Phillips</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kotsopoulos</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Domchek</surname></string-name>, et&#160;al., &#8220;<article-title>Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2</article-title>,&#8221; <source>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</source><volume>43</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>422</fpage>&#8211;<lpage>431</lpage>.<pub-id pub-id-type="pmid">39356978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.24.00176</pub-id><pub-id pub-id-type="pmcid">PMC11771360</pub-id></mixed-citation></ref><ref id="mco270560-bib-0252"><label>252</label><mixed-citation publication-type="journal" id="mco270560-cite-0252"><string-name name-style="western"><given-names>B.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ryu</surname></string-name>, and <string-name name-style="western"><given-names>T. X. M.</given-names><surname>Tran</surname></string-name>, &#8220;<article-title>Trajectories of Breast Density Change over Time and Subsequent Breast Cancer Risk: Longitudinal Study</article-title>,&#8221; <source>BMJ (Clinical research ed)</source><volume>387</volume> (<year>2024</year>): <elocation-id>e079575</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2024-079575</pub-id><pub-id pub-id-type="pmcid">PMC11684031</pub-id><pub-id pub-id-type="pmid">39797631</pub-id></mixed-citation></ref><ref id="mco270560-bib-0253"><label>253</label><mixed-citation publication-type="journal" id="mco270560-cite-0253"><string-name name-style="western"><given-names>G. P.</given-names><surname>Watt</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Thakran</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Sung</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: the IMAGINE Study</article-title>,&#8221; <source>Radiology</source><volume>308</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>e230367</elocation-id>.<pub-id pub-id-type="pmid">37750771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.230367</pub-id><pub-id pub-id-type="pmcid">PMC10546291</pub-id></mixed-citation></ref><ref id="mco270560-bib-0254"><label>254</label><mixed-citation publication-type="journal" id="mco270560-cite-0254"><string-name name-style="western"><given-names>S. H.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;S.</given-names><surname>Ryu</surname></string-name>, <string-name name-style="western"><given-names>M.&#8208;J.</given-names><surname>Jang</surname></string-name>, et&#160;al., &#8220;<article-title>Glandular Tissue Component and Breast Cancer Risk in Mammographically Dense Breasts at Screening Breast US</article-title>,&#8221; <source>Radiology</source><volume>301</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>57</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">34282967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2021210367</pub-id></mixed-citation></ref><ref id="mco270560-bib-0255"><label>255</label><mixed-citation publication-type="journal" id="mco270560-cite-0255"><string-name name-style="western"><given-names>M. H.</given-names><surname>Gail</surname></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>Brinton</surname></string-name>, <string-name name-style="western"><given-names>D. P.</given-names><surname>Byar</surname></string-name>, et&#160;al., &#8220;<article-title>Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>81</volume>, no. <issue>24</issue> (<year>1989</year>): <fpage>1879</fpage>&#8211;<lpage>1886</lpage>.<pub-id pub-id-type="pmid">2593165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/81.24.1879</pub-id></mixed-citation></ref><ref id="mco270560-bib-0256"><label>256</label><mixed-citation publication-type="journal" id="mco270560-cite-0256"><string-name name-style="western"><given-names>J. P.</given-names><surname>Costantino</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Gail</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Pee</surname></string-name>, et&#160;al., &#8220;<article-title>Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>91</volume>, no. <issue>18</issue> (<year>1999</year>): <fpage>1541</fpage>&#8211;<lpage>1548</lpage>.<pub-id pub-id-type="pmid">10491430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/91.18.1541</pub-id></mixed-citation></ref><ref id="mco270560-bib-0257"><label>257</label><mixed-citation publication-type="journal" id="mco270560-cite-0257"><string-name name-style="western"><given-names>D. A.</given-names><surname>Berry</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Parmigiani</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sanchez</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Schildkraut</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Winer</surname></string-name>, &#8220;<article-title>Probability of Carrying a Mutation of Breast&#8208;ovarian Cancer Gene BRCA1 Based on family History</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>89</volume>, no. <issue>3</issue> (<year>1997</year>): <fpage>227</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="pmid">9017003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/89.3.227</pub-id></mixed-citation></ref><ref id="mco270560-bib-0258"><label>258</label><mixed-citation publication-type="journal" id="mco270560-cite-0258"><string-name name-style="western"><given-names>A. C.</given-names><surname>Antoniou</surname></string-name>, <string-name name-style="western"><given-names>P. D.</given-names><surname>Pharoah</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>McMullan</surname></string-name>, et&#160;al., &#8220;<article-title>A Comprehensive Model for Familial Breast Cancer Incorporating BRCA1, BRCA2 and Other Genes</article-title>,&#8221; <source>British Journal of Cancer</source><volume>86</volume>, no. <issue>1</issue> (<year>2002</year>): <fpage>76</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">11857015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6600008</pub-id><pub-id pub-id-type="pmcid">PMC2746531</pub-id></mixed-citation></ref><ref id="mco270560-bib-0259"><label>259</label><mixed-citation publication-type="journal" id="mco270560-cite-0259"><string-name name-style="western"><given-names>J.</given-names><surname>Tyrer</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Duffy</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, &#8220;<article-title>A Breast Cancer Prediction Model Incorporating Familial and Personal Risk Factors</article-title>,&#8221; <source>Statistics in Medicine</source><volume>23</volume>, no. <issue>7</issue> (<year>2004</year>): <fpage>1111</fpage>&#8211;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">15057881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.1668</pub-id></mixed-citation></ref><ref id="mco270560-bib-0260"><label>260</label><mixed-citation publication-type="journal" id="mco270560-cite-0260"><string-name name-style="western"><given-names>J. A.</given-names><surname>Tice</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Cummings</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Smith&#8208;Bindman</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ichikawa</surname></string-name>, <string-name name-style="western"><given-names>W. E.</given-names><surname>Barlow</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Kerlikowske</surname></string-name>, &#8220;<article-title>Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>148</volume>, no. <issue>5</issue> (<year>2008</year>): <fpage>337</fpage>&#8211;<lpage>347</lpage>.<pub-id pub-id-type="pmid">18316752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-148-5-200803040-00004</pub-id><pub-id pub-id-type="pmcid">PMC2674327</pub-id></mixed-citation></ref><ref id="mco270560-bib-0261"><label>261</label><mixed-citation publication-type="journal" id="mco270560-cite-0261"><string-name name-style="western"><given-names>E. M.</given-names><surname>van Veen</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Brentnall</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Byers</surname></string-name>, et&#160;al., &#8220;<article-title>Use of Single&#8208;Nucleotide Polymorphisms and Mammographic Density plus Classic Risk Factors for Breast Cancer Risk Prediction</article-title>,&#8221; <source>JAMA oncology</source><volume>4</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>476</fpage>&#8211;<lpage>482</lpage>.<pub-id pub-id-type="pmid">29346471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2017.4881</pub-id><pub-id pub-id-type="pmcid">PMC5885189</pub-id></mixed-citation></ref><ref id="mco270560-bib-0262"><label>262</label><mixed-citation publication-type="journal" id="mco270560-cite-0262"><string-name name-style="western"><given-names>A.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Mavaddat</surname></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Wilcox</surname></string-name>, et&#160;al., &#8220;<article-title>BOADICEA: a Comprehensive Breast Cancer Risk Prediction Model Incorporating Genetic and Nongenetic Risk Factors</article-title>,&#8221; <source>Genetics in Medicine: Official Journal of the American College of Medical Genetics</source><volume>21</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>1708</fpage>&#8211;<lpage>1718</lpage>.<pub-id pub-id-type="pmid">30643217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-018-0406-9</pub-id><pub-id pub-id-type="pmcid">PMC6687499</pub-id></mixed-citation></ref><ref id="mco270560-bib-0263"><label>263</label><mixed-citation publication-type="journal" id="mco270560-cite-0263"><string-name name-style="western"><given-names>P.</given-names><surname>Pal Choudhury</surname></string-name>, <string-name name-style="western"><given-names>M. N.</given-names><surname>Brook</surname></string-name>, and <string-name name-style="western"><given-names>A. N.</given-names><surname>Hurson</surname></string-name>, &#8220;<article-title>Comparative Validation of the BOADICEA and Tyrer&#8208;Cuzick Breast Cancer Risk Models Incorporating Classical Risk Factors and Polygenic Risk in a Population&#8208;based Prospective Cohort of Women of European Ancestry</article-title>,&#8221; <source>Breast Cancer Research</source><volume>23</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>22</fpage>.<pub-id pub-id-type="pmid">33588869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-021-01399-7</pub-id><pub-id pub-id-type="pmcid">PMC7885342</pub-id></mixed-citation></ref><ref id="mco270560-bib-0264"><label>264</label><mixed-citation publication-type="journal" id="mco270560-cite-0264"><string-name name-style="western"><given-names>K. N.</given-names><surname>Maxwell</surname></string-name> and <string-name name-style="western"><given-names>S. M.</given-names><surname>Domchek</surname></string-name>, &#8220;<article-title>Toward Application of Polygenic Risk Scores to both Enhance and Deintensify Breast Cancer Screening</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>13</issue> (<year>2024</year>): <fpage>1462</fpage>&#8211;<lpage>1465</lpage>.<pub-id pub-id-type="pmid">38422469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.24.00029</pub-id><pub-id pub-id-type="pmcid">PMC11095852</pub-id></mixed-citation></ref><ref id="mco270560-bib-0265"><label>265</label><mixed-citation publication-type="journal" id="mco270560-cite-0265"><string-name name-style="western"><given-names>A. R.</given-names><surname>Martin</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kanai</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kamatani</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Okada</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Neale</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Daly</surname></string-name>, &#8220;<article-title>Clinical Use of Current Polygenic Risk Scores May Exacerbate Health Disparities</article-title>,&#8221; <source>Nature genetics</source><volume>51</volume>, no. <issue>4</issue> (<year>2019</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0379-x</pub-id><pub-id pub-id-type="pmcid">PMC6563838</pub-id><pub-id pub-id-type="pmid">30926966</pub-id></mixed-citation></ref><ref id="mco270560-bib-0266"><label>266</label><mixed-citation publication-type="journal" id="mco270560-cite-0266"><string-name name-style="western"><given-names>G.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ping</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Guo</surname></string-name>, et&#160;al., &#8220;<article-title>Genome&#8208;wide Association Analyses of Breast Cancer in Women of African Ancestry Identify New Susceptibility Loci and Improve Risk Prediction</article-title>,&#8221; <source>Nature Genetics</source><volume>56</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>819</fpage>&#8211;<lpage>826</lpage>.<pub-id pub-id-type="pmid">38741014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-024-01736-4</pub-id><pub-id pub-id-type="pmcid">PMC11284829</pub-id></mixed-citation></ref><ref id="mco270560-bib-0267"><label>267</label><mixed-citation publication-type="journal" id="mco270560-cite-0267"><string-name name-style="western"><given-names>L.</given-names><surname>Ficorella</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Mavaddat</surname></string-name>, et&#160;al., &#8220;<article-title>Adapting the BOADICEA Breast and Ovarian Cancer Risk Models for the Ethnically Diverse UK Population</article-title>,&#8221; <source>British Journal of Cancer</source><volume>133</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>844</fpage>&#8211;<lpage>855</lpage>.<pub-id pub-id-type="pmid">40676226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-025-03117-y</pub-id><pub-id pub-id-type="pmcid">PMC12449465</pub-id></mixed-citation></ref><ref id="mco270560-bib-0268"><label>268</label><mixed-citation publication-type="journal" id="mco270560-cite-0268"><string-name name-style="western"><given-names>A.</given-names><surname>Yala</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Mikhael</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Strand</surname></string-name>, et&#160;al., &#8220;<article-title>Multi&#8208;Institutional Validation of a Mammography&#8208;Based Breast Cancer Risk Model</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume>, no. <issue>16</issue> (<year>2022</year>): <fpage>1732</fpage>&#8211;<lpage>1740</lpage>.<pub-id pub-id-type="pmid">34767469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01337</pub-id><pub-id pub-id-type="pmcid">PMC9148689</pub-id></mixed-citation></ref><ref id="mco270560-bib-0269"><label>269</label><mixed-citation publication-type="journal" id="mco270560-cite-0269"><string-name name-style="western"><given-names>I.</given-names><surname>Heckenbach</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Powell</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Fuller</surname></string-name>, et&#160;al., &#8220;<article-title>Deep Learning Assessment of Senescence&#8208;associated Nuclear Morphologies in Mammary Tissue from Healthy Female Donors to Predict Future Risk of Breast Cancer: a Retrospective Cohort Study</article-title>,&#8221; <source>Lancet Digit Health</source><volume>6</volume>, no. <issue>10</issue> (<year>2024</year>): <fpage>e681</fpage>&#8211;<lpage>e690</lpage>.<pub-id pub-id-type="pmid">39332852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2589-7500(24)00150-X</pub-id></mixed-citation></ref><ref id="mco270560-bib-0270"><label>270</label><mixed-citation publication-type="journal" id="mco270560-cite-0270"><string-name name-style="western"><given-names>A.</given-names><surname>Yala</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Mikhael</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Strand</surname></string-name>, et&#160;al., &#8220;<article-title>Toward Robust Mammography&#8208;based Models for Breast Cancer Risk</article-title>,&#8221; <source>Science translational medicine</source><volume>13</volume>, no. <issue>578</issue> (<year>2021</year>): <elocation-id>eaba4373</elocation-id>.<pub-id pub-id-type="pmid">33504648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aba4373</pub-id></mixed-citation></ref><ref id="mco270560-bib-0271"><label>271</label><mixed-citation publication-type="journal" id="mco270560-cite-0271"><string-name name-style="western"><given-names>H. D.</given-names><surname>Nelson</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Cantor</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pappas</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Daeges</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Humphrey</surname></string-name>, &#8220;<article-title>Effectiveness of Breast Cancer Screening: Systematic Review and Meta&#8208;analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>164</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>244</fpage>&#8211;<lpage>255</lpage>.<pub-id pub-id-type="pmid">26756588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M15-0969</pub-id></mixed-citation></ref><ref id="mco270560-bib-0272"><label>272</label><mixed-citation publication-type="journal" id="mco270560-cite-0272"><string-name name-style="western"><given-names>P. E.</given-names><surname>Freer</surname></string-name>, &#8220;<article-title>Mammographic Breast Density: Impact on Breast Cancer Risk and Implications for Screening</article-title>,&#8221; <source>Radiographics</source><volume>35</volume>, no. <issue>2</issue> (<year>2015</year>): <fpage>302</fpage>&#8211;<lpage>315</lpage>.<pub-id pub-id-type="pmid">25763718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/rg.352140106</pub-id></mixed-citation></ref><ref id="mco270560-bib-0273"><label>273</label><mixed-citation publication-type="journal" id="mco270560-cite-0273"><string-name name-style="western"><given-names>S. S.</given-names><surname>Nazari</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Mukherjee</surname></string-name>, &#8220;<article-title>An Overview of Mammographic Density and Its Association with Breast Cancer</article-title>,&#8221; <source>Breast Cancer (Tokyo, Japan)</source><volume>25</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>259</fpage>&#8211;<lpage>267</lpage>.<pub-id pub-id-type="pmid">29651637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12282-018-0857-5</pub-id><pub-id pub-id-type="pmcid">PMC5906528</pub-id></mixed-citation></ref><ref id="mco270560-bib-0274"><label>274</label><mixed-citation publication-type="journal" id="mco270560-cite-0274"><string-name name-style="western"><given-names>R. E.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Sprague</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Henderson</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification</article-title>,&#8221; <source>Journal of the American College of Radiology: JACR</source><volume>19</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>615</fpage>&#8211;<lpage>624</lpage>.<pub-id pub-id-type="pmid">35341697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacr.2022.02.025</pub-id><pub-id pub-id-type="pmcid">PMC9119699</pub-id></mixed-citation></ref><ref id="mco270560-bib-0275"><label>275</label><mixed-citation publication-type="journal" id="mco270560-cite-0275"><string-name name-style="western"><given-names>P.</given-names><surname>Grabler</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Sighoko</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Allgood</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Ansell</surname></string-name>, &#8220;<article-title>Recall and Cancer Detection Rates for Screening Mammography: Finding the Sweet Spot</article-title>,&#8221; <source>AJR American journal of roentgenology</source><volume>208</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>208</fpage>&#8211;<lpage>213</lpage>.<pub-id pub-id-type="pmid">27680714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.15.15987</pub-id></mixed-citation></ref><ref id="mco270560-bib-0276"><label>276</label><mixed-citation publication-type="journal" id="mco270560-cite-0276"><string-name name-style="western"><given-names>M. L.</given-names><surname>Marinovich</surname></string-name>, <string-name name-style="western"><given-names>K. E.</given-names><surname>Hunter</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Macaskill</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Houssami</surname></string-name>, &#8220;<article-title>Breast Cancer Screening Using Tomosynthesis or Mammography: a Meta&#8208;analysis of Cancer Detection and Recall</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>110</volume>, no. <issue>9</issue> (<year>2018</year>): <fpage>942</fpage>&#8211;<lpage>949</lpage>.<pub-id pub-id-type="pmid">30107542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djy121</pub-id></mixed-citation></ref><ref id="mco270560-bib-0277"><label>277</label><mixed-citation publication-type="journal" id="mco270560-cite-0277"><string-name name-style="western"><given-names>M. D.</given-names><surname>Ryser</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lange</surname></string-name>, <string-name name-style="western"><given-names>L. Y. T.</given-names><surname>Inoue</surname></string-name>, et&#160;al., &#8220;<article-title>Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>175</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>471</fpage>&#8211;<lpage>478</lpage>.<pub-id pub-id-type="pmid">35226520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M21-3577</pub-id><pub-id pub-id-type="pmcid">PMC9359467</pub-id></mixed-citation></ref><ref id="mco270560-bib-0278"><label>278</label><mixed-citation publication-type="journal" id="mco270560-cite-0278"><string-name name-style="western"><given-names>L.</given-names><surname>Ding</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Poelhekken</surname></string-name>, <string-name name-style="western"><given-names>M. J. W.</given-names><surname>Greuter</surname></string-name>, et&#160;al., &#8220;<article-title>Overdiagnosis of Invasive Breast Cancer in Population&#8208;based Breast Cancer Screening: a Short&#8208; and Long&#8208;term Perspective</article-title>,&#8221; <source>European Journal of Cancer</source><volume>173</volume> (<year>2022</year>): <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35839596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.06.027</pub-id></mixed-citation></ref><ref id="mco270560-bib-0279"><label>279</label><mixed-citation publication-type="journal" id="mco270560-cite-0279"><string-name name-style="western"><given-names>S.</given-names><surname>Murphy</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Mooney</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Phelan</surname></string-name>, et&#160;al., &#8220;<article-title>Evaluation of Recall Rates in the Irish National Breast Screening Programme: Insights from Two Million Screening Mammograms</article-title>,&#8221; <source>European Journal of Radiology</source><volume>189</volume> (<year>2025</year>): <elocation-id>112179</elocation-id>.<pub-id pub-id-type="pmid">40412049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2025.112179</pub-id></mixed-citation></ref><ref id="mco270560-bib-0280"><label>280</label><mixed-citation publication-type="journal" id="mco270560-cite-0280"><string-name name-style="western"><given-names>H.</given-names><surname>Lind</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Svane</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Kemetli</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>T&#246;rnberg</surname></string-name>, &#8220;<article-title>Breast Cancer Screening Program in Stockholm County, Sweden &#8208; Aspects of Organization and Quality Assurance</article-title>,&#8221; <source>Breast Care (Basel)</source><volume>5</volume>, no. <issue>5</issue> (<year>2010</year>): <fpage>353</fpage>&#8211;<lpage>357</lpage>.<pub-id pub-id-type="pmid">21779220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000321255</pub-id><pub-id pub-id-type="pmcid">PMC3132962</pub-id></mixed-citation></ref><ref id="mco270560-bib-0281"><label>281</label><mixed-citation publication-type="journal" id="mco270560-cite-0281"><string-name name-style="western"><given-names>L.</given-names><surname>Domingo</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hofvind</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Hubbard</surname></string-name>, et&#160;al., &#8220;<article-title>Cross&#8208;national Comparison of Screening Mammography Accuracy Measures in U.S., Norway, and Spain</article-title>,&#8221; <source>European Radiology</source><volume>26</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>2520</fpage>&#8211;<lpage>2528</lpage>.<pub-id pub-id-type="pmid">26560729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-015-4074-8</pub-id><pub-id pub-id-type="pmcid">PMC4927608</pub-id></mixed-citation></ref><ref id="mco270560-bib-0282"><label>282</label><mixed-citation publication-type="journal" id="mco270560-cite-0282"><string-name name-style="western"><given-names>K.</given-names><surname>Kemp Jacobsen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Abraham</surname></string-name>, <string-name name-style="western"><given-names>D. S. M.</given-names><surname>Buist</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Cumulative False&#8208;positive Risk of Screening Mammography in the United States and Denmark</article-title>,&#8221; <source>Cancer Epidemiology</source><volume>39</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>656</fpage>&#8211;<lpage>663</lpage>.<pub-id pub-id-type="pmid">26013768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canep.2015.05.004</pub-id><pub-id pub-id-type="pmcid">PMC4871241</pub-id></mixed-citation></ref><ref id="mco270560-bib-0283"><label>283</label><mixed-citation publication-type="journal" id="mco270560-cite-0283"><string-name name-style="western"><given-names>H. G.</given-names><surname>Welch</surname></string-name>, <string-name name-style="western"><given-names>P. C.</given-names><surname>Prorok</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>O'Malley</surname></string-name>, and <string-name name-style="western"><given-names>B. S.</given-names><surname>Kramer</surname></string-name>, &#8220;<article-title>Breast&#8208;Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness</article-title>,&#8221; <source>The New England Journal of Medicine</source><volume>375</volume>, no. <issue>15</issue> (<year>2016</year>): <fpage>1438</fpage>&#8211;<lpage>1447</lpage>.<pub-id pub-id-type="pmid">27732805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1600249</pub-id></mixed-citation></ref><ref id="mco270560-bib-0284"><label>284</label><mixed-citation publication-type="journal" id="mco270560-cite-0284"><string-name name-style="western"><given-names>E. R.</given-names><surname>Myers</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Moorman</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Gierisch</surname></string-name>, et&#160;al., &#8220;<article-title>Benefits and Harms of Breast Cancer Screening: a Systematic Review</article-title>,&#8221; <source>Jama</source><volume>314</volume>, no. <issue>15</issue> (<year>2015</year>): <fpage>1615</fpage>&#8211;<lpage>1634</lpage>.<pub-id pub-id-type="pmid">26501537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2015.13183</pub-id></mixed-citation></ref><ref id="mco270560-bib-0285"><label>285</label><mixed-citation publication-type="journal" id="mco270560-cite-0285"><string-name name-style="western"><given-names>E. F.</given-names><surname>Conant</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Talley</surname></string-name>, <string-name name-style="western"><given-names>C. R.</given-names><surname>Parghi</surname></string-name>, et&#160;al., &#8220;<article-title>Mammographic Screening in Routine Practice: Multisite Study of Digital Breast Tomosynthesis and Digital Mammography Screenings</article-title>,&#8221; <source>Radiology</source><volume>307</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>e221571</elocation-id>.<pub-id pub-id-type="pmid">36916891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.221571</pub-id></mixed-citation></ref><ref id="mco270560-bib-0286"><label>286</label><mixed-citation publication-type="journal" id="mco270560-cite-0286"><string-name name-style="western"><given-names>M.</given-names><surname>Alabousi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wadera</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kashif Al&#8208;Ghita</surname></string-name>, et&#160;al., &#8220;<article-title>Performance of Digital Breast Tomosynthesis, Synthetic Mammography, and Digital Mammography in Breast Cancer Screening: a Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>113</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>680</fpage>&#8211;<lpage>690</lpage>.<pub-id pub-id-type="pmid">33372954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa205</pub-id><pub-id pub-id-type="pmcid">PMC8168096</pub-id></mixed-citation></ref><ref id="mco270560-bib-0287"><label>287</label><mixed-citation publication-type="journal" id="mco270560-cite-0287"><string-name name-style="western"><given-names>W.</given-names><surname>Heindel</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Weigel</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Gerss</surname></string-name>, et&#160;al., &#8220;<article-title>Digital Breast Tomosynthesis plus Synthesised Mammography versus Digital Screening Mammography for the Detection of Invasive Breast Cancer (TOSYMA): a Multicentre, Open&#8208;label, Randomised, Controlled, Superiority Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>23</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>601</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">35427470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00194-2</pub-id></mixed-citation></ref><ref id="mco270560-bib-0288"><label>288</label><mixed-citation publication-type="journal" id="mco270560-cite-0288"><string-name name-style="western"><given-names>S.</given-names><surname>Hofvind</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Holen</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Aase</surname></string-name>, et&#160;al., &#8220;<article-title>Two&#8208;view Digital Breast Tomosynthesis versus Digital Mammography in a Population&#8208;based Breast Cancer Screening Programme (To&#8208;Be): a Randomised, Controlled Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>20</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>795</fpage>&#8211;<lpage>805</lpage>.<pub-id pub-id-type="pmid">31078459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30161-5</pub-id></mixed-citation></ref><ref id="mco270560-bib-0289"><label>289</label><mixed-citation publication-type="journal" id="mco270560-cite-0289"><string-name name-style="western"><given-names>G.</given-names><surname>JWP</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Darker</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>JJ</surname></string-name>, et&#160;al., &#8220;<article-title>How Long Does It Take to Read a Mammogram? Investigating the Reading Time of Digital Breast Tomosynthesis and Digital Mammography</article-title>,&#8221; <source>European Journal of Radiology</source><volume>177</volume> (<year>2024</year>): <elocation-id>111535</elocation-id>.<pub-id pub-id-type="pmid">38852330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2024.111535</pub-id></mixed-citation></ref><ref id="mco270560-bib-0290"><label>290</label><mixed-citation publication-type="journal" id="mco270560-cite-0290"><string-name name-style="western"><given-names>K.</given-names><surname>Coffey</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Dodelzon</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Dialani</surname></string-name>, et&#160;al., &#8220;<article-title>Survey on Current Utilization and Perception of Synthesized Mammography</article-title>,&#8221; <source>Journal of Breast Imaging</source><volume>6</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>636</fpage>&#8211;<lpage>645</lpage>.<pub-id pub-id-type="pmid">39159200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbi/wbae045</pub-id></mixed-citation></ref><ref id="mco270560-bib-0291"><label>291</label><mixed-citation publication-type="journal" id="mco270560-cite-0291"><string-name name-style="western"><given-names>M.</given-names><surname>Rebolj</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Assi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Brentnall</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Parmar</surname></string-name>, and <string-name name-style="western"><given-names>S. W.</given-names><surname>Duffy</surname></string-name>, &#8220;<article-title>Addition of Ultrasound to Mammography in the Case of Dense Breast Tissue: Systematic Review and Meta&#8208;analysis</article-title>,&#8221; <source>British Journal of Cancer</source><volume>118</volume>, no. <issue>12</issue> (<year>2018</year>): <fpage>1559</fpage>&#8211;<lpage>1570</lpage>.<pub-id pub-id-type="pmid">29736009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-018-0080-3</pub-id><pub-id pub-id-type="pmcid">PMC6008336</pub-id></mixed-citation></ref><ref id="mco270560-bib-0292"><label>292</label><mixed-citation publication-type="journal" id="mco270560-cite-0292"><string-name name-style="western"><given-names>R.</given-names><surname>Sood</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Rositch</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Shakoor</surname></string-name>, et&#160;al., &#8220;<article-title>Ultrasound for Breast Cancer Detection Globally: a Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Journal of global oncology</source><volume>5</volume> (<year>2019</year>): <fpage>1</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JGO.19.00127</pub-id><pub-id pub-id-type="pmcid">PMC6733207</pub-id><pub-id pub-id-type="pmid">31454282</pub-id></mixed-citation></ref><ref id="mco270560-bib-0293"><label>293</label><mixed-citation publication-type="journal" id="mco270560-cite-0293"><string-name name-style="western"><given-names>N.</given-names><surname>Ohuchi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Suzuki</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Sobue</surname></string-name>, et&#160;al., &#8220;<article-title>Sensitivity and Specificity of Mammography and Adjunctive Ultrasonography to Screen for Breast Cancer in the Japan Strategic Anti&#8208;cancer Randomized Trial (J&#8208;START): a Randomised Controlled Trial</article-title>,&#8221; <source>Lancet</source><volume>387</volume>, no. <issue>10016</issue> (<year>2016</year>): <fpage>341</fpage>&#8211;<lpage>348</lpage>.<pub-id pub-id-type="pmid">26547101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00774-6</pub-id></mixed-citation></ref><ref id="mco270560-bib-0294"><label>294</label><mixed-citation publication-type="journal" id="mco270560-cite-0294"><string-name name-style="western"><given-names>N.</given-names><surname>Harada&#8208;Shoji</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Suzuki</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ishida</surname></string-name>, et&#160;al., &#8220;<article-title>Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection among Women Aged 40&#8211;49 Years with Varying Breast Density Undergoing Screening Mammography: a Secondary Analysis of a Randomized Clinical Trial</article-title>,&#8221; <source>JAMA Network Open</source><volume>4</volume>, no. <issue>8</issue> (<year>2021</year>): <elocation-id>e2121505</elocation-id>.<pub-id pub-id-type="pmid">34406400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.21505</pub-id><pub-id pub-id-type="pmcid">PMC8374606</pub-id></mixed-citation></ref><ref id="mco270560-bib-0295"><label>295</label><mixed-citation publication-type="journal" id="mco270560-cite-0295"><string-name name-style="western"><given-names>A.</given-names><surname>Yi</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Jang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Yim</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>Kwon</surname></string-name>, <string-name name-style="western"><given-names>S. U.</given-names><surname>Shin</surname></string-name>, and and <string-name name-style="western"><given-names>J. M.</given-names><surname>Chang</surname></string-name>, &#8220;<article-title>Addition of Screening Breast US to Digital Mammography and Digital Breast Tomosynthesis for Breast Cancer Screening in Women at Average Risk</article-title>,&#8221; <source>Radiology</source><volume>298</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>568</fpage>&#8211;<lpage>575</lpage>.<pub-id pub-id-type="pmid">33434108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2021203134</pub-id></mixed-citation></ref><ref id="mco270560-bib-0296"><label>296</label><mixed-citation publication-type="journal" id="mco270560-cite-0296"><string-name name-style="western"><given-names>I.</given-names><surname>Allajbeu</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Nanaa</surname></string-name>, et&#160;al., &#8220;<article-title>Introduction of Automated Breast Ultrasound as an Additional Screening Tool for Dense Breasts in the UK: a Practical Approach from the BRAID Trial</article-title>,&#8221; <source>Clinical Radiology</source><volume>79</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>e641</fpage>&#8211;<lpage>e650</lpage>.<pub-id pub-id-type="pmid">38413353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crad.2023.11.029</pub-id></mixed-citation></ref><ref id="mco270560-bib-0297"><label>297</label><mixed-citation publication-type="journal" id="mco270560-cite-0297"><string-name name-style="western"><given-names>F.</given-names><surname>Sardanelli</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Magni</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Rossini</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Kilburn&#8208;Toppin</surname></string-name>, <string-name name-style="western"><given-names>N. A.</given-names><surname>Healy</surname></string-name>, and <string-name name-style="western"><given-names>F. J.</given-names><surname>Gilbert</surname></string-name>, &#8220;<article-title>The Paradox of MRI for Breast Cancer Screening: High&#8208;risk and Dense Breasts&#8208;available Evidence and Current Practice</article-title>,&#8221; <source>Insights Imaging</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>96</fpage>.<pub-id pub-id-type="pmid">38536530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-024-01653-4</pub-id><pub-id pub-id-type="pmcid">PMC10973307</pub-id></mixed-citation></ref><ref id="mco270560-bib-0298"><label>298</label><mixed-citation publication-type="journal" id="mco270560-cite-0298"><string-name name-style="western"><given-names>L. J.</given-names><surname>Grimm</surname></string-name>, <string-name name-style="western"><given-names>V. L.</given-names><surname>Mango</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Harvey</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Plecha</surname></string-name>, and <string-name name-style="western"><given-names>E. F.</given-names><surname>Conant</surname></string-name>, &#8220;<article-title>Implementation of Abbreviated Breast MRI for Screening: AJR Expert Panel Narrative Review</article-title>,&#8221; <source>AJR American Journal of Roentgenology</source><volume>218</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>202</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">34378397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.21.26349</pub-id></mixed-citation></ref><ref id="mco270560-bib-0299"><label>299</label><mixed-citation publication-type="journal" id="mco270560-cite-0299"><string-name name-style="western"><given-names>M. B.</given-names><surname>Lawson</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>D. S.</given-names><surname>Hippe</surname></string-name>, et&#160;al., &#8220;<article-title>Comparative Performance of Contrast&#8208;enhanced Mammography, Abbreviated Breast MRI, and Standard Breast MRI for Breast Cancer Screening</article-title>,&#8221; <source>Radiology</source><volume>308</volume>, no. <issue>2</issue> (<year>2023</year>): <elocation-id>e230576</elocation-id>.<pub-id pub-id-type="pmid">37581498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.230576</pub-id><pub-id pub-id-type="pmcid">PMC10481328</pub-id></mixed-citation></ref><ref id="mco270560-bib-0300"><label>300</label><mixed-citation publication-type="journal" id="mco270560-cite-0300"><string-name name-style="western"><given-names>C. E.</given-names><surname>Comstock</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gatsonis</surname></string-name>, <string-name name-style="western"><given-names>G. M.</given-names><surname>Newstead</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection among Women with Dense Breasts Undergoing Screening</article-title>,&#8221; <source>Jama</source><volume>323</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>746</fpage>&#8211;<lpage>756</lpage>.<pub-id pub-id-type="pmid">32096852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.0572</pub-id><pub-id pub-id-type="pmcid">PMC7276668</pub-id></mixed-citation></ref><ref id="mco270560-bib-0301"><label>301</label><mixed-citation publication-type="journal" id="mco270560-cite-0301"><string-name name-style="western"><given-names>R. M.</given-names><surname>Mann</surname></string-name> and <string-name name-style="western"><given-names>W. B.</given-names><surname>Veldhuis</surname></string-name>, &#8220;<article-title>Contrast&#8208;enhanced Mammography: Moving Ahead with Perfusion Imaging</article-title>,&#8221; <source>Radiology</source><volume>305</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>104</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">36154290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.221073</pub-id></mixed-citation></ref><ref id="mco270560-bib-0302"><label>302</label><mixed-citation publication-type="journal" id="mco270560-cite-0302"><string-name name-style="western"><given-names>C. H.</given-names><surname>Hunt</surname></string-name>, <string-name name-style="western"><given-names>R. P.</given-names><surname>Hartman</surname></string-name>, and <string-name name-style="western"><given-names>G. K.</given-names><surname>Hesley</surname></string-name>, &#8220;<article-title>Frequency and Severity of Adverse Effects of Iodinated and Gadolinium Contrast Materials: Retrospective Review of 456,930 Doses</article-title>,&#8221; <source>AJR American Journal of Roentgenology</source><volume>193</volume>, no. <issue>4</issue> (<year>2009</year>): <fpage>1124</fpage>&#8211;<lpage>1127</lpage>.<pub-id pub-id-type="pmid">19770337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.09.2520</pub-id></mixed-citation></ref><ref id="mco270560-bib-0303"><label>303</label><mixed-citation publication-type="journal" id="mco270560-cite-0303"><string-name name-style="western"><given-names>J. M.</given-names><surname>Chang</surname></string-name>, &#8220;<article-title>Benefits and Trade&#8208;offs of Breast Cancer Screening Using Contrast&#8208;enhanced Mammography</article-title>,&#8221; <source>Radiology</source><volume>308</volume>, no. <issue>2</issue> (<year>2023</year>): <elocation-id>e231652</elocation-id>.<pub-id pub-id-type="pmid">37581496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.231652</pub-id></mixed-citation></ref><ref id="mco270560-bib-0304"><label>304</label><mixed-citation publication-type="journal" id="mco270560-cite-0304"><string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>A Novel Non&#8208;invasive Exhaled Breath Biopsy for the Diagnosis and Screening of Breast Cancer</article-title>,&#8221; <source>Journal of hematology &amp; oncology</source><volume>16</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>63</fpage>.<pub-id pub-id-type="pmid">37328852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-023-01459-9</pub-id><pub-id pub-id-type="pmcid">PMC10276488</pub-id></mixed-citation></ref><ref id="mco270560-bib-0305"><label>305</label><mixed-citation publication-type="journal" id="mco270560-cite-0305"><string-name name-style="western"><given-names>C. M. S.</given-names><surname>Herzog</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Theeuwes</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jones</surname></string-name>, et&#160;al., &#8220;<article-title>Systems Epigenetic Approach towards Non&#8208;invasive Breast Cancer Detection</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>3082</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-53696-2</pub-id><pub-id pub-id-type="pmcid">PMC11965495</pub-id><pub-id pub-id-type="pmid">40175335</pub-id></mixed-citation></ref><ref id="mco270560-bib-0306"><label>306</label><mixed-citation publication-type="journal" id="mco270560-cite-0306"><string-name name-style="western"><given-names>E.</given-names><surname>Heitzer</surname></string-name>, <string-name name-style="western"><given-names>I. S.</given-names><surname>Haque</surname></string-name>, <string-name name-style="western"><given-names>C. E. S.</given-names><surname>Roberts</surname></string-name>, and <string-name name-style="western"><given-names>M. R.</given-names><surname>Speicher</surname></string-name>, &#8220;<article-title>Current and Future Perspectives of Liquid Biopsies in Genomics&#8208;driven Oncology</article-title>,&#8221; <source>Nature Reviews Genetics</source><volume>20</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>71</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-018-0071-5</pub-id><pub-id pub-id-type="pmid">30410101</pub-id></mixed-citation></ref><ref id="mco270560-bib-0307"><label>307</label><mixed-citation publication-type="journal" id="mco270560-cite-0307"><string-name name-style="western"><given-names>D. L.</given-names><surname>Monticciolo</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1291</fpage>&#8211;<lpage>1292</lpage>.<pub-id pub-id-type="pmid">39284195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ANNALS-24-00717</pub-id></mixed-citation></ref><ref id="mco270560-bib-0308"><label>308</label><mixed-citation publication-type="journal" id="mco270560-cite-0308"><string-name name-style="western"><given-names>M. V.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>H. V.</given-names><surname>Garrett</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Weilbaecher</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Toriola</surname></string-name>, and <string-name name-style="western"><given-names>D. L.</given-names><surname>Bennett</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1292</fpage>&#8211;<lpage>1293</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ANNALS-24-00720</pub-id><pub-id pub-id-type="pmid">39284204</pub-id></mixed-citation></ref><ref id="mco270560-bib-0309"><label>309</label><mixed-citation publication-type="journal" id="mco270560-cite-0309"><string-name name-style="western"><given-names>D. B.</given-names><surname>Kopans</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1293</fpage>&#8211;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">39284203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ANNALS-24-00721</pub-id></mixed-citation></ref><ref id="mco270560-bib-0310"><label>310</label><mixed-citation publication-type="journal" id="mco270560-cite-0310"><string-name name-style="western"><given-names>R. P.</given-names><surname>Harris</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s: Should the Message Change?</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>389</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">38316003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M23-2908</pub-id></mixed-citation></ref><ref id="mco270560-bib-0311"><label>311</label><mixed-citation publication-type="journal" id="mco270560-cite-0311"><string-name name-style="western"><given-names>R. P.</given-names><surname>Harris</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1294</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ANNALS-24-00722</pub-id><pub-id pub-id-type="pmid">39284202</pub-id></mixed-citation></ref><ref id="mco270560-bib-0312"><label>312</label><mixed-citation publication-type="journal" id="mco270560-cite-0312"><string-name name-style="western"><given-names>S.</given-names><surname>Destounis</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Arieno</surname></string-name>, &#8220;<article-title>The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>177</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1292</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ANNALS-24-00719</pub-id><pub-id pub-id-type="pmid">39284194</pub-id></mixed-citation></ref><ref id="mco270560-bib-0313"><label>313</label><mixed-citation publication-type="journal" id="mco270560-cite-0313"><string-name name-style="western"><given-names>K. J.</given-names><surname>Bell</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Nickel</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Pathirana</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Blennerhassett</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Carter</surname></string-name>, &#8220;<article-title>Breast Cancer Screening from Age 40 in the US</article-title>,&#8221; <source>BMJ (Clinical research ed)</source><volume>385</volume> (<year>2024</year>): <elocation-id>q1353</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.q1353</pub-id><pub-id pub-id-type="pmid">38914429</pub-id></mixed-citation></ref><ref id="mco270560-bib-0314"><label>314</label><mixed-citation publication-type="journal" id="mco270560-cite-0314"><string-name name-style="western"><given-names>S. W.</given-names><surname>Duffy</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Vulkan</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Cuckle</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of Mammographic Screening from Age 40 Years on Breast Cancer Mortality (UK Age trial): Final Results of a Randomised, Controlled Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>21</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>1165</fpage>&#8211;<lpage>1172</lpage>.<pub-id pub-id-type="pmid">32800099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30398-3</pub-id><pub-id pub-id-type="pmcid">PMC7491203</pub-id></mixed-citation></ref><ref id="mco270560-bib-0315"><label>315</label><mixed-citation publication-type="journal" id="mco270560-cite-0315"><string-name name-style="western"><given-names>K. M.</given-names><surname>Ray</surname></string-name>, <string-name name-style="western"><given-names>B. N.</given-names><surname>Joe</surname></string-name>, <string-name name-style="western"><given-names>R. I.</given-names><surname>Freimanis</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Sickles</surname></string-name>, and <string-name name-style="western"><given-names>R. E.</given-names><surname>Hendrick</surname></string-name>, &#8220;<article-title>Screening Mammography in Women 40&#8211;49 Years Old: Current Evidence</article-title>,&#8221; <source>AJR American Journal of Roentgenology</source><volume>210</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>264</fpage>&#8211;<lpage>270</lpage>.<pub-id pub-id-type="pmid">29064760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.17.18707</pub-id></mixed-citation></ref><ref id="mco270560-bib-0316"><label>316</label><mixed-citation publication-type="journal" id="mco270560-cite-0316"><string-name name-style="western"><given-names>E.</given-names><surname>White</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Miglioretti</surname></string-name>, <string-name name-style="western"><given-names>B. C.</given-names><surname>Yankaskas</surname></string-name>, et&#160;al., &#8220;<article-title>Biennial versus Annual Mammography and the Risk of Late&#8208;stage Breast Cancer</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>96</volume>, no. <issue>24</issue> (<year>2004</year>): <fpage>1832</fpage>&#8211;<lpage>1839</lpage>.<pub-id pub-id-type="pmid">15601639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djh337</pub-id></mixed-citation></ref><ref id="mco270560-bib-0317"><label>317</label><mixed-citation publication-type="journal" id="mco270560-cite-0317"><string-name name-style="western"><given-names>C. H.</given-names><surname>Chapman</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>Schechter</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Cadham</surname></string-name>, et&#160;al., &#8220;<article-title>Identifying Equitable Screening Mammography Strategies for Black Women in the United States Using Simulation Modeling</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>174</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>1637</fpage>&#8211;<lpage>1646</lpage>.<pub-id pub-id-type="pmid">34662151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-6506</pub-id><pub-id pub-id-type="pmcid">PMC9997651</pub-id></mixed-citation></ref><ref id="mco270560-bib-0318"><label>318</label><mixed-citation publication-type="journal" id="mco270560-cite-0318"><string-name name-style="western"><given-names>T.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kharazmi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Fallah</surname></string-name>, &#8220;<article-title>Race and Ethnicity&#8208;Adjusted Age Recommendation for Initiating Breast Cancer Screening</article-title>,&#8221; <source>JAMA Network Open</source><volume>6</volume>, no. <issue>4</issue> (<year>2023</year>): <elocation-id>e238893</elocation-id>.<pub-id pub-id-type="pmid">37074714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.8893</pub-id><pub-id pub-id-type="pmcid">PMC10116360</pub-id></mixed-citation></ref><ref id="mco270560-bib-0319"><label>319</label><mixed-citation publication-type="journal" id="mco270560-cite-0319"><string-name name-style="western"><given-names>A. F.</given-names><surname>Flemban</surname></string-name>, &#8220;<article-title>Overdiagnosis due to Screening Mammography for Breast Cancer among Women Aged 40 Years and Over: a Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Journal of personalized medicine</source><volume>13</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>523</fpage>.<pub-id pub-id-type="pmid">36983705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm13030523</pub-id><pub-id pub-id-type="pmcid">PMC10051653</pub-id></mixed-citation></ref><ref id="mco270560-bib-0320"><label>320</label><mixed-citation publication-type="journal" id="mco270560-cite-0320"><string-name name-style="western"><given-names>E. F.</given-names><surname>Conant</surname></string-name>, <string-name name-style="western"><given-names>W. E.</given-names><surname>Barlow</surname></string-name>, <string-name name-style="western"><given-names>S. D.</given-names><surname>Herschorn</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Digital Breast Tomosynthesis vs Digital Mammography with Cancer Detection and Recall Rates by Age and Breast Density</article-title>,&#8221; <source>JAMA oncology</source><volume>5</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>635</fpage>&#8211;<lpage>642</lpage>.<pub-id pub-id-type="pmid">30816931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2018.7078</pub-id><pub-id pub-id-type="pmcid">PMC6512257</pub-id></mixed-citation></ref><ref id="mco270560-bib-0321"><label>321</label><mixed-citation publication-type="journal" id="mco270560-cite-0321"><string-name name-style="western"><given-names>J. T.</given-names><surname>Henderson</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Webber</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Weyrich</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Miller</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Melnikow</surname></string-name>, &#8220;<article-title>Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force</article-title>,&#8221; <source>Jama</source><volume>331</volume>, no. <issue>22</issue> (<year>2024</year>): <fpage>1931</fpage>&#8211;<lpage>1946</lpage>.<pub-id pub-id-type="pmid">38687490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.25844</pub-id></mixed-citation></ref><ref id="mco270560-bib-0322"><label>322</label><mixed-citation publication-type="journal" id="mco270560-cite-0322"><string-name name-style="western"><given-names>P.</given-names><surname>Autier</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Boniol</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>La Vecchia</surname></string-name>, et&#160;al., &#8220;<article-title>Disparities in Breast Cancer Mortality Trends between 30 European Countries: Retrospective Trend Analysis of WHO Mortality Database</article-title>,&#8221; <source>BMJ</source><volume>341</volume> (<year>2010</year>): <elocation-id>c3620</elocation-id>.<pub-id pub-id-type="pmid">20702548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.c3620</pub-id><pub-id pub-id-type="pmcid">PMC2920378</pub-id></mixed-citation></ref><ref id="mco270560-bib-0323"><label>323</label><mixed-citation publication-type="journal" id="mco270560-cite-0323"><string-name name-style="western"><given-names>L.</given-names><surname>Albarqouni</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Abukmail</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>MohammedAli</surname></string-name>, et&#160;al., &#8220;<article-title>Low&#8208;Value Surgical Procedures in Low&#8208; and Middle&#8208;Income Countries: a Systematic Scoping Review</article-title>,&#8221; <source>JAMA Network Open</source><volume>6</volume>, no. <issue>11</issue> (<year>2023</year>): <elocation-id>e2342215</elocation-id>.<pub-id pub-id-type="pmid">37934494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.42215</pub-id><pub-id pub-id-type="pmcid">PMC10630901</pub-id></mixed-citation></ref><ref id="mco270560-bib-0324"><label>324</label><mixed-citation publication-type="journal" id="mco270560-cite-0324"><string-name name-style="western"><given-names>N. L.</given-names><surname>Schoenborn</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Massare</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Boyd</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Choi</surname></string-name>, and <string-name name-style="western"><given-names>C. E.</given-names><surname>Pollack</surname></string-name>, &#8220;<article-title>Assessment of Clinician Decision&#8208;making on Cancer Screening Cessation in Older Adults with Limited Life Expectancy</article-title>,&#8221; <source>JAMA Network Open</source><volume>3</volume>, no. <issue>6</issue> (<year>2020</year>): <elocation-id>e206772</elocation-id>.<pub-id pub-id-type="pmid">32511720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.6772</pub-id><pub-id pub-id-type="pmcid">PMC7280953</pub-id></mixed-citation></ref><ref id="mco270560-bib-0325"><label>325</label><mixed-citation publication-type="journal" id="mco270560-cite-0325"><string-name name-style="western"><given-names>I. B.</given-names><surname>Richman</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Long</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Soulos</surname></string-name>, <string-name name-style="western"><given-names>S. Y.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>C. P.</given-names><surname>Gross</surname></string-name>, &#8220;<article-title>Estimating Breast Cancer Overdiagnosis after Screening Mammography among Older Women in the United States</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>176</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>1172</fpage>&#8211;<lpage>1180</lpage>.<pub-id pub-id-type="pmid">37549389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M23-0133</pub-id><pub-id pub-id-type="pmcid">PMC10623662</pub-id></mixed-citation></ref><ref id="mco270560-bib-0326"><label>326</label><mixed-citation publication-type="journal" id="mco270560-cite-0326"><string-name name-style="western"><given-names>I.</given-names><surname>Lansdorp&#8208;Vogelaar</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Gulati</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Mariotto</surname></string-name>, et&#160;al., &#8220;<article-title>Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>161</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>104</fpage>&#8211;<lpage>112</lpage>.<pub-id pub-id-type="pmid">25023249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M13-2867</pub-id><pub-id pub-id-type="pmcid">PMC4160041</pub-id></mixed-citation></ref><ref id="mco270560-bib-0327"><label>327</label><mixed-citation publication-type="journal" id="mco270560-cite-0327"><string-name name-style="western"><given-names>E.</given-names><surname>Mathieu</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Noguchi</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Health Benefits and Harms of Mammography Screening in Older Women (75+ years)&#8208;a Systematic Review</article-title>,&#8221; <source>British Journal of Cancer</source><volume>130</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>275</fpage>&#8211;<lpage>296</lpage>.<pub-id pub-id-type="pmid">38030747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-023-02504-7</pub-id><pub-id pub-id-type="pmcid">PMC10803784</pub-id></mixed-citation></ref><ref id="mco270560-bib-0328"><label>328</label><mixed-citation publication-type="journal" id="mco270560-cite-0328"><string-name name-style="western"><given-names>J. A.</given-names><surname>Malmgren</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Parikh</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Atwood</surname></string-name>, and <string-name name-style="western"><given-names>H. G.</given-names><surname>Kaplan</surname></string-name>, &#8220;<article-title>Improved Prognosis of Women Aged 75 and Older with Mammography&#8208;detected Breast Cancer</article-title>,&#8221; <source>Radiology</source><volume>273</volume>, no. <issue>3</issue> (<year>2014</year>): <fpage>686</fpage>&#8211;<lpage>694</lpage>.<pub-id pub-id-type="pmid">25093690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.14140209</pub-id></mixed-citation></ref><ref id="mco270560-bib-0329"><label>329</label><mixed-citation publication-type="journal" id="mco270560-cite-0329"><string-name name-style="western"><given-names>J. S.</given-names><surname>Mandelblatt</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Cronin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bailey</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Mammography Screening under Different Screening Schedules: Model Estimates of Potential Benefits and Harms</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>151</volume>, no. <issue>10</issue> (<year>2009</year>): <fpage>738</fpage>&#8211;<lpage>747</lpage>.<pub-id pub-id-type="pmid">19920274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1059/0003-4819-151-10-200911170-00010</pub-id><pub-id pub-id-type="pmcid">PMC3515682</pub-id></mixed-citation></ref><ref id="mco270560-bib-0330"><label>330</label><mixed-citation publication-type="journal" id="mco270560-cite-0330"><string-name name-style="western"><given-names>J. T.</given-names><surname>Schousboe</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Sprague</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Abraham</surname></string-name>, et&#160;al., &#8220;<article-title>Cost&#8208;Effectiveness of Screening Mammography beyond Age 75 Years: a Cost&#8208;Effectiveness Analysis</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>175</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>11</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">34807717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-8076</pub-id><pub-id pub-id-type="pmcid">PMC9621600</pub-id></mixed-citation></ref><ref id="mco270560-bib-0331"><label>331</label><mixed-citation publication-type="journal" id="mco270560-cite-0331"><string-name name-style="western"><given-names>J.</given-names><surname>Demb</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Abraham</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Miglioretti</surname></string-name>, et&#160;al., &#8220;<article-title>Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>112</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>599</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">31593591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz172</pub-id><pub-id pub-id-type="pmcid">PMC7301094</pub-id></mixed-citation></ref><ref id="mco270560-bib-0332"><label>332</label><mixed-citation publication-type="journal" id="mco270560-cite-0332"><string-name name-style="western"><given-names>X.</given-names><surname>Garcia&#8208;Albeniz</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Hernan</surname></string-name>, <string-name name-style="western"><given-names>R. W.</given-names><surname>Logan</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Price</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Armstrong</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Hsu</surname></string-name>, &#8220;<article-title>Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older than 70 Years</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>172</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>381</fpage>&#8211;<lpage>389</lpage>.<pub-id pub-id-type="pmid">32092767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-1199</pub-id></mixed-citation></ref><ref id="mco270560-bib-0333"><label>333</label><mixed-citation publication-type="journal" id="mco270560-cite-0333"><string-name name-style="western"><given-names>D. J.</given-names><surname>Carmichael</surname></string-name>, <string-name name-style="western"><given-names>G. C.</given-names><surname>Gillard</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Lowther</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Handley</surname></string-name>, and <string-name name-style="western"><given-names>V. B.</given-names><surname>Santer</surname></string-name>, &#8220;<article-title>Carrageenin&#8208;induced Arthritis. IV. Rate Changes in Cartilage Matrix Proteoglycan Synthesis</article-title>,&#8221; <source>Arthritis and Rheumatism</source><volume>20</volume>, no. <issue>3</issue> (<year>1977</year>): <fpage>834</fpage>&#8211;<lpage>840</lpage>.<pub-id pub-id-type="pmid">856216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.1780200313</pub-id></mixed-citation></ref><ref id="mco270560-bib-0334"><label>334</label><mixed-citation publication-type="journal" id="mco270560-cite-0334"><string-name name-style="western"><given-names>L. M.</given-names><surname>Kregting</surname></string-name>, <string-name name-style="western"><given-names>V. D. V.</given-names><surname>Sankatsing</surname></string-name>, <string-name name-style="western"><given-names>E. A. M.</given-names><surname>Heijnsdijk</surname></string-name>, <string-name name-style="western"><given-names>H. J.</given-names><surname>de Koning</surname></string-name>, and <string-name name-style="western"><given-names>N. T.</given-names><surname>van Ravesteyn</surname></string-name>, &#8220;<article-title>Finding the Optimal Mammography Screening Strategy: a Cost&#8208;effectiveness Analysis of 920 Modelled Strategies</article-title>,&#8221; <source>International Journal of Cancer</source><volume>151</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>287</fpage>&#8211;<lpage>296</lpage>.<pub-id pub-id-type="pmid">35285018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34000</pub-id><pub-id pub-id-type="pmcid">PMC9310858</pub-id></mixed-citation></ref><ref id="mco270560-bib-0335"><label>335</label><mixed-citation publication-type="journal" id="mco270560-cite-0335"><string-name name-style="western"><given-names>I. B.</given-names><surname>Richman</surname></string-name> and <string-name name-style="western"><given-names>C. P.</given-names><surname>Gross</surname></string-name>, &#8220;<article-title>New Breast Cancer Screening Technologies in Older Women&#8208;Is It Time to Pump the Brakes?</article-title>,&#8221; <source>JAMA Internal Medicine</source><volume>179</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>289</fpage>&#8211;<lpage>290</lpage>.<pub-id pub-id-type="pmid">30640376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2018.7767</pub-id></mixed-citation></ref><ref id="mco270560-bib-0336"><label>336</label><mixed-citation publication-type="journal" id="mco270560-cite-0336"><string-name name-style="western"><given-names>N. L.</given-names><surname>Schoenborn</surname></string-name>, <string-name name-style="western"><given-names>R. H.</given-names><surname>Nagler</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Schonberg</surname></string-name>, et&#160;al., &#8220;<article-title>Willingness to Stop Screening Mammograms among Older Women in the United States: Results from a National Survey</article-title>,&#8221; <source>Journal of General Internal Medicine</source><volume>38</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>1091</fpage>&#8211;<lpage>1093</lpage>.<pub-id pub-id-type="pmid">36175762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-022-07819-4</pub-id><pub-id pub-id-type="pmcid">PMC10039136</pub-id></mixed-citation></ref><ref id="mco270560-bib-0337"><label>337</label><mixed-citation publication-type="journal" id="mco270560-cite-0337"><string-name name-style="western"><given-names>D.</given-names><surname>Braithwaite</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chicaiza</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Lopez</surname></string-name>, et&#160;al., &#8220;<article-title>Clinician and Patient Perspectives on Screening Mammography among Women Age 75 and Older: a Pilot Study of a Novel Decision Aid</article-title>,&#8221; <source>PEC Innovation</source><volume>2</volume> (<year>2023</year>): <elocation-id>100132</elocation-id>.<pub-id pub-id-type="pmid">37124453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pecinn.2023.100132</pub-id><pub-id pub-id-type="pmcid">PMC10136373</pub-id></mixed-citation></ref><ref id="mco270560-bib-0338"><label>338</label><mixed-citation publication-type="journal" id="mco270560-cite-0338"><string-name name-style="western"><given-names>S.</given-names><surname>Schrager</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Ovsepyan</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Burnside</surname></string-name>, &#8220;<article-title>Breast Cancer Screening in Older Women: the Importance of Shared Decision Making</article-title>,&#8221; <source>Journal of the American Board of Family Medicine: JABFM</source><volume>33</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>473</fpage>&#8211;<lpage>480</lpage>.<pub-id pub-id-type="pmid">32430383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3122/jabfm.2020.03.190380</pub-id><pub-id pub-id-type="pmcid">PMC7822071</pub-id></mixed-citation></ref><ref id="mco270560-bib-0339"><label>339</label><mixed-citation publication-type="journal" id="mco270560-cite-0339"><string-name name-style="western"><given-names>M. L.</given-names><surname>Zuley</surname></string-name>, <string-name name-style="western"><given-names>A. I.</given-names><surname>Bandos</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Duffy</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Screening Interval: Effect on Rate of Late&#8208;Stage Disease at Diagnosis and Overall Survival</article-title>,&#8221; <source>Journal of Clinical Oncology</source> 2024:JCO2400285.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.24.00285</pub-id><pub-id pub-id-type="pmcid">PMC11540751</pub-id><pub-id pub-id-type="pmid">39167740</pub-id></mixed-citation></ref><ref id="mco270560-bib-0340"><label>340</label><mixed-citation publication-type="journal" id="mco270560-cite-0340"><string-name name-style="western"><given-names>C.</given-names><surname>Canelo&#8208;Aybar</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Posso</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Montero</surname></string-name>, et&#160;al., &#8220;<article-title>Benefits and Harms of Annual, Biennial, or Triennial Breast Cancer Mammography Screening for Women at Average Risk of Breast Cancer: a Systematic Review for the European Commission Initiative on Breast Cancer (ECIBC)</article-title>,&#8221; <source>British Journal of Cancer</source><volume>126</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>673</fpage>&#8211;<lpage>688</lpage>.<pub-id pub-id-type="pmid">34837076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-021-01521-8</pub-id><pub-id pub-id-type="pmcid">PMC8854566</pub-id></mixed-citation></ref><ref id="mco270560-bib-0341"><label>341</label><mixed-citation publication-type="journal" id="mco270560-cite-0341"><string-name name-style="western"><given-names>T. W.</given-names><surname>Park&#8208;Simon</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>M&#252;ller</surname></string-name>, <string-name name-style="western"><given-names>U. S.</given-names><surname>Albert</surname></string-name>, et&#160;al., &#8220;<article-title>AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025</article-title>,&#8221; <source>Breast Care (Basel)</source> (<year>2025</year>): <fpage>1</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000545019</pub-id><pub-id pub-id-type="pmcid">PMC11996201</pub-id><pub-id pub-id-type="pmid">40236659</pub-id></mixed-citation></ref><ref id="mco270560-bib-0342"><label>342</label><mixed-citation publication-type="journal" id="mco270560-cite-0342"><string-name name-style="western"><given-names>W. K.</given-names><surname>Nicholson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Silverstein</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Wong</surname></string-name>, et&#160;al., &#8220;<article-title>Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement</article-title>,&#8221; <source>Jama</source><volume>331</volume>, no. <issue>22</issue> (<year>2024</year>): <fpage>1918</fpage>&#8211;<lpage>1930</lpage>.<pub-id pub-id-type="pmid">38687503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.5534</pub-id></mixed-citation></ref><ref id="mco270560-bib-0343"><label>343</label><mixed-citation publication-type="journal" id="mco270560-cite-0343"><string-name name-style="western"><given-names>B. L.</given-names><surname>Niell</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Jochelson</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Amir</surname></string-name>, et&#160;al., &#8220;<article-title>ACR Appropriateness Criteria&#174; Female Breast Cancer Screening: 2023 Update</article-title>,&#8221; <source>Journal of the American College of Radiology: JACR</source><volume>21</volume>, no. <issue>6s</issue> (<year>2024</year>): <fpage>S126</fpage>&#8211;<lpage>S143</lpage>.<pub-id pub-id-type="pmid">38823941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacr.2024.02.019</pub-id></mixed-citation></ref><ref id="mco270560-bib-0344"><label>344</label><mixed-citation publication-type="journal" id="mco270560-cite-0344"><string-name name-style="western"><given-names>H. J.</given-names><surname>Sch&#252;nemann</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Lerda</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Quinn</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Screening and Diagnosis: a Synopsis of the European Breast Guidelines</article-title>,&#8221; <source>Annals of Internal Medicine</source><volume>172</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>46</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">31766052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M19-2125</pub-id></mixed-citation></ref><ref id="mco270560-bib-0345"><label>345</label><mixed-citation publication-type="journal" id="mco270560-cite-0345"><string-name name-style="western"><given-names>H. L.</given-names><surname>Wee</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Canfell</surname></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Chiu</surname></string-name>, et&#160;al., &#8220;<article-title>Cancer Screening Programs in South&#8208;east Asia and Western Pacific</article-title>,&#8221; <source>BMC health services research</source><volume>24</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>102</fpage>.<pub-id pub-id-type="pmid">38238704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12913-023-10327-8</pub-id><pub-id pub-id-type="pmcid">PMC10797973</pub-id></mixed-citation></ref><ref id="mco270560-bib-0346"><label>346</label><mixed-citation publication-type="journal" id="mco270560-cite-0346"><string-name name-style="western"><given-names>Y.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Meng</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Screening Attendance in China from 2014 to 2022: Results from Nationwide Surveys</article-title>,&#8221; <source>The Lancet Regional Health &#8208; Western Pacific</source><volume>55</volume> (<year>2025</year>): <elocation-id>101426</elocation-id>.</mixed-citation></ref><ref id="mco270560-bib-0347"><label>347</label><mixed-citation publication-type="journal" id="mco270560-cite-0347"><string-name name-style="western"><given-names>Y.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Use of Breast Cancer Risk Factors to Identify Risk&#8208;Adapted Starting Age of Screening in China</article-title>,&#8221; <source>JAMA network open</source><volume>5</volume>, no. <issue>11</issue> (<year>2022</year>): <elocation-id>e2241441</elocation-id>.<pub-id pub-id-type="pmid">36355372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.41441</pub-id><pub-id pub-id-type="pmcid">PMC9650608</pub-id></mixed-citation></ref><ref id="mco270560-bib-0348"><label>348</label><mixed-citation publication-type="journal" id="mco270560-cite-0348"><string-name name-style="western"><given-names>K.</given-names><surname>Kerlikowske</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Golmakani</surname></string-name>, et&#160;al., &#8220;<article-title>Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>114</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>676</fpage>&#8211;<lpage>685</lpage>.<pub-id pub-id-type="pmid">35026019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djac008</pub-id><pub-id pub-id-type="pmcid">PMC9086807</pub-id></mixed-citation></ref><ref id="mco270560-bib-0349"><label>349</label><mixed-citation publication-type="journal" id="mco270560-cite-0349"><string-name name-style="western"><given-names>C.</given-names><surname>Turnbull</surname></string-name>, <string-name name-style="western"><given-names>M. I.</given-names><surname>Achatz</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Balma&#241;a</surname></string-name>, et&#160;al., &#8220;<article-title>Breast Cancer Germline Multigene Panel Testing in Mainstream Oncology Based on Clinical&#8208;public Health Utility: ESMO Precision Oncology Working Group Recommendations</article-title>,&#8221; <source>Annals of Oncology</source><volume>36</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>853</fpage>&#8211;<lpage>865</lpage>.<pub-id pub-id-type="pmid">40523834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2025.04.012</pub-id></mixed-citation></ref><ref id="mco270560-bib-0350"><label>350</label><mixed-citation publication-type="journal" id="mco270560-cite-0350"><string-name name-style="western"><given-names>L.</given-names><surname>Cortesi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Miglietta</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Arecco</surname></string-name>, et&#160;al., &#8220;<article-title>Predictive Brca Genetic Testing in Italian Patients with Breast Cancer: a Position Paper of Italian Scientific Societies [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC&#8208;IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]</article-title>,&#8221; <source>Cancer Treatment Reviews</source><volume>139</volume> (<year>2025</year>): <elocation-id>102976</elocation-id>.<pub-id pub-id-type="pmid">40543108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2025.102976</pub-id></mixed-citation></ref><ref id="mco270560-bib-0351"><label>351</label><mixed-citation publication-type="journal" id="mco270560-cite-0351"><string-name name-style="western"><given-names>B.</given-names><surname>Fisher</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Costantino</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Wickerham</surname></string-name>, et&#160;al., &#8220;<article-title>Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P&#8208;1 Study</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>90</volume>, no. <issue>18</issue> (<year>1998</year>): <fpage>1371</fpage>&#8211;<lpage>1388</lpage>.<pub-id pub-id-type="pmid">9747868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/90.18.1371</pub-id></mixed-citation></ref><ref id="mco270560-bib-0352"><label>352</label><mixed-citation publication-type="journal" id="mco270560-cite-0352"><string-name name-style="western"><given-names>T. J.</given-names><surname>Powles</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ashley</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tidy</surname></string-name>, <string-name name-style="western"><given-names>I. E.</given-names><surname>Smith</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Dowsett</surname></string-name>, &#8220;<article-title>Twenty&#8208;year Follow&#8208;up of the Royal Marsden Randomized, Double&#8208;blinded tamoxifen Breast Cancer Prevention Trial</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>99</volume>, no. <issue>4</issue> (<year>2007</year>): <fpage>283</fpage>&#8211;<lpage>290</lpage>.<pub-id pub-id-type="pmid">17312305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djk050</pub-id></mixed-citation></ref><ref id="mco270560-bib-0353"><label>353</label><mixed-citation publication-type="journal" id="mco270560-cite-0353"><string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Sestak</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Cawthorn</surname></string-name>, et&#160;al., &#8220;<article-title>Tamoxifen for Prevention of Breast Cancer: Extended Long&#8208;term Follow&#8208;up of the IBIS&#8208;I Breast Cancer Prevention Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>16</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>67</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">25497694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)71171-4</pub-id><pub-id pub-id-type="pmcid">PMC4772450</pub-id></mixed-citation></ref><ref id="mco270560-bib-0354"><label>354</label><mixed-citation publication-type="journal" id="mco270560-cite-0354"><string-name name-style="western"><given-names>S.</given-names><surname>Martino</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Cauley</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Barrett&#8208;Connor</surname></string-name>, et&#160;al., &#8220;<article-title>Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of raloxifene</article-title>,&#8221; <source>JNCI: Journal of the National Cancer Institute</source><volume>96</volume>, no. <issue>23</issue> (<year>2004</year>): <fpage>1751</fpage>&#8211;<lpage>1761</lpage>.<pub-id pub-id-type="pmid">15572757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djh319</pub-id></mixed-citation></ref><ref id="mco270560-bib-0355"><label>355</label><mixed-citation publication-type="journal" id="mco270560-cite-0355"><string-name name-style="western"><given-names>S. R.</given-names><surname>Land</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Wickerham</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Costantino</surname></string-name>, et&#160;al., &#8220;<article-title>Patient&#8208;reported Symptoms and Quality of Life during Treatment with Tamoxifen or Raloxifene for Breast Cancer Prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P&#8208;2 Trial</article-title>,&#8221; <source>Jama</source><volume>295</volume>, no. <issue>23</issue> (<year>2006</year>): <fpage>2742</fpage>&#8211;<lpage>2751</lpage>.<pub-id pub-id-type="pmid">16754728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.23.joc60075</pub-id></mixed-citation></ref><ref id="mco270560-bib-0356"><label>356</label><mixed-citation publication-type="journal" id="mco270560-cite-0356"><string-name name-style="western"><given-names>H. D.</given-names><surname>Nelson</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zakher</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pappas</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>McDonagh</surname></string-name>, &#8220;<article-title>Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force</article-title>,&#8221; <source>Jama</source><volume>322</volume>, no. <issue>9</issue> (<year>2019</year>): <fpage>868</fpage>&#8211;<lpage>886</lpage>.<pub-id pub-id-type="pmid">31479143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.5780</pub-id></mixed-citation></ref><ref id="mco270560-bib-0357"><label>357</label><mixed-citation publication-type="journal" id="mco270560-cite-0357"><string-name name-style="western"><given-names>V. G.</given-names><surname>Vogel</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Costantino</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Wickerham</surname></string-name>, et&#160;al., &#8220;<article-title>Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P&#8208;2 Trial: Preventing Breast Cancer</article-title>,&#8221; <source>Cancer prevention research (Philadelphia, Pa)</source><volume>3</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>696</fpage>&#8211;<lpage>706</lpage>.<pub-id pub-id-type="pmid">20404000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-10-0076</pub-id><pub-id pub-id-type="pmcid">PMC2935331</pub-id></mixed-citation></ref><ref id="mco270560-bib-0358"><label>358</label><mixed-citation publication-type="journal" id="mco270560-cite-0358"><string-name name-style="western"><given-names>E. K.</given-names><surname>Zaluzec</surname></string-name> and <string-name name-style="western"><given-names>L. F.</given-names><surname>Sempere</surname></string-name>, &#8220;<article-title>Systemic and Local Strategies for Primary Prevention of Breast Cancer</article-title>,&#8221; <source>Cancers (Basel)</source><volume>16</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>248</fpage>.<pub-id pub-id-type="pmid">38254741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16020248</pub-id><pub-id pub-id-type="pmcid">PMC10814018</pub-id></mixed-citation></ref><ref id="mco270560-bib-0359"><label>359</label><mixed-citation publication-type="journal" id="mco270560-cite-0359"><string-name name-style="western"><given-names>M. E.</given-names><surname>Ropka</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Keim</surname></string-name>, and <string-name name-style="western"><given-names>J. T.</given-names><surname>Philbrick</surname></string-name>, &#8220;<article-title>Patient Decisions about Breast Cancer Chemoprevention: a Systematic Review and Meta&#8208;analysis</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>28</volume>, no. <issue>18</issue> (<year>2010</year>): <fpage>3090</fpage>&#8211;<lpage>3095</lpage>.<pub-id pub-id-type="pmid">20458026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.27.8077</pub-id><pub-id pub-id-type="pmcid">PMC2903338</pub-id></mixed-citation></ref><ref id="mco270560-bib-0360"><label>360</label><mixed-citation publication-type="journal" id="mco270560-cite-0360"><string-name name-style="western"><given-names>R.</given-names><surname>Heisey</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Pimlott</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Clemons</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Cummings</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Drummond</surname></string-name>, &#8220;<article-title>Women's Views on Chemoprevention of Breast Cancer: Qualitative Study</article-title>,&#8221; <source>Canadian Family Physician</source><volume>52</volume>, no. <issue>5</issue> (<year>2006</year>): <fpage>624</fpage>&#8211;<lpage>625</lpage>.<pub-id pub-id-type="pmid">17327893</pub-id><pub-id pub-id-type="pmcid">PMC1531726</pub-id></mixed-citation></ref><ref id="mco270560-bib-0361"><label>361</label><mixed-citation publication-type="journal" id="mco270560-cite-0361"><string-name name-style="western"><given-names>S. G.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Sestak</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Howell</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Forbes</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, &#8220;<article-title>Participant&#8208;Reported Symptoms and Their Effect on Long&#8208;Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>35</volume>, no. <issue>23</issue> (<year>2017</year>): <fpage>2666</fpage>&#8211;<lpage>2673</lpage>.<pub-id pub-id-type="pmid">28661758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.71.7439</pub-id><pub-id pub-id-type="pmcid">PMC5549455</pub-id></mixed-citation></ref><ref id="mco270560-bib-0362"><label>362</label><mixed-citation publication-type="journal" id="mco270560-cite-0362"><string-name name-style="western"><given-names>A.</given-names><surname>Bambhroliya</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Chavez&#8208;MacGregor</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>Brewster</surname></string-name>, &#8220;<article-title>Barriers to the Use of Breast Cancer Risk Reduction Therapies</article-title>,&#8221; <source>Journal of the National Comprehensive Cancer Network: JNCCN</source><volume>13</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>927</fpage>&#8211;<lpage>935</lpage>.<pub-id pub-id-type="pmid">26150584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2015.0107</pub-id></mixed-citation></ref><ref id="mco270560-bib-0363"><label>363</label><mixed-citation publication-type="journal" id="mco270560-cite-0363"><string-name name-style="western"><given-names>J.</given-names><surname>Cuzick</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Chu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Keevil</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of Baseline Oestradiol Serum Concentration on the Efficacy of Anastrozole for Preventing Breast Cancer in Postmenopausal Women at High Risk: a Case&#8208;control Study of the IBIS&#8208;II Prevention Trial</article-title>,&#8221; <source>The Lancet Oncology</source><volume>25</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>108</fpage>&#8211;<lpage>116</lpage>.<pub-id pub-id-type="pmid">38070530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00578-8</pub-id></mixed-citation></ref><ref id="mco270560-bib-0364"><label>364</label><mixed-citation publication-type="journal" id="mco270560-cite-0364"><string-name name-style="western"><given-names>I.</given-names><surname>Jatoi</surname></string-name> and <string-name name-style="western"><given-names>Z.</given-names><surname>Kemp</surname></string-name>, &#8220;<article-title>Risk&#8208;Reducing Mastectomy</article-title>,&#8221; <source>Jama</source><volume>325</volume>, no. <issue>17</issue> (<year>2021</year>): <fpage>1781</fpage>&#8211;<lpage>1782</lpage>.<pub-id pub-id-type="pmid">33944884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.22414</pub-id></mixed-citation></ref><ref id="mco270560-bib-0365"><label>365</label><mixed-citation publication-type="journal" id="mco270560-cite-0365"><string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>You</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: a Meta&#8208;analysis and Systematic Review</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>22</volume>, no. <issue>15</issue> (<year>2016</year>): <fpage>3971</fpage>&#8211;<lpage>3981</lpage>.<pub-id pub-id-type="pmid">26979395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-15-1465</pub-id></mixed-citation></ref><ref id="mco270560-bib-0366"><label>366</label><mixed-citation publication-type="journal" id="mco270560-cite-0366"><string-name name-style="western"><given-names>N. D.</given-names><surname>Kauff</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Satagopan</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Robson</surname></string-name>, et&#160;al., &#8220;<article-title>Risk&#8208;reducing Salpingo&#8208;oophorectomy in Women with a BRCA1 or BRCA2 Mutation</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>346</volume>, no. <issue>21</issue> (<year>2002</year>): <fpage>1609</fpage>&#8211;<lpage>1615</lpage>.<pub-id pub-id-type="pmid">12023992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa020119</pub-id></mixed-citation></ref><ref id="mco270560-bib-0367"><label>367</label><mixed-citation publication-type="journal" id="mco270560-cite-0367"><string-name name-style="western"><given-names>X.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Oxley</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sideris</surname></string-name>, et&#160;al., &#8220;<article-title>Quality of Life after Risk&#8208;reducing Surgery for Breast and Ovarian Cancer Prevention: a Systematic Review and Meta&#8208;analysis</article-title>,&#8221; <source>American Journal of Obstetrics and Gynecology</source><volume>229</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>388</fpage>&#8211;<lpage>409</lpage>.<pub-id pub-id-type="pmid">37059410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2023.03.045</pub-id></mixed-citation></ref><ref id="mco270560-bib-0368"><label>368</label><mixed-citation publication-type="journal" id="mco270560-cite-0368"><string-name name-style="western"><given-names>F.</given-names><surname>Gaba</surname></string-name> and <string-name name-style="western"><given-names>R.</given-names><surname>Manchanda</surname></string-name>, &#8220;<article-title>Systematic Review of Acceptability, Cardiovascular, Neurological, Bone Health and HRT Outcomes Following Risk Reducing Surgery in BRCA Carriers</article-title>,&#8221; <source>Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology</source><volume>65</volume> (<year>2020</year>): <fpage>46</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">32192936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpobgyn.2020.01.006</pub-id></mixed-citation></ref><ref id="mco270560-bib-0369"><label>369</label><mixed-citation publication-type="journal" id="mco270560-cite-0369"><string-name name-style="western"><given-names>C.</given-names><surname>Marchetti</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>De Felice</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Boccia</surname></string-name>, et&#160;al., &#8220;<article-title>Hormone Replacement Therapy after Prophylactic Risk&#8208;reducing Salpingo&#8208;oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: a Meta&#8208;analysis</article-title>,&#8221; <source>Critical Reviews in Oncology/Hematology</source><volume>132</volume> (<year>2018</year>): <fpage>111</fpage>&#8211;<lpage>115</lpage>.<pub-id pub-id-type="pmid">30447915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2018.09.018</pub-id></mixed-citation></ref><ref id="mco270560-bib-0370"><label>370</label><mixed-citation publication-type="journal" id="mco270560-cite-0370"><string-name name-style="western"><given-names>F.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Barbacioru</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>mRNA&#8208;Seq Whole&#8208;transcriptome Analysis of a Single Cell</article-title>,&#8221; <source>Nature methods</source><volume>6</volume>, no. <issue>5</issue> (<year>2009</year>): <fpage>377</fpage>&#8211;<lpage>382</lpage>.<pub-id pub-id-type="pmid">19349980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.1315</pub-id></mixed-citation></ref><ref id="mco270560-bib-0371"><label>371</label><mixed-citation publication-type="journal" id="mco270560-cite-0371"><string-name name-style="western"><given-names>K.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kumar</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Archival Single&#8208;cell Genomics Reveals Persistent Subclones during DCIS Progression</article-title>,&#8221; <source>Cell</source><volume>186</volume>, no. <issue>18</issue> (<year>2023</year>): <fpage>3968</fpage>&#8211;<lpage>3982.e15</lpage>.<pub-id pub-id-type="pmid">37586362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.07.024</pub-id><pub-id pub-id-type="pmcid">PMC11831769</pub-id></mixed-citation></ref><ref id="mco270560-bib-0372"><label>372</label><mixed-citation publication-type="journal" id="mco270560-cite-0372"><string-name name-style="western"><given-names>L.&#8208;P.</given-names><surname>Ge</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>ZNF689 deficiency Promotes Intratumor Heterogeneity and Immunotherapy Resistance in Triple&#8208;negative Breast Cancer</article-title>,&#8221; <source>Cell research</source><volume>34</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>58</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">38168642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-023-00909-w</pub-id><pub-id pub-id-type="pmcid">PMC10770380</pub-id></mixed-citation></ref><ref id="mco270560-bib-0373"><label>373</label><mixed-citation publication-type="journal" id="mco270560-cite-0373"><string-name name-style="western"><given-names>Q.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Shao</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Jia</surname></string-name>, et&#160;al., &#8220;<article-title>Genomic Alterations and Evolution of Cell Clusters in Metastatic Invasive Micropapillary Carcinoma of the Breast</article-title>,&#8221; <source>Nature Communications</source><volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>111</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27794-4</pub-id><pub-id pub-id-type="pmcid">PMC8748639</pub-id><pub-id pub-id-type="pmid">35013309</pub-id></mixed-citation></ref><ref id="mco270560-bib-0374"><label>374</label><mixed-citation publication-type="journal" id="mco270560-cite-0374"><string-name name-style="western"><given-names>L.</given-names><surname>Larsson</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fris&#233;n</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Lundeberg</surname></string-name>, &#8220;<article-title>Spatially Resolved Transcriptomics Adds a New Dimension to Genomics</article-title>,&#8221; <source>Nature methods</source><volume>18</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>15</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">33408402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-020-01038-7</pub-id></mixed-citation></ref><ref id="mco270560-bib-0375"><label>375</label><mixed-citation publication-type="journal" id="mco270560-cite-0375"><string-name name-style="western"><given-names>C.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Peng</surname></string-name>, et al., &#8220;<article-title>Pan&#8208;Cancer Spatially Resolved Single&#8208;Cell Analysis Reveals the Crosstalk Between Cancer&#8208;Associated Fibroblasts and Tumor Microenvironment</article-title>,&#8221; <source>Molecular Cancer</source><volume>22</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>170</fpage>.<pub-id pub-id-type="pmid">37833788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01876-x</pub-id><pub-id pub-id-type="pmcid">PMC10571470</pub-id></mixed-citation></ref><ref id="mco270560-bib-0376"><label>376</label><mixed-citation publication-type="journal" id="mco270560-cite-0376"><string-name name-style="western"><given-names>Q.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Balasubramanian</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Asirvatham</surname></string-name>, et&#160;al., &#8220;<article-title>Integrative Spatial Omics Reveals Distinct Tumor&#8208;promoting Multicellular Niches and Immunosuppressive Mechanisms in Black American and White American Patients with TNBC</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>6584</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-61034-3</pub-id><pub-id pub-id-type="pmcid">PMC12271405</pub-id><pub-id pub-id-type="pmid">40675986</pub-id></mixed-citation></ref><ref id="mco270560-bib-0377"><label>377</label><mixed-citation publication-type="journal" id="mco270560-cite-0377"><string-name name-style="western"><given-names>J.</given-names><surname>Lipkova</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>Artificial Intelligence for Multimodal Data Integration in Oncology</article-title>,&#8221; <source>Cancer Cell</source><volume>40</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>1095</fpage>&#8211;<lpage>1110</lpage>.<pub-id pub-id-type="pmid">36220072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2022.09.012</pub-id><pub-id pub-id-type="pmcid">PMC10655164</pub-id></mixed-citation></ref><ref id="mco270560-bib-0378"><label>378</label><mixed-citation publication-type="journal" id="mco270560-cite-0378"><string-name name-style="western"><given-names>K.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Artificial Intelligence in Drug Development</article-title>,&#8221; <source>Nature Medicine</source><volume>31</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>45</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03434-4</pub-id><pub-id pub-id-type="pmid">39833407</pub-id></mixed-citation></ref><ref id="mco270560-bib-0379"><label>379</label><mixed-citation publication-type="journal" id="mco270560-cite-0379"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yuan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Hei</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Liang</surname></string-name>, &#8220;<article-title>Gene co&#8208;expression Network Analysis Reveals Common System&#8208;level Properties of Prognostic Genes across Cancer Types</article-title>,&#8221; <source>Nature Communications</source><volume>5</volume>, (<year>2014</year>): <fpage>3231</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4231</pub-id><pub-id pub-id-type="pmcid">PMC3951205</pub-id><pub-id pub-id-type="pmid">24488081</pub-id></mixed-citation></ref><ref id="mco270560-bib-0380"><label>380</label><mixed-citation publication-type="journal" id="mco270560-cite-0380"><string-name name-style="western"><given-names>M.</given-names><surname>Uhlen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lee</surname></string-name>, et&#160;al., &#8220;<article-title>A Pathology Atlas of the human Cancer Transcriptome</article-title>,&#8221; <source>Science (New York, NY)</source><volume>357</volume>, no. <issue>6352</issue> (<year>2017</year>): <elocation-id>eaan2507</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan2507</pub-id><pub-id pub-id-type="pmid">28818916</pub-id></mixed-citation></ref><ref id="mco270560-bib-0381"><label>381</label><mixed-citation publication-type="journal" id="mco270560-cite-0381"><string-name name-style="western"><given-names>J.</given-names><surname>Jee</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Fong</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Pichotta</surname></string-name>, et&#160;al., &#8220;<article-title>Automated Real&#8208;world Data Integration Improves Cancer Outcome Prediction</article-title>,&#8221; <source>Nature</source><volume>636</volume>, no. <issue>8043</issue> (<year>2024</year>): <fpage>728</fpage>&#8211;<lpage>736</lpage>.<pub-id pub-id-type="pmid">39506116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08167-5</pub-id><pub-id pub-id-type="pmcid">PMC11655358</pub-id></mixed-citation></ref><ref id="mco270560-bib-0382"><label>382</label><mixed-citation publication-type="journal" id="mco270560-cite-0382"><string-name name-style="western"><given-names>W.</given-names><surname>Lotter</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Hassett</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Schultz</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Kehl</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Van Allen</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Cerami</surname></string-name>, &#8220;<article-title>Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions</article-title>,&#8221; <source>Cancer Discovery</source><volume>14</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>711</fpage>&#8211;<lpage>726</lpage>.<pub-id pub-id-type="pmid">38597966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-23-1199</pub-id><pub-id pub-id-type="pmcid">PMC11131133</pub-id></mixed-citation></ref><ref id="mco270560-bib-0383"><label>383</label><mixed-citation publication-type="journal" id="mco270560-cite-0383"><string-name name-style="western"><given-names>S. M.</given-names><surname>Sweeney</surname></string-name>, <string-name name-style="western"><given-names>H. K.</given-names><surname>Hamadeh</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Abrams</surname></string-name>, et&#160;al., &#8220;<article-title>Challenges to Using Big Data in Cancer</article-title>,&#8221; <source>Cancer Research</source><volume>83</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>1175</fpage>&#8211;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">36625843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-22-1274</pub-id><pub-id pub-id-type="pmcid">PMC10102837</pub-id></mixed-citation></ref><ref id="mco270560-bib-0384"><label>384</label><mixed-citation publication-type="journal" id="mco270560-cite-0384"><string-name name-style="western"><given-names>A. T. M.</given-names><surname>Cheung</surname></string-name>, <string-name name-style="western"><given-names>E. L.</given-names><surname>Palapattu</surname></string-name>, <string-name name-style="western"><given-names>I. R.</given-names><surname>Pompa</surname></string-name>, et&#160;al., &#8220;<article-title>Racial and Ethnic Disparities in a Real&#8208;world Precision Oncology Data Registry</article-title>,&#8221; <source>NPJ precision oncology</source><volume>7</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>7</fpage>.<pub-id pub-id-type="pmid">36658153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-023-00351-6</pub-id><pub-id pub-id-type="pmcid">PMC9852424</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>